0000950170-24-12707710-Q Lineage Cell Therapeutics, Inc. 20241114202411141615281615301615300 0 0000950170-24-127077 10-Q 73 20240930 20241114 20241114 Lineage Cell Therapeutics, Inc. 0000876343 2836 943127919 CA 1231 10-Q 34 001-12830 241462507 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 BIOTIME INC 19930328 10-Q 1 lctx-20240930.htm 10-Q 10-Q --12-31falseQ3000087634300008763430000876343us-gaap:PatentsMember2023-12-310000876343us-gaap:FairValueInputsLevel1Memberlctx:MarketableEquitySecuritiesMember2023-12-310000876343us-gaap:NoncontrollingInterestMember2024-06-300000876343us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000876343lctx:CellCureNeurosciencesLtdMember2024-01-012024-09-300000876343202201-012023-12-310000876343lctx:TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember2024-01-012024-09-300000876343lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMember2024-09-300000876343lctx:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortizationMember2023-12-310000876343lctx:AtTheMarketMember2023-07-012023-09-300000876343srt:ParentCompanyMemberlctx:AtmSalesAgreementMember2024-07-012024-09-300000876343lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000876343lctx:AtTheMarketMember2023-01-012023-09-300000876343lctx:CarlsbadSubLeaseMember2024-09-300000876343lctx:TwoThousandAndTwentyOneEquityIncentivePlanMember2024-01-012024-09-300000876343202302-012023-02-280000876343lctx:ITICollaborationAgreementMember2021-08-012021-08-310000876343srt:ParentCompanyMemberlctx:PriorSalesAgreementMember2024-02-290000876343srt:MinimumMember2024-09-300000876343lctx:TwoThousandTwentyOneEquityIncentivePlanMember2024-01-012024-09-300000876343srt:ParentCompanyMemberlctx:AtmSalesAgreementMember2024-09-300000876343us-gaap:FairValueInputsLevel2Member2023-12-310000876343lctx:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortizationMember2024-09-300000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000876343lctx:CellCureNeurosciencesLtdMember2024-09-300000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000876343us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300000876343lctx:AccountingStandardUpdate201409Member2024-09-300000876343us-gaap:FairValueInputsLevel1Member2023-12-310000876343lctx:RoyaltiesLicenseAndOtherRevenuesMember2024-07-012024-09-300000876343srt:ParentCompanyMemberlctx:SettlementAgreementMember2023-01-012023-03-310000876343us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000876343lctx:CorporateCreditCardFacilityMember2024-09-300000876343us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000876343us-gaap:FairValueInputsLevel3Memberlctx:MarketableEquitySecuritiesMember2024-09-300000876343lctx:RoyaltiesLicenseAndOtherRevenuesMember2023-07-012023-09-300000876343us-gaap:CommonStockMember2024-07-012024-09-300000876343lctx:TwoThousandTwentyOneEquityIncentivePlanMember2024-09-300000876343us-gaap:CommonStockMemberlctx:AtTheMarketMember2023-07-012023-09-300000876343lctx:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000876343lctx:LicenseAgreementMembersrt:MaximumMember2020-05-012020-05-310000876343us-gaap:EmployeeStockOptionMember2024-01-012024-09-3000008763432023-12-310000876343lctx:CarlsbadSubLeaseMember2024-02-012024-02-290000876343lctx:SettlementAgreementMemberlctx:InsurersMember2023-02-012023-02-280000876343lctx:MarketableDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMember2024-09-3000008763432023-09-300000876343lctx:AgreementsWithHadasitAndIIAMember2024-09-300000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000876343lctx:RocheAgreementMemberlctx:IsraelInnovationAuthorityMember2022-01-012022-01-310000876343us-gaap:NoncontrollingInterestMember2022-12-310000876343us-gaap:LeaseholdImprovementsMember2024-09-300000876343us-gaap:RetainedEarningsMember2023-12-310000876343srt:ParentCompanyMember2024-02-062024-02-060000876343lctx:MarketableDebtSecuritiesMember2024-09-300000876343lctx:RoyaltyContractsMember2024-09-300000876343lctx:OperatingLeaseMember2024-09-3000008763432023-06-300000876343202409-300000876343lctx:EsCellInternationalPteLtdMember2024-09-300000876343lctx:InProcessResearchAndDevelopmentVACTwoMember2024-09-300000876343srt:ParentCompanyMemberlctx:AtmSalesAgreementMember2024-04-012024-06-300000876343lctx:MarketableEquitySecuritiesMember2024-09-300000876343lctx:TwoThousandTwentyOneEquityIncentivePlanMember2023-01-012023-12-310000876343lctx:CarlsbadSubLeaseMember2024-01-012024-09-300000876343lctx:AccountingStandardUpdate201409Memberus-gaap:CollaborativeArrangementMember2024-09-300000876343lctx:EquipmentFurnitureAndFixturesMember2024-09-300000876343us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000876343us-gaap:NoncontrollingInterestMember2024-09-300000876343us-gaap:RetainedEarningsMember2023-06-300000876343us-gaap:LeaseholdImprovementsMember2023-12-310000876343lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310000876343lctx:AgreementsWithHadasitAndIIAMember2021-12-172021-12-170000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000876343lctx:UpfrontLicenseFeesMember2024-07-012024-09-300000876343lctx:CollaborationRevenuesMember2023-01-012023-09-300000876343lctx:AgreementsWithHadasitAndIIAMember2017-12-170000876343us-gaap:CommonStockMember2023-12-310000876343us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300000876343srt:ParentCompanyMember2024-02-060000876343us-gaap:CommonStockMember2024-09-300000876343us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000876343us-gaap:RetainedEarningsMember2024-01-012024-09-300000876343us-gaap:FairValueInputsLevel3Memberlctx:MarketableEquitySecuritiesMember2023-12-310000876343us-gaap:RetainedEarningsMember2024-06-3000008763432024-01-012024-09-300000876343lctx:RoyaltiesLicenseAndOtherRevenuesMember2024-01-012024-09-300000876343us-gaap:PatentsMember2024-09-300000876343lctx:OperatingLeaseMember2024-09-300000876343us-gaap:FairValueInputsLevel3Memberlctx:MarketableDebtSecuritiesMember2024-09-300000876343lctx:BRileySecuritiesIncMemberlctx:AtmSalesAgreementMember2024-01-012024-09-300000876343us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000876343srt:ParentCompanyMemberlctx:PriorSalesAgreementMember2021-12-310000876343us-gaap:RetainedEarningsMember2023-07-012023-09-300000876343lctx:InProcessResearchAndDevelopmentOPCOneMember2024-09-300000876343lctx:UpfrontLicenseFeesMember2023-01-012023-09-300000876343lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-09-300000876343us-gaap:CommonStockMemberlctx:AtTheMarketMember2023-01-012023-09-300000876343lctx:MarketableEquitySecuritiesMember2023-12-3100008763432023-01-012023-09-300000876343us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300000876343lctx:CollaborationRevenuesMember2024-01-012024-09-300000876343srt:ParentCompanyMemberlctx:AtmSalesAgreementMember2024-03-310000876343us-gaap:CommonStockMember2023-07-012023-09-300000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000876343us-gaap:CommonStockMember2023-06-300000876343us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-09-300000876343us-gaap:FairValueInputsLevel3Member2024-09-300000876343us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-09-300000876343us-gaap:RetainedEarningsMember2023-09-300000876343lctx:TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember2023-12-310000876343lctx:FinancingLeasesMember2024-09-300000876343us-gaap:CommonStockMember2022-12-310000876343lctx:RocheAgreementMemberlctx:UpfrontLicenseFeesMember2022-01-012022-01-310000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000876343lctx:CarlsbadSubLeaseMember2022-09-012022-09-300000876343us-gaap:CommonStockMember2023-09-300000876343lctx:CorporateCreditCardFacilityMember2023-09-300000876343lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2024-09-300000876343lctx:DepositsAndOtherLongTermAssetsMemberlctx:CarlsbadSubLeaseMember2024-09-300000876343lctx:InProcessResearchAndDevelopmentOPCOneMember2024-09-300000876343us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310000876343srt:ParentCompanyMemberlctx:PriorSalesAgreementMember2024-01-012024-03-310000876343us-gaap:CommonStockMemberlctx:DirectFinancingMember2024-01-012024-09-300000876343lctx:CollaborationRevenuesMember2023-07-012023-09-300000876343lctx:CellCureLeasesMember2024-09-300000876343us-gaap:USTreasurySecuritiesMember2023-12-310000876343lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310000876343lctx:EquipmentFurnitureAndFixturesMember2023-12-310000876343us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000876343us-gaap:MoneyMarketFundsMember2023-12-310000876343lctx:AgreementsWithHadasitAndIIAMember2021-11-012021-11-300000876343lctx:TwoThousandTwentyOneEquityIncentivePlanMember2023-12-310000876343us-gaap:RetainedEarningsMember2022-12-310000876343us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300000876343us-gaap:FairValueInputsLevel1Member2024-09-300000876343us-gaap:InProcessResearchAndDevelopmentMember2024-09-300000876343us-gaap:NoncontrollingInterestMember2024-01-012024-09-300000876343srt:MaximumMember2024-09-300000876343lctx:UpfrontLicenseFeesMember2023-07-012023-09-3000008763432023-07-012023-09-300000876343lctx:TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember2024-09-300000876343lctx:SettlementAgreementMember2023-02-012023-02-280000876343lctx:FinancingLeasesMember2023-12-310000876343lctx:OperatingLeaseMember2023-12-310000876343us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000876343lctx:MarketableDebtSecuritiesMember2023-12-310000876343us-gaap:CommonStockMember2024-01-012024-09-300000876343lctx:DirectFinancingMember2024-01-012024-09-300000876343lctx:CellCureLeasesMember2024-01-012024-09-300000876343lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-09-300000876343lctx:RocheAgreementMemberlctx:HadasitMedicalResearchServicesAndDevelopmentLtdMember2022-01-012022-01-310000876343us-gaap:CommonStockMember2023-01-012023-09-300000876343lctx:RoyaltiesLicenseAndOtherRevenuesMember2023-01-012023-09-300000876343us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000876343lctx:AtTheMarketMember2024-01-012024-09-300000876343lctx:CarlsbadSubLeaseMember2022-09-300000876343lctx:AgreementsWithHadasitAndIIAMember2021-12-170000876343us-gaap:RetainedEarningsMember2023-01-012023-09-300000876343us-gaap:FairValueInputsLevel2Member2024-09-300000876343us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000876343lctx:InProcessResearchAndDevelopmentOPCOneMember2023-12-310000876343us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000876343us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000876343us-gaap:MoneyMarketFundsMember2024-09-300000876343lctx:UpfrontLicenseFeesMember2024-01-012024-09-300000876343lctx:BroadwoodPartnersLPMember2024-02-062024-02-060000876343lctx:RocheAgreementMember2022-01-012022-01-310000876343lctx:NealBradsherMemberlctx:BroadwoodPartnersLPMember2019-02-012023-07-310000876343us-gaap:RetainedEarningsMember2024-07-012024-09-300000876343lctx:TwoThousandTwentyOneEquityIncentivePlanMembersrt:MaximumMember2024-09-300000876343lctx:ITICollaborationAgreementMember2021-04-012021-04-300000876343us-gaap:FairValueInputsLevel1Memberlctx:MarketableEquitySecuritiesMember2024-09-300000876343us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000876343lctx:CarlsbadLeaseMember2019-05-3100008763432024-06-300000876343lctx:InProcessResearchAndDevelopmentVACTwoMember2023-12-310000876343lctx:RocheAgreementMember2021-12-012021-12-3100008763432022-12-310000876343us-gaap:FairValueInputsLevel3Member2023-12-310000876343us-gaap:USTreasurySecuritiesMember2024-09-3000008763432024-07-012024-09-300000876343lctx:CarlsbadLeaseMember2019-05-012019-05-310000876343us-gaap:CommonStockMember2024-06-300000876343us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000876343lctx:TwoThousandTwentyOneEquityIncentivePlanMember2023-09-012023-09-300000876343us-gaap:FairValueInputsLevel2Memberlctx:MarketableEquitySecuritiesMember2024-09-300000876343lctx:LicenseAgreementMember2020-05-012020-05-310000876343lctx:CollaborationRevenuesMember2024-07-012024-09-300000876343lctx:CarlsbadLeaseMember2024-09-300000876343us-gaap:NoncontrollingInterestMember2023-09-300000876343lctx:ITICollaborationAgreementMember2024-09-300000876343us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310000876343lctx:RoyaltyContractsMember2023-12-310000876343us-gaap:NoncontrollingInterestMember2023-06-3000008763432024-11-080000876343us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000876343us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000876343lctx:FinancingLeasesMember2024-09-3000008763432023-01-012023-03-310000876343us-gaap:FairValueInputsLevel2Memberlctx:MarketableEquitySecuritiesMember2023-12-310000876343lctx:MarketableDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2024-09-300000876343us-gaap:RetainedEarningsMember2024-09-300000876343lctx:DonMBaileyMember2024-02-062024-02-060000876343lctx:EsCellInternationalPteLtdMember2024-01-012024-09-300000876343lctx:CarlsbadLeaseMember2023-03-010000876343us-gaap:CommonStockMemberlctx:AtTheMarketMember2024-01-012024-09-300000876343lctx:RocheAgreementMember2021-12-172021-12-170000876343srt:ParentCompanyMemberlctx:AtmSalesAgreementMember2024-05-140000876343us-gaap:NoncontrollingInterestMember2023-12-310000876343us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-30utr:sqmxbrli:pureiso4217:USDxbrli:sharesutr:sqftxbrli:sharesiso4217:GBPiso4217:USDiso4217:ILS Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from _____ to _____ Â Commission file number 001-12830 Â Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) Â California 94-3127919 (State or other jurisdiction ofincorporation or organization) (IRS EmployerIdentification No.) Â 2173 Salk Avenue, Suite 200 Carlsbad, California 92008 (Address of principal executive offices) (Zip code) Â (Registrantâ€™s telephone number, including area code) (442) 287-8990 Â Securities registered pursuant to Section 12(b) of the Act Â Title of each class Trading Symbol Name of exchange on which registered Common shares LCTX NYSEÂ American LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. â˜’ Yes â˜ No Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). â˜’ Yes â˜ No Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). â˜ Yes â˜’ No Â The number of common shares outstanding as of November 8, 2024 was 188,837,375. Â Â Lineage Cell Therapeutics, Inc. Table of Contents Â Â Â Â Page PART I. FINANCIAL INFORMATION 5 Item 1. Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Â Condensed Consolidated Statements of Changes in Shareholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to the Condensed Consolidated Interim Financial Statements 11 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Result of Operations 30 Item 3. Quantitative and Qualitative Disclosures about Market Risk 38 Item 4. Controls and Procedures 38 PART II. OTHER INFORMATION 39 Item 1. Legal Proceedings 39 Item 1A. Risk Factors 39 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 39 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 39 Item 6. Exhibits 40 Signatures 41 Â 2 Â SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 2. â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ of this report, but are also contained elsewhere in this report. We make such forward-looking statements pursuant to the safe harbor

provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by the words â€œmay,â€ â€œmight,â€ â€œwill,â€ â€œcould,â€ â€œwould,â€ â€œshould,â€ â€œexpect,â€ â€œintend,â€ â€œplan,â€ â€œobjective,â€ â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œproject,â€ â€œpotential,â€ â€œcontinueâ€ and â€œongoing,â€ or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements in this report include, but are not limited to, statements about: â€¢the potential to receive developmental, regulatory, and commercialization milestone and royalty payments under our Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc.; â€¢our plans to research, develop and commercialize our product candidates; â€¢the initiation, progress, success, cost and timing of our clinical trials and other product development activities; â€¢the therapeutic potential of our product candidates, and the indications for which we intend to develop our product candidates; â€¢our ability to successfully manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and costs of such manufacture; â€¢the potential of our cell therapy platform; â€¢our ability to obtain additional capital to fund our operations; â€¢our expectations and plans regarding existing and potential future collaborations with third parties such as pharmaceutical and biotechnology companies, government agencies, academic laboratories, and research institutes for the discovery, development, and/or commercialization of novel cell therapy products; â€¢the size and growth of the potential markets for our product candidates and our ability to serve those markets; â€¢the potential scope and value of our intellectual property rights; and â€¢the effects on our operations of the Israel-Hamas war and broader regional conflict, other geopolitical conflicts, political and economic instability, public health emergencies and macroeconomic conditions. Forward-looking statements reflect our views and expectations as of the date of this report about future events and our future performance and condition, and involve known and unknown risks, uncertainties and other factors that may cause our actual activities, performance, results or condition to be materially different from those expressed or implied by the forward-looking statements. You should refer to â€œItem 1A. Risk Factorsâ€ in Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the â€œ2023 10-Kâ€) as filed with the Securities and Exchange Commission (the â€œSECâ€) on March 7, 2024, for a discussion of important factors that may cause our actual activities, performance, results and condition to differ materially from those expressed or implied by our forward-looking statements. As a result of a variety of factors, including those discussed in Part I, Item 1A of the 2023 10-K, our forward-looking statements may prove to be inaccurate, and the inaccuracy may be material. Accordingly, you should not place undue reliance on any forward-looking statement. We anticipate that subsequent events and developments may cause our current views and expectations to change. However, while we may elect to update the forward-looking statements in this report at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date after the date of this report. You should read this report completely and with the understanding that our actual future performance, results and condition may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. 3 Â MARKET DATA AND TRADEMARKS This report may also contain market data, industry forecasts and other data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. All brand names or trademarks appearing in this report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this report are referred to without the symbols Â® and TM, but such references should not be construed as any indication that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. ****** Unless otherwise stated or the context requires otherwise, references in this report to â€œLineage,â€ the â€œCompany,â€ â€œour company,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ refer collectively to Lineage Cell Therapeutics, Inc. and its consolidated subsidiaries. 4 Â PART I â€“ FINANCIAL INFORMATION Item 1. Financial Statements LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS) (UNAUDITED) Â Â Â September 30, 2024 Â Â December 31, 2023 Â ASSETS Â Â Â Â Â Â CURRENT ASSETS Â Â Â Â Â Â Cash and cash equivalents Â $ 27,750 Â Â $ 35,442 Â Marketable securities Â Â 4,961 Â Â Â 50 Â Accounts receivable, net Â Â 405 Â Â Â 745 Â Prepaid expenses and other current assets Â Â 1,285 Â Â Â 2,204 Â Total current assets Â Â 34,401 Â Â Â 38,441 Â Â Â Â Â Â Â NONCURRENT ASSETS Â Â Â Â Â Â Property and equipment, net Â Â 2,013 Â Â Â 2,245 Â Operating lease right-of-use assets Â Â 2,362 Â Â Â 2,522 Â Deposits and other long-term assets Â Â 606 Â Â Â 577 Â Goodwill Â Â 10,672 Â Â Â 10,672 Â Intangible assets, net Â Â 46,540 Â Â Â 46,562 Â TOTAL ASSETS Â $ 96,594 Â Â $ 101,019 Â Â Â Â Â Â Â LIABILITIES AND SHAREHOLDERSâ€™ EQUITY Â Â Â Â Â Â CURRENT LIABILITIES Â Â Â Â Â Â Accounts payable and accrued liabilities Â $ 4,477 Â Â $ 6,270 Â Operating lease liabilities, current portion Â Â 1,083 Â Â Â 830 Â Finance lease liabilities, current portion Â Â 54 Â Â Â 52 Â Deferred revenues, current portion Â Â 8,250 Â Â Â 10,808 Â Total current liabilities Â Â 13,864 Â Â Â 17,960 Â Â Â Â Â Â Â LONG-TERM LIABILITIES Â Â Â Â Â Â Deferred tax liability Â Â 273 Â Â Â 273 Â Deferred revenues, net of current portion Â Â 16,050 Â Â Â 18,693 Â Operating lease liabilities, net of current portion Â Â 1,533 Â Â Â 1,979 Â Finance lease liabilities, net of current portion Â Â 80 Â Â Â 91 Â TOTAL LIABILITIES Â Â 31,800 Â Â Â 38,996 Â Â Â Â Â Â Â Commitments and contingenciesÂ (Note 13) Â Â Â Â Â Â Â Â Â Â Â Â SHAREHOLDERSâ€™ EQUITY Â Â Â Â Â Â Preferred shares, noÂ par value, 2,000Â shares authorized; noneÂ issued and Â Â Â outstanding as of September 30, 2024 and December 31, 2023 Â Â â€” Â Â Â â€” Â Common shares, noÂ par value, 450,000Â shares authorized as of September 30, 2024 Â Â Â and December 31, 2023; 188,837Â and 174,987Â shares issued and outstanding Â Â Â as of September 30, 2024 and December 31, 2023, respectively Â Â 469,268 Â Â Â 451,343 Â Accumulated other comprehensive loss Â Â (2,890) Â Â (3,068) Accumulated deficit Â Â (400,192) Â Â (384,856) Lineage's shareholdersâ€™ equity Â Â 66,186 Â Â Â 63,419 Â Noncontrolling deficit Â Â (1,392) Â Â (1,396) Total shareholdersâ€™ equity Â Â 64,794 Â Â Â 62,023 Â TOTAL LIABILITIES AND SHAREHOLDERSâ€™ EQUITY Â $ 96,594 Â Â $ 101,019 Â Â See accompanying notes to the condensed consolidated interim financial statements. 5 Â LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â REVENUES: Â Â Â Â Â Â Â Â Â Â Â Â Collaboration revenues Â $ 3,386 Â Â $ 957 Â Â $ 5,671 Â Â $ 5,949 Â Royalties, license and other revenues Â Â 393 Â Â Â 289 Â Â Â 960 Â Â Â 908 Â Total revenues Â Â 3,779 Â Â Â 1,246 Â Â Â 6,631 Â Â Â 6,857 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OPERATING EXPENSES: Â Â Â Â Â Â Â Â Â Â Â Â Cost of sales Â Â 38 Â Â Â 169 Â Â Â 180 Â Â Â 415 Â Research and development Â Â 3,171 Â Â Â 3,741 Â Â Â 9,049 Â Â Â 11,799 Â General and administrative Â Â 4,410 Â Â Â 4,041 Â Â Â 13,770 Â Â Â 13,014 Â Total operating expenses Â Â 7,619 Â Â Â 7,951 Â Â Â 22,999 Â Â Â 25,228 Â Loss from operations Â Â (3,840) Â Â (6,705) Â Â (16,368) Â Â (18,371) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OTHER INCOME (EXPENSES): Â Â Â Â Â Â Â Â Â Â Â Â Interest income Â Â 397 Â Â Â 433 Â Â Â 1,322 Â Â Â 1,225 Â Loss on marketable equity securities, net Â Â (6) Â Â (60) Â Â (21) Â Â (170) Foreign currency transaction gain (loss), net Â Â 448 Â Â Â (827) Â Â (284) Â Â (1,796) Other income (expense) Â Â â€” Â Â Â 1 Â Â Â 19 Â Â Â 544 Â Total other income (expenses) Â Â 839 Â Â Â (453) Â Â 1,036 Â Â Â (197) Â Â Â Â Â Â Â Â Â Â Â Â LOSS BEFORE INCOME TAXES Â Â (3,001) Â Â (7,158) Â Â (15,332) Â Â (18,568) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Provision for income tax benefit Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 1,803 Â Â Â Â Â Â Â Â Â Â Â Â NET LOSS Â Â (3,001) Â Â (7,158) Â Â (15,332) Â Â (16,765) Â Â Â Â Â Â Â Â Â Â Â Â Net (income) loss attributable to noncontrolling interest Â Â (33) Â Â 48 Â Â Â (4) Â Â 54 Â Â Â Â Â Â Â Â Â Â Â Â NET LOSS ATTRIBUTABLE TO LINEAGE Â $ (3,034) Â $ (7,110) Â $ (15,336) Â $ (16,711) Â Â Â Â Â Â Â Â Â Â Â Â Net loss per common share attributable to LineageÂ Â Â basic and diluted Â $ (0.02) Â $ (0.04) Â $ (0.08) Â $ (0.10) Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average common shares used to compute basic and Â Â Â diluted net loss per common share Â Â 188,835 Â Â Â 174,868 Â Â Â 186,860 Â Â Â 171,880 Â Â Â Â Â Â See accompanying notes to the condensed consolidated interim financial statements. 6 Â LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (IN THOUSANDS) (UNAUDITED) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â NET LOSS Â $ (3,001) Â $ (7,158) Â $ (15,332) Â $ (16,765) Other comprehensive loss, net of tax: Â Â Â Â Â Â Â Â Â Â Â Â Foreign currency translation adjustment Â Â (432) Â Â 518 Â Â Â 173 Â Â Â 1,337 Â Unrealized gain on marketable debt securities Â Â 12 Â Â Â 9 Â Â Â 5 Â Â Â 150 Â COMPREHENSIVE LOSS Â Â (3,421) Â Â (6,631) Â Â (15,154) Â Â (15,278) Less: Comprehensive (income) loss attributable to Â Â Â noncontrolling interest Â Â (33) Â Â 48 Â Â Â (4) Â Â 54 Â COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE Â Â Â COMMON SHAREHOLDERS Â $ (3,454) Â $ (6,583) Â $ (15,158) Â $ (15,224) Â Â Â Â Â See accompanying notes to the condensed consolidated interim financial statements. Â Â 7 Â LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERSâ€™ EQUITY (IN THOUSANDS) (UNAUDITED) Â Three Months Ended September 30, 2024 Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other Â Â Total Â Â Â Common Shares Â Â Accumulated Â Â Noncontrolling Â Â Comprehensive Â Â Shareholdersâ€™ Â Â Â Shares Â Â Amount Â Â Deficit Â Â Deficit Â Â Income / (Loss) Â Â Equity Â BALANCE - June 30, 2024 Â Â 188,824 Â Â Â $ 467,928 Â Â Â $ (397,158) Â $ (1,425) Â $ (2,470) Â Â Â 66,875 Â Shares issued upon exercise of stock options Â Â 13 Â Â Â 10 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 10 Â Stock-based compensation Â Â â€” Â Â Â 1,330 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 1,330 Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 12 Â Â Â 12 Â Foreign currency translation adjustment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (432) Â Â (432) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (3,034) Â Â Â 33 Â Â Â â€” Â Â Â (3,001) BALANCE - September 30, 2024 Â Â 188,837 Â Â Â $ 469,268 Â Â Â $ (400,192) Â $ (1,392) Â $ (2,890) Â $ 64,794 Â Â Â Â Three Months Ended September 30, 2023 Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other Â Â Total Â Â Â Common Shares Â Â Accumulated Â Â Noncontrolling Â Â Comprehensive Â Â Shareholdersâ€™ Â Â Â Shares Â Â Amount Â Â Deficit Â Â Deficit Â Â Income / (Loss) Â Â Equity Â BALANCE - June 30, 2023 Â Â 174,439 Â Â Â $ 448,249 Â Â Â $ (372,971) Â $ (1,409) Â $ (2,611) Â $ 71,258 Â Shares issued through ATM Â Â 538 Â Â Â 784 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 784 Â Financing related fees Â Â â€” Â Â Â (28) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (28) Shares issued upon exercise of stock options Â Â 10 Â Â Â 8 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 8 Â Stock-based compensation Â Â â€” Â Â Â 1,269 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 1,269 Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 9 Â Â Â 9 Â Foreign currency translation adjustment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 518 Â Â Â 518 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (7,110) Â Â (48) Â Â â€” Â Â Â (7,158) BALANCE - September 30, 2023 Â Â 174,987 Â Â Â $ 450,282 Â Â Â $ (380,081) Â $ (1,457) Â $ (2,084) Â $ 66,660 Â Â See accompanying notes to the condensed consolidated interim financial statements. 8 Â LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERSâ€™ EQUITY (CONTINUED) (IN THOUSANDS) (UNAUDITED) Â Nine Months Ended September 30, 2024 Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other Â Â Total Â Â Â Common Shares Â Â Accumulated Â Â Noncontrolling Â Â Comprehensive Â Â Shareholdersâ€™ Â Â Â Shares Â Â Amount Â Â Deficit Â Â Deficit Â Â Income / (Loss) Â Â Equity Â BALANCE - December 31, 2023 Â Â 174,987 Â Â Â $ 451,343 Â Â Â $ (384,856) Â $ (1,396) Â $ (3,068) Â $ 62,023 Â Shares issued through registered direct financing Â Â 13,462 Â Â Â 14,000 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 14,000 Â Shares issued through ATM Â Â 56 Â Â Â 70 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 70 Â Financing related fees Â Â â€” Â Â Â (113) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (113) Shares issued upon vesting of restricted stock units, Â Â Â net of shares retired to pay employeesâ€™ taxes Â Â 45 Â Â Â (23) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (23) Shares issued upon exercise of stock options Â Â 287 Â Â Â 229 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 229 Â Stock-based compensation Â Â â€” Â Â Â 3,762 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 3,762 Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 5 Â Â Â 5 Â Foreign currency translation adjustment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 173 Â Â Â 173 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (15,336) Â Â Â 4 Â Â Â â€” Â Â Â (15,332) BALANCE - September 30, 2024 Â Â 188,837 Â Â Â $ 469,268 Â Â Â $ (400,192) Â $ (1,392) Â $ (2,890) Â $ 64,794 Â Â Â Â Nine Months Ended September 30, 2023 Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other Â Â Total Â Â Â Common Shares Â Â Accumulated Â Â Noncontrolling Â Â Comprehensive Â Â Shareholdersâ€™ Â Â Â Shares Â Â Amount Â Â Deficit Â Â Deficit Â Â Income / (Loss) Â Â Equity Â BALANCE - December 31, 2022 Â Â 170,093 Â Â Â $ 440,280 Â Â Â $ (363,370) Â $ (1,403) Â $ (3,571) Â $ 71,936 Â Shares issued through ATM Â Â 4,775 Â Â Â 6,625 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 6,625 Â Financing related fees Â Â â€” Â Â Â (221) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (221) Shares issued upon vesting of restricted stock units, Â Â Â net of shares retired to pay employeesâ€™ taxes Â Â 53 Â Â Â (37) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (37) Shares issued upon exercise of stock options Â Â 66 Â Â Â 55 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 55 Â Stock-based compensation Â Â â€” Â Â Â 3,580 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 3,580 Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 150 Â Â Â 150 Â Foreign currency translation adjustment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 1,337 Â Â Â 1,337 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (16,711) Â Â (54) Â Â â€” Â Â Â (16,765) BALANCE - September 30, 2023 Â Â 174,987 Â Â Â $ 450,282 Â Â Â $ (380,081) Â $ (1,457) Â $ (2,084) Â $ 66,660 Â Â See accompanying notes to the condensed consolidated interim financial statements. 9 Â LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS) (UNAUDITED) Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Net loss attributable to Lineage Â $ (15,336) Â $ (16,711) Net loss attributable to noncontrolling interest Â Â 4 Â Â Â (54) Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. Â Â Â to net cash used in operating activities: Â Â Â Â Â Â Loss on marketable equity securities, net Â Â 21 Â Â Â 170 Â Accretion of income on marketable debt securities Â Â (184) Â Â (647) Depreciation and amortization expense Â Â 436 Â Â Â 419 Â Change in right-of-use assets and liabilities Â Â (31) Â Â 86 Â Amortization of intangible assets Â Â 22 Â Â Â 98 Â Stock-based compensation Â Â 3,762 Â Â Â 3,580 Â Deferred income tax benefit Â Â â€” Â Â Â (1,803) Foreign currency remeasurement and other loss Â Â 309 Â Â Â 1,892 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â 339 Â Â Â (141) Prepaid expenses and other current assets Â Â 891 Â Â Â 56 Â Accounts payable and accrued liabilities Â Â (1,778) Â Â (3,456) Deferred revenue Â Â (5,201) Â Â (6,036) Net cash used in operating activities Â Â (16,746) Â Â (22,547) Â Â Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Proceeds from the sale of marketable equity securities Â Â 18 Â Â Â 196 Â Purchases of marketable debt securities Â Â (8,761) Â Â (16,403) Maturities of marketable debt securities Â Â 4,000 Â Â Â 53,497 Â Purchase of equipment Â Â (200) Â Â (583) Net cash (used in) provided by investing activities Â Â (4,943) Â Â 36,707 Â Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Proceeds from employee options exercised Â Â 229 Â Â Â 88 Â Common shares received and retired for employee taxes paid Â Â (23) Â Â (37) Proceeds from sale of common shares Â Â 14,070 Â Â Â 6,625 Â Payments for offering costs Â Â (113) Â Â (199) Repayment of finance lease liabilities Â Â (40) Â Â (41) Net cash provided by financing activities Â Â 14,123 Â Â Â 6,436 Â Effect of exchange rate changes on cash, cash equivalents and restricted cash Â Â (120) Â Â (532) NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND Â Â Â RESTRICTED CASH Â Â (7,686) Â Â 20,064 Â Â Â Â Â Â Â Â CASH, CASH EQUIVALENTS AND RESTRICTED CASH: Â Â Â Â Â Â At beginning of the period Â Â 35,992 Â Â Â 11,936 Â At end of the period Â $ 28,306 Â Â $ 32,000 Â Â Â Â Â Â Â Â SUPPLEMENTAL DISCLOSURES: Â Â Â Â Â Â Cash paid for interest Â $ 6 Â Â $ 8 Â Â Â Â Â Â Â Â SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND Â Â Â INVESTING ACTIVITIES: Â Â Â Â Â Â Property and equipment expenditures in accounts payable Â $ 11 Â Â $ 8 Â Â Â Â Â Â Â Â Reconciliation of cash, cash equivalents and restricted cash, end of period: Â Â Â Â Â Â Cash and cash equivalents Â $ 27,750 Â Â $ 31,474 Â Restricted cash included in deposits and other long-term assets Â Â Â (see Note 13 (Commitments and Contingencies)) Â Â 556 Â Â Â 526 Â Total cash, cash equivalents, and restricted cash Â $ 28,306 Â Â $ 32,000 Â Â See accompanying notes to the condensed consolidated interim financial statements. 10 Â LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) 1. Organization and Business OverviewWe are a clinical-stage biotechnology company developing novel allogeneic, or â€œoff-the-shelfâ€, cell therapies to address unmet medical needs. Our programs are based on our proprietary, cell-based technology platform, and associated development, formulation, delivery and manufacturing capabilities. From this platform, we design, develop, manufacture, and test specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. The cells we manufacture are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages which are relevant to the

underlying condition are transplanted into patients in an effort to (a) replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and (b) restore or augment the patientâ€™s functional activity.Our business strategy is to efficiently leverage our technology platform and our development and manufacturing capabilities to advance our programs internally or in conjunction with strategic partners to further enhance their value and probability of success.A significant area of focus is a collaboration we entered into with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (collectively or individually, â€œRocheâ€ or â€œGenentechâ€), under which our lead cell therapy program known as OpRegenÂ®, is being developed for the treatment of ocular disorders, including geographic atrophy (â€œGAâ€) secondary to age-related macular degeneration (â€œAMDâ€). OpRegen (also known as RG6501) is a suspension of human allogeneic retinal pigmented epithelial (â€œRPEâ€) cells and is currently being evaluated in a Phase 2a multicenter clinical trial in patients with GA secondary to AMD. OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. Under the terms of the Collaboration and License Agreement we entered into with Roche in December 2021 (the â€œRoche Agreementâ€), we received a $50.0 million upfront payment in January 2022 and are eligible to receive up to an additional $620.0 million in developmental, regulatory, and commercialization milestone payments. We also are eligible to receive tiered, double-digit-percentage royalties on net sales of OpRegen in the U.S. and other major markets. On May 7, 2024, we entered into a service agreement with Genentech pursuant to which we will provide supplemental clinical, technical, training, manufacturing, and procurement services to support the ongoing advancement and optimization of the OpRegen program. In September 2024, Roche and Genentech announced receipt of Regenerative Medicine Advanced Therapy (â€œRMATâ€) designation from the U.S. Food and Drug Administration (â€œFDAâ€) for OpRegen for the treatment of GA secondary to dry AMD.Our most advanced unpartnered product candidate is OPC1, an allogeneic oligodendrocyte progenitor cell therapy designed to improve recovery following a spinal cord injury (â€œSCIâ€). OPC1 has been tested in two clinical trials to date: a five patient Phase 1 clinical trial in acute thoracic SCI, where all subjects are followed for at least 10 years; and a 25 patient Phase 1/2a multicenter clinical trial in subacute cervical SCI, where all subjects were evaluated for at least two years. Results from both studies have been published in the Journal of Neurosurgery Spine. OPC1 clinical development has been supported in part by a $14.3 million grant from the California Institute for Regenerative Medicine (â€œCIRMâ€). We plan to apply for additional funding from CIRM for continued clinical development of OPC1 for the treatment of SCI. In December 2023, we filed an Investigational New Drug (â€œINDâ€) amendment for OPC1 as it relates to our proposed DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study, to evaluate the safety and utility of a novel spinal cord delivery device to administer OPC1 to the spinal parenchyma in subacute and chronic SCI patients. In March 2024, we received written correspondence from the FDA, advising us that due to significant workload and conflicting PDUFA priorities at the agency, its review of our IND amendment and the DOSED study protocol is still ongoing. Since that time we have been engaging with the FDA to aid in their review, including through an informal teleconference meeting with the CBER and CDRH divisions of the FDA held on November 12, 2024. Based on that discussion we plan to submit an additional amendment to the IND and final protocol with clarifying information to the FDA by the end of the year. We currently anticipate that the FDA will complete its review of this amendment in Q1 2025 and we do not expect any further feedback or additional information requests that would delay start of the study. We currently plan to commence enrolling the DOSED study as soon as feasible after submitting these updates. Our pipeline of allogeneic, or â€œoff-the-shelfâ€, cell therapy programs currently includes:â€¢RG6501 (OpRegen), an allogeneic RPE cell replacement therapy currently in a Phase 2a multicenter, open-label, single arm clinical trial, being conducted by Roche, for the treatment of GA secondary to AMD, also known as atrophic or dry AMD. â€¢OPC1, an allogeneic oligodendrocyte progenitor cell therapy which we plan to evaluate in the DOSED clinical study, to test the safety and utility of a novel spinal cord delivery device in both subacute and chronic spinal cord injuries and 11 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â continues to be evaluated in long-term follow-up from a Phase 1/2a multicenter clinical trial for subacute cervical spinal cord injuries. â€¢ANP1, an allogeneic auditory neuron progenitor cell transplant currently in preclinical development for the treatment of debilitating hearing loss.â€¢PNC1, an allogeneic photoreceptor cell transplant currently being developed for the treatment of vision loss due to photoreceptor dysfunction or damage.â€¢RND1, a novel, hypoimmune iPSCs line being developed in collaboration with Factor Bioscience Limited, as assignee from Eterna Therapeutics, Inc., which will be evaluated for differentiation into cell transplant product candidates for central nervous system diseases and other neurology indications.Other ProgramsWe have additional undisclosed product candidates being considered for development and we may consider others which cover a range of therapeutic areas and unmet medical needs. Generally, these product candidates are based on the same platform technology and employ a similar, guided cell differentiation and transplant approach as most of the product candidates described above, but in some cases may also include genetic modifications designed to enhance efficacy and/or safety profiles.In addition to seeking to create value for shareholders by developing product candidates and advancing those candidates through clinical development, we also may seek to create value from our intellectual property or related technologies and capabilities, through licensing collaborations and/or strategic transactions, such as our business development approach to our VAC dendritic cell therapy platform. 2. Basis of Presentation, Liquidity and Summary of Significant Accounting PoliciesThe accompanying unaudited condensed consolidated interim financial statements were prepared in accordance with generally accepted accounting principles in the United States (â€œGAAPâ€) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2023 10-K.The accompanying unaudited condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of our financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts in the condensed consolidated interim financial statements and accompanying notes have been reclassified to conform to the current period presentation. The reclassification of these items had no impact on net loss, net loss per share, financial position or cash flows in the current or prior periods. Specifically, our reclassifications are (i) operating lease right-of-use assets are now presented separately from property and equipment, net, on the condensed consolidated balance sheets, (ii) cost of sales are now included in operating expenses on the condensed consolidated statements of operations, and (iii) foreign currency transaction gains (losses) are now presented separately from other income (expenses) on the condensed consolidated statements of operations. 12 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â Principles of ConsolidationThe accompanying unaudited condensed consolidated interim financial statements include the accounts of our subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. The following table sets out Lineageâ€™s ownership, directly or indirectly, of the outstanding shares of its subsidiaries as of September 30, 2024:Â Subsidiary Â Field of Business Â Lineage Ownership Â Country Cell Cure Neurosciences Ltd. Â Manufacturing of Lineageâ€™s product candidates Â 94%(1) Â Israel ES Cell International Pte. Ltd. Â Research and clinical grade cell lines Â 100% Â Singapore Â (1)Includes shares owned by Lineage and ES Cell International Pte. Ltd.Lineage consolidates its direct and indirect wholly owned or majority-owned subsidiaries because Lineage has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholdersâ€™ equity on Lineageâ€™s condensed consolidated balance sheets.LiquidityAt September 30, 2024, we had $32.7 million of cash, cash equivalents and marketable securities. At September 30, 2024 and 2023, the Company had restricted cash of $0.1 million required to be set aside for its corporate credit card facility. Additionally, Cell Cure has restricted cash related to its lease. See Note 13 (Commitments and Contingencies). Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities, together with our projected cash flows, will be sufficient to enable us to carry out our planned operations through at least twelve months from the issuance date of the accompanying condensed consolidated interim financial statements.Capital ResourcesSince inception, we have incurred significant operating losses and have funded our operations primarily through the issuance of equity securities, the sale of common stock of our former subsidiaries, OncoCyte Corporation and AgeX Therapeutics, Inc., receipt of proceeds from research grants, revenues from collaborations, royalties from product sales, and sales of research products and services.As of September 30, 2024, $39.97 million remained available for sale under our at-the-market offering program (â€œATMâ€). See Note 10 (Shareholdersâ€™ Equity) for additional information.Additional Capital RequirementsOur financial obligations primarily consist of obligations to licensors under license agreements, obligations related to grants received from government entities, including the Israel Innovation Authority (â€œIIAâ€), obligations under contracts with vendors who provide research services and purchase commitments with suppliers.Our obligations to licensors under license agreements and our obligations related to grants received from government entities require us to make future payments, such as sublicense fees, milestone payments, redemption fees, royalty fees and patent maintenance fees. Sublicense fees are payable to licensors or government entities when we sublicense the applicable intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments, including those related to the Roche Agreement, are due to licensors or government entities upon achievement of commercial, development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of milestone payments and royalties received under the Roche Agreement. See Note 13 (Commitment and Contingencies) for additional information. Royalties, including those related to royalties we may receive under the Roche Agreement, are payable to licensors or government entities based on a percentage of net sales of licensed products. Patent maintenance costs are payable to licensors as reimbursement for the cost of maintaining license patents. Due to the contingent nature of the payments, the amounts and timing of payments to licensors under our in-license agreements are uncertain and may fluctuate significantly from period to period. As of September 30, 2024, we have not included these commitments on our condensed consolidated balance sheet because the achievement of events that would trigger our payment obligations and the timing thereof are not fixed and determinable. 13 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided.Significant Accounting PoliciesWe describe our significant accounting policies in Note 2 to the consolidated financial statements in Item 8 of the 2023 10-K. There have been no changes to our significant accounting policies during the nine months ended September 30, 2024.Recently Issued Accounting Pronouncements Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and does not believe any will have a material impact on the Companyâ€™s condensed consolidated interim financial statements or related financial statement disclosures.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 expands disclosures about a public entityâ€™s reportable segments and requires more enhanced information about a reportable segmentâ€™s expenses, interim segment profit or loss, and how a public entityâ€™s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. We are currently assessing the new guidance and we believe this will not have a significant impact on our consolidated financial statements.In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40): Disaggregation of Income Statement Expenses (â€œASU 2024-03â€). The purpose of ASU 2024-03 is to improve the disclosures about a public business entityâ€™s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development) ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently assessing the impact that this new guidance will have on our consolidated financial statements. Â 14 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â 3. RevenueOur disaggregated revenues were as follows for the periods presented (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues under collaborative agreements Â Upfront license fees (1) Â $ 3,386 Â Â $ 957 Â Â $ 5,671 Â Â $ 5,949 Â Total revenues under collaborative agreements Â Â 3,386 Â Â Â 957 Â Â Â 5,671 Â Â Â 5,949 Â Royalties, license and other revenues (2) Â Â 393 Â Â Â 289 Â Â Â 960 Â Â Â 908 Â Total revenue Â $ 3,779 Â Â $ 1,246 Â Â $ 6,631 Â Â $ 6,857 Â Â (1)All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement. (2)Included within royalties, license and other revenues recognized for the nine months ended September 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively.We are recognizing the $50.0 million upfront payment under the Roche Agreement utilizing an input method of costs incurred over total estimated costs to be incurred. At each reporting period, we update our total estimated collaboration costs, and any resulting adjustments are recorded on a cumulative basis which would affect revenue and deferred revenue in the period of adjustment. We believe the input methodology represents the most appropriate measure of progress towards satisfaction of the identified performance obligations.For contracts with customers including collaboration partners which are within the scope of Accounting Standards Update (â€œASUâ€) 2014-09 â€“ Revenue from Contracts with Customers (Topic 606), the aggregate amount of the transaction price allocated to remaining performance obligations as of September 30, 2024 was $28.1 million, of which $24.3 million is reported as deferred revenues. The $28.1 million is expected to be converted to revenue substantially by December 2026.Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts receivable, net - beginning of the year (1) Â $ 676 Â Â $ 297 Â Accounts receivable, net - end of the period (1) Â $ 392 Â Â $ 676 Â Contract liabilities (1) Â Â Â Â Â Â Â Deferred revenues - beginning of the year Â $ 29,501 Â Â $ 37,146 Â Deferred revenues - end of the period Â $ 24,300 Â Â $ 29,501 Â Â (1)Excludes grants receivable which are outside the scope of ASU 2014-09. 15 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â 4. Marketable SecuritiesThe following table summarizes the fair value of marketable securities held by the Company and their location in the Companyâ€™s condensed consolidated balance sheet (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Marketable debt securities Â Included within cash and cash equivalents (1) Â $ 7,332 Â Â $ 8,856 Â Included within marketable securities Â $ 4,949 Â Â $ â€” Â Marketable equity securities Â Included within marketable securities Â $ 12 Â Â $ 50 Â Â (1)Cash equivalents have an original maturity of three months or less when purchased. Marketable Debt SecuritiesThe following table summarizes the available-for-sale debt securities classified within cash and cash equivalents and within marketable securities in the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024 and December 31, 2023 (in thousands):Â Â Â September 30, 2024 Â Financial Assets: Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Fair Value Â U.S. Treasury securities Â $ 12,274 Â Â $ 7 Â Â $ â€” Â Â $ 12,281 Â Total Â $ 12,274 Â Â $ 7 Â Â $ â€” Â Â $ 12,281 Â Â Â Â Â December 31, 2023 Â Financial Assets: Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Fair Value Â U.S. Treasury securities Â $ 8,855 Â Â $ 1 Â Â $ â€” Â Â $ 8,856 Â Total Â $ 8,855 Â Â $ 1 Â Â $ â€” Â Â $ 8,856 Â Â The Company has not recognized an allowance for credit losses on any securities in an unrealized loss position as of September 30, 2024 or December 31, 2023. The Company believes that any individual unrealized losses represent temporary declines resulting from changes in interest rates, and we intend to hold these marketable debt securities to their maturity. As of September 30, 2024, the amortized cost and estimated fair value of the Companyâ€™s available-for-sale debt securities by contractual maturity are shown below (in thousands):Â Available-for-sale debt securities maturing: Â Amortized Cost Â Â Estimated Fair Value Â In one year or less Â $ 12,274 Â Â $ 12,281 Â Total available-for-sale debt securities Â $ 12,274 Â Â $ 12,281 Â Â Marketable Equity SecuritiesMarketable equity securities are reported at fair value with unrealized gains and losses related to

mark-to-market adjustments included in income. Lineageâ€™s marketable equity securities have consisted of shares of common stock of OncoCyte Corporation (â€œOCXâ€) and of Hadasit Bio-Holdings Ltd. (â€œHBLâ€). All share prices are determined based on the closing price of OCX and HBL common stock on the last trading day of the applicable quarter. Subsequent to June 30, 2024, Lineage no longer owned any shares of OCX. 16 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â The following table represents the realized and unrealized (loss) gain on marketable equity securities for the periods presented (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Loss on marketable equity securities, net Â $ (6) Â $ (60) Â $ (21) Â $ (170) Less: Loss recognized in earnings on marketable equity Â Â Â securities sold Â Â â€” Â Â Â 23 Â Â Â 4 Â Â Â 23 Â Unrealized loss recognized on marketable equity Â Â Â securities held at end of period, net Â $ (6) Â $ (37) Â $ (17) Â $ (147) Â 5. Property and Equipment, NetProperty and equipment, including finance leases, are stated at cost, net of accumulated depreciation and amortization. The cost of property and equipment is depreciated or amortized using the straight-line method over the estimated useful life of the asset, ranging from 3 to 10 years. Finance lease right-of-use assets are amortized over the lease term. Leasehold improvements are amortized over the shorter of the useful life or the lease term.At September 30, 2024 and December 31, 2023, property and equipment, net was comprised of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Equipment, furniture and fixtures Â $ 3,742 Â Â $ 3,614 Â Leasehold improvements Â Â 2,262 Â Â Â 2,313 Â Right-of-use assets - finance lease Â Â 202 Â Â Â 198 Â Accumulated depreciation and amortization Â Â (4,193) Â Â (3,880) Property and equipment, net Â $ 2,013 Â Â $ 2,245 Â Â Depreciation and amortization expense was $141,000 and $143,000 for the three months ended September 30, 2024 and 2023, respectively, and $436,000 and $419,000 for the nine months ended September 30, 2024 and 2023, respectively. These amounts include amortization expense for right-of-use finance lease assets of $13,000 and $14,000 for the three months ended September 30, 2024 and 2023, respectively, and $41,000 and $37,000 for the nine months ended September 30, 2024 and 2023, respectively. 17 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â 6. Goodwill and Intangible Assets, NetAt September 30, 2024 and December 31, 2023, goodwill and intangible assets, net consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Goodwill (1) Â $ 10,672 Â Â $ 10,672 Â Â Â Â Â Â Â Â Intangible assets: Â Â Â Â Â Â Acquired IPR&D â€“ OPC1 (from the Asterias Merger) (2) Â $ 31,700 Â Â $ 31,700 Â Acquired IPR&D â€“ VAC (from the Asterias Merger) (2) Â Â 14,840 Â Â Â Â 14,840 Â Intangible assets subject to amortization: Â Â Â Â Â Â Acquired patents Â Â 18,953 Â Â Â 18,953 Â Acquired royalty contracts (3) Â Â 650 Â Â Â 650 Â Total intangible assets Â Â 66,143 Â Â Â 66,143 Â Accumulated amortization (4) Â Â (19,603) Â Â (19,581) Intangible assets, net Â $ 46,540 Â Â $ 46,562 Â Â (1)Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitments and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment.(2)Asterias had two in-process research and development ("IPR&D") intangible assets that were valued at $46.5 million as part of the purchase price allocation that was performed in connection with the Asterias Merger. The fair value of these assets at the acquisition date consisted of $31.7 million pertaining to the OPC1 program and $14.8 million pertaining to the VAC platform.(3)Asterias had royalty cash flows under patent families it acquired from Geron Corporation. Such patent families are expected to continue to generate revenue, are not used in the OPC1 or the VAC platform, and are considered to be separate long-lived intangible assets under ASC Topic 805, Business Combinations.(4)The acquired patents and acquired royalty contracts were fully amortized as of the end of the first quarter of 2024.Lineage amortizes its intangible assets over an estimated period of 5 to 10 years on a straight-line basis. Lineage recognized $0 and $33,000 in amortization expense of intangible assets during the three months ended September 30, 2024 and 2023, respectively, and $22,000 and $98,000 during the nine months ended September 30, 2024 and 2023, respectively. 7. Accounts Payable and Accrued LiabilitiesAt September 30, 2024 and December 31, 2023, accounts payable and accrued liabilities consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts payable Â $ 1,599 Â Â $ 2,050 Â Accrued compensation Â Â 2,494 Â Â Â 3,123 Â Accrued liabilities Â Â 384 Â Â Â 1,097 Â Total Â $ 4,477 Â Â $ 6,270 Â Â 8. Fair Value MeasurementsFair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value in accordance with ASC 820-10-50, Fair Value Measurements and Disclosures:â€¢Level 1 â€“ Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.â€¢Level 2 â€“ Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. 18 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â â€¢Level 3 â€“ Inputs to the valuation methodology that are unobservable. Unobservable inputs are those in which little or no market data exists, reflect those that a market participant would use, and are therefore determined using estimates and assumptions developed by the Company.We have not transferred any instruments between the three levels of the fair value hierarchy. The carrying value of cash, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate their respective fair values due to their relative short maturities. We measure our cash equivalents and marketable securities at fair value on a recurring basis. The fair values of such assets were as follows as of September 30, 2024 and December 31, 2023 (in thousands):Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Balance at September 30, 2024 Â Â Quoted Prices in Active Markets for Identical Assets (Level 1) Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Money market fund (1) Â $ 14,466 Â Â $ 14,466 Â Â $ â€” Â Â $ â€” Â Marketable debt securities (1) Â Â 7,332 Â Â Â 7,332 Â Â Â â€” Â Â Â â€” Â Marketable debt securities Â Â 4,949 Â Â Â 4,949 Â Â Â â€” Â Â Â â€” Â Marketable equity securities (2) Â Â 12 Â Â Â 12 Â Â Â â€” Â Â Â â€” Â Total assets measured at fair value Â $ 26,759 Â Â $ 26,759 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Balance at December 31, 2023 Â Â Quoted Prices in Active Markets for Identical Assets (Level 1) Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Money market fund (1) Â $ 21,029 Â Â $ 21,029 Â Â $ â€” Â Â $ â€” Â Marketable debt securities (1) Â Â 8,856 Â Â Â 8,856 Â Â Â â€” Â Â Â â€” Â Marketable equity securities (2) Â Â 50 Â Â Â 50 Â Â Â â€” Â Â Â â€” Â Total assets measured at fair value Â $ 29,935 Â Â $ 29,935 Â Â $ â€” Â Â $ â€” Â Â (1)Included in cash and cash equivalents in the accompanying condensed consolidated balance sheet. Marketable debt securities purchased with an original maturity of three months or less have been classified as cash equivalents. (2)Lineageâ€™s marketable equity securities include the shares of stock of OCX and HBL. Both securities have readily determinable fair values quoted on the NASDAQ or TASE (Level 1). These securities are measured at fair value and reported as current assets on the accompanying condensed consolidated balance sheets based on the closing trading price of the security as of the date being presented. Subsequent to June 30, 2024, Lineage no longer owned any shares of OCX. 9. Related Party TransactionsIn connection with the putative shareholder class action lawsuits filed in February 2019 and October 2019 challenging the Asterias Merger (see Note 13 (Commitments and Contingencies)), Lineage agreed to pay the expenses for the legal defense of Neal Bradsher, a member of the Lineage board of directors, Broadwood Partners, L.P., a shareholder of Lineage and an affiliate of Mr. Bradsher, and Broadwood Capital, Inc., which serves as the general partner of Broadwood Partners, L.P., all of whom were named defendants in the lawsuits, prior to being dismissed. From inception of the matter through July 2023, Lineage incurred approximately $626,000 in legal expenses on behalf of the foregoing parties, and since then Lineage has not incurred any additional such expenses.On February 6, 2024, Lineage entered into a stock purchase agreement with certain investors relating to the purchase and sale in a registered direct offering of an aggregate of 13,461,540 of Lineageâ€™s common shares. The offering price was $1.04 per common share. The offering closed on February 8, 2024. Broadwood Partners, L.P. purchased 6,730,770 common shares in the offering and Don Bailey, a member of Lineageâ€™s board of directors, purchased 96,155 shares in the offering. 19 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â 10. Shareholdersâ€™ EquityPreferred SharesLineage is authorized to issue 2,000,000 preferred shares, no par value. The preferred shares may be issued in one or more series as the Lineage board of directors may determine by resolution. The Lineage board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The Lineage board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. As of September 30, 2024 and December 31, 2023, there were no preferred shares issued or outstanding.Common SharesAt December 31, 2022, Lineage was authorized to issue 250,000,000 common shares, no par value. In September 2023, our shareholders approved an increase in the number of authorized common shares, no par value, from 250,000,000 to 450,000,000. As of September 30, 2024 and December 31, 2023, there were 188,837,375 and 174,986,671 common shares issued and outstanding, respectively.At-The-Market Offering ProgramIn May 2020, Lineage entered into a Controlled Equity OfferingSM Sales Agreement (the â€œPrior Sales Agreementâ€) with Cantor Fitzgerald & Co., as sales agent, pursuant to which Lineage could sell its common shares from time to time through an ATM program.In December 2021, Lineage filed a prospectus supplement with the SEC in connection with the offer and sale of up to $64.1 million of common shares through the ATM program under the Prior Sales Agreement, which was updated, amended and supplemented by a prospectus supplement filed with the SEC on May 18, 2023 (the prospectus supplement filed in December 2021, as updated, amended and supplemented by the prospectus supplement filed in May 2023, the â€œPrior Prospectus Supplementâ€).In March 2024, Lineage terminated the Prior Sales Agreement and entered into a sales agreement (the â€œATM Sales Agreementâ€) with B. Riley Securities, Inc., as sales agent (â€œSales Agentâ€), under which Lineage may offer and sell its common shares from time to time through an ATM program.In March 2024, Lineage filed a prospectus supplement with the SEC in connection with the offer and sale of $40.00 million of common shares through the ATM program under the ATM Sales Agreement which was updated, amended and supplemented by a prospectus supplement filed with the SEC on May 14, 2024 in connection with the offer and sale of $39.97 million of common shares through the ATM program under the ATM Sales Agreement (the prospectus supplement filed in March 2024, as updated, amended and supplemented by the prospectus supplement filed in May 2024, the â€œ2024 Prospectus Supplementâ€). Prior to its termination in March 2024, Lineage had sold 4,912,803 common shares under the Prior Prospectus Supplement at a weighted average price per share of $1.41 for gross proceeds of $6.9 million. During the three months ended March 31, 2024, Lineage sold 30,000 common shares under the Prior Prospectus Supplement at a weighted average price per share of $1.23 for gross proceeds of $37,000. During the three months ended June 30, 2024, Lineage sold 25,830 common shares under the 2024 Prospectus Supplement at a weighted average price per share of $1.30 for gross proceeds of $33,000. Lineage did not sell any common shares under the 2024 Prospectus Supplement during the three months ended September 30, 2024. As of September 30, 2024, $39.97 million remained available for sale under the 2024 Prospectus Supplement. The shares offered under the 2024 Prospectus Supplement are registered pursuant to Lineageâ€™s effective shelf registration statement on Form S-3 (File No. 333-277758), which was filed with the SEC on March 7, 2024 and declared effective on May 14, 2024.Lineage agreed to pay Sales Agent a commission of up to 3.0% of the aggregate gross proceeds from the sale of shares under the ATM Sales Agreement, reimburse its legal fees and disbursements, and provide Sales Agent with customary indemnification and contribution rights. The Sales Agreement may be terminated by Sales Agent or Lineage at any time upon notice to the other party, or by Sales Agent at any time in certain circumstances, including the occurrence of a material and adverse change in Lineageâ€™s business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. 20 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â 11. Stock-Based AwardsEquity Incentive Plan AwardsIn September 2021, our shareholders approved the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan, and in September 2023, our shareholders approved an amendment to increase the number of common shares that may be issued thereunder by 19,500,000 (as amended to date, the â€œ2021 Planâ€). The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units ("RSUs"), and other stock awards. All of our employees (including those of our affiliates), non-employee directors and consultants are eligible to participate in the 2021 Plan. Subject to adjustment for certain changes in our capitalization, the aggregate number of our common shares that may be issued under the 2021 Plan will not exceed the sum of (i) 34,500,000 shares and (ii) the number of shares subject to awards granted under the Lineage Cell Therapeutics Inc. 2012 Equity Incentive Plan (the â€œ2012 Planâ€) that were outstanding when the 2021 Plan became effective and are not issued because such awards expire or otherwise terminate. As a result of the approval of the 2021 Plan by our shareholders, no additional awards will be granted under the 2012 Plan. As of September 30, 2024, there were 21,727,737 shares available for grant under the 2021 Plan.A summary of activity under the 2021 Plan is as follows (in thousands, except per share amounts):Â Â Â Number of Options Outstanding(in thousands) Â Â Weighted Average Exercise Price(per share) Â Â Weighted Average RemainingContractualTerm (years) Â Â Aggregate Intrinsic Value(in thousands) Â Balance at December 31, 2023 Â Â 10,824 Â Â $ 1.42 Â Â Â 8.63 Â Â $ 4 Â Options granted Â Â 6,567 Â Â $ 1.11 Â Â Â Â Â Â Â Options exercised Â Â (20) Â $ 1.40 Â Â Â Â Â Â Â Options expired/forfeited/cancelled Â Â (563) Â $ 1.37 Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 16,808 Â Â $ 1.30 Â Â Â 8.45 Â Â $ 1 Â Options exercisable at September 30, 2024 Â Â 5,492 Â Â $ 1.42 Â Â Â 7.57 Â Â $ â€” Â Options exercisable and expected to vest Â Â Â Â Â at September 30, 2024 Â Â 16,808 Â Â $ 1.30 Â Â Â 8.45 Â Â $ 1 Â Â Â Â Â Number of RSUs Outstanding Â Â WeightedAverage GrantDate Fair Valueper Share Â Balance at December 31, 2023 Â Â 668 Â Â $ 1.11 Â RSUs forfeited Â Â (100) Â $ 0.21 Â RSUs vested Â Â (67) Â $ 1.50 Â Balance at September 30, 2024 Â Â 501 Â Â $ 1.24 Â Â A summary of activity of the 2012 Plan, and the 2018 inducement option (which was issued to a Lineage executive outside of all equity plans), is as follows (in thousands, except per share amounts):Â Â Â Number of Options Outstanding(in thousands) Â Â Weighted Average Exercise Price(per share) Â Balance at December 31, 2023 Â Â 10,839 Â Â $ 1.83 Â Options exercised Â Â (267) Â $ 0.75 Â Options expired/forfeited/cancelled Â Â (504) Â $ 2.15 Â Balance at September 30, 2024 Â Â 10,068 Â Â $ 1.84 Â Options exercisable at September 30, 2024 Â Â 9,589 Â Â $ 1.81 Â Â 21 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â Stock-Based Compensation ExpenseOperating expenses within the condensed consolidated statements of operations include stock-based compensation expense as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 172 Â Â $ 260 Â Â $ 476 Â Â $ 729 Â General and administrative Â Â 1,158 Â Â Â 1,009 Â Â Â 3,286 Â Â Â 2,851 Â Total stock-based compensation expense Â $ 1,330 Â Â $ 1,269 Â Â $ 3,762 Â Â $ 3,580 Â Â As of September 30, 2024, total unrecognized compensation costs related to unvested stock options and unvested RSUs under all equity plans, was $9.5 million, which is expected to be recognized as expense over a weighted average period of approximately 2.6 years for stock options and 1.3 years for RSUs. Basic and Diluted Net Income (Loss) per Share Attributable to Common ShareholdersBasic earnings per share is calculated by dividing net income or loss attributable to Lineage common shareholders by the weighted average number of common shares outstanding, net of stock options and RSUs, subject to repurchase by Lineage, if any, during the period. Diluted earnings per share is calculated by dividing the net income or loss attributable to Lineage common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under any outstanding stock options, RSUs, warrants (using the treasury-stock method), or convertible preferred stock (using the if-converted method).For the three and nine months ended September 30, 2024 and 2023, Lineage reported a net loss attributable to common shareholders, and therefore, all potentially dilutive common shares were considered antidilutive for those periods.The following common share equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive (in thousands):Â Â Â Three and Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 26,876 Â Â Â 23,168 Â Restricted stock units Â Â 501 Â Â Â 759 Â Â 22 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â 12. Income TaxesThe provision for income taxes for interim periods is generally determined using an estimated annual effective tax rate as prescribed by ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances and changes in valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Lineage conducts business. ASC 740-270 also states that if an entity is unable to reliably estimate some or a part of its ordinary income or loss, the income tax provision or benefit applicable to the item that cannot be estimated shall be reported in the interim period in which the item is reported. For items that Lineage cannot

reliably estimate on an annual basis, Lineage uses the actual year to date effective tax rate rather than an estimated annual effective tax rate to determine the tax effect of each item, including the use of all available net operating losses and other credits or deferred tax assets.Under ASC 740, a valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Lineage established a full valuation allowance as of December 31, 2018 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by its subsidiaries.For the tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 (â€œTCJAâ€) eliminated the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement for research activities performed in the United States, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it will decrease our tax deduction for research and development expenses in future years.The 2017 Tax Act subjects a U.S. stockholder to Global Intangible Low-Taxed Income (â€œGILTIâ€) earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. stockholderâ€™s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI: however, this deduction is limited to the companyâ€™s pre-GILTI U.S. income. For the three and nine months ended September 30, 2024, no GILTI was included in the Companyâ€™s tax provision; any GILTI incurred would be fully offset by net operating loss carryforwards. For the three and nine months ended September 30, 2023, Lineage incurred GILTI which was fully offset by net operating loss carryforwards. Lineage did not record a deferred tax benefit or provision expense for the three or nine months ended September 30, 2024 or for the three months ended September 30, 2023. For the first quarter of 2023, Lineage recorded a $1.8 million deferred tax benefit, due to the ability to offset certain deferred tax assets against the deferred tax liability associated with IPR&D, and the related release of the valuation allowance. It was determined that a portion of the deferred tax liability related to the indefinite lived assets may be realized prior to the expiration of certain pre 2018 net operating losses. 13. Commitments and ContingenciesReal Property LeasesCarlsbad LeaseIn May 2019, Lineage entered into a lease for approximately 8,841 square feet of rentable space in an office park in Carlsbad, California. The lease was amended in December 2022, and the term was extended for a period of thirty-seven months (the â€œExtended Termâ€) commencing on March 1, 2023 (the â€œExtended Term Commencement Dateâ€). Monthly base rent for the first twelve months of the Extended Term was $25,200, and is subject to 3% annual increases. Rent was abated for months two through four of the Extended Term. As security for the performance of its obligations under the lease, Lineage provided the landlord a security deposit of $17,850, which is included in deposits and other long-term assets on the condensed consolidated balance sheet as of September 30, 2024.In addition to base rent, Lineage pays a pro-rata portion of increases in certain expenses, including real property taxes, utilities (to the extent not separately metered to the leased space) and the landlordâ€™s operating expenses, over the amounts of those expenses incurred by the landlord. These pro-rata charges are expensed as incurred and excluded from the calculation of the right-of-use (â€œROUâ€) assets and lease liabilities. 23 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â Carlsbad SubleaseIn September 2022, Lineage entered into a sublease for approximately 4,500 square feet of rentable industrial space in Carlsbad, California for a term that commenced on October 1, 2022 and was originally set to expire on March 31, 2024. In February 2024, Lineage extended the term of the sublease for 24 months through March 31, 2026 on similar terms. During the extension period, the base rent is $23,000 per month for the first twelve months and will increase to $23,500 for the remaining twelve months. As security for the performance of its obligations under the sublease, Lineage provided the landlord with a security deposit of $22,500, which is included in deposits and other long-term assets on the condensed consolidated balance sheet as of September 30, 2024. Cell Cure LeaseAs of September 30, 2024, Cell Cure leases approximately 2,096 square meters (approximately 22,600 square feet) of combined office and laboratory space in Jerusalem, Israel under a master lease, as amended, that expires December 31, 2027. Cumulative base rent and construction allowance payments are approximately 165,000 Israeli New Shekels (â€˜ILSâ€) per month (approximately $44,000 as of September 30, 2024), excluding any future rent escalations, and includes options to extend the lease term for five years. The U.S. dollar value of the ILS denominated base rent and construction allowance payments fluctuates based upon currency exchange rates. In addition to base rent, Cell Cure pays a pro-rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located, including parking usage fees. These pro-rata charges are expensed as incurred and excluded from the calculation of the ROU assets and lease liabilities. Cell Cure has security deposits denominated in ILS with the landlord for this master lease held as restricted cash during the term the lease. The U.S. dollars value of the ILS denominated security deposits fluctuates based upon currency exchange rates and was $456,000 as of September 30, 2024, which is included in deposits and other long-term assets on the condensed consolidated balance sheet.Supplemental Information â€“ LeasesSupplemental cash flow information related to leases is as follows (in thousands):Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for amounts included in the measurement of Â Â Â lease liabilities: Â Â Â Â Â Â Operating cash flows from operating leases Â $ 913 Â Â $ 833 Â Operating cash flows from finance leases Â $ 6 Â Â $ 8 Â Financing cash flows from finance leases Â $ 40 Â Â $ 41 Â Â Â Â Â Â Â Â Right-of-use assets obtained in exchange for lease obligations: Â Â Â Â Â Â Operating leases Â $ 597 Â Â $ â€” Â Finance leases Â $ 36 Â Â $ 79 Â Â 24 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Operating leases Â Â Â Â Â Â Right-of-use assets Â $ 2,362 Â Â $ 2,522 Â Â Â Â Â Â Â Â Â Right-of-use lease liabilities, current Â $ 1,083 Â Â $ 830 Â Right-of-use lease liabilities, noncurrent Â Â 1,533 Â Â Â 1,979 Â Total operating lease liabilities Â $ 2,616 Â Â $ 2,809 Â Â Â Â Â Â Â Â Finance leases Â Â Â Â Â Â Right-of-use assets Â $ 202 Â Â $ 198 Â Accumulated amortization Â Â (74) Â Â (67) Right-of-use assets, net Â $ 128 Â Â $ 131 Â Â Â Â Â Â Â Â Â Right-of-use lease liabilities, current Â $ 54 Â Â $ 52 Â Right-of-use lease liabilities, noncurrent Â Â 80 Â Â Â 91 Â Total finance lease liabilities Â $ 134 Â Â $ 143 Â Â Â Â Â Â Â Â Â Weighted average remaining lease term Â Â Â Â Â Â Operating leases Â 2.7Â years Â Â 3.5Â years Â Finance leases Â 2.6Â years Â Â 3.0Â years Â Â Â Â Â Â Â Weighted average discount rate Â Â Â Â Â Â Operating leases Â Â 6.3 % Â Â 6.5 % Finance leases Â Â 7.0 % Â Â 6.9 % Â Future minimum lease commitments are as follows as of September 30, 2024 (in thousands):Â Â Â Operating Leases Â Â Finance Leases Â Year Ending December 31, Â Â Â Â Â Â Â 2024 Â $ 293 Â Â $ 16 Â 2025 Â Â 1,165 Â Â Â 64 Â 2026 Â Â 730 Â Â Â 39 Â 2027 Â Â 677 Â Â Â 28 Â Total lease payments Â Â 2,865 Â Â Â 147 Â Less imputed interest Â Â (249) Â Â (13) Total Â $ 2,616 Â Â $ 134 Â Â Operating lease expense was $0.3 million and $0.9 million for each of the three and nine months ended September 30, 2024 and 2023, respectively.CollaborationsRoche AgreementIn December 2021, Lineage entered into the Roche Agreement, wherein Lineage granted to Roche exclusive worldwide rights to develop and commercialize RPE cell therapies, including Lineageâ€™s proprietary cell therapy known as OpRegen, for the treatment of ocular disorders, including GA secondary to AMD.Under the terms of the Roche Agreement, Roche paid Lineage a $50.0 million upfront payment and Lineage is eligible to receive up to an additional $620.0 million in developmental, regulatory and commercialization milestone payments. Lineage also is eligible for tiered, double-digit-percentage royalties on net sales of OpRegen in the U.S. and other major markets. All regulatory and commercial milestone payments and royalty payments are subject to the existence of certain intellectual property rights that cover OpRegen at the time such payments would otherwise become due, and the royalty payments on net sales of OpRegen are subject to financial offsets based on the existence of competing products. Roche assumed responsibility for further clinical development and commercialization of 25 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â OpRegen. Lineage is responsible for completing activities related to the ongoing clinical study, for which enrollment is complete, and performing certain manufacturing and process development activities.Unless earlier terminated by either party, the Roche Agreement will expire on a product-by-product and country-by-country basis upon the expiration of all of Rocheâ€™s payment obligations under the agreement. Roche may terminate the agreement in its entirety, or on a product-by-product or country-by-country basis, at any time with advance written notice. Either party may terminate the agreement in its entirety with written notice for the other partyâ€™s material breach if such party fails to cure the breach or upon certain insolvency events involving the other party.In January 2022, Lineage received the $50.0 million upfront payment from Roche. Subsequently, Lineage, via Cell Cure, paid $12.1 million to the IIA, and $8.9 million to Hadasit Medical Research Services and Development Ltd. (â€œHadasitâ€). Such payments were made in accordance with obligations under the Innovation Law (as discussed below) and under the terms of Cell Cureâ€™s agreements with Hadasit (as discussed below). The payment obligation to Hadasit was reduced by $1.9 million in accordance with the provisions of such agreements discussed below that reduce the sublicensing fee payable to Hadasit for costs related to Lineageâ€™s performance obligations under the Roche Agreement. To the extent such costs are not incurred within five years after the execution of the Roche Agreement, Cell Cure will be required to pay Hadasit 21.5% of the amount of costs not incurred.ITI Collaboration AgreementIn April 2021, Lineage entered into a collaborative agreement with Immunomic Therapeutics, Inc. (â€œITIâ€) whereby Lineage agreed to perform up to approximately $2.2 million worth of certain research, development, manufacturing, and oversight activities related to the development of an allogeneic VAC-CMV product candidate. ITI will reimburse Lineage for these costs and full-time employee costs for the manufacturing of the VAC-CMV product candidate. As of September 30, 2024, Lineage has a remaining performance obligation of approximately $1.6 million for the aforementioned activities. Upon execution of the agreement in April 2021, $0.5 million was paid by ITI to Lineage. Upon delivery of research-grade VAC-CMV product generated by Lineage, ITI paid an additional $0.5 million in August 2021. ITI is currently evaluating its next step under the agreement.Agreements with Hadasit and IIAThe OpRegen program was supported in part with licenses to technology obtained from Hadasit, the technology transfer company of Hadassah Medical Center, and through a series of research grants from the IIA, an independent agency created to address the needs of global innovation ecosystems. A subset of the intellectual property underlying OpRegen was originally generated at Hadassah Medical Center and licensed to Cell Cure for further development.Under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744, and the regulations, guidelines, rules, procedures and benefit tracks thereunder (collectively, the â€œInnovation Lawâ€), annual research and development programs that meet specified criteria and were approved by a committee of the IIA were eligible for grants. The grants awarded were typically up to 50% of the projectâ€™s expenditures, as determined by the IIA committee and subject to the benefit track under which the grant was awarded.The terms of the grants under the Innovation Law generally require that the products developed as part of the programs under which the grants were given be manufactured in Israel. The know-how developed thereunder may not be transferred outside of Israel unless prior written approval is received from the IIA. Transfer of IIA-funded know-how outside of Israel is subject to approval and payment of a redemption fee to the IIA calculated according to formulas provided under the Innovation Law. In November 2021, the IIA research committee approved an application made by Cell Cure with respect to the grant of an exclusive license and transfer of the technological know-how for OpRegen to Roche. Under the provisions for the redemption fee, Lineage paid the IIA approximately 24.1% of the upfront payment it received under the Roche Agreement, or $12.1 million, and is obligated to pay the IIA approximately 24.1% of any milestone and royalty payments which may be received under the Roche Agreement, up to an aggregate cap on all payments, such cap growing over time via interest accrual until paid in full. As of September 30, 2024, the aggregate cap amount was approximately $94.8 million.Pursuant to the Second Amended and Restated License Agreement, dated June 15, 2017, between Cell Cure and Hadasit, and a certain letter agreement entered into on December 17, 2021, Cell Cure paid a sublicensing fee to Hadasit of $8.9 million or 21.5% of the $50.0 million upfront payment under the Roche Agreement (subject to certain reductions), and Cell Cure is obligated to pay Hadasit 26 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â (i) a maximum of 21.5% of all milestone payments Lineage receives under the Roche Agreement (subject to certain reductions, including for costs related to Lineageâ€™s performance obligations under the Roche Agreement), and (ii) up to 50% of all royalty payments (subject to a maximum payment of 5% of net sales of products), Lineage receives under the Roche Agreement. The letter agreement generally terminates upon the termination of the Roche Agreement.Second Amendment to Clinical Trial and Option Agreement and License Agreement with Cancer Research UKIn May 2020, Lineage and Asterias entered into a Second Amendment to the Clinical Trial and Option Agreement (the â€œSecond CTOA Amendmentâ€) with CRUK and Cancer Research Technology (â€œCRTâ€). The Second CTOA Amendment amended the initial agreement and the first amendment to the Clinical Trial and Option Agreement, each of which is dated September 8, 2014, between Asterias, CRUK and CRT. Pursuant to the Second CTOA Amendment, Lineage assumed all obligations of Asterias and exercised early its option to acquire data generated in the Phase 1 clinical trial of VAC2 in non-small cell lung cancer being conducted by CRUK.Lineage and CRT effectuated the option by simultaneously entering into a license agreement (the â€œCRT License Agreementâ€) pursuant to which Lineage paid a signature fee of Â£1,250,000 (approximately $1.6 million based upon exchange rates in effect when the fee was paid). For the primary licensed product for the first indication, the CRT License Agreement provides for milestone fees of up to Â£8,000,000 based upon initiation of a Phase 3 clinical trial and the filing for regulatory approval and up to Â£22,500,000 in sales-based milestones payments. Additional milestone fees and sales-based milestone payments would be payable for other products or indications, and mid-single-digit royalty payments are payable on sales of commercial products.Either party may terminate the CRT License Agreement for the uncured material breach of the other party. CRT may terminate the CRT License Agreement in the case of Lineageâ€™s insolvency or if Lineage ceases all development and commercialization of all products under the CRT License Agreement.Other Contingent ObligationsWe have obligations under license agreements and grants received from government entities to make future payments to third parties, which become due and payable on the achievement of certain development, regulatory and commercial milestones or on the sublicense of our rights to another party. These commitments include sublicense fees, milestone payments, redemption fees and royalties. Sublicense fees are payable to licensors or government entities when we sublicense underlying intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments are due to licensors or government entities upon the future achievement of certain development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of any milestone or royalty payment received in respect of IIA-funded programs. Royalties are payable to licensors or government entities based on a percentage of net sales of licensed products. As of September 30, 2024, we have not included these commitments on our condensed consolidated balance sheet because the achievement and timing of these events are not fixed and determinable.Litigation â€“ GeneralFrom time to time, we are subject to legal proceedings and claims in the ordinary course of business. While management presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, cash flows, or overall trends in results of operations, legal proceedings are subject to inherent uncertainties, and unfavorable rulings or outcomes could occur that have individually or in aggregate, a material adverse effect on our business, financial condition or operating results. We are not currently subject to any pending material litigation, other than ordinary routine litigation incidental to our business.Asterias MergerIn November 2018, Lineage, Asterias Biotherapeutics, Inc. (â€œAsteriasâ€), and Patrick Merger Sub, Inc., a wholly owned subsidiary of Lineage, entered into an Agreement and Plan of Merger pursuant to which Lineage agreed to acquire all of the outstanding common stock of Asterias in a stock-for-stock transaction (the â€œAsterias Mergerâ€). The Asterias Merger closed in March 2019. In October 2019, a putative class action lawsuit was filed against the company and certain other named defendants challenging the Asterias Merger.In February 2023, the court approved a Stipulation and Agreement of Compromise and Settlement pursuant to which, Lineage and certain insurers of the defendants paid $10.65 million (the â€œSettlement Amountâ€) into a fund created for the benefit of the purported 27 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â class and in consideration for the full and final release, settlement and discharge of all claims. Approximately $7.12 million of the Settlement Amount was funded by certain insurers and approximately $3.53 million was paid by Lineage during the first quarter of 2023.Lineage and all defendants have denied, and continue to deny, the claims alleged in the lawsuit and the settlement does not reflect or constitute any admission, concession, presumption, proof, evidence or finding of any liability, fault, wrongdoing or injury or damages, or of any wrongful conduct, acts or omissions on the part any defendant.Premvia Litigation SettlementIn July 2019, the Company, along with other named defendants, was sued in the Superior Court of the State of California in a matter captioned Gonzalez v. Aronowitz, M.D., et al. The plaintiff asserted medical negligence and product liability causes of action relating to the 2017 and 2018 use in a clinical trial of a product candidate, Premvia, that the Company is no longer developing and has no plans to pursue, and that is not related to the cell therapy candidates the Company currently is developing. In February 2023, the Company and the other defendants each entered into settlement agreements with the plaintiff pursuant to which the defendants without admitting any liability, which the defendants expressly denied, each agreed to pay specified amounts to the plaintiff in exchange for a full settlement and release and discharge of claims. The Companyâ€™s insurance covered the full amount paid by the Company excluding the $25,000 insurance deductible.HBL Books and Records RequestOn April 17, 2023, Cell Cure

received a motion for disclosure of documents pursuant to Section 198A of the Israeli Companies Law 5759-1999. The motion was filed in the district court in Tel Aviv-Yafo (the â€œCourtâ€) by HBL Hadasit Bio-Holdings Ltd. (â€œHBLâ€), currently an approximately 5% shareholder of Cell Cure. According to the motion, the requested production of documents is intended to allow HBL to examine the possibility of pursuing a derivative action related to, among other things, the validity of an intercompany Collaboration and License Agreement (the â€œIntercompany Agreementâ€) entered into between Lineage and Cell Cure pursuant to which Cell Cure conveyed certain rights and other assets to Lineage, and Lineage agreed to undertake certain liabilities and obligations of Cell Cure relating to the OpRegen program. In its motion, HBL alleges, among other things, that Lineage, in its capacity as Cell Cureâ€™s controlling shareholder, and members of Cell Cureâ€™s board of directors caused damage to Cell Cure because the Intercompany Agreement was an interested party transaction that was not fairly priced and exploits Cell Cureâ€™s resources for the benefit of Lineage. The motion seeks an order to compel Cell Cure to disclose and deliver to HBL the documents described in the motion, such additional, cumulative, or alternative relief as the court deems appropriate, and reimbursement of HBLâ€™s expenses, including attorneysâ€™ fees. The Court held a hearing on the motion on March 14, 2024 at which the Court proposed, and the parties agreed, to retain a third-party valuation firm to assess the fairness of the valuation that was performed in support of the Intercompany Agreement. It is impossible at this time to assess whether the outcome of this proceeding will have a material adverse effect on Lineageâ€™s consolidated results of operations, cash flows or financial position. Therefore, in accordance with ASC 450, Contingencies, Lineage has not recorded any accrual for a contingent liability associated with this legal proceeding based on its belief that a liability, while possible, is not probable nor estimable, and any range of potential contingent liability amounts cannot be reasonably estimated at this time. Lineage records legal expenses as incurred.Employment ContractsLineage has employment agreements with all of its executive officers. Under the provisions of the agreements, Lineage may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations.IndemnificationIn the normal course of business, Lineage may agree to indemnify and reimburse other parties, typically Lineageâ€™s clinical research organizations, investigators, clinical sites, and suppliers, for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of Lineageâ€™s products and services. Indemnification could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to Lineage products and services. The term of these indemnification agreements generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. In addition, Lineage has entered into 28 LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED)(UNAUDITED)Â Â indemnification agreements with officers and members of its board of directors that will require Lineage, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as officers or directors. The potential future payments Lineage could be required to make under the indemnification agreements described in this paragraph will generally not be subject to any specified maximum amount. Generally, Lineage has not been subject to any material claims or demands for indemnification. Lineage maintains liability insurance policies that limit its financial exposure under the indemnification agreements described in this paragraph. Accordingly, Lineage has not recorded any liabilities for these agreements as of September 30, 2024 or December 31, 2023.Royalty Obligations and License FeesWe have licensing agreements with research institutions, universities and other parties providing us with certain rights to use intellectual property in conducting research and development activities in exchange for the payment of royalties on future product sales, if any. In addition, in order to maintain these licenses and other rights, we must comply with various conditions including the payment of patent related costs and annual minimum maintenance fees.As part of the Asterias Merger, Lineage acquired royalty revenues for cash flows generated under patent families that Asterias acquired from Geron Corporation. Lineage continues to make royalty payments to Geron from royalties generated from these patents. Royalty revenues and royalty payments are included within royalties, license and other revenues and cost of sales, respectively, in our condensed consolidated statements of operations. 29 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Result of Operations The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated interim financial statements and notes thereto included in this report and our audited financial statements and notes thereto for the year ended December 31, 2023 included in the 2023 10-K. Past operating results are not necessarily indicative of results that may occur in future periods. The following discussion includes forward-looking statements. See â€œSpecial Note Regarding Forward-Looking Statements,â€ above. Forward-looking statements are not guarantees of future performance and our actual results may differ materially from those currently anticipated and from historical results depending upon a variety of factors, including, but not limited to, those discussed in Part I, Item 1A. Risk Factors of our 2023 10-K, and in our subsequent filings with the SEC, including any discussed in Part II, Item 1A of this report under the heading â€œRisk Factors.â€ All information presented in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years. Organization and Business Overview We are a clinical-stage biotechnology company developing novel allogeneic, or â€œoff-the-shelfâ€, cell therapies to address unmet medical needs. Our programs are based on our proprietary, cell-based technology platform, and associated development, formulation, delivery and manufacturing capabilities. From this platform, we design, develop, manufacture, and test specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. The cells we manufacture are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages which are relevant to the underlying condition are transplanted into patients in an effort to (a) replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and (b) restore or augment the patientâ€™s functional activity. Our business strategy is to efficiently leverage our technology platform and our development and manufacturing capabilities to advance our programs internally or in conjunction with strategic partners to further enhance their value and probability of success. A significant area of focus is a collaboration we entered into with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (collectively or individually, â€œRocheâ€ or â€œGenentechâ€), under which our lead cell therapy program known as OpRegenÂ®, is being developed for the treatment of ocular disorders, including geographic atrophy (â€œGAâ€) secondary to age-related macular degeneration (â€œAMDâ€). OpRegen (also known as RG6501) is a suspension of human allogeneic retinal pigmented epithelial (â€œRPEâ€) cells and is currently being evaluated in a Phase 2a multicenter clinical trial in patients with GA secondary to AMD. OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. Under the terms of the Collaboration and License Agreement we entered into with Roche in December 2021 (the â€œRoche Agreementâ€), we received a $50.0 million upfront payment in January 2022 and are eligible to receive up to an additional $620.0 million in developmental, regulatory, and commercialization milestone payments. We also are eligible to receive tiered, double-digit-percentage royalties on net sales of OpRegen in the U.S. and other major markets. On May 7, 2024, we entered into a service agreement with Genentech pursuant to which we will provide supplemental clinical, technical, training, manufacturing, and procurement services to support the ongoing advancement and optimization of the OpRegen program. In September 2024, Roche and Genentech announced receipt of Regenerative Medicine Advanced Therapy (â€œRMATâ€) designation from the U.S. Food and Drug Administration (â€œFDAâ€) for OpRegen for the treatment of GA secondary to dry AMD. Our most advanced unpartnered product candidate is OPC1, an allogeneic oligodendrocyte progenitor cell therapy designed to improve recovery following a spinal cord injury (â€œSCIâ€). OPC1 has been tested in two clinical trials to date; a five patient Phase 1 clinical trial in acute thoracic SCI, where all subjects are followed for at least 10 years, and a 25 patient Phase 1/2a multicenter clinical trial in subacute cervical SCI, where all subjects were evaluated for at least two years. Results from both studies have been published in the Journal of Neurosurgery Spine. OPC1 clinical development has been supported in part by a $14.3 million grant from the California Institute for Regenerative Medicine (â€œCIRMâ€). We plan to apply for additional funding from CIRM for continued clinical development of OPC1 for the treatment of SCI. In December 2023, we filed an Investigational New Drug (â€œINDâ€) amendment for OPC1 as it relates to our proposed DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study, to evaluate the safety and utility of a novel spinal cord delivery device to administer OPC1 to the spinal parenchyma in subacute and chronic SCI patients. In March 2024, we received written correspondence from the FDA, advising us that due to significant workload and conflicting PDUFA priorities at the agency, its review of our IND amendment and the DOSED study protocol is still ongoing. Since that time we have been engaging with the FDA to aid in their review, including through an informal teleconference meeting with the CBER and CDRH divisions of the FDA held on November 12, 2024. Based on that discussion we plan to submit an additional 30 Â amendment to the IND and final protocol with clarifying information to the FDA by the end of the year. We currently anticipate that the FDA will complete its review of this amendment in Q1 2025 and we do not expect any further feedback or additional information requests that would delay start of the study. We currently plan to commence enrolling the DOSED study as soon as feasible after submitting these updates. Our pipeline of allogeneic, or â€œoff-the-shelfâ€, cell therapy programs currently includes: â€¢RG6501 (OpRegen), an allogeneic RPE cell replacement therapy currently in a Phase 2a multicenter, open-label, single arm clinical trial, being conducted by Roche, for the treatment of GA secondary to AMD, also known as atrophic or dry AMD. â€¢OPC1, an allogeneic oligodendrocyte progenitor cell therapy which we plan to evaluate in the DOSED clinical study, to test the safety and utility of a novel spinal cord delivery device in both subacute and chronic spinal cord injuries and continues to be evaluated in long-term follow-up from a Phase 1/2a multicenter clinical trial for subacute cervical spinal cord injuries. â€¢ANP1, an allogeneic auditory neuron progenitor cell transplant currently in preclinical development for the treatment of debilitating hearing loss. â€¢PNC1, an allogeneic photoreceptor cell transplant currently being developed for the treatment of vision loss due to photoreceptor dysfunction or damage. â€¢RND1, a novel, hypoimmune iPSCs line being developed in collaboration with Factor Bioscience Limited, as assignee from Eterna Therapeutics, Inc., which will be evaluated for differentiation into cell transplant product candidates for central nervous system diseases and other neurology indications. Other Programs We have additional undisclosed product candidates being considered for development, and we may consider others which cover a range of therapeutic areas and unmet medical needs. Generally, these product candidates are based on the same platform technology and employ a similar, guided cell differentiation and transplant approach as most of the product candidates described above, but in some cases may also include genetic modifications designed to enhance efficacy and/or safety profiles. In addition to seeking to create value for shareholders by developing product candidates and advancing those candidates through clinical development, we also may seek to create value from our non-core intellectual property or related technologies and capabilities, through licensing collaborations and/or strategic transactions, such as our business development approach to our VAC dendritic cell therapy platform. Israel-Hamas War All of our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, are conducted by our subsidiary, Cell Cure, at its facility in Jerusalem, Israel, and more than two-thirds of our workforce are Cell Cure employees who are based in the same facility. As of the date of the filing of this report, our operations have not been materially or adversely impacted as a result of the Israel-Hamas war that began in October 2023 nor the broader regional conflict that has developed since. As a result of safety concerns and in response to government-imposed restrictions on movement and travel and other precautions taken at the outset of the war, our operations at our facilities in Israel were temporarily impacted. Further, a number of the employees in Israel are members of the military reserves and subject to immediate call-up in response to the ongoing war in Israel. A number of the employees in Israel have been activated for military duty and additional employees may also be activated. In addition, the general impact on employees operating in a region at war could adversely impact our operations. Although we have business continuity plans in place to address medium- or long-term disruptions that could result from the war, any long-term closure of our facilities in Israel, or if those facilities were damaged, or if hostilities otherwise disrupt the ongoing operation of our facilities, or if a meaningful number of employees are unable to work for significant portions of time, our operations would be materially and adversely impacted. It is currently not possible to predict the scope, duration or severity of the ongoing war or its effects on our operations, financial condition or operating results. The ongoing war is rapidly evolving, and could materially adversely impact our business and operations, including our ability to raise capital, as well as the overall economy in Israel and the value of the New Israeli Shekel. See the risk factor titled, â€œAll of our manufacturing operations currently are conducted at our facility in Jerusalem, Israel. Accordingly, political and economic conditions in Israel and war, terrorist attacks or other armed conflicts involving Israel, such as the Israel-Hamas war that began in October 2023 and broader regional conflict that has developed since, could directly affect our business. Any event or condition that significantly disrupts our ordinary course of operations at our Jerusalem facility could harm our business and materially and adversely affect our financial condition and operating results,â€ in our 2023 10-K. 31 Â Our commercial insurance may not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Critical Accounting Estimates An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. See Part II, Item 7 â€“ Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2023 10-K for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated interim financial statements, financial condition and results of operations and which require complex management judgment and assumptions or involve uncertainties. The estimates and judgments involved in our accounting policies as described in Part II, Item 8 on Form 10-K for the year ended December 31, 2023, continue to be our critical accounting policies and there have been no other material changes to our critical accounting policies during the nine months ended September 30, 2024. Results of Operations Comparison of Three and Nine Months Ended September 30, 2024 and 2023 Revenues The amounts in the table below show our consolidated revenues, by source, for the periods presented (in thousands except percentages). Â Â Â Three Months Ended September 30, Â Â Dollar Increase Â Â Percent Increase Â Nine Months Ended September 30, Â Â Dollar Increase Â Â Percent Increase Â Â 2024 Â Â 2023 Â Â (Decrease) Â Â (Decrease) Â 2024 Â Â 2023 Â Â (Decrease) Â Â (Decrease) Collaboration revenues Â $ 3,386 Â Â $ 957 Â Â $ 2,429 Â Â 254% Â $ 5,671 Â Â $ 5,949 Â Â $ (278) Â (5)% Royalties, license and other revenues Â Â 393 Â Â Â Â 289 Â Â Â Â 104 Â Â 36% Â Â 960 Â Â Â Â 908 Â Â Â Â 52 Â Â 6% Total revenues Â $ 3,779 Â Â $ 1,246 Â Â $ 2,533 Â Â 203% Â $ 6,631 Â Â $ 6,857 Â Â $ (226) Â (3)% Â For the three months and nine months ended September 30, 2024, the $2.5 million increase and $0.2 million decrease in total revenues, was primarily related to collaboration revenues recognized under the Roche Agreement, resulting from updates in total estimated costs to be incurred under this collaboration agreement. Collaboration revenues may fluctuate from period to period based on changes in estimated costs to support performance obligations. The collaboration revenue was included within deferred revenue at the beginning of each reporting period. See Note 3 (Revenue) to our condensed consolidated financial statements included in this report for additional information. Operating expenses Our operating expenses consist of cost of sales, research and development expenses, and general and administrative expenses. Cost of sales. These expenses consist of costs associated with royalty revenue which has resulted from product sales by our sublicensees. Research and development expenses. These expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct expenses and indirect research-related overhead expenses including compensation and related benefits, stock-based compensation, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses which have an alternative future use will be capitalized as intangible assets, and research and development costs with no future benefit or alternative use will be expensed as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant income recognized in our consolidated statements of operations. Royalties and sublicensing fees are recorded as research and development expenses, unless they are associated with royalties from product sales, which we classify as cost of sales in our consolidated statements of operations. We expect our total research and development expenses to fluctuate each reporting period based on several factors including (i) the stage of development for each cell therapy program, (ii) the availability of resources to work on each program, and (iii) the timing of contractual obligations. 32 Â General and administrative expenses. These expenses consist of employee and director compensation and related benefits, including stock-based compensation, for executive and corporate personnel, professional and consulting fees, and allocated overhead such as facilities rent and equipment rent and maintenance, insurance costs allocated to general and administrative expenses, costs of patent applications, prosecution and maintenance, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, and other miscellaneous expenses. The following table shows our operating expenses for the periods presented (in thousands, except percentages). Â Â Â Three Months Ended September 30, Â Â DollarIncrease Â Â PercentIncrease Â Nine Months Ended September 30, Â Â Dollar Increase Â Â Percent Increase Â Â 2024 Â Â 2023

Â Â (Decrease) Â Â (Decrease) Â 2024 Â Â 2023 Â Â (Decrease) Â Â (Decrease) Cost of sales Â $ 38 Â Â $ 169 Â Â $ (131) Â (78)% Â $ 180 Â Â $ 415 Â Â $ (235) Â (57)% Research and development Â $ 3,171 Â Â $ 3,741 Â Â $ (570) Â (15)% Â $ 9,049 Â Â $ 11,799 Â Â $ (2,750) Â (23)% General and administrative Â Â 4,410 Â Â Â 4,041 Â Â Â 369 Â Â 9% Â Â 13,770 Â Â Â 13,014 Â Â Â 756 Â Â 6% Total Â $ 7,619 Â Â $ 7,951 Â Â $ (332) Â (4)% Â $ 22,999 Â Â $ 25,228 Â Â $ (2,229) Â (9)% Â Research and development expenses. For the three months ended September 30, 2024, the $0.6 million quarter-over-quarter decrease in total research and development expenses was attributable to: (i) a $0.6 million decrease related to our OPC1 program; (ii) a $0.4 million net decrease for our preclinical programs; (iii) a $0.1 million decrease for our other research and development programs; and (iv) partially offset by a $0.5 million increase for our OpRegen program. For the nine months ended September 30, 2024, the $2.8 million year-over-year decrease in total research and development expenses was attributable to: (i) a $1.6 million decrease related to our OPC1 program; (ii) a $1.0 million net decrease for our preclinical programs; (iii) a $0.4 million decrease for our other research and development programs; and (iv) partially offset by a $0.2 million increase for our OpRegen program. The below table shows the amount of our total research and development expenses allocated by program for the periods presented (in thousands, except percentages). Â Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â Amount Â Â Percent of Total Â Amount Â Â Percent of Total Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 OpRegenÂ® Â $ 1,746 Â Â $ 1,284 Â Â 55% Â 34% Â $ 4,561 Â Â $ 4,381 Â Â 50% Â 37% OPC1 Â Â 844 Â Â Â 1,402 Â Â 27% Â 38% Â Â 2,661 Â Â Â 4,236 Â Â 29% Â 36% ANP1 Â Â 574 Â Â Â 415 Â Â 18% Â 11% Â Â 1,518 Â Â Â 1,556 Â Â 17% Â 13% PNC1 Â Â â€” Â Â Â 115 Â Â 0% Â 3% Â Â 156 Â Â Â 348 Â Â 2% Â 3% RND1 Â Â 2 Â Â Â 444 Â Â 0% Â 12% Â Â 9 Â Â Â 751 Â Â 0% Â 6% Other programs and non-program expenses Â Â 5 Â Â Â 81 Â Â 0% Â 2% Â Â 144 Â Â Â 527 Â Â 2% Â 5% Total research and development expenses Â $ 3,171 Â Â $ 3,741 Â Â 100% Â 100% Â $ 9,049 Â Â $ 11,799 Â Â 100% Â 100% Â General and administrative expenses. For the three months ended September 30, 2024, the $0.4 million quarter-over-quarter increase in general and administrative expenses was primarily attributable to (i) a $0.3 million increase in personnel costs and (ii) $0.1 million increase in stock-based compensation expense. For the nine months ended September 30, 2024, the $0.8 million year-over-year increase in general and administrative expenses was primarily attributable to: (i) a $0.4 million increase in personnel costs and (ii) $0.4 million increase in stock-based compensation expense. 33 Â Other income and (expenses) The following table shows the amount of other income and (expense), net, for the periods presented (in thousands, except percentages): Â Â Â Three Months Ended September 30, Â Â Dollar Increase Â Â Percent Increase Â Nine Months Ended September 30, Â Â Dollar Increase Â Â Percent Increase Other income (expenses) Â 2024 Â Â 2023 Â Â (Decrease) Â Â (Decrease) Â 2024 Â Â 2023 Â Â (Decrease) Â Â (Decrease) Interest income Â $ 397 Â Â $ 433 Â Â $ (36) Â (8)% Â $ 1,322 Â Â $ 1,225 Â Â $ 97 Â Â 8% Loss on marketable equity Â Â Â securities, net Â Â (6) Â Â (60) Â Â 54 Â Â 90% Â Â (21) Â Â (170) Â Â 149 Â Â 88% Foreign currency transaction gain (loss), net Â Â 448 Â Â Â (827) Â Â 1,275 Â Â 154% Â Â (284) Â Â (1,796) Â Â 1,512 Â Â 84% Other income (expense) Â Â â€” Â Â Â 1 Â Â Â (1) Â (100)% Â Â 19 Â Â Â 544 Â Â Â (525) Â (97)% Total Â $ 839 Â Â $ (453) Â $ 1,292 Â Â 285% Â $ 1,036 Â Â $ (197) Â $ 1,233 Â Â 626% Â Â Interest income. Interest income was lower for the three months ended September 30, 2024 as compared to the same period in the prior year primarily driven by lower balances within our money market funds, Interest income was greater for the nine months ended September 30, 2024 as compared to the same period in the prior year primarily due to a nominal increase in interest rates within our marketable debt security holdings and our money market funds. Marketable equity securities, net. We expect our net gain or loss on marketable equitable securities to fluctuate each reporting period based on the changes in the market price of the common stock held by us which could impact our net income or loss reported in our condensed consolidated statements of operations for a particular reporting period. These shares are carried at fair market value on our consolidated balance sheet. See Note 4 (Marketable Securities) to our condensed consolidated interim financial statements included in this report for additional information regarding our marketable equity securities. For the three and nine months ended September 30, 2024 and 2023, Lineage recognized a net loss on marketable equity securities primarily related to changes in the fair market value of the securities during the respective periods. Foreign currency transaction gain (loss), net. Foreign currency transaction gain (loss), net, for each of the three and nine months ended September 30, 2024 and 2023 consisted of net foreign currency transaction gains and losses recognized by our subsidiaries Cell Cure and ES Cell International Pte. Ltd. Foreign currency transaction gains and losses for the periods presented are principally related to the remeasurement of the U.S. dollar denominated notes payable and notes receivable between Cell Cure and Lineage. Other income. For the nine months ended September 30, 2023, the Company recorded an employee retention credit of $0.5 million, and no comparable credit was recorded in 2024. The employee retention credit is a payroll tax refund per employee, under the Coronavirus Aid, Relief, and Economic Security Act which was designed by the U.S. Treasury Department to assist businesses that retained employees during the COVID pandemic. The company qualified for this credit due to a decline in the quarterly revenue during 2020 and 2021 as compared to the same quarterly period in 2019. Income Taxes Under ASC 740, Income Taxes, a valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. We established a full valuation allowance as of December 31, 2018 due to the uncertainty of realizing future tax benefits from the net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by our subsidiaries. Lineage recorded a $1.8 million deferred tax benefit due to the ability to offset certain deferred tax assets against the deferred tax liability associated with in-process research and development ("IPR&D"), and the related release of the valuation allowance in the first quarter of 2023. It was determined that a portion of the deferred tax liability related to the indefinite lived assets may be realized prior to the expiration of certain pre 2018 net operating losses. Lineage did not record a deferred tax benefit for the three and six months ended September 30, 2023, and did not record a deferred tax benefit for the three and nine months ended September 30, 2024. Liquidity and Capital Resources Overview During the nine months ended September 30, 2024, we incurred a loss from operations of $16.4 million and had negative cash flow from operations of $16.7 million. As of September 30, 2024, our accumulated deficit was $400.2 million. Since inception, we have incurred significant operating losses and we expect to continue to incur significant operating losses for the foreseeable future. 34 Â As of September 30, 2024, we had $32.7 million in cash, cash equivalents and marketable securities. In February 2024, we raised approximately $13.8 million in net proceeds through a registered direct offering of our common shares. We have historically funded our operations primarily through proceeds from the sale of our common shares and securities exercisable for or convertible into our common shares, the sale of common stock of our former subsidiaries, research grants, revenues from collaborations, and royalties from product sales that are unrelated to our current cell therapy product candidates. We do not expect sales of shares of our former subsidiaries that we own to be a significant source of additional funds. See Note 4 (Marketable Securities) to our condensed consolidated financial statements included in this report for additional information regarding those marketable equity securities. During the nine months ended September 30, 2024, we issued and sold 55,830 common shares under our at-the-market offering program for gross proceeds of $70,000. As of September 30, 2024, $39.97 million remained available for sale under our at-the-market offering program. See Note 10 (Shareholdersâ€™ Equity) to our condensed consolidated financial statements included in this report for additional information regarding our at-the-market offering program. Cash Flows Â Â Â Nine Months Ended September 30, Â (in thousands) Â 2024 Â Â 2023 Â Cash provided by (used in): Â Â Â Â Â Â Operating activities Â $ (16,746) Â $ (22,547) Investing activities Â Â (4,943) Â Â 36,707 Â Financing activities Â Â 14,123 Â Â Â 6,436 Â Effect of exchange rate changes on cash, cash equivalents Â Â Â and restricted cash Â Â (120) Â Â (532) Net (decrease) increase in cash, cash equivalents, and restricted cash Â $ (7,686) Â $ 20,064 Â Â Cash used in operating activities Net cash used in operating activities was $16.7 million for the nine months ended September 30, 2024, which primarily reflects the loss from operations of $16.4 million plus the changes in operating assets and liabilities of $5.7 million. These items were partially offset by the non-cash expenses of $3.8 million for stock-based compensation and $0.5 million for depreciation and amortization. The foreign currency remeasurement had no effect on cash flows. Net cash used in operating activities was $22.5 million for the nine months ended September 30, 2023, which primarily reflects the loss from operations of $18.4 million plus the changes in operating assets and liabilities of $9.6 million. These items were offset by the non-cash expenses of $3.6 million for stock-based compensation and $0.6 million for depreciation and amortization. The foreign currency remeasurement and deferred tax benefit had no effect on cash flows. Cash (used in) provided by investing activities Cash used in investing activities for the nine months ended September 30, 2024 was $4.9 million and primarily resulted from the purchase of U.S. Treasury securities, net of proceeds from maturities of U.S. Treasury securities. Cash provided by investing activities for the nine months ended September 30, 2023 was $36.7 million and consisted of $53.5 million in U.S. Treasury securities which matured during the period and $0.2 million in proceeds from the sale of marketable equity securities, partially offset by $16.4 million used to purchase U.S. Treasury securities and $0.6 million used to purchase equipment. Cash provided by financing activities Cash provided by financing activities for the nine months ended September 30, 2024 was $14.1 million and primarily consisted of net proceeds from the sale of our common shares in our registered direct offering and from the sale of our common shares under our at-the-market offering program. Cash provided by financing activities for the nine months ended September 30, 2023 was $6.4 million and primarily consisted of net proceeds from the sale of our common shares under our at-the-market offering program. 35 Â Financial Obligations Our financial obligations primarily consist of obligations to our licensors under license agreements, obligations related to grants received from government entities, including the IIA, obligations under vendor contracts for research services and other purchase commitments with suppliers. Our obligations to licensors under license agreements and to government entities under the terms of grants we have received require us to make future payments relating to sublicense fees, milestone payments, redemption fees, royalties and patent maintenance costs. Sublicense fees are payable to licensors or government entities when we sublicense underlying intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments are due to licensors or government entities upon future achievement of certain commercial, development and regulatory milestones, including those related to the Roche Agreement. Redemption fees due to the IIA under the Innovation Law are due upon receipt of any milestone payments and royalties received under the Roche Agreement, see Note 13 (Commitments and Contingencies) to the condensed consolidated financial statements included in this report for additional information. Royalties are payable to licensors or government entities based on a percentage of net sales of licensed products, including those related to the Roche Agreement. Patent maintenance costs are payable to licensors as reimbursement for the cost of maintaining licensed patents. Due to the contingent nature of the payments, the amounts and timing of payments to licensors under our in-license agreements and to government entities under the terms of grants we have received are uncertain and may fluctuate significantly from period to period. As of September 30, 2024, we have not included these commitments on our consolidated balance sheet because the achievement and timing of these events are not fixed and determinable. As discussed above, we have received grants under the Innovation Law and are required to pay royalties to the IIA from the revenues generated from the sale of product candidates and related services developed, in whole or in part pursuant to, or as a result of, a research and development program funded by the IIA. Under the Innovation Law, we are also required to pay redemption fees to the IIA. To date, through a series of separate grants beginning in 2007, Cell Cure has received a total of $15.4 million from the IIA to support the OpRegen program. We are obligated to pay approximately 24.1% of any future payments we may receive under the Roche Agreement to the IIA, up to an aggregate cap on all payments to IIA, such cap growing over time via interest accrual until paid in full. As of September 30, 2024, the aggregate cap amount was approximately $94.8 million. Redemption fees due to the IIA under the Innovation Law are due upon receipt of any milestone payments and royalties received under the Roche Agreement. As of September 30, 2024, we have not included any future financial obligations due to the IIA under the Innovation Law in our consolidated balance sheet because the achievement and timing of the events that would require future payments to the IIA under the Innovation Law is not fixed and determinable. See Note 13 (Commitments and Contingencies) to our condensed consolidated interim financial statements included in this report for additional information. As of September 30, 2024, under the terms of the leases for the facilities from which Cell Cure and Lineage operate, a total of $2.9 million of rent payments will become due, of which $0.3 million will become due in the remainder of 2024. In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided. Future Funding Requirements We expect to continue to incur losses for at least the next several years. We expect that our operating expenses will continue to increase for the foreseeable future as we continue the development of, and seek regulatory approval for, our product candidates. As a result, we will need significant additional capital to fund our operations. Our determination as to when we will seek additional capital and the amount of additional capital that we will need will be based on our evaluation of the progress we make in our research and development programs, changes to the scope and focus of those programs, changes in grant funding for certain of those programs, and projection of future costs, revenues, and rates of expenditure. If we are unable to raise additional capital when and as needed, we may be required to delay, postpone, or cancel our clinical trials or limit the number of clinical trial sites. We may seek to obtain the additional capital we may need through one or more equity offerings, debt financings, government or other grant funding, or other third-party funding transactions, including potential strategic alliances and licensing or collaboration agreements, or structured financings such as royalty monetization transactions. We cannot provide any assurance that adequate additional capital will be available on favorable terms, if at all. The issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our common shares to decline, and the issuance of additional equity securities could result in the dilution of the interests of our current shareholders. If we obtain additional capital through strategic alliances and licensing or collaboration agreements or structured financing, we may be required to relinquish rights to our intellectual property, our product candidates or rights to future revenue streams or otherwise agree to terms unfavorable to us. The unavailability or inadequacy 36 Â of additional capital to meet future capital needs could force us to modify, curtail, delay, or suspend some or all aspects of our current planned operations. Our ability to raise additional capital may be adversely impacted due to external factors beyond our control, such as unfavorable global economic conditions, disruptions to and volatility in the credit and financial markets in the United States and worldwide, public health emergencies, geopolitical conflicts, political and economic instability, inflation and relatively high interest rates, and other macroeconomic factors. We believe that our $32.7 million in cash, cash equivalents and marketable securities at September 30, 2024, will be sufficient to fund our planned operations through at least twelve months from the issuance date of our condensed consolidated interim financial statements included elsewhere in this report. We believe we will meet our longer-term expected future cash requirements and obligations with our current cash and cash equivalents, milestone and other payments we expect to receive under our collaboration agreements, and proceeds we receive from sales of our common shares under our at-the-market offering program. 37 Â Item 3. Quantitative and Qualitative Disclosures about Market Risk Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures It is managementâ€™s responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Exchange Act. Our management, including our Chief Executive Officer and our Chief Financial Officer, reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Following this review and evaluation, management collectively determined that our disclosure controls and procedures were effective as of the end of the period covered by this report to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act: (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) is accumulated and communicated to management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 38 Â PART II - OTHER INFORMATION Item 1. Legal Proceedings We are not currently a party to any material legal proceedings. From time-to-time we may be involved in a variety of legal proceedings. Such proceedings may initially be viewed as immaterial but could later prove to be material. Legal proceedings are inherently unpredictable and excessive verdicts do occur. Given the inherent uncertainties in litigation, even when we can reasonably estimate the amount of possible loss or range of loss and reasonably estimable loss contingencies, the actual outcome may change in the future due to new developments or changes in approach. In addition, legal proceedings could involve significant expense and diversion of managementâ€™s attention and resources from other matters. For a discussion of legal proceedings in which we are involved, see Note 13 (Commitments and Contingencies) in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report. Item 1A. Risk Factors An investment in our common shares involves a high degree of risk. You should carefully consider the risks and uncertainties described in the 2023 10-K, in addition to other information in this report, when evaluating our business and before deciding whether to purchase, hold or sell our common shares. Each of these risks and uncertainties, as well as additional risks and uncertainties not presently known to us or that we currently consider immaterial, could harm our business, financial

condition, results of operations and/or growth prospects, as well as adversely affect the market price of our common shares, in which case you may lose all or part of your investment. There have been no material changes from the risk factors disclosed in Part I, Item 1A. Risk Factors in the 2023 10-K. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Not applicable. Item 3. Default Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information (a)None. (b)None. (c)During the quarter covered by this report, none of our directors or officers (as defined in Rule 16a-1(f)under the Exchange Act) adopted or terminated any Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) ofRegulation S-K) or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K). 39 Â Item 6. Exhibits Â Incorporation by Reference ExhibitNumber Description ExhibitNumber Filing Filing Date File No. 3.1 Restated Articles of Incorporation, as amended 3.1 Â 10-Q November 9, 2023 001-12830 3.2 Certificate of Ownership 3.1 8-K August 12, 2019 001-12830 3.3 Second Amended and Restated Bylaws 3.1(a) 8-K June 13, 2024 001-12830 31.1* Â Certification of Chief Executive Officer pursuant to Form of Rule 13a-14(a), as Adopted Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â 31.2* Â Certification of Chief Financial Officer pursuant to Form of Rule 13a-14(a), as Adopted Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â 32.1# Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS* XBRL Instance Document - the instance document does not appear in the Interactive Data as its XBRL tags are embedded within the Inline XBRL document 101.SCH* Inline XBRL Taxonomy Extension Schema With Embedded Linkbase documents 104* Cover page formatted as Inline XBRL and contained in Exhibit 101 Â * Filed herewith # Furnished herewith Â Â 40 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â LINEAGE CELL THERAPEUTICS, INC. Date: November 14, 2024 /s/ Brian M. Culley Brian M. Culley Chief Executive Officer Date: November 14, 2024 /s/ Jill Ann Howe Jill Ann Howe Chief Financial Officer Â 41 EX-31.1 2 lctx-ex31_1.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATIONS I, Brian M. Culley, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Lineage Cell Therapeutics, Inc. 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 Â Â Â /s/ Brian M. Culley Brian M. Culley Chief Executive Officer(Principal Executive Officer) Â EX-31.2 3 lctx-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATIONS I, Jill Ann Howe, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Lineage Cell Therapeutics, Inc. 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 Â /s/ Jill Ann Howe Jill Ann Howe Chief Financial Officer(Principal Financial Officer) Â EX-32.1 4 lctx-ex32_1.htm EX-32.1 EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report on Form 10-Q of Lineage Cell Therapeutics, Inc. (the â€œCompanyâ€) for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), we, Brian M. Culley, Chief Executive Officer of the Company, and Jill Ann Howe, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 14, 2024 Â /s/ Brian M. Culley Brian M. Culley Chief Executive Officer(Principal Executive Officer) Â /s/ Jill Ann Howe Jill Ann Howe Chief Financial Officer(Principal Financial Officer) Â A signed original of this written statement required by Section 906 has been provided to Lineage Cell Therapeutics, Inc. and will be retained by Lineage Cell Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 5 lctx-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Business Overview link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Shareholdersâ€™ Equity link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Stock-Based Awards link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Stock-Based Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Organization and Business Overview - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Revenue - Schedule of Disaggregated Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Revenue - Schedule of Contract with Customer Contract Liability and Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Marketable Securities - Schedule Of Fair Value Of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Marketable Securities - Summary of Available for Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Marketable Debt Securities - Schedule of Amortized cost And Estimated fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Marketable Securities - Schedule Of Marketable Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Shareholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Stock-Based Awards - Schedule of Share-based Compensation Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Stock-Based Awards - Schedule Of Computation Of Diluted Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Stock-Based Awards - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Maturities of marketable debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total Statement [Line Items] Accounts receivable Increase (Decrease) in Accounts Receivable Plan Name [Domain] Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes Entity Address, Postal Zip Code Revenue, Remaining Performance Obligation, Amount Remaining performance obligations Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Finance Lease, Liability, to be Paid Total lease payments Total lease payments Revenues [Abstract] Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Royalties, license and other revenues. Royalties, License and Other Revenues [Member] Royalties, License and Other Revenues [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price of Options exercisable Finance Lease, Right-of-Use Asset, Accumulated Amortization Finance leases, Accumulated amortization Ending Balance, shares Beginning Balance, shares Shares, Outstanding Fair Value Hierarchy and NAV [Axis] Auditor Name Fair Value, Inputs, Level 2 [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] License Agreement [Member] License Agreement [Member] Roche and Immunomic Therapeutics Collaboration Agreement [Member] Roche and Immunomic Therapeutics Collaboration Agreement [Member] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Product and Service [Axis] Deferred tax liability Deferred Income Tax Liabilities, Net Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance Indefinite-Lived Intangible Assets (Excluding Goodwill), Total Indefinite-Lived Intangible Assets (Excluding Goodwill) Intangible assets Fair value of intangible assets Finite-Lived Intangible Assets by Major Class [Axis] GILTI income Effective Income Tax Rate Reconciliation, GILTI, Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Noncash Investing and Financing Items [Abstract] SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTINGACTIVITIES: Deposits and Other Long-Term Assets [Member] Deposits and Other Long-Term Assets [Member] Equity [Text Block] Shareholders' Equity Title and Position [Axis] Royalties, license and other revenues. Royalties, License and Other Revenues Royalties, license and other revenues Revenue from Contract with Customer [Text Block] Revenue Weighted Average Exercise Price of Options, RSUs. Weighted Average Exercise Price of Options Outstanding, RSUs granted Sale of Stock [Domain] Cash and Cash Equivalents [Domain] Debt Securities, Available-for-Sale, Unrealized Loss

Position, Fair Value [Table Text Block] Schedule of Amortized cost And Estimated fair Value Finite-Lived Intangible Asset, Useful Life Finite-lived intangible asset, useful life Estimated useful life Additional Capital Requirements Additional Capital Requirements [Policy Text Block] Additional capital requirements. Entity Central Index Key CIK Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Equity Securities, FV-NI, Realized Gain (Loss), Total Equity Securities, FV-NI, Realized Gain (Loss) Less: Loss recognized in earnings on marketable equity securities sold Loss on sale of marketable equity securities Loss on sale of marketable equity securities Common Stock, Shares, Issued Common stock, shares issued Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Number of RSUs Outstanding, restricted stock units granted. Number of RSUs Outstanding, Options granted Preferred Stock [Member] Preferred Shares Upfront and Royalty payment Upfront And Royalty Payment Percentage Upfront and royalty payment percentage Income Statement [Abstract] Entity Address, State or Province Finance Lease, Liability, to be Paid, Year One 2024 LOSS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before net income tax benefit Lessee operating leases option to extend. Lessee Operating Leases Option To Extend Lessee operating lease renewal term description Deposits and other longterm assets non current. Deposits And Other Longterm Assets Non Current Deposits and other long-term assets Sublicensing Fee Percentage. Sublicensing fee percentage Loss Contingencies [Table] Accretion of income on marketable debt securities AccretionOfIncomeOnMarketableDebtSecurities Accretion of income on marketable debt securities Royalty Payment Percentage. Royalty payment percentage Included within marketable securities Marketable Securities Marketable securities Marketable Securities, Total ITI Collaboration Agreement [Member] ITI Collaboration Agreement [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Increase in shares authorized for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Options exercisable Cover [Abstract] Cover Operating Lease [Member] Operating Lease [Member] Earnings Per Share, Basic Earnings Per Share, Basic, Total Basic net loss per share Net loss per common share attributable to Lineage, basic Es CellInternational Pte Ltd [Member] Es CellInternational Pte Ltd [Member] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized gains Operating Expenses [Abstract] OPERATING EXPENSES: Finance Lease, Principal Payments Repayment of finance lease liabilities Financing cash flows from finance leases Repayment of finance lease liabilities Number of options outstanding, RSU vesting. Number of Options Outstanding, Rsu vested Investments, Debt and Equity Securities [Abstract] Alameda Lease [Member] Alameda Lease [Member] Sales related milestones. Sales related milestones Share-Based Payment Arrangement, Expense Total stock-based compensation expense Finance Lease, Weighted Average Discount Rate, Percent Weighted average discount rate Contingency withheld amount. Contingency withheld amount Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Accumulated deficit Plan Name [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Options Outstanding, Ending balance Number of Options Outstanding, Beginning balance Assets, Current [Abstract] CURRENT ASSETS Number of RSUs outstanding, options expired/forfeited/cancelled. Number of RSUs Outstanding, Options expired/forfeited/cancelled Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Per Share, RSUs forfeited Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract] CASH, CASH EQUIVALENTS AND RESTRICTED CASH: Number of Options Exercisable and Expected to Vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Product and Service [Domain] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss Property and equipment, net Total Property and equipment, net Property and equipment, net (Notes 6 and 14) Lessee, Operating Lease, Liability, to be Paid, Year Four 2027 Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Cantor Fitzgerald and Co Member [Member] Cantor Fitzgerald and Co Member [Member] 2017 Sales Agreement [Member] 2017 Sales Agreement [Member] Increase in base rent amount. Increased rent amount Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis Finance lease, right of use asset, before accumulated amortization. Finance Lease, Right Of Use Asset, Before Accumulated Amortization [Member] Right-of-use assets - Finance Lease [Member] Other finance lease liabilities current. OtherFinanceLeaseLiabilitiesCurrent Other current liabilities Royalty Contracts [Member] Royalty Contracts [Member] Share-Based Payment Arrangement, Option [Member] Unrealized gain on marketable debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Deferred revenues Deferred revenue Contract with Customer, Liability Deferred revenues - end of the period Contract with Customer, Liability, Total Deferred revenues - beginning of the year Statement of Cash Flows [Abstract] Israel Innovation Authority [Member] Israel Innovation Authority [Member] Preferred Stock, No Par Value Preferred stock, no par value Payments for Legal Settlements Litigation settlement amount Entity [Domain] All Entities Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table] Equity Components [Axis] Entity Address, Address Line One Equity securities available for sale Equity Securities, FV-NI Equity Securities, FV-NI, Total Employee-related Liabilities, Current Accrued compensation Employee-related Liabilities, Current, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of RSUs Outstanding, RSUs granted Number of restricted stock units, granted Number of RSUs Outstanding, RSUs granted Intangible Asset, Finite-Lived [Table] Lease commencement date. Leases Commencement Date Lease commencement date Property, Plant and Equipment [Line Items] This refer to base rent increase rate per year as per lease agreement. Base rent increase rate Nonoperating Income (Expense) other income (expenses) Total other income (expenses) Schedule Of Computation Of Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share Change in right-of-use assets and liabilities. Change in right-of-use assets and liabilities Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of RSUs Outstanding, Ending balance Number of RSUs Outstanding, Beginning balance Cell Cure Warrants [Member] Cell Cure Warrants [Member] Subsidiary or Equity Method Investee [Line Items] Amendment Flag Amendment Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest, Total Net (income) loss attributable to noncontrolling interest Number of RSUs outstanding, options exercised. Number of RSUs Outstanding, Options exercised Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Right-of-use lease liabilities, noncurrent offering price Sale of Stock, Price Per Share Net loss attributable to Lineage NET LOSS ATTRIBUTABLE TO LINEAGE Lessee, Lease, Description [Table] Number of Options Outstanding, Options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Shares issued upon exercise of stock options, shares Schedule Of Fair Value Of Marketable Securities Securities Owned Not Readily Marketable [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of Options exercisable Research and Development Expense [Member] Thousand Twenty Atlantic Premises [Member] Thousand Twenty Atlantic Premises [Member] Number of options outstanding, RSU granted. Number of Options Outstanding, RSUs granted Equity Component [Domain] Statistical Measurement [Domain] ATM Sales Agreement [Member] ATM Sales Agreement [Member] ATM Sales Agreement. General and Administrative Expense General and administrative General and Administrative Expense, Total Other income (expense) Other income Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Disaggregation of Revenue [Table] Net income (loss) Net loss NET LOSS NET LOSS Deferred revenues, current portion Deferred Revenue, Current Current deferred revenue Deferred Revenue, Current, Total Preferred Stock, Shares Issued Preferred stock, shares issued Operating Lease, Payments Operating cash flows from operating leases Proceeds from Stock Options Exercised Proceeds from employee options exercised Sublicensing Fee Sublicensing Fee Sublicensing fee Payables and Accruals [Abstract] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Industrial Microbes, Inc [Member] Industrial Microbes, Inc [Member] Operating lease expense Operating Lease, Expense Deferred revenues, net of current portion Deferred Revenue, Noncurrent Deferred Revenue, Noncurrent, Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price of Options exercisable and expected to vest Proceeds from Collaborators Amount of grants received Upfront payment Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies)) Restricted Cash, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Axis] January 2018 Lease [Member] January 2018 Lease [Member] Comprehensive Income (Loss), Net of Tax, Attributable to Parent COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE COMMON SHAREHOLDERS Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Finite-Lived Intangible Assets, Major Class Name [Domain] Common stock capital value reserved for future issuance. Common Stock Capital Value Reserved For Future Issuance Amount reserved for future issuance Equity securities available for sale Subsidiary, Ownership Percentage, Parent Ownership percentage by parent Ownership percentage Accounts receivable, net - end of the period Accounts receivable, net - beginning of the period Accounts Receivable Net Current Excludes Scope Of ASU 2014 -09 Accounts receivable net current excludes scope of ASU 2014 -09. Accounts receivable, net - beginning of the year Finite-Lived Intangible Assets [Line Items] Entity Interactive Data Current Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Estimated fair value, In one year or less Lease Expiration Date Lease expiration date Share based compensation arrangement by share based payment award options forfeited restricted stock units Number of Options Outstanding, RSUs forfeited Marketable Securities [Table] Accounting Standards Update [Domain] Document Quarterly Report Consolidated Entities [Axis] Marketable Securities [Table Text Block] Schedule Of Marketable Equity Securities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Per Share, RSUs Vested Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents At end of the period At beginning of the period Total cash, cash equivalents, and restricted cash Related Party Transactions Disclosure [Text Block] Related Party Transactions Statement of Financial Position Location, Balance [Axis] Finance Lease, Liability, Undiscounted Excess Amount Less imputed interest Statistical Measurement [Axis] Maximum milestone payments to be received upon performance conditions. Maximum milestone payments to be received upon performance conditions Assets, Fair Value Disclosure Assets Assets, Fair Value Disclosure, Total Parent Company [Member] Disaggregation of Revenue [Table Text Block] Schedule of Disaggregated Revenues Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Future Minimum Lease Commitments Finance Lease, Interest Payment on Liability Operating cash flows from finance leases Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Marketable Equity Securities [Member] Marketable Equity Securities [Member] Finite-Lived Intangible Assets, Gross, Total Finite-Lived Intangible Assets, Gross Intangible assets subject to amortization Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available for grant Financing Leases [Member] Financing Leases [Member] Finance leases [Member] Basis of Presentation, Liquidity and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant-date fair value per share of RSUs granted Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average period for recognition Contract Liabilities [Member] Contract liabilities. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of exchange rate changes on cash, cash equivalents and restricted cash Ownership [Domain] Statement of Income Location, Balance [Axis] Indefinite-Lived Intangible Assets [Line Items] Cash and Cash Equivalents [Axis] Assets TOTAL ASSETS Base rent and construction allowance per month. Base rent and construction allowance per month Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Number of RSUs Outstanding, RSUs vested Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Entity Address, City or Town Accumulated Other Comprehensive Income / (Loss) [Member] AOCI Attributable to Parent [Member] Equity [Abstract] Auditor Location Payments of Stock Issuance Costs Financing related fees Payments for offering costs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of restricted stock units, forfeited Number of RSUs Outstanding, RSUs forfeited Finance Lease, Liability, to be Paid, Year Two 2025 Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Stock Based Compensation Expense December Twenty Twenty Four Prospectus Supplement [Member] December Twenty Twenty Four Prospectus Supplement [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Team (Years), Options exercisable and expected to vest Loss Contingency Accrual, Payments Loss contingency accrual, payments Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Amortized cost, In one year or less Share-Based Payment Arrangement [Text Block] Stock-Based Awards Schedule of Share-based Compensation Activity Legal fees related to reimbursable under insurance policies. Legal Fees Related to Reimbursable under Insurance Policies Legal fees related to reimbursable insurance policies Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized for issuance Direct financing Direct Financing [Member] Direct Financing . Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate Fair Value Disclosures [Abstract] Refers to the base monthly rent as per lease agreement. Base rent Base monthly rent Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Unrealized loss recognized on marketable equity securities held at end of period, net Equity Securities, FV-NI, Unrealized Gain (Loss), Total Equity Securities, FV-NI, Unrealized Gain (Loss) Agreed signature fee amount. Agreed signature fee amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price of Options Outstanding, Options expired/forfeited/cancelled 2021 Equity Incentive Plan [Member] 2021 Equity Incentive Plan [Member] [Default Label] 2021 Equity Incentive Plan [Member] Shares issued, Value Stock Issued During Period, Value, New Issues Field of business description. Field of business description Stock Issued During Period, Value, Stock Options Exercised Shares issued upon exercise of stock options Sales Agreement [Member] Sales Agreement [Member] Sales Agreement [Member] Lessee, Lease, Description [Line Items] Liabilities, Current [Abstract] CURRENT LIABILITIES Lease Contractual Term [Axis] Cash and Cash Equivalents [Member] Cash and Cash Equivalents [Member] Document Type Document Type Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Goodwill and Intangible Assets Net Accounting Standards Update [Axis] Corporate credit card facility. Corporate Credit Card Facility [Member] Corporate Credit Card Facility [Member] Title of 12(b) Security Included within cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Statement of Financial Position Location, Balance [Domain] Lease, Cost [Table Text Block] Schedule of Supplemental Balance Sheet Information Related to Leases Maximum Percentage of Milestone Payments Maximum Percentage of Milestone Payments Maximum percentage of milestone payments Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Total intrinsic value of options exercised Research and Development Expense Research and development Research and Development Expense, Total Payment, Tax Withholding, Share-Based Payment Arrangement Common shares received and retired for employee taxes paid Significant Accounting Policies Significant Accounting Policies [Policy Text Block] Significant accounting policies. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of Options Outstanding, Options granted Indefinite-Lived Intangible Assets [Axis] Asset Class [Domain] Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property and equipment, gross Property, Plant and Equipment, Gross, Total Principles of Consolidation Consolidation, Policy [Policy Text Block] Insurance Recoveries Insurance reimbursed amount Finance Lease, Right-of-Use Asset, after Accumulated Amortization Finance leases, Right-of-use assets, net Finance leases, Right-of-use assets, net Number of building for lease description. Number of buildings for lease Payments for Rent Payments for rent Financial Instruments [Domain] Roche Agreement [Member] Roche Agreement [Member] Assets, Noncurrent [Abstract] NONCURRENT ASSETS Sale of Stock [Axis] Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Patents [Member] Lease modification. Lease modification Two thousand twelve equity incentive plan and two thousand eighteen inducement option. Two Thousand Twelve Equity Incentive Plan And Two Thousand Eighteen Inducement Option [Member] 2012 Equity Incentive Plan and 2018 Inducement Option [Member] Marketable Securities, Current Marketable securities Marketable

debt securities Revenue from Contract with Customer, Excluding Assessed Tax Total revenues Total revenues Income Tax Disclosure [Text Block] Income Taxes Weighted average price per share Weighted Average Price Per Share Weighted average price per share. Ownership [Axis] Consolidated Entities [Domain] Credit Facility [Domain] Cell Cure Neurosciences Ltd [Member] Cell Cure Neurosciences Ltd [Member] Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction, Total Subsidiary or Equity Method Investee, Sale of Stock [Table] Entity Address, Address Line Two Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Document Period End Date Period End Date Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Net Rentable Area Rentable area ICFR Auditor Attestation Flag Liabilities, Noncurrent [Abstract] LONG-TERM LIABILITIES Antidilutive securities, shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share, amount Financing related fees. Financing related fees Liquidity Liquidity [Policy Text Block] Liquidity. Accrued Liabilities, Current Accrued liabilities Accrued Liabilities, Current, Total Deferred Revenue Deferred revenues - end of the period Deferred revenues - beginning of the period Deferred revenue Deferred Revenue, Total Deferred revenues Provision for income tax benefit Income Tax Expense (Benefit) Income tax expense Income Tax Expense (Benefit), Total 2021 Equity Incentive Plan [Member] 2021 Equity Incentive Plan [Member] 2021 Equity Incentive Plan [Member] Trading Symbol Equity, Attributable to Parent Equity, Attributable to Parent, Ending Balance Equity, Attributable to Parent, Beginning Balance Lineage's shareholders' equity Thousand Ten Atlantic Premises [Member] 1010 Atlantic Premises [Member] Long-Lived Tangible Asset [Axis] Capital Resources Capital Resources [Policy Text Block] Capital resources. Other Liabilities, Noncurrent Other long-term liabilities Reconciliation of cash cash equivalents and restricted cash end of period. Reconciliation Of Cash Cash Equivalents And Restricted Cash End Of Period [Abstract] Reconciliation of cash, cash equivalents and restricted cash, end of period: Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Restricted Stock Units [Member] Sale of stock Sale of Stock, Number of Shares Issued in Transaction Related Party Transactions [Abstract] Deferred revenue Increase (Decrease) in Deferred Revenue Property, Plant and Equipment [Table] Goodwill, Ending Balance Goodwill, Beginning Balance Goodwill, Total Goodwill Goodwill Land Subject to Ground Leases Land subject to ground leases Loss on marketable equity securities, net Equity Securities, FV-NI, Gain (Loss) Loss on marketable equity securities, net Loss on marketable equity securities, net Security Deposit Security deposit Deferred income tax benefit Deferred Income Tax Expense (Benefit) Deferred income tax benefit Deferred Income Tax Expense (Benefit), Total Deferred tax benefit Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Aggregate Intrinsic Value, Options exercisable and expected to vest Finance Lease, Liability, to be Paid, Year Three 2026 Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized losses Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount unrecognized compensation costs Prior Sales Agreement [Member] Prior Sales Agreement [Member] Prior sales agreement. Collaborative Arrangement [Member] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Schedule of Contract with Customer Contract Liability and Receivable Security Exchange Name Equipment Furniture And Fixtures Member Equipment Furniture And Fixtures [Member] Additional right of use asset and lease liability. Additional right of use asset and lease liability Revenue recognized included in deferred revenue Revenue Recognized From Deferred Revenue At Beginning Of Period Revenue recognized from deferred revenue at beginning of period. Long-Lived Tangible Asset [Domain] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated depreciation and amortization Legal Entity [Axis] Legal Entity: Fair Value Disclosures [Text Block] Fair Value Measurements Lessee, Operating Lease, Liability, to be Paid, Year Three 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant-date fair value per share of options granted Maximum [Member] Maximum [Member] Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERSâ€™ EQUITY Intangible Assets, Gross (Excluding Goodwill) Total intangible assets Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Development Cost, Period Cost Operating lease right-of-use assets Right-of-use assets, net Right-of-use assets, net SUPPLEMENTAL DISCLOSURES : Supplemental Cash Flow Information [Abstract] Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Diluted net loss per share Net loss per common share attributable to Lineage, diluted Leasehold Improvements [Member] Weighted average price per share issuance of common stock. Weighted Average Price Per Share Issuance Of Common Stock Weighted average price per share issuance of common stock Liabilities TOTAL LIABILITIES Fair Value Hierarchy and NAV [Domain] Upfront License Fees [Member] Upfront License Fees [Member] Upfront license fees [Member] Assets, Current Total current assets Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Collaboration Revenues Member Collaboration Revenues [Member] Collaboration Revenues [Member] Shares issued, shares Stock Issued During Period, Shares, New Issues Entity Filer Category Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets, Net Property, Plant and Equipment [Abstract] Foreign currency remeasurement and other loss Foreign Currency Transaction, Gain (Loss), before Tax and Other Loss Foreign currency remeasurement, gain (loss), before tax and other loss. Ending Balance Beginning Balance Equity, Including Portion Attributable to Noncontrolling Interest Total shareholdersâ€™ equity Organization and Business Overview Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Payments to Acquire Marketable Securities Purchases of marketable debt securities Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSES): Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Schedule of Share-based Compensation Activity Current Fiscal Year End Date Payments for Advance to Affiliate Upfront payment Insurance deductable Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] SHAREHOLDERS' EQUITY Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Fair value of the options vested Noncontrolling Deficit [Member] Noncontrolling Interest [Member] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Less imputed interest B. Riley Securities, Inc. [Member] B. Riley Securities, Inc. [Member] B. Riley Securities, Inc. [Member] Finance lease liability excluding other liabilities current. Finance Lease Liability Excluding Other Liabilities Current Finance leases, Right-of-use lease liabilities, current Share-Based Payment Arrangement, Noncash Expense Total stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense, Total Stock-based compensation Legal Fees Legal expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Options Outstanding, Ending Balance Aggregate Intrinsic Value, Options Outstanding, Beginning balance Aggregate Intrinsic Value, Options Outstanding Entity Registrant Name Registrant Name Finance Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Indefinite-Lived Intangible Assets, Major Class Name [Domain] Share-based compensation arrangement by share-based payment award, options, exercisable and expected to vest, weighted average exercise price. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable and Expected to Vest, Weighted Average Exercise Price Weighted Average Exercise Price of Options exercisable and expected to vest Cost of sales Cost of Revenue Cost of Revenue, Total Cost of sales - royalties Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Operating lease, right of use asset, before accumulated amortization. Operating Lease, Right Of Use Asset, Before Accumulated Amortization [Member] Right-of-use assets - Operating Lease [Member] Entity Emerging Growth Company Upfront payment. Upfront payment Money Market Funds [Member] Other Liabilities, Current Other current liabilities Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Basic Weighted-average common shares used to compute net loss per common share, basic Marketable Securities [Abstract] Loss Contingencies [Line Items] Finance lease liabilities, net of current portion Finance Lease, Liability, Noncurrent Finance leases, Right-of-use lease liabilities, noncurrent Interest Income (Expense), Nonoperating Interest income Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Common Stock, Shares Authorized Common stock, shares authorized Estimated useful life of asset Property, Plant and Equipment, Useful Life Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Proceeds from sale of common shares Proceeds from Sale and Maturity of Marketable Securities Proceeds from the sale of marketable equity securities Cash and Cash Equivalents [Abstract] Fair Value, Inputs, Level 1 [Member] Clinical regulatory milestone. Clinical regulatory milestone Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Adjustments to common stock share based compensation requisite service period recognition value. Adjustments To Common Stock Share Based Compensation Requisite Service Period Recognition Value Stock-based compensation Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price of Options Outstanding, Options granted Amortization of Intangible Assets Amortization of intangible assets Deferred Compensation Arrangement with Individual, Excluding Share-Based Payment and Postretirement Benefit [Table] Financial Instrument [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Team (Years),Options Outstanding General and Administrative Expense [Member] Share based compensation arrangements by share based payment award options forfeited in period weighted average exercise price RSU Weighted Average Exercise Price of Options Outstanding, RSUs forfeited Share-Based Payment Arrangement [Abstract] Hadasit Medical Research Services And Development Ltd [Member] Hadasit Medical Research Services and Development Ltd [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] ATM At the Market [Member] At the market . IPR&D - VAC [Member] In Process Research And Development VAC [Member] In Process Research And Development VAC [Member] Debt Securities, Available-for-Sale Fair value Lineage's available-for-sale debt securities Estimated fair value, Total available-for-sale debt securities Accounting Policies [Abstract] Cash and Cash Equivalents [Line Items] Income Tax Disclosure [Abstract] Gross proceeds Gross Proceeds from Sale of Common Stock Gross Proceeds from Sale of Common Stock Gross proceeds from issuance of common stock Gross Proceeds from Issuance of Common Stock Gross proceeds from issuance of common stock. Statement [Table] Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment, Net March 2024 Prospectus Supplement [Member] March Twenty Twenty Four Prospectus Supplement [Member] March Twenty Twenty Four Prospectus Supplement [Member] Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total Less: Comprehensive (income) loss attributable to noncontrolling interest Preferred Stock, Shares Authorized Preferred stock, shares authorized Revenue from Contract with Customer, Including Assessed Tax Total revenues under collaborative agreements Collaboration revenues Entity File Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Revenue from Contract with Customer [Abstract] Loss Contingency, Receivable, Proceeds Upfront payment Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Operating Income (Loss) Loss from operations Loss from operations Common Stock, No Par Value Common stock, no par value Entity Shell Company Purchase Obligation Purchase obligation Purchase Obligation, Total Entity Tax Identification Number Assets [Abstract] ASSETS Entity Current Reporting Status Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Team (Years),Options exercisable Finance Lease, Liability, to be Paid, Year Four 2027 Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Accounts Payable and Accrued Liabilities Property, Plant and Equipment Disclosure [Text Block] Property and Equipment, Net Subsequent Events [Abstract] Cash and cash equivalents and marketable securities Cash and cash equivalents and marketable securities Cash And Cash Equivalents And MarketableSecurities. Document Fiscal Year Focus Expected convertion to revenue by 2026. Expected Convertion to Revenue by 2026 Expected convertion to revenue by 2026 Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Number of Options Outstanding, Options forfeited Broadwood Partners, L.P [Member] Broadwood Partners, L.P [Member] Accounting standard update 2014-09. Accounting Standard Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Capital Expenditures Incurred but Not yet Paid Property and equipment expenditures in accounts payable Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization City Area Code 2012 and 2018 Equity Incentive Plan [Member] 2012 and 2018 Equity Incentive Plan [Member] 2012 and 2018 Equity Incentive Plan Liabilities, Current Total current liabilities Pay costs percentage. Pay costs percentage Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Upfront Payment Percentage Upfront Payment Percentage Upfront payment percentage Commitments and Contingencies Disclosure [Abstract] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Neal Bradsher [Member] Neal Bradsher [Member] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Amortized cost Amortized cost, Total available-for-sale debt securities Operating lease liabilities, current portion Operating Lease, Liability, Current Right-of-use lease liabilities, current Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Finance leases In Process Research and Development [Member] Foreign currency translation adjustment Comprehensive loss foreign currency translation adjustments, net of tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Accumulated Deficit [Member] Retained Earnings [Member] Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Purchase of equipment Upfront payment received. Upfont payment received Upfront payment received Document Transition Report Share based compensation arrangement by share based payment award equity instruments other than options to be vested in period. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options to be Vested In Period Number of restricted stock units to be vested Rent for remaining twelve months Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Operating Lease Right Of Use Asset Accumulated Amortization Operating Lease Right Of Use Asset Accumulated Amortization Accumulated amortization Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price of Options, Options exercised Auditor Firm ID Minimum [Member] Common Stock [Member] Common Shares Restricted Cash Restricted cash Restricted Cash, Total Deposit assets Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Per Share, Ending balance Weighted Average Grant Date Fair Value Per Share, Beginning balance IPR&D - OPC1 [Member] IPR&D - OPC1 [Member] Office and Laboratory Space, Jerusalem, Israel [Member] Office and Laboratory Space, Jerusalem, Israel [Member] Common stock capital value maximum authorized shares available for future issuance. Common Stock Capital Value Maximum Authorized Shares Available For Future Issuance Amount reserved for future issuance Net proceeds Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc.to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Lessee, Operating Sublease, Option to Extend Sublease agreement option to extend Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss, net of tax: Statement of Income Location, Balance [Domain] Rent for first twelve months Lessee, Operating Lease, Liability, to be Paid, Year One 2024 Goodwill and Intangible Assets Disclosure [Abstract] Entity Common Stock, Shares Outstanding Disaggregation of Revenue [Line Items] Schedule of supplemental cash flow information related to leases [Table Text Block] Schedule of Supplemental Cash Flow Information Related to Leases Equity, Attributable to Noncontrolling Interest Equity, Attributable to Noncontrolling Interest, Ending Balance Equity, Attributable to Noncontrolling Interest, Beginning Balance Noncontrolling deficit Equity, Attributable to Noncontrolling Interest, Total Noncontrolling deficit Title and Position [Domain] Cell cure leases. Cell Cure Leases [Member] Finance lease liabilities, current portion Finance Lease, Liability, Current Finance leases, Right-of-use lease liabilities, current Finance Lease, Right-of-Use Asset, before Accumulated Amortization Finance leases, Right-of-use assets Common shares, no par value, 450,000 shares authorized as of September 30, 2024 and December 31, 2023; 188,837 and 174,987 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Marketable Debt Securities [Member] Marketable Debt Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Amortization expense for right-of-use finance lease assets Finance Lease, Right-of-Use Asset, Amortization Aggregate Cap Amount. Aggregate cap amount Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalent [Table] Insurers [Member] Insurers [Member] Carlsbad Lease [Member] Carlsbad Lease [Member] Operating lease expense Total operating lease liabilities Total operating lease liabilities Total Debt Securities, Available-for-Sale [Table Text Block] Summary of Available for Sale Debt Securities Don M. Bailey [Member] Don M. Bailey [Member] Don M. Bailey. Commitments and contingencies (Note 13) Commitments and

Contingencies Marketable Securities [Line Items] Loss Contingency, Receivable Loss Contingency, Receivable, Ending Balance Loss Contingency, Receivable, Beginning Balance Insurance recovery receivable Loss Contingency, Receivable, Total Settlement Agreement [Member] Settlement Agreement [Member] Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total DILUTED Weighted-average common shares used to compute net loss per common share, diluted Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, net - end of the period Accounts receivable, net - beginning of the period Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivables amounted Lessee, Operating Lease, Liability, to be Paid Total lease payments Total lease payments Insurance deductable. Insurance deductable Budgetary commitment. Budgetary commitment amount Finance Lease, Liability Total Total finance lease liabilities Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest COMPREHENSIVE LOSS Entity Small Business IPR&D - VAC2 [Member] IPR&D - VAC2 [Member] Refers to a commission payable to the seller as a percentage of gross proceeds from the sale of shares of the entity. Percentage of commission payable Intangible Asset, Indefinite-Lived [Table] Entity Bankruptcy Proceedings, Reporting Current Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries Securities owned readily marketable. Schedule Of Securities Owned Readily Marketable [Table Text Block] Schedule Of Fair Value Of Marketable Securities Revenues Revenues Total revenues Total revenues US Treasury Securities [Member] Foreign currency transaction gain (loss), net Gain (Loss), Foreign Currency Transaction, before Tax Gain (Loss), Foreign Currency Transaction, before Tax, Total Foreign currency remeasurement and other loss Credit Facility [Axis] Carlsbad Sub Lease [Member] Carlsbad Sub Lease [Member] Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Operating Lease Right Of Use Asset Before Accumulated Amortization Operating Lease Right Of Use Asset Before Accumulated Amortization Right-of-use assets Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price of Options Outstanding, Ending balance Weighted Average Exercise Price of Options Outstanding, Beginning balance Asset Class [Axis] Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Intangible assets, net Agreements With Hadasit And I I A. Agreements With Hadasit And I I A [Member] Agreements With Hadasit and IIA [Member] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating leases Fair Value, Inputs, Level 3 [Member] Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Subsequent Events [Text Block] Subsequent Events Grants Awarded Percentage. Grants awarded percentage Unrealized gain on marketable debt securities Unrealized gain on marketable debt securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Total operating expenses Costs and Expenses Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Total XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 08, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --12-31 Â Entity File Number 001-12830 Â Entity Registrant Name Lineage Cell Therapeutics, Inc. Â Entity Central Index Key 0000876343 Â Entity Tax Identification Number 94-3127919 Â Entity Incorporation, State or Country Code CA Â Entity Address, Address Line One 2173 Salk Avenue Â Entity Address, Address Line Two Suite 200 Â Entity Address, City or Town Carlsbad Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 92008 Â City Area Code 442 Â Local Phone Number 287-8990 Â Title of 12(b) Security Common shares Â Trading Symbol LCTX Â Security Exchange Name NYSE Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 188,837,375 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 CURRENT ASSETS Â Â Cash and cash equivalents $ 27,750 $ 35,442 Marketable securities 4,961 50 Accounts receivable, net 405 745 Prepaid expenses and other current assets 1,285 2,204 Total current assets 34,401 38,441 NONCURRENT ASSETS Â Â Property and equipment, net 2,013 2,245 Operating lease right-of-use assets 2,362 2,522 Deposits and other long-term assets 606 577 Goodwill [1] 10,672 10,672 Intangible assets, net 46,540 46,562 TOTAL ASSETS 96,594 101,019 CURRENT LIABILITIES Â Â Accounts payable and accrued liabilities 4,477 6,270 Operating lease liabilities, current portion 1,083 830 Finance lease liabilities, current portion 54 52 Deferred revenues, current portion 8,250 10,808 Total current liabilities 13,864 17,960 LONG-TERM LIABILITIES Â Â Deferred tax liability 273 273 Deferred revenues, net of current portion 16,050 18,693 Operating lease liabilities, net of current portion 1,533 1,979 Finance lease liabilities, net of current portion 80 91 TOTAL LIABILITIES 31,800 38,996 Commitments and contingencies (Note 13) SHAREHOLDERS' EQUITY Â Â Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 Common shares, no par value, 450,000 shares authorized as of September 30, 2024 and December 31, 2023; 188,837 and 174,987 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 469,268 451,343 Accumulated other comprehensive loss (2,890) (3,068) Accumulated deficit (400,192) (384,856) Lineage's shareholders' equity 66,186 63,419 Noncontrolling deficit (1,392) (1,396) Total shareholdersâ€™ equity 64,794 62,023 TOTAL LIABILITIES AND SHAREHOLDERSâ€™ EQUITY $ 96,594 $ 101,019 [1] Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitments and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment. X - DefinitionDeposits and other longterm assets non current. + ReferencesNo definition available. + Details Name: lctx_DepositsAndOtherLongtermAssetsNonCurrent Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10

-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as

noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5:

http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name

Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Statement of Financial Position [Abstract] Â Â Â Â Preferred stock, no par value $ 0 $ 0 Â Â Preferred stock, shares authorized 2,000,000 2,000,000 Â Â Preferred stock, shares issued 0 0 Â Â Preferred stock, shares outstanding 0 0 Â Â Common stock, no par value $ 0 $ 0 Â $ 0 Common stock, shares authorized 450,000,000 450,000,000 450,000,000 250,000,000 Common stock, shares issued 188,837,375 174,986,671 Â Â Common stock, shares outstanding 188,837,375 174,986,671 Â Â X - DefinitionFace amount per share of no-par value common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockNoParValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockNoParValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues [Abstract] Â Â Â Â Total revenues $ 3,779 $ 1,246 $ 6,631 $ 6,857 OPERATING EXPENSES: Â Â Â Â Cost of sales 38 169 180 415 Research and development 3,171 3,741 9,049 11,799 General and administrative 4,410 4,041 13,770 13,014 Total operating expenses 7,619 7,951 22,999 25,228 Loss from operations (3,840) (6,705) (16,368) (18,371) OTHER INCOME (EXPENSES): Â Â Â Â Interest income 397 433 1,322 1,225 Loss on marketable equity securities, net (6) (60) (21) (170) Foreign currency transaction gain (loss), net 448 (827) (284) (1,796) Other income (expense) 0 1 19 544 Total other income (expenses) 839 (453) 1,036 (197) LOSS BEFORE INCOME TAXES (3,001) (7,158) (15,332) (18,568) Provision for income tax benefit 0 0 0 1,803 NET LOSS (3,001) (7,158) (15,332) (16,765) Net (income) loss attributable to noncontrolling interest (33) 48 (4) 54 NET LOSS ATTRIBUTABLE TO LINEAGE $ (3,034) $ (7,110) $ (15,336) $ (16,711) Net loss per common share attributable to Lineage, basic $ (0.02) $ (0.04) $ (0.08) $ (0.1) Net loss per common share attributable to Lineage, diluted $ (0.02) $ (0.04) $ (0.08) $ (0.1) Weighted-average common shares used to compute net loss per common share, basic 188,835 174,868 186,860 171,880 Weighted-average common shares used to compute net loss per common share, diluted 188,835 174,868 186,860 171,880 Collaboration Revenues [Member] Â Â Â Â Revenues [Abstract] Â Â Â Â Total revenues $ 3,386 $ 957 $ 5,671 $ 5,949 Royalties, License and Other Revenues [Member] Â Â Â Â Revenues [Abstract] Â Â Â Â Total revenues $ 393 $ 289 $ 960 $ 908 X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-

1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=lctx_CollaborationRevenuesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=lctx_RoyaltiesLicenseAndOtherRevenuesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â NET LOSS $ (3,001) $ (7,158) $ (15,332) $ (16,765) Other comprehensive loss, net of tax: Â Â Â Â Foreign currency translation adjustment (432) 518 173 1,337 Unrealized gain on marketable debt securities 12 9 5 150 COMPREHENSIVE LOSS (3,421) (6,631) (15,154) (15,278) Less: Comprehensive (income) loss attributable to noncontrolling interest (33) 48 (4) 54 COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE COMMON SHAREHOLDERS $ (3,454) $ (6,583) $ (15,158) $ (15,224) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40

-Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands Total Direct financing ATM Common Stock [Member] Common Stock [Member] Direct financing Common Stock [Member] ATM Retained Earnings [Member] Noncontrolling Interest [Member] Accumulated Other Comprehensive Income / (Loss) [Member] Beginning Balance at Dec. 31, 2022 $ 71,936 Â Â $ 440,280 Â Â $ (363,370) $ (1,403) $ (3,571) Beginning Balance, shares at Dec. 31, 2022 Â Â Â 170,093 Â Â Â Â Â Shares issued, Value Â Â $ 6,625 Â Â $ 6,625 Â Â Â Shares issued, shares Â Â Â Â Â 4,775 Â Â Â Financing related fees (221) Â Â $ (221) Â Â Â Â Â Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes (37) Â Â $ (37) Â Â Â Â Â Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares Â Â Â 53 Â Â Â Â Â Shares issued upon exercise of stock options 55 Â Â $ 55 Â Â Â Â Â Shares issued upon exercise of stock options, shares Â Â Â 66 Â Â Â Â Â Stock-based compensation 3,580 Â Â $ 3,580 Â Â Â Â Â Unrealized gain on marketable debt securities 150 Â Â Â Â Â Â Â 150 Foreign currency translation adjustment 1,337 Â Â Â Â Â Â Â 1,337 NET LOSS (16,765) Â Â Â Â Â (16,711) (54) Â Ending Balance at Sep. 30, 2023 66,660 Â Â $ 450,282 Â Â (380,081) (1,457) (2,084) Ending Balance, shares at Sep. 30, 2023 Â Â Â 174,987 Â Â Â Â Â Beginning Balance at Jun. 30, 2023 71,258 Â Â $ 448,249 Â Â (372,971) (1,409) (2,611) Beginning Balance, shares at Jun. 30, 2023 Â Â Â 174,439 Â Â Â Â Â Shares issued, Value Â Â 784 Â Â $ 784 Â Â Â Shares issued, shares Â Â Â Â Â 538 Â Â Â Financing related fees (28) Â Â $ (28) Â Â Â Â Â Shares issued upon exercise of stock options 8 Â Â $ 8 Â Â Â Â Â Shares issued upon exercise of stock options, shares Â Â Â 10 Â Â Â Â Â Stock-based compensation 1,269 Â Â $ 1,269 Â Â Â Â Â Unrealized gain on marketable debt securities 9 Â Â Â Â Â Â Â 9 Foreign currency translation adjustment 518 Â Â Â Â Â Â Â 518 NET LOSS (7,158) Â Â Â Â Â (7,110) (48) Â Ending Balance at Sep. 30, 2023 66,660 Â Â $ 450,282 Â Â (380,081) (1,457) (2,084) Ending Balance, shares at Sep. 30, 2023 Â Â Â 174,987 Â Â Â Â Â Beginning Balance at Dec. 31, 2023 62,023 Â Â $ 451,343 Â Â (384,856) (1,396) (3,068) Beginning Balance, shares at Dec. 31, 2023 Â Â Â 174,987 Â Â Â Â Â Shares issued, Value Â $ 14,000 $ 70 Â $ 14,000 $ 70 Â Â Â Shares issued, shares Â Â Â Â 13,462 56 Â Â Â Financing related fees (113) Â Â $ (113) Â Â Â Â Â Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes (23) Â Â $ (23) Â Â Â Â Â Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares Â Â Â 45 Â Â Â Â Â Shares issued upon exercise of stock options 229 Â Â $ 229 Â Â Â Â Â Shares issued upon exercise of stock options, shares Â Â Â 287 Â Â Â Â Â Stock-based compensation 3,762 Â Â $ 3,762 Â Â Â Â Â Unrealized gain on marketable debt securities 5 Â Â Â Â Â Â Â 5 Foreign currency translation adjustment 173 Â Â Â Â Â Â Â 173 NET LOSS (15,332) Â Â Â Â Â (15,336) 4 Â Ending Balance at Sep. 30, 2024 64,794 Â Â $ 469,268 Â Â (400,192) (1,392) (2,890) Ending Balance, shares at Sep. 30, 2024 Â Â Â 188,837 Â Â Â Â Â Beginning Balance at Jun. 30, 2024 66,875 Â Â $ 467,928 Â Â (397,158) (1,425) (2,470) Beginning Balance, shares at Jun. 30, 2024 Â Â Â 188,824 Â Â Â Â Â Shares issued upon exercise of stock options 10 Â Â $ 10 Â Â Â Â Â Shares issued upon exercise of stock options, shares Â Â Â 13 Â Â Â Â Â Stock-based compensation 1,330 Â Â $ 1,330 Â Â Â Â Â Unrealized gain on marketable debt securities 12 Â Â Â Â Â Â Â 12 Foreign currency translation adjustment (432) Â Â Â Â Â Â Â (432) NET LOSS (3,001) Â Â Â Â Â (3,034) 33 Â Ending Balance at Sep. 30, 2024 $ 64,794 Â Â $ 469,268 Â Â $ (400,192) $ (1,392) $ (2,890) Ending Balance, shares at Sep. 30, 2024 Â Â Â 188,837 Â Â Â Â Â X - DefinitionAdjustments to common stock share based compensation requisite service period recognition value. + ReferencesNo definition available. + Details Name: lctx_AdjustmentsToCommonStockShareBasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFinancing related fees. + ReferencesNo definition available. + Details Name: lctx_FinancingRelatedFees Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Net loss attributable to Lineage $ (3,034,000) $ (7,110,000) $ (15,336,000) $ (16,711,000) Net loss attributable to noncontrolling interest 33,000 (48,000) 4,000 (54,000) Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc.to net cash used in operating activities: Â Â Â Â Loss on marketable equity securities, net 6,000 60,000 21,000 170,000 Accretion of income on marketable debt securities Â Â (184,000) (647,000) Depreciation and amortization expense 141,000 143,000 436,000 419,000 Change in right-of-use assets and liabilities Â Â (31,000) 86,000 Amortization of intangible assets 0 33,000 22,000 98,000 Stock-based compensation Â Â 3,762,000 3,580,000 Deferred income tax benefit 0 0 0 (1,803,000) Foreign currency remeasurement and other loss Â Â 309,000 1,892,000 Changes in operating assets and liabilities: Â Â Â Â Accounts receivable Â Â 339,000 (141,000) Prepaid expenses and other current assets Â Â 891,000 56,000 Accounts payable and accrued liabilities Â Â (1,778,000) (3,456,000) Deferred revenue Â Â (5,201,000) (6,036,000) Net cash used in operating activities Â Â (16,746,000) (22,547,000) CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Proceeds from the sale of marketable equity securities Â Â 18,000 196,000 Purchases of marketable debt securities Â Â (8,761,000) (16,403,000) Maturities of marketable debt securities Â Â 4,000,000 53,497,000 Purchase of equipment Â Â (200,000) (583,000) Net cash (used in) provided by investing activities Â Â (4,943,000) 36,707,000 CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Proceeds from employee options exercised Â Â 229,000 88,000 Common shares received and retired for employee taxes paid Â Â (23,000) (37,000) Proceeds from sale of common shares Â Â 14,070,000 6,625,000 Payments for offering costs Â Â (113,000) (199,000) Repayment of finance lease liabilities Â Â (40,000) (41,000) Net cash provided by financing activities Â Â 14,123,000 6,436,000 Effect of exchange rate changes on cash, cash equivalents and restricted cash Â Â (120,000) (532,000) NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Â Â (7,686,000) 20,064,000 CASH, CASH EQUIVALENTS AND RESTRICTED CASH: Â Â Â Â At beginning of the period Â Â 35,992,000 11,936,000 At end of the period 28,306,000 32,000,000 28,306,000 32,000,000 SUPPLEMENTAL DISCLOSURES : Â Â Â Â Cash paid for interest Â Â 6,000 8,000 SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTINGACTIVITIES: Â Â Â Â Property and equipment expenditures in accounts payable Â Â 11,000 8,000 Reconciliation of cash, cash equivalents and restricted cash, end of period: Â Â Â Â Cash and cash equivalents 27,750,000 31,474,000 27,750,000 31,474,000 Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies)) 556,000 526,000 556,000 526,000 Total cash, cash equivalents, and restricted cash $ 28,306,000 $ 32,000,000 $ 28,306,000 $ 32,000,000 X - DefinitionAccretion of income on marketable debt securities + ReferencesNo definition available. + Details Name: lctx_AccretionOfIncomeOnMarketableDebtSecurities Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionChange in right-of-use assets and liabilities. + ReferencesNo definition available. + Details Name: lctx_ChangeInRightofuseAssetsAndLiabilities Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionForeign currency remeasurement, gain (loss), before tax and other loss. + ReferencesNo definition available. + Details Name: lctx_ForeignCurrencyRemeasurementGainLossBeforeTaxAndOtherLoss Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionReconciliation of cash cash equivalents and restricted cash end of period. + ReferencesNo definition available. + Details Name: lctx_ReconciliationOfCashCashEquivalentsAndRestrictedCashEndOfPeriodAbstract Namespace Prefix: lctx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of

borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. +

ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (3,034) $ (7,110) $ (15,336) $ (16,711) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Business Overview 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Organization and Business Overview 1. Organization and Business OverviewWe are a clinical-stage biotechnology company developing novel allogeneic, or â€œoff-the-shelfâ€, cell therapies to address unmet medical needs. Our programs are based on our proprietary, cell-based technology platform, and associated development, formulation, delivery and manufacturing capabilities. From this platform, we design, develop, manufacture, and test specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. The cells we manufacture are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages which are relevant to the underlying condition are transplanted into patients in an effort to (a) replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and (b) restore or augment the patientâ€™s functional activity.Our business strategy is to efficiently leverage our technology platform and our development and manufacturing capabilities to advance our programs internally or in conjunction with strategic partners to further enhance their value and probability of success.A significant area of focus is a collaboration we entered into with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (collectively or individually, â€œRocheâ€ or â€œGenentechâ€), under which our lead cell therapy program known as OpRegenÂ®, is being developed for the treatment of ocular disorders, including geographic atrophy (â€œGAâ€) secondary to age-related macular degeneration (â€œAMDâ€). OpRegen (also known as RG6501) is a suspension of human allogeneic retinal pigmented epithelial (â€œRPEâ€) cells and is currently being evaluated in a Phase 2a multicenter clinical trial in patients with GA secondary to AMD. OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. Under the terms of the Collaboration and License Agreement we entered into with Roche in December 2021 (the â€œRoche Agreementâ€), we received a $50.0 million upfront payment in January 2022 and are eligible to receive up to an additional $620.0 million in developmental, regulatory, and commercialization milestone payments. We also are eligible to receive tiered, double-digit-percentage royalties on net sales of OpRegen in the U.S. and other major markets. On May 7, 2024, we entered into a service agreement with Genentech pursuant to which we will provide supplemental clinical, technical, training, manufacturing, and procurement services to support the ongoing advancement and optimization of the OpRegen program. In September 2024, Roche and Genentech announced receipt of Regenerative Medicine Advanced Therapy (â€œRMATâ€) designation from the U.S. Food and Drug Administration (â€œFDAâ€) for OpRegen for the treatment of GA secondary to dry AMD.Our most advanced unpartnered product candidate is OPC1, an allogeneic oligodendrocyte progenitor cell therapy designed to improve recovery following a spinal cord injury (â€œSCIâ€). OPC1 has been tested in two clinical trials to date: a five patient Phase 1 clinical trial in acute thoracic SCI, where all subjects are followed for at least 10 years; and a 25 patient Phase 1/2a multicenter clinical trial in subacute cervical SCI, where all subjects were evaluated for at least two years. Results from both studies have been published in the Journal of Neurosurgery Spine. OPC1 clinical development has been supported in part by a $14.3 million grant from the California Institute for Regenerative Medicine (â€œCIRMâ€). We plan to apply for additional funding from CIRM for continued clinical development of OPC1 for the treatment of SCI. In December 2023, we filed an Investigational New Drug (â€œINDâ€) amendment for OPC1 as it relates to our proposed DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study, to evaluate the safety and utility of a novel spinal cord delivery device to administer OPC1 to the spinal parenchyma in subacute and chronic SCI patients. In March 2024, we received written correspondence from the FDA, advising us that due to significant workload and conflicting PDUFA priorities at the agency, its review of our IND amendment and the DOSED study protocol is still ongoing. Since that time we have been engaging with the FDA to aid in their review, including through an informal teleconference meeting with the CBER and CDRH divisions of the FDA held on November 12, 2024. Based on that discussion we plan to submit an additional amendment to the IND and final protocol with clarifying information to the FDA by the end of the year. We currently anticipate that the FDA will complete its review of this amendment in Q1 2025 and we do not expect any further feedback or additional information requests that would delay start of the study. We currently plan to commence enrolling the DOSED study as soon as feasible after submitting these updates. Our pipeline of allogeneic, or â€œoff-the-shelfâ€, cell therapy programs currently includes:â€¢RG6501 (OpRegen), an allogeneic RPE cell replacement therapy currently in a Phase 2a multicenter, open-label, single arm clinical trial, being conducted by Roche, for the treatment of GA secondary to AMD, also known as atrophic or dry AMD. â€¢OPC1, an allogeneic oligodendrocyte progenitor cell therapy which we plan to evaluate in the DOSED clinical study, to test the safety and utility of a novel spinal cord delivery device in both subacute and chronic spinal cord injuries and continues to be evaluated in long-term follow-up from a Phase 1/2a multicenter clinical trial for subacute cervical spinal cord injuries. â€¢ANP1, an allogeneic auditory neuron progenitor cell transplant currently in preclinical development for the treatment of debilitating hearing loss.â€¢PNC1, an allogeneic photoreceptor cell transplant currently being developed for the treatment of vision loss due to photoreceptor dysfunction or damage.â€¢RND1, a novel, hypoimmune iPSCs line being developed in collaboration with Factor Bioscience Limited, as assignee from Eterna Therapeutics, Inc., which will be evaluated for differentiation into cell transplant product candidates for central nervous system diseases and other neurology indications.Other ProgramsWe have additional undisclosed product candidates being considered for development and we may consider others which cover a range of therapeutic areas and unmet medical needs. Generally, these product candidates are based on the same platform technology and employ a similar, guided cell differentiation and transplant approach as most of the product candidates described above, but in some cases may also include genetic modifications designed to enhance efficacy and/or safety profiles.In addition to seeking to create value for shareholders by developing product candidates and advancing those candidates through clinical development, we also may seek to create value from our intellectual property or related technologies and capabilities, through licensing collaborations and/or strategic transactions, such as our business development approach to our VAC dendritic cell therapy platform. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 17 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation, Liquidity and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation, Liquidity and Summary of Significant Accounting Policies 2. Basis of Presentation, Liquidity and Summary of Significant Accounting PoliciesThe accompanying unaudited condensed consolidated interim financial statements were prepared in accordance with generally accepted accounting principles in the United States (â€œGAAPâ€) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2023 10-K.The accompanying unaudited condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of our financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts in the condensed consolidated interim financial statements and accompanying notes have been reclassified to conform to the current period presentation. The reclassification of these items had no impact on net loss, net loss per share, financial position or cash flows in the current or prior periods. Specifically, our reclassifications are (i) operating lease right-of-use assets are now presented separately from property and equipment, net, on the condensed consolidated balance sheets, (ii) cost of sales are now included in operating expenses on the condensed consolidated statements of operations, and (iii) foreign currency transaction gains (losses) are now presented separately from other income (expenses) on the condensed consolidated statements of operations.Principles of ConsolidationThe accompanying unaudited condensed consolidated interim financial statements include the accounts of our subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. The following table sets out Lineageâ€™s ownership, directly or indirectly, of the outstanding shares of its subsidiaries as of September 30, 2024:Â Subsidiary Â Field of Business Â Lineage Ownership Â Country Cell Cure Neurosciences Ltd. Â Manufacturing of Lineageâ€™s product candidates Â 94%(1) Â Israel ES Cell International Pte. Ltd. Â Research and clinical grade cell lines Â 100% Â Singapore Â (1)Includes shares owned by Lineage and ES Cell International Pte. Ltd.Lineage consolidates its direct and indirect wholly owned or majority-owned subsidiaries because Lineage has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholdersâ€™ equity on Lineageâ€™s condensed consolidated balance sheets.LiquidityAt September 30, 2024, we had $32.7 million of cash, cash equivalents and marketable securities. At September 30, 2024 and 2023, the Company had restricted cash of $0.1 million required to be set aside for its corporate credit card facility. Additionally, Cell Cure has restricted cash related to its lease. See Note 13 (Commitments and Contingencies). Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities, together with our projected cash flows, will be sufficient to enable us to carry out our planned operations through at least twelve months from the issuance date of the accompanying condensed consolidated interim financial statements.Capital ResourcesSince inception, we have incurred significant operating losses and have funded our operations primarily through the issuance of equity securities, the sale of common stock of our former subsidiaries, OncoCyte Corporation and AgeX Therapeutics, Inc., receipt of proceeds from research grants, revenues from collaborations, royalties from product sales, and sales of research products and services.As of September 30, 2024, $39.97 million remained available for sale under our at-the-market offering program (â€œATMâ€). See Note 10 (Shareholdersâ€™ Equity) for additional information.Additional Capital RequirementsOur financial obligations primarily consist of obligations to licensors under license agreements, obligations related to grants received from government entities, including the Israel Innovation Authority (â€œIIAâ€), obligations under contracts with vendors who provide research services and purchase commitments with suppliers.Our obligations to licensors under license agreements and our obligations related to grants received from government entities require us to make future payments, such as sublicense fees, milestone payments, redemption fees, royalty fees and patent maintenance fees. Sublicense fees are payable to licensors or government entities when we sublicense the applicable intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments, including those related to the Roche Agreement, are due to licensors or government entities upon achievement of commercial, development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of milestone payments and royalties received under the Roche Agreement. See Note 13 (Commitment and Contingencies) for additional information. Royalties, including those related to royalties we may receive under the Roche Agreement, are payable to licensors or government entities based on a percentage of net sales of licensed products. Patent maintenance costs are payable to licensors as reimbursement for the cost of maintaining license patents. Due to the contingent nature of the payments, the amounts and timing of payments to licensors under our in-license agreements are uncertain and may fluctuate significantly from period to period. As of September 30, 2024, we have not included these commitments on our condensed consolidated balance sheet because the achievement of events that would trigger our payment obligations and the timing thereof are not fixed and determinable.In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided.Significant Accounting PoliciesWe describe our significant accounting policies in Note 2 to the consolidated financial statements in Item 8 of the 2023 10-K. There have been no changes to our significant accounting policies during the nine months ended September 30, 2024.Recently Issued Accounting Pronouncements Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and does not believe any will have a material impact on the Companyâ€™s condensed consolidated interim financial statements or related financial statement disclosures.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 expands disclosures about a public entityâ€™s reportable segments and requires more enhanced information about a reportable segmentâ€™s expenses, interim segment profit or loss, and how a public entityâ€™s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. We are currently assessing the new guidance and we believe this will not have a significant impact on our consolidated financial statements.In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40): Disaggregation of Income Statement Expenses (â€œASU 2024-03â€). The purpose of ASU 2024-03 is to improve the disclosures about a public business entityâ€™s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development) ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently assessing the impact that this new guidance will have on our consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue 3. RevenueOur disaggregated revenues were as follows for the periods presented (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues under collaborative agreements Â Â Â Â Â Â Â Â Â Â Â Â Upfront license fees (1) Â $ 3,386 Â Â $ 957 Â Â $ 5,671 Â Â $ 5,949 Â Total revenues under collaborative agreements Â Â 3,386 Â Â Â 957 Â Â Â 5,671 Â Â Â 5,949 Â Â Â Â Â Â Â Â Â Â Â Â Â Royalties, license and other revenues (2) Â Â 393 Â Â Â 289 Â Â Â 960 Â Â Â 908 Â Â Â Â Â Â Â Â Â Â Â Â Â Total revenue Â $ 3,779 Â Â $ 1,246 Â Â $ 6,631 Â Â $ 6,857 Â Â (1)All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement. (2)Included within royalties, license and other revenues recognized for the nine months ended September 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively.We are recognizing the $50.0 million upfront payment under the Roche Agreement utilizing an input method of costs incurred over total estimated costs to be incurred. At each reporting period, we update our total estimated collaboration costs, and any resulting adjustments are recorded on a cumulative basis which would affect revenue and deferred revenue in the period of adjustment. We believe the input methodology represents the most appropriate measure of progress towards satisfaction of the identified performance obligations.For contracts with customers including collaboration partners which are within the scope of Accounting Standards Update (â€œASUâ€) 2014-09 â€“ Revenue from Contracts with Customers (Topic 606), the aggregate amount of the transaction price allocated to remaining performance obligations as of September 30, 2024 was $28.1 million, of which $24.3 million is reported as deferred revenues. The $28.1 million is expected to be converted to revenue substantially by December 2026.Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts receivable, net - beginning of the year (1) Â $ 676 Â Â $ 297 Â Accounts receivable, net - end of the period (1) Â $ 392 Â Â $ 676 Â Â Â Â Â Â Â Â Contract liabilities (1) Â Â Â Â Â Â Deferred revenues - beginning of the year Â $ 29,501 Â Â $ 37,146 Â Deferred revenues - end of the period Â $ 24,300 Â Â $ 29,501 Â Â (1)Excludes grants receivable which are outside the scope of ASU 2014-09. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] Â Marketable Securities 4. Marketable SecuritiesThe following table summarizes the fair value of marketable securities held by the Company and their location in the Companyâ€™s condensed consolidated balance sheet (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Marketable debt securities Â Â Â Â Â Â Included within cash and cash equivalents (1) Â $ 7,332 Â Â $ 8,856 Â Included within marketable securities Â $ 4,949 Â Â $ â€” Â Marketable equity securities Â Â Â Â Â Â Included within marketable securities Â $ 12 Â Â $ 50 Â Â (1)Cash equivalents have an original maturity of three months or less when purchased. Marketable Debt SecuritiesThe following table summarizes the available-for-sale debt securities classified within cash and cash equivalents and within marketable securities in the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024 and December 31, 2023 (in thousands):Â Â Â September 30, 2024 Â Financial Assets: Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Fair Value Â U.S. Treasury securities Â $ 12,274 Â Â $ 7 Â Â $ â€” Â Â $ 12,281 Â Total Â $ 12,274 Â Â $ 7 Â Â $ â€” Â Â $ 12,281 Â Â Â Â December 31, 2023 Â Financial Assets: Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Fair Value Â U.S. Treasury securities Â $ 8,855 Â Â $ 1 Â Â $ â€” Â Â $ 8,856 Â Total Â $ 8,855 Â Â $ 1 Â Â $ â€” Â Â $ 8,856 Â The Company has not recognized an allowance for credit losses on any securities in an unrealized loss position as of September 30, 2024 or December 31, 2023. The Company believes that any individual unrealized losses represent temporary declines resulting from changes in interest rates, and we intend to hold these marketable debt securities to their maturity. As of September 30, 2024, the amortized cost and estimated fair value of the Companyâ€™s available-for-sale debt securities by contractual maturity are shown below (in thousands):Â Available-for-sale debt securities maturing: Â Amortized Cost Â Â Estimated Fair Value Â In one year or less Â $ 12,274 Â Â $ 12,281 Â Total available-for-sale debt securities Â $ 12,274 Â Â $ 12,281 Â Â Marketable Equity SecuritiesMarketable equity securities are reported at fair value with unrealized gains and losses related to mark-to-market adjustments included in income. Lineageâ€™s marketable equity securities have consisted of shares of common stock of OncoCyte Corporation (â€œOCXâ€) and of Hadasit Bio-Holdings Ltd. (â€œHBLâ€). All share prices are determined based on the closing price of OCX and HBL common stock on the last trading day of the applicable quarter. Subsequent to June 30, 2024, Lineage no longer owned any shares of OCX. The following table represents the realized and unrealized (loss) gain on marketable equity securities for the periods presented (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Loss on marketable equity securities, net Â $ (6) Â $ (60) Â $ (21) Â $ (170) Less: Loss recognized in earnings on marketable equity Â Â Â securities sold Â Â â€” Â Â Â 23 Â Â Â 4 Â Â Â 23 Â Unrealized loss recognized on marketable equity Â Â Â securities held at end of period, net Â $ (6) Â $ (37) Â $ (17) Â $ (147) X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Property and Equipment, Net 5. Property and Equipment, NetProperty and equipment, including finance leases, are stated at cost, net of accumulated depreciation and amortization. The cost of property and equipment is depreciated or amortized using the straight-line method over the estimated useful life of the asset, ranging from 3 to 10 years. Finance lease right-of-use assets are amortized over the lease term. Leasehold improvements are amortized over the shorter of the useful life or the lease term.At September 30, 2024 and December 31, 2023, property and equipment, net was comprised of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Equipment, furniture and fixtures Â $ 3,742 Â Â $ 3,614 Â Leasehold improvements Â Â 2,262 Â Â Â 2,313 Â Right-of-use assets - finance lease Â Â 202 Â Â Â 198 Â Accumulated depreciation and amortization Â Â (4,193) Â Â (3,880) Property and equipment, net Â $ 2,013 Â Â $ 2,245 Â Â Depreciation and amortization expense was $141,000 and $143,000 for the three months ended September 30, 2024 and 2023, respectively, and $436,000 and $419,000 for the nine months ended September 30, 2024 and 2023, respectively. These amounts include amortization expense for right-of-use finance lease assets of $13,000 and $14,000 for the three months ended September 30, 2024 and 2023, respectively, and $41,000 and $37,000 for the nine months ended September 30, 2024 and 2023, respectively X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill and Intangible Assets, Net 6. Goodwill and Intangible Assets, NetAt September 30, 2024 and December 31, 2023, goodwill and intangible assets, net consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Goodwill (1) Â $ 10,672 Â Â $ 10,672 Â Â Â Â Â Â Â Â Intangible assets: Â Â Â Â Â Â Acquired IPR&D â€“ OPC1 (from the Asterias Merger) (2) Â $ 31,700 Â Â $ 31,700 Â Acquired IPR&D â€“ VAC (from the Asterias Merger) (2) Â Â 14,840 Â Â Â 14,840 Â Intangible assets subject to amortization: Â Â Â Â Â Â Acquired patents Â Â 18,953 Â Â Â 18,953 Â Acquired royalty contracts (3) Â Â 650 Â Â Â 650 Â Total intangible assets Â Â 66,143 Â Â Â 66,143 Â Accumulated amortization (4) Â Â (19,603) Â Â (19,581) Intangible assets, net Â $ 46,540 Â Â $ 46,562 Â Â (1)Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitments and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment.(2)Asterias had two in-process research and development ("IPR&D") intangible assets that were valued at $46.5 million as part of the purchase price allocation that was performed in connection with the Asterias Merger. The fair value of these assets at the acquisition date consisted of $31.7 million pertaining to the OPC1 program and $14.8 million pertaining to the VAC platform.(3)Asterias had royalty cash flows under patent families it acquired from Geron Corporation. Such patent families are expected to continue to generate revenue, are not used in the OPC1 or the VAC platform, and are considered to be separate long-lived intangible assets under ASC Topic 805, Business Combinations.(4)The acquired patents and acquired royalty contracts were fully amortized as of the end of the first quarter of 2024.Lineage amortizes its intangible assets over an estimated period of 5 to 10 years on a straight-line basis. Lineage recognized $0 and $33,000 in amortization expense of intangible assets during the three months ended September 30, 2024 and 2023, respectively, and $22,000 and $98,000 during the nine months ended September 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Accrued Liabilities 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Accounts Payable and Accrued Liabilities 7. Accounts Payable and Accrued LiabilitiesAt September 30, 2024 and December 31, 2023, accounts payable and accrued liabilities consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts payable Â $ 1,599 Â Â $ 2,050 Â Accrued compensation Â Â 2,494 Â Â Â 3,123 Â Accrued liabilities Â Â 384 Â Â Â 1,097 Â Total Â $ 4,477 Â Â $ 6,270 Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 8. Fair Value MeasurementsFair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value in accordance with ASC 820-10-50, Fair Value Measurements and Disclosures:â€¢Level 1 â€“ Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.â€¢Level 2 â€“ Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.â€¢Level 3 â€“ Inputs to the valuation methodology that are unobservable. Unobservable inputs are those in which little or no market data exists, reflect those that a market participant would use, and are therefore determined using estimates and assumptions developed by the Company.We have not transferred any instruments between the three levels of the fair value hierarchy. The carrying value of cash, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate their respective fair values due to their relative short maturities. We measure our cash equivalents and marketable securities at fair value on a recurring basis. The fair values of such assets were as follows as of September 30, 2024 and December 31, 2023 (in thousands):Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Balance at September 30, 2024 Â Â Quoted Prices in Active Markets for Identical Assets (Level 1) Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Money market fund (1) Â $ 14,466 Â Â $ 14,466 Â Â $ â€“ Â Â $ â€“ Â Marketable debt securities (1) Â Â 7,332 Â Â Â 7,332 Â Â Â â€“ Â Â Â â€“ Â Marketable debt securities Â Â 4,949 Â Â Â 4,949 Â Â Â â€“ Â Â Â â€“ Â Marketable equity securities (2) Â Â 12 Â Â Â 12 Â Â Â â€“ Â Â Â â€“ Â Total assets measured at fair value Â $ 26,759 Â Â $ 26,759 Â Â $ â€“ Â Â $ â€“ Â Â Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Balance at December 31, 2023 Â Â Quoted Prices in Active Markets for Identical Assets (Level 1) Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Money market fund (1) Â $ 21,029 Â Â $ 21,029 Â Â $ â€“ Â Â $ â€“ Â Marketable debt securities (1) Â Â 8,856 Â Â Â 8,856 Â Â Â â€“ Â Â Â â€“ Â Marketable equity securities (2) Â Â 50 Â Â Â 50 Â Â Â â€“ Â Â Â â€“ Â Total assets measured at fair value Â $ 29,935 Â Â $ 29,935 Â Â $ â€“ Â Â $ â€“ Â (1)Included in cash and cash equivalents in the accompanying condensed consolidated balance sheet. Marketable debt securities purchased with an original maturity of three months or less have been classified as cash equivalents. (2)Lineageâ€™s marketable equity securities include the shares of stock of OCX and HBL. Both securities have readily determinable fair values quoted on the NASDAQ or TASE (Level 1). These securities are measured at fair value and reported as current assets on the accompanying condensed consolidated balance sheets based on the closing trading price of the security as of the date being presented. Subsequent to June 30, 2024, Lineage no longer owned any shares of OCX. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Party Transactions 9. Related Party TransactionsIn connection with the putative shareholder class action lawsuits filed in February 2019 and October 2019 challenging the Asterias Merger (see Note 13 (Commitments and Contingencies)), Lineage agreed to pay the expenses for the legal defense of Neal Bradsher, a member of the Lineage board of directors, Broadwood Partners, L.P., a shareholder of Lineage and an affiliate of Mr. Bradsher, and Broadwood Capital, Inc., which serves as the general partner of Broadwood Partners, L.P., all of whom were named defendants in the lawsuits, prior to being dismissed. From inception of the matter through July 2023, Lineage incurred approximately $626,000 in legal expenses on behalf of the foregoing parties, and since then Lineage has not incurred any additional such expenses.On February 6, 2024, Lineage entered into a stock purchase agreement with certain investors relating to the purchase and sale in a registered direct offering of an aggregate of 13,461,540 of Lineageâ€™s common shares. The offering price was $1.04 per common share. The offering closed on February 8, 2024. Broadwood Partners, L.P. purchased 6,730,770 common shares in the offering and Don Bailey, a member of Lineageâ€™s board of directors, purchased 96,155 shares in the offering. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards

Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholdersâ€™ Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Shareholders' Equity 10. Shareholdersâ€™ EquityPreferred SharesLineage is authorized to issue 2,000,000 preferred shares, no par value. The preferred shares may be issued in one or more series as the Lineage board of directors may determine by resolution. The Lineage board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The Lineage board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. As of September 30, 2024 and December 31, 2023, there were no preferred shares issued or outstanding.Common SharesAt December 31, 2022, Lineage was authorized to issue 250,000,000 common shares, no par value. In September 2023, our shareholders approved an increase in the number of authorized common shares, no par value, from 250,000,000 to 450,000,000. As of September 30, 2024 and December 31, 2023, there were 188,837,375 and 174,986,671 common shares issued and outstanding, respectively.At-The-Market Offering ProgramIn May 2020, Lineage entered into a Controlled Equity OfferingSM Sales Agreement (the â€œPrior Sales Agreementâ€) with Cantor Fitzgerald & Co., as sales agent, pursuant to which Lineage could sell its common shares from time to time through an ATM program.In December 2021, Lineage filed a prospectus supplement with the SEC in connection with the offer and sale of up to $64.1 million of common shares through the ATM program under the Prior Sales Agreement, which was updated, amended and supplemented by a prospectus supplement filed with the SEC on May 18, 2023 (the prospectus supplement filed in December 2021, as updated, amended and supplemented by the prospectus supplement filed in May 2023, the â€œPrior Prospectus Supplementâ€).In March 2024, Lineage terminated the Prior Sales Agreement and entered into a sales agreement (the â€œATM Sales Agreementâ€) with B. Riley Securities, Inc., as sales agent (â€œSales Agentâ€), under which Lineage may offer and sell its common shares from time to time through an ATM program.In March 2024, Lineage filed a prospectus supplement with the SEC in connection with the offer and sale of $40.00 million of common shares through the ATM program under the ATM Sales Agreement which was updated, amended and supplemented by a prospectus supplement filed with the SEC on May 14, 2024 in connection with the offer and sale of $39.97 million of common shares through the ATM program under the ATM Sales Agreement (the prospectus supplement filed in March 2024, as updated, amended and supplemented by the prospectus supplement filed in May 2024, the â€œ2024 Prospectus Supplementâ€). Prior to its termination in March 2024, Lineage had sold 4,912,803 common shares under the Prior Prospectus Supplement at a weighted average price per share of $1.41 for gross proceeds of $6.9 million. During the three months ended March 31, 2024, Lineage sold 30,000 common shares under the Prior Prospectus Supplement at a weighted average price per share of $1.23 for gross proceeds of $37,000. During the three months ended June 30, 2024, Lineage sold 25,830 common shares under the 2024 Prospectus Supplement at a weighted average price per share of $1.30 for gross proceeds of $33,000. Lineage did not sell any common shares under the 2024 Prospectus Supplement during the three months ended September 30, 2024. As of September 30, 2024, $39.97 million remained available for sale under the 2024 Prospectus Supplement. The shares offered under the 2024 Prospectus Supplement are registered pursuant to Lineageâ€™s effective shelf registration statement on Form S-3 (File No. 333-277758), which was filed with the SEC on March 7, 2024 and declared effective on May 14, 2024.Lineage agreed to pay Sales Agent a commission of up to 3.0% of the aggregate gross proceeds from the sale of shares under the ATM Sales Agreement, reimburse its legal fees and disbursements, and provide Sales Agent with customary indemnification and contribution rights. The Sales Agreement may be terminated by Sales Agent or Lineage at any time upon notice to the other party, or by Sales Agent at any time in certain circumstances, including the occurrence of a material and adverse change in Lineageâ€™s business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Awards 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Awards 11. Stock-Based AwardsEquity Incentive Plan AwardsIn September 2021, our shareholders approved the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan, and in September 2023, our shareholders approved an amendment to increase the number of common shares that may be issued thereunder by 19,500,000 (as amended to date, the â€œ2021 Planâ€). The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units ("RSUs"), and other stock awards. All of our employees (including those of our affiliates), non-employee directors and consultants are eligible to participate in the 2021 Plan. Subject to adjustment for certain changes in our capitalization, the aggregate number of our common shares that may be issued under the 2021 Plan will not exceed the sum of (i) 34,500,000 shares and (ii) the number of shares subject to awards granted under the Lineage Cell Therapeutics Inc. 2012 Equity Incentive Plan (the â€œ2012 Planâ€) that were outstanding when the 2021 Plan became effective and are not issued because such awards expire or otherwise terminate. As a result of the approval of the 2021 Plan by our shareholders, no additional awards will be granted under the 2012 Plan. As of September 30, 2024, there were 21,727,737 shares available for grant under the 2021 Plan.A summary of activity under the 2021 Plan is as follows (in thousands, except per share amounts):Â Â Â Number of Options Outstanding(in thousands) Â Â Weighted Average Exercise Price(per share) Â Â Weighted Average RemainingContractualTerm (years) Â Â Aggregate Intrinsic Value(in thousands) Â Balance at December 31, 2023 Â Â 10,824 Â Â Â $ 1.42 Â Â Â 8.63 Â Â Â $ 4 Â Options granted Â Â 6,567 Â Â $ 1.11 Â Â Â Â Â Â Â Options exercised Â Â (20) Â $ 1.40 Â Â Â Â Â Â Â Options expired/forfeited/cancelled Â Â (563) Â $ 1.37 Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 16,808 Â Â $ 1.30 Â Â Â 8.45 Â Â Â $ 1 Â Options exercisable at September 30, 2024 Â Â 5,492 Â Â $ 1.42 Â Â Â 7.57 Â Â $ â€” Â Options exercisable and expected to vest Â Â Â Â Â Â at September 30, 2024 Â Â 16,808 Â Â $ 1.30 Â Â Â 8.45 Â Â $ 1 Â Â Â Â Â Number of RSUs Outstanding Â Â WeightedAverage GrantDate Fair Valueper Share Â Balance at December 31, 2023 Â Â 668 Â Â $ 1.11 Â RSUs forfeited Â Â (100) Â $ 0.21 Â RSUs vested Â Â (67) Â $ 1.50 Â Balance at September 30, 2024 Â Â 501 Â Â $ 1.24 Â Â A summary of activity of the 2012 Plan, and the 2018 inducement option (which was issued to a Lineage executive outside of all equity plans), is as follows (in thousands, except per share amounts):Â Â Â Number of Options Outstanding(in thousands) Â Â Weighted Average Exercise Price(per share) Â Balance at December 31, 2023 Â Â 10,839 Â Â $ 1.83 Â Options exercised Â Â (267) Â $ 0.75 Â Options expired/forfeited/cancelled Â Â (504) Â $ 2.15 Â Balance at September 30, 2024 Â Â 10,068 Â Â $ 1.84 Â Options exercisable at September 30, 2024 Â Â 9,589 Â Â $ 1.81 Â Â Stock-Based Compensation ExpenseOperating expenses within the condensed consolidated statements of operations include stock-based compensation expense as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 172 Â Â $ 260 Â Â $ 476 Â Â $ 729 Â General and administrative Â Â 1,158 Â Â Â 1,009 Â Â Â 3,286 Â Â Â 2,851 Â Total stock-based compensation expense Â $ 1,330 Â Â $ 1,269 Â Â $ 3,762 Â Â $ 3,580 Â Â As of September 30, 2024, total unrecognized compensation costs related to unvested stock options and unvested RSUs under all equity plans, was $9.5 million, which is expected to be recognized as expense over a weighted average period of approximately 2.6 years for stock options and 1.3 years for RSUs. Basic and Diluted Net Income (Loss) per Share Attributable to Common ShareholdersBasic earnings per share is calculated by dividing net income or loss attributable to Lineage common shareholders by the weighted average number of common shares outstanding, net of stock options and RSUs, subject to repurchase by Lineage, if any, during the period. Diluted earnings per share is calculated by dividing the net income or loss attributable to Lineage common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under any outstanding stock options, RSUs, warrants (using the treasury-stock method), or convertible preferred stock (using the if-converted method).For the three and nine months ended September 30, 2024 and 2023, Lineage reported a net loss attributable to common shareholders, and therefore, all potentially dilutive common shares were considered antidilutive for those periods.The following common share equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive (in thousands):Â Â Â Three and Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 26,876 Â Â Â 23,168 Â Restricted stock units Â Â 501 Â Â Â 759 Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes 12. Income TaxesThe provision for income taxes for interim periods is generally determined using an estimated annual effective tax rate as prescribed by ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances and changes in valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Lineage conducts business. ASC 740-270 also states that if an entity is unable to reliably estimate some or a part of its ordinary income or loss, the income tax provision or benefit applicable to the item that cannot be estimated shall be reported in the interim period in which the item is reported. For items that Lineage cannot reliably estimate on an annual basis, Lineage uses the actual year to date effective tax rate rather than an estimated annual effective tax rate to determine the tax effect of each item, including the use of all available net operating losses and other credits or deferred tax assets.Under ASC 740, a valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Lineage established a full valuation allowance as of December 31, 2018 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by its subsidiaries.For the tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 (â€œTCJAâ€) eliminated the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement for research activities performed in the United States, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it will decrease our tax deduction for research and development expenses in future years.The 2017 Tax Act subjects a U.S. stockholder to Global Intangible Low-Taxed Income (â€œGILTIâ€) earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. stockholderâ€™s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI: however, this deduction is limited to the companyâ€™s pre-GILTI U.S. income. For the three and nine months ended September 30, 2024, no GILTI was included in the Companyâ€™s tax provision; any GILTI incurred would be fully offset by net operating loss carryforwards. For the three and nine months ended September 30, 2023, Lineage incurred GILTI which was fully offset by net operating loss carryforwards. Lineage did not record a deferred tax benefit or provision expense for the three or nine months ended September 30, 2024 or for the three months ended September 30, 2023. For the first quarter of 2023, Lineage recorded a

$1.8 million deferred tax benefit, due to the ability to offset certain deferred tax assets against the deferred tax liability associated with IPR&D, and the related release of the valuation allowance. It was determined that a portion of the deferred tax liability related to the indefinite lived assets may be realized prior to the expiration of certain pre 2018 net operating losses. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 13. Commitments and ContingenciesReal Property LeasesCarlsbad LeaseIn May 2019, Lineage entered into a lease for approximately 8,841 square feet of rentable space in an office park in Carlsbad, California. The lease was amended in December 2022, and the term was extended for a period of thirty-seven months (the â€œExtended Termâ€) commencing on March 1, 2023 (the â€œExtended Term Commencement Dateâ€). Monthly base rent for the first twelve months of the Extended Term was $25,200, and is subject to 3% annual increases. Rent was abated for months two through four of the Extended Term. As security for the performance of its obligations under the lease, Lineage provided the landlord a security deposit of $17,850, which is included in deposits and other long-term assets on the condensed consolidated balance sheet as of September 30, 2024.In addition to base rent, Lineage pays a pro-rata portion of increases in certain expenses, including real property taxes, utilities (to the extent not separately metered to the leased space) and the landlordâ€™s operating expenses, over the amounts of those expenses incurred by the landlord. These pro-rata charges are expensed as incurred and excluded from the calculation of the right-of-use (â€œROUâ€) assets and lease liabilities.Carlsbad SubleaseIn September 2022, Lineage entered into a sublease for approximately 4,500 square feet of rentable industrial space in Carlsbad, California for a term that commenced on October 1, 2022 and was originally set to expire on March 31, 2024. In February 2024, Lineage extended the term of the sublease for 24 months through March 31, 2026 on similar terms. During the extension period, the base rent is $23,000 per month for the first twelve months and will increase to $23,500 for the remaining twelve months. As security for the performance of its obligations under the sublease, Lineage provided the landlord with a security deposit of $22,500, which is included in deposits and other long-term assets on the condensed consolidated balance sheet as of September 30, 2024. Cell Cure LeaseAs of September 30, 2024, Cell Cure leases approximately 2,096 square meters (approximately 22,600 square feet) of combined office and laboratory space in Jerusalem, Israel under a master lease, as amended, that expires December 31, 2027. Cumulative base rent and construction allowance payments are approximately 165,000 Israeli New Shekels (â€˜ILSâ€) per month (approximately $44,000 as of September 30, 2024), excluding any future rent escalations, and includes options to extend the lease term for five years. The U.S. dollar value of the ILS denominated base rent and construction allowance payments fluctuates based upon currency exchange rates. In addition to base rent, Cell Cure pays a pro-rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located, including parking usage fees. These pro-rata charges are expensed as incurred and excluded from the calculation of the ROU assets and lease liabilities. Cell Cure has security deposits denominated in ILS with the landlord for this master lease held as restricted cash during the term the lease. The U.S. dollars value of the ILS denominated security deposits fluctuates based upon currency exchange rates and was $456,000 as of September 30, 2024, which is included in deposits and other long-term assets on the condensed consolidated balance sheet.Supplemental Information â€“ LeasesSupplemental cash flow information related to leases is as follows (in thousands):Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for amounts included in the measurement of Â Â Â lease liabilities: Â Â Â Â Â Â Operating cash flows from operating leases Â $ 913 Â Â $ 833 Â Operating cash flows from finance leases Â $ 6 Â Â $ 8 Â Financing cash flows from finance leases Â $ 40 Â Â $ 41 Â Â Â Â Â Â Â Â Â Right-of-use assets obtained in exchange for lease obligations: Â Â Â Â Â Â Operating leases Â $ 597 Â Â $ â€” Â Finance leases Â $ 36 Â Â $ 79 Â Â Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate):Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Operating leases Â Â Â Â Â Â Â Right-of-use assets Â $ 2,362 Â Â $ 2,522 Â Â Â Â Â Â Â Â Right-of-use lease liabilities, current Â $ 1,083 Â Â $ 830 Â Right-of-use lease liabilities, noncurrent Â Â 1,533 Â Â Â 1,979 Â Total operating lease liabilities Â $ 2,616 Â Â $ 2,809 Â Â Â Â Â Â Â Â Finance leases Â Â Â Â Â Â Right-of-use assets Â $ 202 Â Â $ 198 Â Accumulated amortization Â Â (74) Â Â (67) Right-of-use assets, net Â $ 128 Â Â $ 131 Â Â Â Â Â Â Â Â Right-of-use lease liabilities, current Â $ 54 Â Â $ 52 Â Right-of-use lease liabilities, noncurrent Â Â 80 Â Â Â 91 Â Total finance lease liabilities Â $ 134 Â Â $ 143 Â Â Â Â Â Â Â Â Weighted average remaining lease term Â Â Â Â Â Â Operating leases Â 2.7Â years Â Â 3.5Â years Â Finance leases Â 2.6Â years Â Â 3.0Â years Â Â Â Â Â Â Â Â Weighted average discount rate Â Â Â Â Â Â Operating leases Â Â 6.3 % Â Â 6.5 % Finance leases Â Â 7.0 % Â Â 6.9 % Â Future minimum lease commitments are as follows as of September 30, 2024 (in thousands):Â Â Â Operating Leases Â Â Finance Leases Â Year Ending December 31, Â Â Â Â Â Â Â 2024 Â $ 293 Â Â $ 16 Â 2025 Â Â 1,165 Â Â Â 64 Â 2026 Â Â 730 Â Â Â 39 Â 2027 Â Â 677 Â Â Â 28 Â Total lease payments Â Â 2,865 Â Â Â 147 Â Less imputed interest Â Â (249) Â Â (13) Total Â $ 2,616 Â Â $ 134 Â Â Operating lease expense was $0.3 million and $0.9 million for each of the three and nine months ended September 30, 2024 and 2023, respectively.CollaborationsRoche AgreementIn December 2021, Lineage entered into the Roche Agreement, wherein Lineage granted to Roche exclusive worldwide rights to develop and commercialize RPE cell therapies, including Lineageâ€™s proprietary cell therapy known as OpRegen, for the treatment of ocular disorders, including GA secondary to AMD.Under the terms of the Roche Agreement, Roche paid Lineage a $50.0 million upfront payment and Lineage is eligible to receive up to an additional $620.0 million in developmental, regulatory and commercialization milestone payments. Lineage also is eligible for tiered, double-digit-percentage royalties on net sales of OpRegen in the U.S. and other major markets. All regulatory and commercial milestone payments and royalty payments are subject to the existence of certain intellectual property rights that cover OpRegen at the time such payments would otherwise become due, and the royalty payments on net sales of OpRegen are subject to financial offsets based on the existence of competing products. Roche assumed responsibility for further clinical development and commercialization of OpRegen. Lineage is responsible for completing activities related to the ongoing clinical study, for which enrollment is complete, and performing certain manufacturing and process development activities.Unless earlier terminated by either party, the Roche Agreement will expire on a product-by-product and country-by-country basis upon the expiration of all of Rocheâ€™s payment obligations under the agreement. Roche may terminate the agreement in its entirety, or on a product-by-product or country-by-country basis, at any time with advance written notice. Either party may terminate the agreement in its entirety with written notice for the other partyâ€™s material breach if such party fails to cure the breach or upon certain insolvency events involving the other party.In January 2022, Lineage received the $50.0 million upfront payment from Roche. Subsequently, Lineage, via Cell Cure, paid $12.1 million to the IIA, and $8.9 million to Hadasit Medical Research Services and Development Ltd. (â€œHadasitâ€). Such payments were made in accordance with obligations under the Innovation Law (as discussed below) and under the terms of Cell Cureâ€™s agreements with Hadasit (as discussed below). The payment obligation to Hadasit was reduced by $1.9 million in accordance with the provisions of such agreements discussed below that reduce the sublicensing fee payable to Hadasit for costs related to Lineageâ€™s performance obligations under the Roche Agreement. To the extent such costs are not incurred within five years after the execution of the Roche Agreement, Cell Cure will be required to pay Hadasit 21.5% of the amount of costs not incurred.ITI Collaboration AgreementIn April 2021, Lineage entered into a collaborative agreement with Immunomic Therapeutics, Inc. (â€œITIâ€) whereby Lineage agreed to perform up to approximately $2.2 million worth of certain research, development, manufacturing, and oversight activities related to the development of an allogeneic VAC-CMV product candidate. ITI will reimburse Lineage for these costs and full-time employee costs for the manufacturing of the VAC-CMV product candidate. As of September 30, 2024, Lineage has a remaining performance obligation of approximately $1.6 million for the aforementioned activities. Upon execution of the agreement in April 2021, $0.5 million was paid by ITI to Lineage. Upon delivery of research-grade VAC-CMV product generated by Lineage, ITI paid an additional $0.5 million in August 2021. ITI is currently evaluating its next step under the agreement.Agreements with Hadasit and IIAThe OpRegen program was supported in part with licenses to technology obtained from Hadasit, the technology transfer company of Hadassah Medical Center, and through a series of research grants from the IIA, an independent agency created to address the needs of global innovation ecosystems. A subset of the intellectual property underlying OpRegen was originally generated at Hadassah Medical Center and licensed to Cell Cure for further development.Under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744, and the regulations, guidelines, rules, procedures and benefit tracks thereunder (collectively, the â€œInnovation Lawâ€), annual research and development programs that meet specified criteria and were approved by a committee of the IIA were eligible for grants. The grants awarded were typically up to 50% of the projectâ€™s expenditures, as determined by the IIA committee and subject to the benefit track under which the grant was awarded.The terms of the grants under the Innovation Law generally require that the products developed as part of the programs under which the grants were given be manufactured in Israel. The know-how developed thereunder may not be transferred outside of Israel unless prior written approval is received from the IIA. Transfer of IIA-funded know-how outside of Israel is subject to approval and payment of a redemption fee to the IIA calculated according to formulas provided under the Innovation Law. In November 2021, the IIA research committee approved an application made by Cell Cure with respect to the grant of an exclusive license and transfer of the technological know-how for OpRegen to Roche. Under the provisions for the redemption fee, Lineage paid the IIA approximately 24.1% of the upfront payment it received under the Roche Agreement, or $12.1 million, and is obligated to pay the IIA approximately 24.1% of any milestone and royalty payments which may be received under the Roche Agreement, up to an aggregate cap on all payments, such cap growing over time via interest accrual until paid in full. As of September 30, 2024, the aggregate cap amount was approximately $94.8 million.Pursuant to the Second Amended and Restated License Agreement, dated June 15, 2017, between Cell Cure and Hadasit, and a certain letter agreement entered into on December 17, 2021, Cell Cure paid a sublicensing fee to Hadasit of $8.9 million or 21.5% of the $50.0 million upfront payment under the Roche Agreement (subject to certain reductions), and Cell Cure is obligated to pay Hadasit (i) a maximum of 21.5% of all milestone payments Lineage receives under the Roche Agreement (subject to certain reductions, including for costs related to Lineageâ€™s performance obligations under the Roche Agreement), and (ii) up to 50% of all royalty payments (subject to a maximum payment of 5% of net sales of products), Lineage receives under the Roche Agreement. The letter agreement generally terminates upon the termination of the Roche Agreement.Second Amendment to Clinical Trial and Option Agreement and License Agreement with Cancer Research UKIn May 2020, Lineage and Asterias entered into a Second Amendment to the Clinical Trial and Option Agreement (the â€œSecond CTOA Amendmentâ€) with CRUK and Cancer Research Technology (â€œCRTâ€). The Second CTOA Amendment amended the initial agreement and the first amendment to the Clinical Trial and Option Agreement, each of which is dated September 8, 2014, between Asterias, CRUK and CRT. Pursuant to the Second CTOA Amendment, Lineage assumed all obligations of Asterias and exercised early its option to acquire data generated in the Phase 1 clinical trial of VAC2 in non-small cell lung cancer being conducted by CRUK.Lineage and CRT effectuated the option by simultaneously entering into a license agreement (the â€œCRT License Agreementâ€) pursuant to which Lineage paid a signature fee of Â£1,250,000 (approximately $1.6 million based upon exchange rates in effect when the fee was paid). For the primary licensed product for the first indication, the CRT License Agreement provides for milestone fees of up to Â£8,000,000 based upon initiation of a Phase 3 clinical trial and the filing for regulatory approval and up to Â£22,500,000 in sales-based milestones payments. Additional milestone fees and sales-based milestone payments would be payable for other products or indications, and mid-single-digit royalty payments are payable on sales of commercial products.Either party may terminate the CRT License Agreement for the uncured material breach of the other party. CRT may terminate the CRT License Agreement in the case of Lineageâ€™s insolvency or if Lineage ceases all development and commercialization of all products under the CRT License Agreement.Other Contingent ObligationsWe have obligations under license agreements and grants received from government entities to make future payments to third parties, which become due and payable on the achievement of certain development, regulatory and commercial milestones or on the sublicense of our rights to another party. These commitments include sublicense fees, milestone payments, redemption fees and royalties. Sublicense fees are payable to licensors or government entities when we sublicense underlying intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments are due to licensors or government entities upon the future achievement of certain development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of any milestone or royalty payment received in respect of IIA-funded programs. Royalties are payable to licensors or government entities based on a percentage of net sales of licensed products. As of September 30, 2024, we have not included these commitments on our condensed consolidated balance sheet because the achievement and timing of these events are not fixed and determinable.Litigation â€“ GeneralFrom time to time, we are subject to legal proceedings and claims in the ordinary course of business. While management presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, cash flows, or overall trends in results of operations, legal proceedings are subject to inherent uncertainties, and unfavorable rulings or outcomes could occur that have individually or in aggregate, a material adverse effect on our business, financial condition or operating results. We are not currently subject to any pending material litigation, other than ordinary routine litigation incidental to our business.Asterias MergerIn November 2018, Lineage, Asterias Biotherapeutics, Inc. (â€œAsteriasâ€), and Patrick Merger Sub, Inc., a wholly owned subsidiary of Lineage, entered into an Agreement and Plan of Merger pursuant to which Lineage agreed to acquire all of the outstanding common stock of Asterias in a stock-for-stock transaction (the â€œAsterias Mergerâ€). The Asterias Merger closed in March 2019. In October 2019, a putative class action lawsuit was filed against the company and certain other named defendants challenging the Asterias Merger.In February 2023, the court approved a Stipulation and Agreement of Compromise and Settlement pursuant to which, Lineage and certain insurers of the defendants paid $10.65 million (the â€œSettlement Amountâ€) into a fund created for the benefit of the purported class and in consideration for the full and final release, settlement and discharge of all claims. Approximately $7.12 million of the Settlement Amount was funded by certain insurers and approximately $3.53 million was paid by Lineage during the first quarter of 2023.Lineage and all defendants have denied, and continue to deny, the claims alleged in the lawsuit and the settlement does not reflect or constitute any admission, concession, presumption, proof, evidence or finding of any liability, fault, wrongdoing or injury or damages, or of any wrongful conduct, acts or omissions on the part any defendant.Premvia Litigation SettlementIn July 2019, the Company, along with other named defendants, was sued in the Superior Court of the State of California in a matter captioned Gonzalez v. Aronowitz, M.D., et al. The plaintiff asserted medical negligence and product liability causes of action relating to the

2017 and 2018 use in a clinical trial of a product candidate, Premvia, that the Company is no longer developing and has no plans to pursue, and that is not related to the cell therapy candidates the Company currently is developing. In February 2023, the Company and the other defendants each entered into settlement agreements with the plaintiff pursuant to which the defendants without admitting any liability, which the defendants expressly denied, each agreed to pay specified amounts to the plaintiff in exchange for a full settlement and release and discharge of claims. The Companyâ€™s insurance covered the full amount paid by the Company excluding the $25,000 insurance deductible.HBL Books and Records RequestOn April 17, 2023, Cell Cure received a motion for disclosure of documents pursuant to Section 198A of the Israeli Companies Law 5759-1999. The motion was filed in the district court in Tel Aviv-Yafo (the â€œCourtâ€) by HBL Hadasit Bio-Holdings Ltd. (â€œHBLâ€), currently an approximately 5% shareholder of Cell Cure. According to the motion, the requested production of documents is intended to allow HBL to examine the possibility of pursuing a derivative action related to, among other things, the validity of an intercompany Collaboration and License Agreement (the â€œIntercompany Agreementâ€) entered into between Lineage and Cell Cure pursuant to which Cell Cure conveyed certain rights and other assets to Lineage, and Lineage agreed to undertake certain liabilities and obligations of Cell Cure relating to the OpRegen program. In its motion, HBL alleges, among other things, that Lineage, in its capacity as Cell Cureâ€™s controlling shareholder, and members of Cell Cureâ€™s board of directors caused damage to Cell Cure because the Intercompany Agreement was an interested party transaction that was not fairly priced and exploits Cell Cureâ€™s resources for the benefit of Lineage. The motion seeks an order to compel Cell Cure to disclose and deliver to HBL the documents described in the motion, such additional, cumulative, or alternative relief as the court deems appropriate, and reimbursement of HBLâ€™s expenses, including attorneysâ€™ fees. The Court held a hearing on the motion on March 14, 2024 at which the Court proposed, and the parties agreed, to retain a third-party valuation firm to assess the fairness of the valuation that was performed in support of the Intercompany Agreement. It is impossible at this time to assess whether the outcome of this proceeding will have a material adverse effect on Lineageâ€™s consolidated results of operations, cash flows or financial position. Therefore, in accordance with ASC 450, Contingencies, Lineage has not recorded any accrual for a contingent liability associated with this legal proceeding based on its belief that a liability, while possible, is not probable nor estimable, and any range of potential contingent liability amounts cannot be reasonably estimated at this time. Lineage records legal expenses as incurred.Employment ContractsLineage has employment agreements with all of its executive officers. Under the provisions of the agreements, Lineage may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations.IndemnificationIn the normal course of business, Lineage may agree to indemnify and reimburse other parties, typically Lineageâ€™s clinical research organizations, investigators, clinical sites, and suppliers, for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of Lineageâ€™s products and services. Indemnification could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to Lineage products and services. The term of these indemnification agreements generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. In addition, Lineage has entered into indemnification agreements with officers and members of its board of directors that will require Lineage, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as officers or directors. The potential future payments Lineage could be required to make under the indemnification agreements described in this paragraph will generally not be subject to any specified maximum amount. Generally, Lineage has not been subject to any material claims or demands for indemnification. Lineage maintains liability insurance policies that limit its financial exposure under the indemnification agreements described in this paragraph. Accordingly, Lineage has not recorded any liabilities for these agreements as of September 30, 2024 or December 31, 2023.Royalty Obligations and License FeesWe have licensing agreements with research institutions, universities and other parties providing us with certain rights to use intellectual property in conducting research and development activities in exchange for the payment of royalties on future product sales, if any. In addition, in order to maintain these licenses and other rights, we must comply with various conditions including the payment of patent related costs and annual minimum maintenance fees.As part of the Asterias Merger, Lineage acquired royalty revenues for cash flows generated under patent families that Asterias acquired from Geron Corporation. Lineage continues to make royalty payments to Geron from royalties generated from these patents. Royalty revenues and royalty payments are included within royalties, license and other revenues and cost of sales, respectively, in our condensed consolidated statements of operations. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Principles of Consolidation Principles of ConsolidationThe accompanying unaudited condensed consolidated interim financial statements include the accounts of our subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. The following table sets out Lineageâ€™s ownership, directly or indirectly, of the outstanding shares of its subsidiaries as of September 30, 2024:Â Subsidiary Â Field of Business Â Lineage Ownership Â Country Cell Cure Neurosciences Ltd. Â Manufacturing of Lineageâ€™s product candidates Â 94%(1) Â Israel ES Cell International Pte. Ltd. Â Research and clinical grade cell lines Â 100% Â Singapore Â (1)Includes shares owned by Lineage and ES Cell International Pte. Ltd.Lineage consolidates its direct and indirect wholly owned or majority-owned subsidiaries because Lineage has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholdersâ€™ equity on Lineageâ€™s condensed consolidated balance sheets. Liquidity LiquidityAt September 30, 2024, we had $32.7 million of cash, cash equivalents and marketable securities. At September 30, 2024 and 2023, the Company had restricted cash of $0.1 million required to be set aside for its corporate credit card facility. Additionally, Cell Cure has restricted cash related to its lease. See Note 13 (Commitments and Contingencies). Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities, together with our projected cash flows, will be sufficient to enable us to carry out our planned operations through at least twelve months from the issuance date of the accompanying condensed consolidated interim financial statements. Capital Resources Capital ResourcesSince inception, we have incurred significant operating losses and have funded our operations primarily through the issuance of equity securities, the sale of common stock of our former subsidiaries, OncoCyte Corporation and AgeX Therapeutics, Inc., receipt of proceeds from research grants, revenues from collaborations, royalties from product sales, and sales of research products and services.As of September 30, 2024, $39.97 million remained available for sale under our at-the-market offering program (â€œATMâ€). See Note 10 (Shareholdersâ€™ Equity) for additional information. Additional Capital Requirements Additional Capital RequirementsOur financial obligations primarily consist of obligations to licensors under license agreements, obligations related to grants received from government entities, including the Israel Innovation Authority (â€œIIAâ€), obligations under contracts with vendors who provide research services and purchase commitments with suppliers.Our obligations to licensors under license agreements and our obligations related to grants received from government entities require us to make future payments, such as sublicense fees, milestone payments, redemption fees, royalty fees and patent maintenance fees. Sublicense fees are payable to licensors or government entities when we sublicense the applicable intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments, including those related to the Roche Agreement, are due to licensors or government entities upon achievement of commercial, development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of milestone payments and royalties received under the Roche Agreement. See Note 13 (Commitment and Contingencies) for additional information. Royalties, including those related to royalties we may receive under the Roche Agreement, are payable to licensors or government entities based on a percentage of net sales of licensed products. Patent maintenance costs are payable to licensors as reimbursement for the cost of maintaining license patents. Due to the contingent nature of the payments, the amounts and timing of payments to licensors under our in-license agreements are uncertain and may fluctuate significantly from period to period. As of September 30, 2024, we have not included these commitments on our condensed consolidated balance sheet because the achievement of events that would trigger our payment obligations and the timing thereof are not fixed and determinable.In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided. Significant Accounting Policies Significant Accounting PoliciesWe describe our significant accounting policies in Note 2 to the consolidated financial statements in Item 8 of the 2023 10-K. There have been no changes to our significant accounting policies during the nine months ended September 30, 2024. Recently Issued Accounting Pronouncements Not Yet Adopted Recently Issued Accounting Pronouncements Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and does not believe any will have a material impact on the Companyâ€™s condensed consolidated interim financial statements or related financial statement disclosures.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 expands disclosures about a public entityâ€™s reportable segments and requires more enhanced information about a reportable segmentâ€™s expenses, interim segment profit or loss, and how a public entityâ€™s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. We are currently assessing the new guidance and we believe this will not have a significant impact on our consolidated financial statements.In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40): Disaggregation of Income Statement Expenses (â€œASU 2024-03â€). The purpose of ASU 2024-03 is to improve the disclosures about a public business entityâ€™s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development) ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently assessing the impact that this new guidance will have on our consolidated financial statements. X - DefinitionAdditional capital requirements. + ReferencesNo definition available. + Details Name: lctx_AdditionalCapitalRequirementsPolicyTextBlock Namespace Prefix: lctx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionCapital resources. + ReferencesNo definition available. + Details Name: lctx_CapitalResourcesPolicyTextBlock Namespace Prefix: lctx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLiquidity. + ReferencesNo definition available. + Details Name: lctx_LiquidityPolicyTextBlock Namespace Prefix: lctx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSignificant accounting policies. + ReferencesNo definition available. + Details Name: lctx_SignificantAccountingPoliciesPolicyTextBlock Namespace Prefix: lctx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries Subsidiary Â Field of Business Â Lineage Ownership Â Country Cell Cure Neurosciences Ltd. Â Manufacturing of Lineageâ€™s product candidates Â 94%(1) Â Israel ES Cell International Pte. Ltd. Â Research and clinical grade cell lines Â 100% Â Singapore Â (1)Includes shares owned by Lineage and ES Cell International Pte. Ltd. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4M -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4MReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of Disaggregated Revenues Our disaggregated revenues were as follows for the periods presented (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues under collaborative agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Upfront license fees (1) Â $ 3,386 Â Â $ 957 Â Â $ 5,671 Â Â $ 5,949 Â Total revenues under collaborative agreements Â Â 3,386 Â Â Â 957 Â Â Â 5,671 Â Â Â 5,949 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalties, license and other revenues (2) Â Â 393 Â Â Â 289 Â Â Â 960 Â Â Â 908 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total revenue Â $ 3,779 Â Â $ 1,246 Â Â $ 6,631 Â Â $ 6,857 Â Â Â (1)All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement. (2)Included within royalties, license and other revenues recognized for the nine months ended September 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively. Schedule of Contract with Customer Contract Liability and Receivable Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts receivable, net - beginning of the year (1) Â $ 676 Â Â $ 297 Â Accounts receivable, net - end of the period (1) Â $ 392 Â Â $ 676 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contract liabilities (1) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenues - beginning of the year Â $ 29,501 Â Â $ 37,146 Â Deferred revenues - end of the period Â $ 24,300 Â Â $ 29,501 Â Â Â (1)Excludes grants receivable which are outside the scope of ASU 2014-09. X - DefinitionTabular

disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities (Tables) 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] Â Schedule Of Fair Value Of Marketable Securities The following table summarizes the fair value of marketable securities held by the Company and their location in the Companyâ€™s condensed consolidated balance sheet (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Marketable debt securities Â Â Â Â Â Â Included within cash and cash equivalents (1) Â $ 7,332 Â Â $ 8,856 Â Included within marketable securities Â $ 4,949 Â Â $ â€” Â Marketable equity securities Â Â Â Â Â Â Included within marketable securities Â $ 12 Â Â $ 50 Â Â (1)Cash equivalents have an original maturity of three months or less when purchased. Summary of Available for Sale Debt Securities The following table summarizes the available-for-sale debt securities classified within cash and cash equivalents and within marketable securities in the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024 and December 31, 2023 (in thousands):Â Â Â September 30, 2024 Â Financial Assets: Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Fair Value Â U.S. Treasury securities Â $ 12,274 Â Â $ 7 Â Â $ â€” Â Â $ 12,281 Â Total Â $ 12,274 Â Â $ 7 Â Â $ â€” Â Â $ 12,281 Â Â Â Â December 31, 2023 Â Financial Assets: Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Fair Value Â U.S. Treasury securities Â $ 8,855 Â Â $ 1 Â Â $ â€” Â Â $ 8,856 Â Total Â $ 8,855 Â Â $ 1 Â Â $ â€” Â Â $ 8,856 Â Schedule of Amortized cost And Estimated fair Value As of September 30, 2024, the amortized cost and estimated fair value of the Companyâ€™s available-for-sale debt securities by contractual maturity are shown below (in thousands):Â Available-for-sale debt securities maturing: Â Amortized Cost Â Â Estimated Fair Value Â In one year or less Â $ 12,274 Â Â $ 12,281 Â Total available-for-sale debt securities Â $ 12,274 Â Â $ 12,281 Â Schedule Of Marketable Equity Securities The following table represents the realized and unrealized (loss) gain on marketable equity securities for the periods presented (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Loss on marketable equity securities, net Â $ (6) Â $ (60) Â $ (21) Â $ (170) Less: Loss recognized in earnings on marketable equity Â Â Â securities sold Â Â â€” Â Â 23 Â Â Â 4 Â Â 23 Â Unrealized loss recognized on marketable equity Â Â Â securities held at end of period, net Â $ (6) Â $ (37) Â $ (17) Â $ (147) X - DefinitionSecurities owned readily marketable. + ReferencesNo definition available. + Details Name: lctx_ScheduleOfSecuritiesOwnedReadilyMarketableTableTextBlock Namespace Prefix: lctx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net (Tables) 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Schedule of Property and Equipment, Net At September 30, 2024 and December 31, 2023, property and equipment, net was comprised of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Equipment, furniture and fixtures Â $ 3,742 Â Â $ 3,614 Â Leasehold improvements Â Â 2,262 Â Â Â 2,313 Â Right-of-use assets - finance lease Â Â 202 Â Â Â 198 Â Accumulated depreciation and amortization Â Â (4,193) Â Â (3,880) Property and equipment, net Â $ 2,013 Â Â $ 2,245 Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of Goodwill and Intangible Assets Net At September 30, 2024 and December 31, 2023, goodwill and intangible assets, net consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Goodwill (1) Â $ 10,672 Â Â $ 10,672 Â Â Â Â Â Â Â Â Intangible assets: Â Â Â Â Â Â Acquired IPR&D â€“ OPC1 (from the Asterias Merger) (2) Â $ 31,700 Â Â $ 31,700 Â Acquired IPR&D â€“ VAC (from the Asterias Merger) (2) Â Â 14,840 Â Â Â 14,840 Â Intangible assets subject to amortization: Â Â Â Â Â Â Acquired patents Â Â 18,953 Â Â Â 18,953 Â Acquired royalty contracts (3) Â Â 650 Â Â Â 650 Â Total intangible assets Â Â 66,143 Â Â Â 66,143 Â Accumulated amortization (4) Â Â (19,603) Â Â (19,581) Intangible assets, net Â $ 46,540 Â Â $ 46,562 Â Â (1)Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitments and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment.(2)Asterias had two in-process research and development ("IPR&D") intangible assets that were valued at $46.5 million as part of the purchase price allocation that was performed in connection with the Asterias Merger. The fair value of these assets at the acquisition date consisted of $31.7 million pertaining to the OPC1 program and $14.8 million pertaining to the VAC platform.(3)Asterias had royalty cash flows under patent families it acquired from Geron Corporation. Such patent families are expected to continue to generate revenue, are not used in the OPC1 or the VAC platform, and are considered to be separate long-lived intangible assets under ASC Topic 805, Business Combinations.(4)The acquired patents and acquired royalty contracts were fully amortized as of the end of the first quarter of 2024.Lineage amortizes its intangible assets over an estimated period of 5 to 10 years on a straight-line basis. Lineage recognized $0 and $33,000 in amortization expense of intangible assets during the three months ended September 30, 2024 and 2023, respectively, and $22,000 and $98,000 during the nine months ended September 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Accrued Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Schedule of Accounts Payable and Accrued Liabilities At September 30, 2024 and December 31, 2023, accounts payable and accrued liabilities consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts payable Â $ 1,599 Â Â $ 2,050 Â Accrued compensation Â Â 2,494 Â Â Â 3,123 Â Accrued liabilities Â Â 384 Â Â Â 1,097 Â Total Â $ 4,477 Â Â $ 6,270 Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis The fair values of such assets were as follows as of September 30, 2024 and December 31, 2023 (in thousands):Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Balance at September 30, 2024 Â Â Quoted Prices in Active Markets for Identical Assets (Level 1) Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Money market fund (1) Â $ 14,466 Â Â $ 14,466 Â Â $ â€” Â Â $ â€” Â Marketable debt securities (1) Â Â 7,332 Â Â Â 7,332 Â Â Â â€” Â Â Â â€” Â Marketable debt securities Â Â 4,949 Â Â Â 4,949 Â Â Â â€” Â Â Â â€” Â Marketable equity securities (2) Â Â 12 Â Â Â 12 Â Â Â â€” Â Â Â â€” Â Total assets measured at fair value Â $ 26,759 Â Â $ 26,759 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Fair Value Measurements Using Â Â Â Balance at December 31, 2023 Â Â Quoted Prices in Active Markets for Identical Assets (Level 1) Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Money market fund (1) Â $ 21,029 Â Â $ 21,029 Â Â $ â€” Â Â $ â€” Â Marketable debt securities (1) Â Â 8,856 Â Â Â 8,856 Â Â Â â€” Â Â Â â€” Â Marketable equity securities (2) Â Â 50 Â Â Â 50 Â Â Â â€” Â Â Â â€” Â Total assets measured at fair value Â $ 29,935 Â Â $ 29,935 Â Â $ â€” Â Â $ â€” Â Â (1)Included in cash and cash equivalents in the accompanying condensed consolidated balance sheet. Marketable debt securities purchased with an original maturity of three months or less have been classified as cash equivalents. (2)Lineageâ€™s marketable equity securities include the shares of stock of OCX and HBL. Both securities have readily determinable fair values quoted on the NASDAQ or TASE (Level 1). These securities are measured at fair value and reported as current assets on the accompanying condensed consolidated balance sheets based on the closing trading price of the security as of the date being presented. Subsequent to June 30, 2024, Lineage no longer owned any shares of OCX. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Awards (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Schedule of Stock Based Compensation Expense Operating expenses within the condensed consolidated statements of operations include stock-based compensation expense as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 172 Â Â $ 260 Â Â $ 476 Â Â $ 729 Â General and administrative Â Â 1,158 Â Â Â 1,009 Â Â Â 3,286 Â Â Â 2,851 Â Total stock-based compensation expense Â $ 1,330 Â Â $ 1,269 Â Â $ 3,762 Â Â $ 3,580 Â Schedule Of Computation Of Diluted Net Loss Per Common Share The following common share equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive (in thousands):Â Â Â Three and Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 26,876 Â Â Â 23,168 Â Restricted stock units Â Â 501 Â Â Â 759 Â 2021 Equity Incentive Plan [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Schedule of Share-based Compensation Activity A summary of activity under the 2021 Plan is as follows (in thousands, except per share amounts):Â Â Â Number of Options Outstanding(in thousands) Â Â Weighted Average Exercise Price(per share) Â Â Weighted Average RemainingContractualTerm (years) Â Â Aggregate Intrinsic Value(in thousands) Â Balance at December 31, 2023 Â Â 10,824 Â Â Â $ 1.42 Â Â Â Â 8.63 Â Â Â $ 4 Â Options granted Â Â 6,567 Â Â Â $ 1.11 Â Â Â Â Â Â Â Â Options exercised Â Â (20) Â $ 1.40 Â Â Â Â Â Â Â Â Options expired/forfeited/cancelled Â Â (563) Â $ 1.37 Â Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 16,808 Â Â Â $ 1.30 Â Â Â Â 8.45 Â Â Â $ 1 Â Options exercisable at September 30, 2024 Â Â 5,492 Â Â Â $ 1.42 Â Â Â Â 7.57 Â Â Â $ â€” Â Options exercisable and expected to vest

Â Â Â Â Â at September 30, 2024 Â Â 16,808 Â Â $ 1.30 Â Â Â 8.45 Â Â $ 1 Â Â Â Â Number of RSUs Outstanding Â Â WeightedAverage GrantDate Fair Valueper Share Â Balance at December 31, 2023 Â Â 668 Â Â $ 1.11 Â RSUs forfeited Â Â (100) Â $ 0.21 Â RSUs vested Â Â (67) Â $ 1.50 Â Balance at September 30, 2024 Â Â 501 Â Â $ 1.24 Â 2012 Equity Incentive Plan and 2018 Inducement Option [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Schedule of Share-based Compensation Activity A summary of activity of the 2012 Plan, and the 2018 inducement option (which was issued to a Lineage executive outside of all equity plans), is as follows (in thousands, except per share amounts):Â Â Â Number of Options Outstanding(in thousands) Â Â Weighted Average Exercise Price(per share) Â Balance at December 31, 2023 Â Â 10,839 Â Â $ 1.83 Â Options exercised Â Â (267) Â $ 0.75 Â Options expired/forfeited/cancelled Â Â (504) Â $ 2.15 Â Balance at September 30, 2024 Â Â 10,068 Â Â $ 1.84 Â Options exercisable at September 30, 2024 Â Â 9,589 Â Â $ 1.81 Â X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of employee stock purchase plan activity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=lctx_TwoThousandAndTwentyOneEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=lctx_TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Supplemental Cash Flow Information Related to Leases Supplemental cash flow information related to leases is as follows (in thousands):Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for amounts included in the measurement of Â Â Â lease liabilities: Â Â Â Â Â Â Operating cash flows from operating leases Â $ 913 Â Â $ 833 Â Operating cash flows from finance leases Â $ 6 Â Â $ 8 Â Financing cash flows from finance leases Â $ 40 Â Â $ 41 Â Â Â Â Â Â Â Â Â Right-of-use assets obtained in exchange for lease obligations: Â Â Â Â Â Â Operating leases Â $ 597 Â Â $â€” Â Finance leases Â $ 36 Â Â $ 79 Â Schedule of Supplemental Balance Sheet Information Related to Leases Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Operating leases Â Â Â Â Â Â Right-of-use assets Â $ 2,362 Â Â $ 2,522 Â Â Â Â Â Â Â Â Right-of-use lease liabilities, current Â $ 1,083 Â Â $ 830 Â Right-of-use lease liabilities, noncurrent Â Â 1,533 Â Â Â 1,979 Â Total operating lease liabilities Â $ 2,616 Â Â $ 2,809 Â Â Â Â Â Â Â Â Finance leases Â Â Â Â Â Â Right-of-use assets Â $ 202 Â Â $ 198 Â Accumulated amortization Â Â (74) Â Â (67) Right-of-use assets, net Â $ 128 Â Â $ 131 Â Â Â Â Â Â Â Â Right-of-use lease liabilities, current Â $ 54 Â Â $ 52 Â Right-of-use lease liabilities, noncurrent Â Â 80 Â Â Â 91 Â Total finance lease liabilities Â $ 134 Â Â $ 143 Â Â Â Â Â Â Â Â Weighted average remaining lease term Â Â Â Â Â Â Operating leases Â 2.7Â years Â Â 3.5Â years Â Finance leases Â 2.6Â years Â Â 3.0Â years Â Â Â Â Â Â Â Â Weighted average discount rate Â Â Â Â Â Â Operating leases Â Â 6.3 % Â Â 6.5 % Finance leases Â Â 7.0 % Â Â 6.9 % Schedule of Future Minimum Lease Commitments Future minimum lease commitments are as follows as of September 30, 2024 (in thousands):Â Â Â Operating Leases Â Â Finance Leases Â Year Ending December 31, Â Â Â Â Â Â Â 2024 Â $ 293 Â Â $ 16 Â 2025 Â Â 1,165 Â Â Â 64 Â 2026 Â Â 730 Â Â Â 39 Â 2027 Â Â 677 Â Â Â 28 Â Total lease payments Â Â 2,865 Â Â Â 147 Â Less imputed interest Â Â (249) Â Â (13) Total Â $ 2,616 Â Â $ 134 Â X - DefinitionSchedule of supplemental cash flow information related to leases [Table Text Block] + ReferencesNo definition available. + Details Name: lctx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock Namespace Prefix: lctx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Business Overview - Additional Information (Details) - USD ($) $ in Millions 1 Months Ended 24 Months Ended Dec. 17, 2021 Jan. 31, 2022 Dec. 31, 2021 Dec. 31, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Amount of grants received Â Â Â $ 14.3 Roche Agreement [Member] Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Upfront payment $ 50.0 $ 50.0 $ 50.0 Â Maximum milestone payments to be received upon performance conditions Â $ 620.0 $ 620.0 Â X - DefinitionMaximum milestone payments to be received upon performance conditions. + ReferencesNo definition available. + Details Name: lctx_MaximumMilestonePaymentsToBeReceivedUponPerformanceConditions Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUpfront payment. + ReferencesNo definition available. + Details Name: lctx_UpfrontPayment Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash received from collaborators during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromCollaborators Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=lctx_RocheAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries (Details) 9 Months Ended Sep. 30, 2024 Cell Cure Neurosciences Ltd [Member] Â Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Â Field of business description Manufacturing of Lineageâ€™s product candidates Ownership percentage by parent 94.00% [1] Es CellInternational Pte Ltd [Member] Â Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Â Field of business description Research and clinical grade cell lines Ownership percentage by parent 100.00% [1] Includes shares owned by Lineage and ES Cell International Pte. Ltd. X - DefinitionField of business description. + ReferencesNo definition available. + Details Name: lctx_FieldOfBusinessDescription Namespace Prefix: lctx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByParent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: srt_OwnershipAxis=lctx_CellCureNeurosciencesLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=lctx_EsCellInternationalPteLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands Sep. 30, 2024 Sep. 30, 2023 Cash and Cash Equivalents [Line Items] Â Â Cash and cash equivalents and marketable securities $ 32,700 Â Amount reserved for future issuance 39,970 Â Corporate Credit Card Facility [Member] Â Â Cash and Cash Equivalents [Line Items] Â Â Restricted cash $ 100 $ 100 X - DefinitionCash And Cash Equivalents And MarketableSecurities. + ReferencesNo definition available. + Details Name: lctx_CashAndCashEquivalentsAndMarketableSecurities Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCommon stock capital value reserved for future issuance. + ReferencesNo definition available. + Details Name: lctx_CommonStockCapitalValueReservedForFutureIssuance Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=lctx_CorporateCreditCardFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue - Schedule of Disaggregated Revenues (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Royalties, license and other revenues [1] $ 393 $ 289 $ 960 $ 908 Total revenues under collaborative agreements 3,386 957 5,671 5,949 Total revenues 3,779 1,246 6,631 6,857 Upfront License Fees [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues under collaborative agreements [2] $ 3,386 $ 957 $ 5,671 $ 5,949 [1] Included within royalties, license and other revenues recognized for the nine months ended September 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively. [2] All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement. X - DefinitionRoyalties, license and other revenues. + ReferencesNo definition available. + Details Name: lctx_RoyaltiesLicenseAndOtherRevenues Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=lctx_UpfrontLicenseFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue - Schedule of Contract with Customer Contract Liability and Receivable (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Revenue from Contract with Customer [Abstract] Â Â Accounts receivable, net - beginning of the year [1] $ 676 $ 297 Accounts receivable, net - end of the period [1] 392 676 Deferred revenues - beginning of the year [1] 29,501 37,146 Deferred revenues - end of the period [1] $ 24,300 $ 29,501 [1] Excludes grants receivable which are outside the scope of ASU 2014-09. X - DefinitionAccounts receivable net current excludes scope of ASU 2014 -09. + ReferencesNo definition available. + Details Name: lctx_AccountsReceivableNetCurrentExcludesScopeOfAsu201409 Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue - Additional Information (Details) - USD ($) 1 Months Ended 9 Months Ended Dec. 17, 2021 Jan. 31, 2022 Dec. 31, 2021 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Revenue recognized included in deferred revenue Â Â Â $ 30,000 $ 87,000 Accounting Standards Update 2014-09 [Member] Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Remaining performance obligations Â Â Â 28,100,000 Â Expected convertion to revenue by 2026 Â Â Â 28,100,000 Â Roche Agreement [Member] Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Upfront payment $ 50,000,000 $ 50,000,000 $ 50,000,000 Â Â Roche Agreement [Member] | Upfront license fees [Member] Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Upfront payment Â $ 50,000,000 Â Â Collaborative Arrangement [Member] | Accounting Standards Update 2014-09 [Member] Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Deferred revenues Â Â Â $ 24,300,000 Â X - DefinitionExpected convertion to revenue by 2026. + ReferencesNo definition available. + Details Name: lctx_ExpectedConvertionToRevenueBy2026 Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRevenue recognized from deferred revenue at beginning of period. + ReferencesNo definition available. + Details Name: lctx_RevenueRecognizedFromDeferredRevenueAtBeginningOfPeriod Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUpfront payment. + ReferencesNo definition available. + Details Name: lctx_UpfrontPayment Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=lctx_AccountingStandardUpdate201409Member Namespace Prefix:

Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lctx_RocheAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=lctx_UpfrontLicenseFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities - Schedule Of Fair Value Of Marketable Securities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Marketable Securities [Line Items] Â Â Â Included within cash and cash equivalents $ 27,750 $ 35,442 $ 31,474 Marketable Debt Securities [Member] Â Â Â Marketable Securities [Line Items] Â Â Â Included within cash and cash equivalents [1] 7,332 8,856 Â Included within marketable securities 4,949 Â Marketable Equity Securities [Member] Â Â Â Marketable Securities [Line Items] Â Â Â Included within marketable securities $ 12 $ 50 Â [1] Cash equivalents have an original maturity of three months or less when purchased. X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByAssetClassAxis=lctx_MarketableDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=lctx_MarketableEquitySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities - Summary of Available for Sale Debt Securities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cash and Cash Equivalents [Line Items] Â Â Amortized cost $ 12,274 $ 8,855 Unrealized gains 7 1 Unrealized losses 0 Fair value 12,281 8,856 US Treasury Securities [Member] Â Â Cash and Cash Equivalents [Line Items] Â Â Amortized cost 12,274 8,855 Unrealized gains 7 1 Unrealized losses 0 Fair value $ 12,281 $ 8,856 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Debt Securities - Schedule of Amortized cost And Estimated fair Value (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cash and Cash Equivalents [Abstract] Â Â Amortized cost, In one year or less $ 12,274 Â Amortized cost, Total available-for-sale debt securities 12,274 $ 8,855 Estimated fair value, In one year or less 12,281 Â Estimated fair value, Total available-for-sale debt securities $ 12,281 $ 8,856 X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities - Schedule Of Marketable Equity Securities (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Investments, Debt and Equity Securities [Abstract] Â Â Â Â Loss on marketable equity securities, net $ (6) $ (60) $ (21) $ (170) Less: Loss recognized in earnings on marketable equity securities sold 0 23 4 23 Unrealized loss recognized on marketable equity securities held at end of period, net $ (6) $ (37) $ (17) $ (147) X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Accumulated depreciation and amortization $ (4,193) $ (3,880) Property and equipment, net 2,013 2,245 Equipment Furniture And Fixtures [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 3,742 3,614 Leasehold Improvements [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 2,262 2,313 Right-of-use assets - Finance Lease [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross $ 202 $ 198 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 +

Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=lctx_EquipmentFurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=lctx_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property, Plant and Equipment [Line Items] Â Â Â Â Depreciation and amortization expense $ 141,000 $ 143,000 $ 436,000 $ 419,000 Amortization expense for right-of-use finance lease assets $ 13,000 $ 14,000 $ 41,000 $ 37,000 Maximum [Member] Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Estimated useful life of asset 10 years Â 10 years Â Minimum [Member] Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Estimated useful life of asset 3 years Â 3 years Â X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Goodwill [1] $ 10,672 $ 10,672 Total intangible assets 66,143 66,143 Accumulated amortization [2] (19,603) (19,581) Intangible assets, net 46,540 46,562 IPR&D - OPC1 [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible assets [3] 31,700 31,700 IPR&D - VAC2 [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible assets [3] 14,840 14,840 Patents [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible assets subject to amortization 18,953 18,953 Royalty Contracts [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible assets subject to amortization [4] $ 650 $ 650 [1] Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitments and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment. [2] The acquired patents and acquired royalty contracts were fully amortized as of the end of the first quarter of 2024. [3] Asterias had two in-process research and development ("IPR&D") intangible assets that were valued at $46.5 million as part of the purchase price allocation that was performed in connection with the Asterias Merger. The fair value of these assets at the acquisition date consisted of $31.7 million pertaining to the OPC1 program and $14.8 million pertaining to the VAC platform. [4] Asterias had royalty cash flows under patent families it acquired from Geron Corporation. Such patent families are expected to continue to generate revenue, are not used in the OPC1 or the VAC platform, and are considered to be separate long-lived intangible assets under ASC Topic 805, Business Combinations X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lctx_InProcessResearchAndDevelopmentOPCOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lctx_InProcessResearchAndDevelopmentVACTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lctx_RoyaltyContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details) (Parenthetical) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 IPR&D - VAC2 [Member] Â Â Indefinite-Lived Intangible Assets [Line Items] Â Â Fair value of intangible assets [1] $ 14,840 $ 14,840 In Process Research and Development [Member] Â Â Indefinite-Lived

Intangible Assets [Line Items] Â Â Fair value of intangible assets 46,500 Â IPR&D - OPC1 [Member] Â Â Indefinite-Lived Intangible Assets [Line Items] Â Â Fair value of intangible assets $ 31,700 Â [1] Asterias had two in-process research and development ("IPR&D") intangible assets that were valued at $46.5 million as part of the purchase price allocation that was performed in connection with the Asterias Merger. The fair value of these assets at the acquisition date consisted of $31.7 million pertaining to the OPC1 program and $14.8 million pertaining to the VAC platform. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lctx_InProcessResearchAndDevelopmentVACTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=lctx_InProcessResearchAndDevelopmentOPCOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Amortization of intangible assets $ 0 $ 33,000 $ 22,000 $ 98,000 Minimum [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Estimated useful life 5 years Â 5 years Â Maximum [Member] Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Estimated useful life 10 years Â 10 years Â X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Accounts payable $ 1,599 $ 2,050 Accrued compensation 2,494 3,123 Accrued liabilities 384 1,097 Total $ 4,477 $ 6,270 X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 55 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets $ 26,759 $ 29,935 Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 26,759 29,935 Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Money Market Funds [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 14,466 21,029 Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 14,466 21,029 Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Marketable Debt Securities [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 4,949 8,856 Marketable Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 4,949 8,856 Marketable Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Marketable Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Marketable Debt Securities [Member] | Cash and Cash Equivalents [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 7,332 Â Marketable Debt Securities [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 7,332 Â Marketable Debt Securities [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Â Marketable Debt Securities [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Â Marketable Equity Securities [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 12 50 Marketable Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets 12 50 Marketable Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets Marketable Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Assets X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=lctx_MarketableDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=lctx_MarketableEquitySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions - Additional Information (Details) - USD ($) 54 Months Ended Feb. 06, 2024 Jul. 31, 2023 Broadwood Partners, L.P [Member] Â Â Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Â Â Sale of stock 6,730,770 Â Parent Company [Member] Â Â Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Â Â offering price $ 1.04 Â Sale of stock 13,461,540 Â Neal Bradsher [Member] | Broadwood Partners, L.P [Member] Â Â Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Â Â

Legal expenses Â $ 626,000 Don M. Bailey [Member] Â Â Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Â Â Sale of stock 96,155 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification - Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LegalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: dei_LegalEntityAxis=lctx_BroadwoodPartnersLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=lctx_NealBradsherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=lctx_DonMBaileyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Feb. 06, 2024 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 May 14, 2024 Feb. 29, 2024 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 Subsidiary or Equity Method Investee [Line Items] Â Â Â Â Â Â Â Â Â Â Â Preferred stock, shares authorized Â 2,000,000 Â Â 2,000,000 Â Â Â 2,000,000 Â Â Preferred stock, no par value Â $ 0 Â Â $ 0 Â Â Â $ 0 Â Â Preferred stock, shares issued Â 0 Â Â 0 Â Â Â 0 Â Â Preferred stock, shares outstanding Â 0 Â Â 0 Â Â Â 0 Â Â Common stock, shares authorized Â 450,000,000 Â Â 450,000,000 450,000,000 Â Â 450,000,000 250,000,000 Â Common stock, no par value Â $ 0 Â Â $ 0 Â Â Â $ 0 $ 0 Â Common stock, shares issued Â 188,837,375 Â Â 188,837,375 Â Â Â 174,986,671 Â Â Common stock, shares outstanding Â 188,837,375 Â Â 188,837,375 Â Â Â 174,986,671 Â Â Net proceeds from issuance of common stock Â Â Â Â $ 14,070 $ 6,625 Â Â Â Â Â Equity securities available for sale Â $ 39,970 Â Â $ 39,970 Â Â Â Â Â Â Parent Company [Member] Â Â Â Â Â Â Â Â Â Â Subsidiary or Equity Method Investee [Line Items] Â Â Â Â Â Â Â Â Â Â Sale of stock 13,461,540 Â Â Â Â Â Â Â Â Â Prior Sales Agreement [Member] | Parent Company [Member] Â Â Â Â Â Â Â Â Â Subsidiary or Equity Method Investee [Line Items] Â Â Â Â Â Â Â Â Â Common stock, shares issued Â Â Â Â Â Â 4,912,803 Â Â Â Net proceeds Â Â Â Â Â Â Â Â Â $ 64,100 Sale of stock Â Â Â 30,000 Â Â Â Â Â Â Â Â Weighted average price per share Â Â Â Â Â Â Â $ 1.41 Â Â Â Gross proceeds Â Â Â Â Â Â Â $ 6,900 Â Â Â Weighted average price per share issuance of common stock Â Â Â $ 1.23 Â Â Â Â Â Â Â Gross proceeds from issuance of common stock Â Â Â $ 37,000 Â Â Â Â Â Â Â ATM Sales Agreement [Member] | B. Riley Securities, Inc. [Member] Â Â Â Â Â Â Â Â Â Â Subsidiary or Equity Method Investee [Line Items] Â Â Â Â Â Â Â Â Â Â Percentage of commission payable Â Â Â Â 3.00% Â Â Â Â Â Â ATM Sales Agreement [Member] | Parent Company [Member] Â Â Â Â Â Â Â Â Â Â Subsidiary or Equity Method Investee [Line Items] Â Â Â Â Â Â Â Â Â Â Net proceeds Â Â Â $ 40,000 Â Â $ 39,970 Â Â Â Â Sale of stock Â 0 25,830 Â Â Â Â Â Â Â Â Â Equity securities available for sale Â $ 39,970 Â Â $ 39,970 Â Â Â Â Â Â Weighted average price per share issuance of common stock Â Â $ 1.3 Â Â Â Â Â Â Â Gross proceeds from issuance of common stock Â Â $ 33,000 Â Â Â Â Â Â Â X - DefinitionCommon stock capital value maximum authorized shares available for future issuance. + ReferencesNo definition available. + Details Name: lctx_CommonStockCapitalValueMaximumAuthorizedSharesAvailableForFutureIssuance Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCommon stock capital value reserved for future issuance. + ReferencesNo definition available. + Details Name: lctx_CommonStockCapitalValueReservedForFutureIssuance Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionGross proceeds from issuance of common stock. + ReferencesNo definition available. + Details Name: lctx_GrossProceedsFromIssuanceOfCommonStock Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross Proceeds from Sale of Common Stock + ReferencesNo definition available. + Details Name: lctx_GrossProceedsFromSaleOfCommonStock Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRefers to a commission payable to the seller as a percentage of gross proceeds from the sale of shares of the entity. + ReferencesNo definition available. + Details Name: lctx_SalesCommissionPercentageOfGrossProceeds Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price per share. + ReferencesNo definition available. + Details Name: lctx_WeightedAveragePricePerShare Namespace Prefix: lctx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price per share issuance of common stock. + ReferencesNo definition available. + Details Name: lctx_WeightedAveragePricePerShareIssuanceOfCommonStock Namespace Prefix: lctx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionFace amount per share of no-par value common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockNoParValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification - Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockNoParValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification - Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=lctx_PriorSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=lctx_AtmSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=lctx_BRileySecuritiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Awards - Schedule of Share-based Compensation Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Weighted Average Grant Date Fair Value Per Share, Beginning balance | $ / shares $ 1.11 Â Weighted Average Grant Date Fair Value Per Share, RSUs forfeited | $ / shares 0.21 Â Weighted Average Grant Date Fair Value Per Share, RSUs Vested | $ / shares 1.50 Â Weighted Average Grant Date Fair Value Per Share, Ending balance | $ / shares $ 1.24 $ 1.11 2021 Equity Incentive Plan [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of Options Outstanding, Beginning balance | shares 10,824 Â Number of RSUs Outstanding, Beginning balance | shares 668 Â Weighted Average Exercise Price of Options Outstanding, Beginning balance | $ / shares $ 1.42 Â Number of Options Outstanding, Options granted | shares 6,567 Â Weighted Average Exercise Price of Options Outstanding, Options granted | $ / shares $ 1.11 Â Number of Options Outstanding, Options exercised | shares (20) Â Weighted Average Exercise Price of Options, Options exercised | $ / shares $ 1.4 Â Number of Options Outstanding, Options forfeited | shares (563) Â Weighted Average Exercise Price of Options Outstanding, Options expired/forfeited/cancelled | $ / shares $ 1.37 Â Number of RSUs Outstanding, RSUs forfeited | shares (100) Â Number of RSUs Outstanding, RSUs vested | shares (67) Â Number of Options Outstanding, Ending balance | shares 16,808 10,824 Number of RSUs Outstanding, Ending balance | shares 501 668 Weighted Average Exercise Price of Options Outstanding, Ending balance | $ / shares $ 1.3 $ 1.42 Number of Options exercisable | shares 5,492 Â Number of Options Exercisable and Expected to Vest | shares 16,808 Â Weighted Average Exercise Price of Options exercisable | $ / shares $ 1.42 Â Weighted Average Exercise Price of Options exercisable and expected to vest | $ / shares $ 1.3 Â Weighted Average Remaining Contractual Team (Years),Options Outstanding 8 years 5 months 12 days 8 years 7 months 17 days Weighted Average Remaining Contractual Team (Years),Options exercisable 7 years 6 months 25 days Â Weighted Average Remaining Contractual Team (Years), Options exercisable and expected to vest 8 years 5 months 12 days Â Aggregate Intrinsic Value, Options Outstanding | $ $ 1 $ 4 Aggregate Intrinsic Value, Options exercisable | $ 0 Â Aggregate Intrinsic Value, Options exercisable and expected to vest | $ $ 1 Â 2012 Equity Incentive Plan and 2018 Inducement Option [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of Options Outstanding, Beginning balance | shares 10,839 Â Weighted Average Exercise Price of Options Outstanding, Beginning balance | $ / shares $ 1.83 Â Number of Options Outstanding, Options exercised | shares (267) Â Weighted Average Exercise Price of Options, Options exercised | $ / shares $ 0.75 Â Number of Options Outstanding, Options forfeited | shares (504) Â Weighted Average Exercise Price of Options Outstanding, Options expired/forfeited/cancelled | $ / shares $ 2.15 Â Number of Options Outstanding, Ending balance | shares 10,068 10,839 Weighted Average Exercise Price of Options Outstanding, Ending balance | $ / shares $ 1.84 $ 1.83 Number of Options exercisable | shares 9,589 Â Weighted Average Exercise Price of Options exercisable | $ / shares $ 1.81 Â X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option

plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -

SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=lctx_TwoThousandTwentyOneEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=lctx_TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Total stock-based compensation expense $ 1,330 $ 1,269 $ 3,762 $ 3,580 Research and Development Expense [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Total stock-based compensation expense 172 260 476 729 General and Administrative Expense [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Total stock-based compensation expense $ 1,158 $ 1,009 $ 3,286 $ 2,851 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Awards - Schedule Of Computation Of Diluted Net Loss Per Common Share (Details) - shares shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement, Option [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Antidilutive securities, shares 26,876 23,168 26,876 23,168 Restricted Stock Units (RSUs) [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Antidilutive securities, shares 501 759 501 759 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Awards - Additional Information (Details) - USD ($) $ in Millions 1 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â unrecognized compensation costs Â $ 9.5 Weighted average period for recognition Â 2 years 7 months 6 days Restricted Stock Units (RSUs) [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Weighted average period for recognition Â 1 year 3 months 18 days 2021 Equity Incentive Plan [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Increase in shares authorized for issuance 19,500,000 Â Number of shares available for grant Â 21,727,737 2021 Equity Incentive Plan [Member] | Maximum [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of shares authorized for issuance Â 34,500,000 X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-

2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=lctx_TwoThousandTwentyOneEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Â GILTI income $ 0 Â Â $ 0 Â Deferred tax benefit $ 0 $ 0 $ 1,800,000 $ 0 $ 1,803,000 X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 63 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Operating cash flows from operating leases $ 913 $ 833 Operating cash flows from finance leases 6 8 Financing cash flows from finance leases 40 41 Operating leases 597 0 Finance leases $ 36 $ 79 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 64 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Lessee, Lease, Description [Line Items] Â Â Right-of-use assets, net $ 2,362 $ 2,522 Right-of-use lease liabilities, current 1,083 830 Right-of-use lease liabilities, noncurrent 1,533 1,979 Total operating lease liabilities 2,616 2,809 Finance leases, Right-of-use lease liabilities, current 54 52 Finance leases, Right-of-use lease liabilities, noncurrent 80 91 Total finance lease liabilities $ 134 $ 143 Weighted average remaining lease term 2 years 8 months 12 days 3 years 6 months Weighted average remaining lease term 2 years 7 months 6 days 3 years Weighted average discount rate 6.30% 6.50% Weighted average discount rate 7.00% 6.90% Operating Lease [Member] Â Â Lessee, Lease, Description [Line Items] Â Â Right-of-use assets, net $ 2,362 $ 2,522 Finance leases [Member] Â Â Lessee, Lease, Description [Line Items] Â Â Finance leases, Right-of-use assets 202 198 Finance leases, Accumulated amortization (74) (67) Finance leases, Right-of-use assets, net $ 128 $ 131 X - DefinitionFinance lease liability excluding other liabilities current. + ReferencesNo definition available. + Details Name: lctx_FinanceLeaseLiabilityExcludingOtherLiabilitiesCurrent Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated amortization of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=lctx_OperatingLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=lctx_FinancingLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Â Â Total $ 2,616 $ 2,809 Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Â Â Total 134 $ 143 Operating Lease [Member] Â Â Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Â Â 2024 293 Â 2025 1,165 Â 2026 730 Â 2027 677 Â Total lease payments 2,865 Â Less imputed interest (249) Â Total 2,616 Â Financing Leases [Member] Â Â Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Â Â 2024 16 Â 2025 64 Â 2026 39 Â 2027 28 Â Total lease payments 147 Â Less imputed interest (13) Â Total $ 134 Â X - ReferencesNo definition available. + Details Name: us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=lctx_OperatingLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=lctx_FinancingLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) 1 Months Ended 3 Months Ended 9 Months Ended 24 Months Ended Dec. 17, 2021 USD ($) Feb. 29, 2024 Feb. 28, 2023 USD ($) Sep. 30, 2022 ftÂ² Jan. 31, 2022 USD ($) Dec. 31, 2021 USD ($) Nov. 30, 2021 USD ($) Aug. 31, 2021 USD ($) Apr. 30, 2021 USD ($) May 31, 2020 USD ($) May 31, 2020 GBP (Â£) May 31, 2019 ftÂ² Sep. 30, 2024 USD ($) ftÂ² mÂ² Sep. 30, 2023 USD ($) Mar. 31, 2023 USD ($) Sep. 30, 2024 USD ($) ftÂ² mÂ² Sep. 30, 2024 ILS (â‚ª) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Mar. 01, 2023 USD ($) Dec. 17, 2017 Loss Contingencies [Line Items] Â Operating lease expense Â Â Â Â Â Â Â Â Â Â Â Â $ 2,616,000 Â Â $ 2,616,000 Â Â $ 2,809,000 Â Â Operating lease expense Â Â Â Â Â Â Â Â Â Â Â Â 300,000 $ 300,000 Â 900,000 Â $ 900,000 Â Â Â Upfront payment Â $ 14,300,000 Â Â Insurance deductable Â Â $ 25,000 Â Roche Agreement [Member] Â Loss Contingencies [Line Items] Â Upfront payment $ 50,000,000 Â Â Â $ 50,000,000 $ 50,000,000 Â Maximum milestone payments to be received upon performance conditions Â Â Â Â 620,000,000 $ 620,000,000 Â Roche Agreement [Member] | Israel Innovation Authority [Member] Â Loss Contingencies [Line Items] Â Loss contingency accrual, payments Â Â Â Â 12,100,000 Â Roche Agreement [Member] | Hadasit Medical Research Services and Development Ltd [Member] Â Loss Contingencies [Line Items] Â Loss contingency accrual, payments Â Â Â Â 8,900,000 Â Contingency withheld amount Â Â Â Â $ 1,900,000 Â Pay costs percentage Â Â Â Â 21.50% Â ITI Collaboration Agreement [Member] Â Loss Contingencies [Line Items] Â Upfront payment Â Â Â Â Â Â $ 500,000 $ 500,000 Â Â Â Â Â Â Â Â Â Â Â Â Budgetary commitment amount Â Â Â Â Â Â Â Â $ 2,200,000 Â Â Â Â Â Â Â Â Â Â Â Â Purchase obligation Â Â Â Â Â Â Â Â Â Â Â Â $ 1,600,000 Â Â $ 1,600,000 Â Â Â Â Â Agreements With Hadasit and IIA [Member] Â Loss Contingencies [Line Items] Â Upfront payment percentage Â Â Â Â Â 24.10% Â Â Â Â Â Â Â Â Â Â Â Â Upfront and Royalty payment Â Â Â Â Â 24.10% Â Â Â Â Â Â Â Â Â Â Â Upfront payment received Â Â Â Â Â Â $ 12,100,000 Â Â Â Â Â Â Â Â Â Â Â Â Grants awarded percentage Â Â Â Â Â Â Â Â Â Â Â 50.00% Â Â 50.00% Â Â Â Â Royalty payment percentage Â 50.00% Aggregate cap amount Â Â Â Â Â Â Â Â Â Â Â $ 94,800,000 Â Â $ 94,800,000 Â Â Â Â Â Sublicensing fee $ 8,900,000 Â Sublicensing fee percentage 21.50% Â Maximum percentage of milestone payments 21.50% Â License Agreement [Member] Â Loss Contingencies [Line Items] Â Agreed signature fee amount Â Â Â Â Â Â Â Â $ 1,600,000 Â£ 1,250,000 Â Â Â Â Â Â Â Â Â License Agreement [Member] | Maximum [Member] Â Loss Contingencies [Line Items] Â Clinical regulatory milestone | Â£ Â Â Â Â Â Â Â Â Â 8,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Sales related milestones | Â£ Â Â Â Â Â Â Â Â Â Â Â Â Â£ 22,500,000 Â Â Â Â Â Â Â Â Â Â Â Settlement Agreement [Member] Â Loss Contingencies [Line Items] Â Litigation settlement amount Â Â 10,650,000 Â Settlement Agreement [Member] | Insurers [Member] Â Loss Contingencies [Line Items] Â Litigation settlement amount Â Â $ 7,120,000 Â Settlement Agreement [Member] | Parent Company [Member] Â Loss Contingencies [Line Items] Â Litigation settlement amount Â $ 3,530,000 Â Â Â Â Â Â Â Â Carlsbad Lease [Member] Â Loss Contingencies [Line Items] Â Rentable area | ftÂ² Â Â Â Â Â Â Â Â Â 8,841 Â Â Â Â Â Â Â Â Â Base monthly rent Â $ 25,200 Â Security deposit Â Â Â Â Â Â Â Â Â Â 17,850 Â Â 17,850 Â Â Â Â Â Lease commencement date Â Â Â Â Â Â Â Â Â Mar. 01, 2023 Â Â Â Â Â Â Â Â Base rent increase rate Â 3.00% Â Carlsbad Sub Lease [Member] Â Loss Contingencies [Line Items] Â Rentable area | ftÂ² Â Â Â 4,500 Â Lease expiration date Â Mar. 31, 2026 Â Mar. 31, 2024 Â Lease commencement date Â Â Â Oct. 01, 2022 Â Rent for first twelve months Â Â Â Â Â Â Â Â Â Â Â Â 23,000 Â Â 23,000 Â Â Â Â Â Â Â Rent for remaining twelve months Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 23,500 Â Â $ 23,500 Â Â Â Â Â Sublease agreement option to extend Â In February 2024, Lineage extended the term of the sublease for 24 months through March 31, 2026 on similar terms. In February 2024, Lineage extended the term of the sublease for 24 months through March 31, 2026 on similar terms. Â Â Â Â Carlsbad Sub Lease [Member] | Deposits and Other Long-Term Assets [Member] Â Loss Contingencies [Line Items] Â Security deposit Â $ 22,500 Â Â $ 22,500 Â Â Â Â Â Cell Cure Leases [Member] Â Loss Contingencies [Line Items] Â Rentable area | ftÂ² Â 22,600 Â Â 22,600 Â Â Â Â Â Lease expiration date Â Dec. 31, 2027 Dec. 31, 2027 Â Â Â Â Land subject to ground leases | mÂ² Â 2,096 Â Â 2,096 Â Â Â Â Â Lessee operating lease renewal term description Â options to extend the lease term for five years options to extend the lease term for five years Â Â Â Â Base rent and construction allowance per month Â $ 44,000 â‚ª 165,000 Â Â Â Â Deposit

assets Â Â Â Â Â Â Â Â Â Â Â Â $ 456,000 Â Â $ 456,000 Â Â Â Â Â X - DefinitionAggregate Cap Amount. + ReferencesNo definition available. + Details Name: lctx_AggregateCapAmount Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAgreed signature fee amount. + ReferencesNo definition available. + Details Name: lctx_AgreedSignatureFeeAmount Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRefers to the base monthly rent as per lease agreement. + ReferencesNo definition available. + Details Name: lctx_BaseRent Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionBase rent and construction allowance per month. + ReferencesNo definition available. + Details Name: lctx_BaseRentAndConstructionAllowancePerMonth Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis refer to base rent increase rate per year as per lease agreement. + ReferencesNo definition available. + Details Name: lctx_BaseRentIncreaseRate Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionBudgetary commitment. + ReferencesNo definition available. + Details Name: lctx_BudgetaryCommitment Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionClinical regulatory milestone. + ReferencesNo definition available. + Details Name: lctx_ClinicalRegulatoryMilestone Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContingency withheld amount. + ReferencesNo definition available. + Details Name: lctx_ContingencyWithheldAmount Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGrants Awarded Percentage. + ReferencesNo definition available. + Details Name: lctx_GrantsAwardedPercentage Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionInsurance deductable. + ReferencesNo definition available. + Details Name: lctx_InsuranceDeductable Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLease commencement date. + ReferencesNo definition available. + Details Name: lctx_LeasesCommencementDate Namespace Prefix: lctx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLessee operating leases option to extend. + ReferencesNo definition available. + Details Name: lctx_LesseeOperatingLeasesOptionToExtend Namespace Prefix: lctx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum milestone payments to be received upon performance conditions. + ReferencesNo definition available. + Details Name: lctx_MaximumMilestonePaymentsToBeReceivedUponPerformanceConditions Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum Percentage of Milestone Payments + ReferencesNo definition available. + Details Name: lctx_MaximumPercentageOfMilestonePayments Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPay costs percentage. + ReferencesNo definition available. + Details Name: lctx_PayCostsPercentage Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty Payment Percentage. + ReferencesNo definition available. + Details Name: lctx_RoyaltyPaymentPercentage Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionSales related milestones. + ReferencesNo definition available. + Details Name: lctx_SalesRelatedMilestones Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSublicensing Fee + ReferencesNo definition available. + Details Name: lctx_SublicensingFee Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSublicensing Fee Percentage. + ReferencesNo definition available. + Details Name: lctx_SublicensingFeePercentage Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionUpfront and royalty payment percentage + ReferencesNo definition available. + Details Name: lctx_UpfrontAndRoyaltyPaymentPercentage Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionUpfront payment. + ReferencesNo definition available. + Details Name: lctx_UpfrontPayment Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUpfront Payment Percentage + ReferencesNo definition available. + Details Name: lctx_UpfrontPaymentPercentage Namespace Prefix: lctx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionUpfront payment received. + ReferencesNo definition available. + Details Name: lctx_UpfrontPaymentReceived Namespace Prefix: lctx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionArea of land subject to a ground lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LandSubjectToGroundLeases Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of terms and conditions of option to extend operating sublease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingSubleaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow reducing loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNet rentable area for properties owned. + ReferencesNo definition available. + Details Name: us-gaap_NetRentableArea Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of cash paid for the settlement of litigation or for other legal issues during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForLegalSettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received from collaborators during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromCollaborators Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecurityDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=lctx_RocheAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=lctx_IsraeliInnovationAuthorityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=lctx_HadasitMedicalResearchServicesAndDevelopmentLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lctx_ITICollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lctx_AgreementsWithHadasitAndIIAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lctx_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lctx_SettlementAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=lctx_InsurersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=lctx_CarlsbadLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=lctx_CarlsbadSubLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=lctx_DepositsAndOtherLongTermAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=lctx_CellCureLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

MO%M"*45O+3T8;6C@(,X1UE 42K&4VHHV@R8B87J;L4GRZ&16+$6.9V=#,61] MY-SJISMW". -NU%D2',@E0 ^JDQH,>DC[H4Q8&CUL47]0O8CWAN(2Y9*F@5Q M;3A\Z#EMAU!P/+%5TAZ)YR&X@5EX'!;+FJ LH=>7.")I9>0*WHF&R(8I*ND< M4!VD(E(4ZC01SX3=@*AR%%N#*_787^13-1Q!,'?:CJ)'%=H,%!T\ /HM!-
M*3:W_T3$$3%0^B03HC7.&Q;Z**1;BR7*TD$7@2]25J8R&'L.,S W0+\)>\M5 M%KU]]_5!-#G44BE)R$N5X:%9'O;X@BVJB[ZPB:)#2XX2$C0,IV#0:BW1"=F2 MX*3U@0'Y)B3Q+;8;P214LJ_!56%<1VITDO- .#^/]R%O\CJ0=7>/(\;2+FOG+9$0&M"V3[R$Y//=+"H30")"@P-0/D(:N %-<(^!"8&/:1 M?C-
%YJ&G*HT^(?"3\9=B:VDJ^#P)U,D%RQ@CV1_1K*- :!?REHN7DWB/\MD$= MY-:ZG: (@+MWA+:6(4TGE,W:HTA]^ M,X_+MN*55LAQ6/>L=V (@1SX@GD@N]U^0SV<>(Z"1/RL>FL MRZ9?0BL])P*0N2H5XJI$:87H![\EEVP/SL5?Q?!)@;AP5JKJFY=SP6=94W+K-OAN1-T$YR,_B+.3H_NH4,'ZSY=47:9^!Q#7%P" M=F/DHO'YH&+P 1B1D3CN=YW &Z@*F["*G@U:
(28ZUH?*+?@]F22N@L%$5V*_]Z",U*=]YGMV/ M>X\ KJ,<] 69!V6@;'6'WX!;8)"@$J!44/]"[2TWY^S&E_P3:1VXD#7E64'# MF9K5RLN7/4UM6.Q,7-1.M2]OH^
CX2!7B,N1/;"$:A..';@)G,!UIOB0JG/4 MCVJ<*B?B%P#&\VU'<>']..;LLY7Z%V4[*UO5HUW&6D#OT83*-J5;!@S8NU"J M#/JW$=2!X]PW6#A8TZOPN
HR85)%8XU6UD1YZE:XZS"U95'-%]HX9Q$.2SR M^J/)CRXX[F](BQ-"E0='#P98L8KFK 2"EU)7[($4R*PVLH1E3#"0+0Z#2AF[U['^40>I5.Q/]^'I"_98GZ2(1,HY"UP#A:9RS$ ^8C_
M9=1DF46E5]<\)K1W;/5L :(,.02>;ZP+HOKOB(^55;&GS+=D<.1-ZFV?I@(K M0/T^2+ 3RJ9D0* MBWR4;?F;UPJ8! L4!OC <$+/X,!C^MQ+@##'R$@K\-]=LFS6J)TW*N>3P9=4
M73 5.K&B(J2G/C)V9]S1:DN<62+TB+G^7C1("4F&SLJFD>VC<=SF%W,@K/RMR':?I*;Q"JSD:'W M=?_QIR=<6(^!"8WD+ZBAQN+DQVUR:W
]S8>>JLE!M9@X%INDY%O9'#RV6Y\H[_1 M6"1EI.!-9E_J<;F]2\;? 7V$<;HYW(6 A%I-G'W[*A$H M4_44W7"'K/I)\Q@_J\(Q_M-M>3M64]G0N SSJQS-
8YW[*_J=9[F9\M3@B0,;5_I3%EEE\E124'3NG MR1NZ=B>>&6K>8V'Z:C9_EBX@Z8*-0\6%U30+X.T+4_K1#-"#3I2!W7!D'#C(MY+A#7"BT%OQ6!?>KWH^' 06TB#:\#Y5-
T%J0YQ:A"77BA5ML\XD@]^%L:IE- M1],%0,;K73.>6\>TQJ:4O>-Y?AO*>/@$!.ZT M8AIO%5I5EGW_G6EU(4[O3P\>BHN:XDZE;.:7<=Z-.U]D=[&IC1N.&-JY[$<:
MYD.I;G21BTZV[ZA&X,K2EP^#WNQPLO,GQXMCKO<=HL02T*\I/Y7C:]! ^#J) M1#U.[2?)$&$%N<)2\^V+O\KA,8/9W,@GI<%E-IV(4T=N12S:$A5EX:N$78>, MF"<(I?
F&XSEV7*\LKZ!4S/=>564*?YZ-\Y2QPK7+(H/RS!*:AQ?1G1S-6%>Z MX9I(+BE3IOOKD^_#_;4?W^87?#YM@KW/H@2T>BDMO<9 (1ZN
MEKGCX9#MK*%8)S$J;G3H+G9T+Y;=U(0;M-T#**0)@I8PT'..DIH9>0&#JUZ7 M2<>C"9]V/O8)$$+\YZ@^0$"HI6[/)]B]OS&J#T_G"*D$7-RA8R[2A>1%_[Z M:9Y
X66\+MM'%]KYD#Z='IY35'_6]G%(T_E#2!.XMKUMC:^YLC5DUHXO0PD_ M6)I;8CT6:U>#*=WYL9.7I:4U%/&*N@ N@75S22T77(^\FD$!:)${[8+!+CB
MV;;^XTC4]X<&*4XX_&510U4LFL:)0)M8F:WB6IEVA?>'2@5O*W3XAGH)&/I' M_,:U:JAJ#L);*36_'S"X:.!!%++U!>1^'$Z,[D8!U#]^)^OVT6P2K_^'VYZL MV3VX:H,_$?0_?
+6@OW='T-\1BB&:N!K@T!O%YI"#/SG<<KW3=IR\@KN^*W M,LD** G\JXOIU_3BLY"L-OI9V17?(E5IBZ_3HWO=[_KX]?D$X\MN/ M"]-UIN:/:R513-
,"/*=W=N(7.B"]#OOT?U!+ P04 " #J@6Y9N*,+>"JGL17?E7'G:[]ML!06W/5V"PB\+;0KN\-4L M^[8TP'-O5,A^$L>C?L&%ZEZ>^[$;%@AO#;%44W&RN0.KU17?0;09N
MQ7+E:*!_>5[R)=R!>RAO#+[U6Y1<%*"LT(H96%QT9X/3JR'-]Q-^%["V._\9 M>3+7^CN]?,DONC$1 @F9(P2.CT>X!BD)"&G\76-VVR7)KUSU#[+VA@9%$*%
M)W^J==@QF,1O&"2U0>)YAX4\RT_<\56^-Y(2BH-PY@U\% MVKG+6W@$5<%YWR$8#?6SVO J&"9O&$[95ZWI1XO/>P96QA=L&OD:C #4%VW8M=>5S#LC]G<^O$_ M]PD0\(?
[\:E:3FW),[CH8CE8,(_0O?SP;C"*SPZP'[;LAX?0#\7EL&':8XWG MOU6&Y<+RY=+ DCO(L8K\%\O68(!QRQ9:8EG2TS"W E:"$3JWS'NDR.I(*/RB
M*\M5;H]/._>U^_*"M_DAU7>$:!)94186(0MA3Y;ZW",HRK_(:_:>/L1Q[(??L\G8 MOT2(;DOPS4-N(@1'B7Y$8ONVQI94_86K"ML@IL%+,KL+]M@W=-EL@TTQ^3\Z
ML\HA#P_#%3I15HX5@!6>$ZE,6^==J[PK^I% ?/Z"=:+PH0YSG,8D:6?VV,R% M)#10:N,(/J0,:DM9G*,IT]4^M+8,T0V/'7DMN-J0$MA=/=?\+]RT0X$V9C]BORL%OU2-LN
M>=BCU,4F:D,S>=2+U.ML?P3-)FEPUM+:O;6I,;I-MS>4MN MG*(001\2LLY>6M9F>-8C#K,LTY7RNM\YU,L3?0@Q//KP;I(D\=GL[L'.9GF W=P%E= M8]H.AA_C*:.!P>",
[6V]]GGOQ;WR7IH.FD"*:&=3!#\->VE:8W_4[8HW;K5!KVO+3SEE_LX^L.M %NZEX_&E/?3*;C0P"@\N?-JSDH3), T;G> MMSGCI,ZG5X*^Q8=81"]T' V&H[VVKZE0;D4IMI<6@,A]?
O(MQ;(E9OPS MIW8*%F]6%C>(%Q5[]]!486_?Z;._:$% MV@OHY;]02P,$% @ ZH%N62,!6L0 !@ 2Q !D !X;"]W;W)K&ULO5C;;ALW$'W75PR4(+ !67=?XAM@*TZ=PFF"V$X#
M%'V@=D=:UKODAN1:4;^^,[/2>BW+BHL"?;&X)&=X.#QGAO3QS+H[GR &^)&E MQI\TDQ#RPT['1PEFRK=MCN9&)HWO=[E#%8I2EG7ZWN]?)E#;-TV/I
M^^Q.CVT14FWPLP-?9)ER\W-,[>RDV6LN.[[H:1*XHW-ZG*LI7F.XS3\[^NI4 M7F*=H?':&G X.6F>]0[/ASQ?)GS5./.U-O!.QM;>\<>'^*3994"88A38@Z*?
M>QQAFK(C@O%]X;-9+:P4'W&8/^PJ ON,N% M!.4[%=3IL;,S<#R;O'%#MBK6!$X;/I3KX&A4DUTX_:C<'08U3A&N,2J<#AK] M<2>0:Y[0B19NSDLW_6??S68WPS:L]00W"<+$
MIJ1+;:90#I?BU'_3<.!AI1U0I Hs.$'R'>56[\@YL$TQC&M(S:-0V'>,XU" W/I(#H+8BH)+:0D.]HR0YI8(T= M6[UM> W[K<&@3[\'K8/=O2?6Z\/R&H:MM\.W]"M[[1_5 ?$28;X)TG-.>XQC
MMRO 1JMH$W6/M ^P3D^U42EY"6PZY],+B4.$K-2II9-![V&6H(&\<%"J2U^ MQ)1W'+1_1Q=UKW3* SM4+G:\>AIZB%+EO]HEP2?.S&[]P2GD.RAHF\:I/ MV/0""C;>4\A-
I"GL9]YC\(=PEED7*#]4=JP/<&NH;J;R_0O52U_ON+)DX^$] M"^XK"ZYQV[YNPPU-\(6;KY*@U=\?,C$?Z+7H/N@U;FP@##^;]50P_Q]^UM$N
M0WD$K%37$OV&.4+%9:HAXH*Q@6X(D9T:P4{*4,Q3.6UB(D0.8QTH%PE&O@R8 M^0]/R*9XV W/A-QZ75X=GJ,*N7X2QO8C=&-,-=Z+/%207;6]);V."]KDRH(T MRZ'4$1.
ELJMHWL2*2CBE,Z#GNX:++Z)LQF09,VT!*]-0!JE(!#1?:L4#DHW M)V(+B4TE(7NL*VE5FS2Q3-K+M-$F)JS?>JO4>\6/B/G!RQ(*G8G<'M>.=3I]
M0;J@ND(:EOI9/]'Y1;6%&IL_4%8U"'-4 MKDJ>-8D]DMX+]O7$M)YY+\KJ4,N]FT]'Q(*(0WM@[H=ZX#E[UFDV%=GR.56$
M2V6G=/1,C)U=@=TJ"@(K,HNMG)HE8+XN3<"VR&:;ABCA)U_;],+--$*4P<3+6 MGE'W.EH$;X824!TQ"@M.EH4EHC"QX&2J@!M]DW7)V0KPTH"J&VG7*48!L9HOJ;_R/-611.=
[H>BD M7!NNB[&G4(G:+?Q:$+T>Y+4(+Z4V.BK2.,%N9B2WS6NQ(SCMM86Y2B1E8:X(MP-AK?-AB&FP++7@'&\^0$RG[RM%I&U-Z+!=@+ROBNY&;1OU%L))!?J/-;1AO
M2'*5LENU&EQ@?H:Q!8:8^QJV8 ^VR]_NHM'O+1J]?>IJ7)%^#Z5HU0L'[8/T M;81!:Y=:%B)"1K &C=N5DE'SM=:^#FVP7R%:-H;46O=PZ-0>>!FZJ3QC^9Y3
MF%"^]:K>ZJ5\5CX0'Z:7SVS*)%/. 2E.R+3;WM]M@BN?KN5'L+D\%\&PO=V]R:W-H965T.DM@%G+]@"W<)(>GDH^D!+(XM8B=225)STZSND9,7&VNX%^R)QAIPS
M9V8X)&=;J3[K$M' /"6\R<;J46,]F:B@M<*=!M73/U*W6%46B&A\Z3&]P:4UW!_OT#^XV"F6-=/X5E:_\]R4LU8;6??&)-=<='_VW.=ASV :GC"(
M>X/8\>X<.9;OF&&+F9);4'8UH=F!"]59$SDN;%$>C:)93G9FL5)47V5>@(D< MWG]I>4,9-S[\C&86&')@EP59#W;?@<4GP&[ADQ2FU/!>Y)@?V@=$;& 7[]C= MQV@8O&:)-'%
[R#]'ZL*J8,(=!PQ_+M3:*]LF?QT+OD-/C MR+9W[G3#,IQ[U!P:U1-ZB^^_BR;A#V=XIP/O]!SZ?ZW2>;#K,9S!.YS#USDN MLJK-N=A P043&4*%U [:!Z80M&$&T3*C>+VO#:F;
<:B[:"BA=H?=I)IC42><7$Q@6])-20@)$0A?""#)0>PX?] M\$$Y5[*X(KC.7KN$O#(;7'<&!E4]AI_LN)15#KRF:) 0!GC24I>DHG%/\X#Y MU]A+]0X!NLUF>RZQZ7R'6:]-G+:Q#^1ZJZ
6Z:I),2/:\NF7=Z(C3KQR.]G9;T2K!36M#@)M\%?[9C#1>0^#=I/Z3*!V=2%7L MQY.8ODF4C!Z.%.']<)]:[Q#=3D?+?[LEX0VD?G2;P"6-$%G\Z#>%R=*H[;+HN MB$T8)>X?I]<4_#ET?
*:+E7C9)%] E$9^&(:T#'(G)DXL)'3U-:5"VLS=\8KV M>#U5XZZLE,@&W8U7T6EG]1>0)I/>AY.BV]Y%YT&X;OE?#ESS:K=S6UN:[JC MX_%:?P=-^[M MN>/Y8J/-
%YLA.OB6[\)>!IESY7F,;Y,,;A"I3>701QL-SI*=>9XBS^[M'.4;[!#]4=X;>NNW**G,L:!2%V!P=1G,X_.K$9_W!SY+W-B]-; G2ZV_\,M- M>AE$:[J3!PC"'K_(J-
/V/&2[2R_C]LZK/C80!)99W.&V&R()=%_13?FCCL"4RC M)P0&C<# VUTK\E9>"R=F%T9OP/!I0N.%=]5+DW&RX*3<.4-?)$#NHN^(T5\O)\TH%^P[,$P"F$0#4;/X
U;KX<>;_A37L.UM(G2MC((?\V7 MUAGBSM_'PE!K&1W7PO5T;DN1X&5 !6/1W&,P>_4BGD1OGO%AU/HP>@[]9S/W M+.AQDR<]^!_*8.Z \N0P7Z)ID^4%KC%I=F. _PQAO0\H=X"B
2P(,-%4^]9A M"GH%+D-8:45-1!9KZ,B"=G1E2=QVST^.*#Y0>M(ZT8F[\!+B*)R<#MK%R4]Z"YUA%R;CB/1./FDGU&&R8#()X]&P M>1!84N65$IRMY
2N@,R(O(#X+)]$0FN5X&D/WT),Z_R]A- G'HZA93 8^<6T6 M#7]*LCL<,?R6H+5;JI2523+JUE :F2#H>R*"IY"0!NZ%JG![DC7MU#,;4*4
M*REXX]!;L0T6GU5T2BKI)%K^7N7(;#Z6P1 L(GS0#B$>0F>A\URZW%O/0 N* M.!$;BX2@NL1T ZO*$(Z!E+I19?TMJ(]"]^"3AI0"'L(&(1/WY)1V%)]$KPOY
MW9OZL*LXF9<4!%;=\ZQJT3*1@MMHTR5>LBT1@I;! M0?=(E%PF'%E#'=0'FTRH\]D;TRVFE+^0+=!N"=AXNW=]J:348X&G:X"U&=L;AO M!12QM1&Y#Q2UE%%O^HP$UWD))
<+>]'R-/4I"6X;"9K"BEF>AHIO4-.5+'A$T M4TZZ'1U]ZWB'AA0NM"FU\<'KP5U%Z?M14!@NF)+B1Y)D5.+I1Q&B-9$0#4?! M4+YI+_2GF5&5W=';.ZW-
@3NACP!+^""2U;6&)5(!4+X96.EB_5K1-':D]3>> MSN\6Q.I2)C"-QB%<599N*B(DU\0;WWA$ 6B=S'U/ M)#9(I>'")P7]$]*&;<-A&-$-0UEY
MU&PYN87UC#\T*JV.)R.YYS)#;2FOQS7D<>VI2[R^MZDA,&LH=^HA;$P8#+P) M]4W:IP]>3;[K:_&^;UN+PI7O_H M>"_,6A*3%*Y(-.J=C@,P]2!?OSA=^N%YJ1V-XGZ9T6\?-'R
OJ\T=?3FA16T MOZ9F_P)02P,$% @ ZH%N6:VMSI^4 @ &P8 !D !X;"]W;W)K&ULI97?;]HP$,??^2NL:)HV*2(AA%(81()VU2:M$FKW MXV':@Y-J\A[ECLI+K3)8 A#Q47>NF5 MQM3S(-
!9"1750UF#P)M"]HH:/*IMH&L%-'=!%0^B,#P+*LJ$ERR<;:.2A6P, M9P(VBNBFJJAZ7 .7NZ4W\O:&&[8MC34$R:*F6[@%\[7>*#P%/25G%0C-I" * MBJ6W&LW7L?
5W#M\8[/3!GMA*4BGO[.%3OO1"*P@X9,82*"[W< &<6Q#*^-4Q MO3ZE#3S<[^E7KG:L):4:+B3_SG)3+KUSC^10T(:;&[G["%T]$\O+)-?ND^Q: MWQ@S9HTVLN]"\5PQT:[TH?
L>#@+.PQ<"HBX@?&4T99X:!7@0& ML]F8(.O(ZY8D6LI3*Q)!Y%#_F=\@"I[]=%>ZCHZ:R%>DC&H4^B,(I/ M\,9]Z6/'&[_ ZRK63R53KLF/5:]-PA_+5V,EM\3X.-$VT%S7-
(.EAQVB0=V# ME[QY-3H+WY_0&_=ZXU/T_WJD^3CNJ=#\]\9R8R8<#8= M?)&&VD^^5=OP3^[MV+RF M:LN$)AP*# V'TXE'5#N*VH.1M6O_5!H<)FY;XO0&91WPOI#2[
\V0?]_D/P& M4$L#!!0 (_J!;EF>/EX^L@8 *P1 9 >&PO=V]R:W-H965T'@V)GDO\$W TK;&C#R9:7U-#Q?926= @$!"ZL@"QY\;. EE76ZB,J(H! J_/+;&
(>6PO[@$84D*B0>=UC(HWS#'3\]-GK) M#$FC-1IX5[TV@A.*DC)U!M*U'.G[[@P!N7%;!+X+8R@!%W]KCOT#B))--H MZ"P82AXQ=, NM7*Y96]5!ME=_3Z":I E-
;*SY$F#4RA[;#3HLF20C)^P-VH\ M'7EIH__V[(VPJ=3DK&5_36;6&2R.OS?Y'$R-YNDACFT)4_AI(.=8<'<0.?T MMQ?#W<'1$X#'#>#Q4]:?
DYHG#6V&N=]CCRP0YF_\O+!4XF@O8]PREP,KC4@! M1]QAOU4R8S/ YDP!>RMC3C-L.,DXMINU2"G:L)(+_P*#K.P<#.-,"CX34K@5 M$XIDM%*BM< M'7TA"]S#+,#E.M-
2+P1*538$(=IN+T>>IBEZRA7&;RE:<-IA=FJ+13+%"2"IPJK<(& M<6 *]D>:V.C _?B.GI?D!GZEUMAZ[&OKJ?:4I%#1^@I=Y@+#C0A<\%?I.PI! MK; .&P8W3MI5HUY8;$.C1H+
INCZ(@Y+ 6IK'&5 0?#44EEJ/+!.X#8+H>(Q M*E51DF=$01@"/(?X8)/7Y]37:M5CWX'E_";DLB880V2EB%N0V*O00S6;D+++ M#0"39-/6.6@U:M/ _2"=$(=R8%
<$+;U$^Y3:G&*!UD5(%A GJ[HK6"FP8JKN9 M+/DJSI!O:6HJ5&QW&"]+HV]] @1PL$52@A-MX:'P4 4(?E>1G(O87-M'.; M52;6S_>&XIBNC
?)X$>%R&1#*R%GOAPLI%&5Z+45#SHZD4^5,10&/ ()&T+3 M1H5QB:WJBWF)6::V#;1J;8@2N*4[*&;89O6^'L@- Q9FAWYVQ%X)2I6N++ZV MVX=;CU'C5RJ6O&BX;A+
3L5"B3G.8,E^ M]"SP<=TFL=W:,G?:*+S?"J8.M_ 0!*NZ%^85>O=JN,U>LN&X.][=;0]\/R=' MZ]'6Y3H;&ZK M?=%NO5/$(LONE*%26>$YG^+NF87Z^ '%B$"X1(*>KXD_ M4HWW
T7G)!Q9+446=M&8:G^3Z;$GXE-62,Z<#/A#E#\^BH50Z%VDOU5@=6+Y M(MQ):&\%\->,;.-()48"LQR.-C>1]IS@?R FQ->3+W?>T>VS98/(R]"1+S# M-N%_TZ;8]-)QH=@OK'
M9/IF\HD\^S*9OF6OXB%KVU.SO$0.!+$_'Z?I,\HL)M/ZF MW%"EHRNIX@Z=T6^X0\2M-P)=Q3V"IL@BIBF(HC,*%^BQ*1ZE,.X$#_>_WRL% MS3;2K7-%)Q:IU0(;6R]5/
BLTX%9Z+%-5[-^ZP9=@%GX_PDP'+1YA\MT,]O\ M%3$)-_"U>/@? TL7]]%BP&ULE5;;MLX$/V5@5L4+6#8\I8F! M)-UBNVC:R.W/BSV@9;&%A&*U))TE?S]G]%DQ2T2
WVQ16KFS)DS,Z3,&^?O M0LDU9%)IEBW&E MM!TLS|/>K5^>NVTTVO*MI["M*N4?KMBXYF(P&>PVONA-&65CO#ROU8;_3LZNYV">#OS0W8>^9)).5R^%!<##(AQ(;S M*
@*?]_YFHT1(-#XK\,<|"%+= M!DHLWZFHEN?>-># %&FCRD%)-WB"GK13E:_1XJ^$7EU_8J,@%W2H?'^B;5S:H MI%C%99&\/D)
[WI.>'T'^O0H>Q3D=T0(,/EG)G;39%03MCH&6FL#:&WI;_\%D..RDU.2=F"/N?1K>"8-O)2 M&<-VH^TFA;@,D;U6@6[8;V#T.C#3)Q>9)C-Z?>VJ2D> CD?AO!RJFB<:\6T+'L?1[ZY2"(
M!X@9(P9-Z2IJV#-954&QI$>A1& 4+^G4E71(M=>BG:,52[D*'2H= AN^! MHFW.=>]"3C&L]PJJZ]NY>PX-A])(6T\4P MRS+AT-:I+Q_@5XRF6>^BH)Z\<4)(\D8?
M,H%H2,&MH]60B?KXEY4^T"J*+20 M1HRPA:2[0"/ZO->\B_;D>62.%F2?.AQZH,C1Y7>8#X]^#EW]29NVLY.SC[@5 M88QJ2H[UZ<3*=':+\-&.BJ@GBI'9'=MY(?P5!9B-5
GYTZK@\C8KS#ZRN%T^3A MQY'\.;VGQO(QCNE&#DZ>B:.Z*FS>;QWDU9R%LGW@JBXM;&]5/O=_I/DLXV) M'\W;[YD;Y7&^'173R&J]9Z/AH0+[]1F@7T=7I7EZYB%L^/9;XK&
(O!GB_=C@ MNX4$Z#_4EO\#4$L#!!0 (_J!;EDLR|S)JP< "87 9 >&PO=V]R M:W-H965T^#+>*QB]W?/K"+JZ72GTPF MA&5?BKPTUYW.VI-MVN23!3W8E<+:\
[_4XS\5$N,DL3W9NKBB_$5-A_ M5X\:H^Z:2RH+41JI2J;%_+ISVW]S-Z+];L-_I%B:UC>G?611-C^;KB_=[I#EQDWXE[EO\K49M>=28>E M8L[KW'Y4RQ]$T.>,^"4J-^X_6_]J
YR8U,:](A!C7,C2__(O 8<6P:1WA& 0 M" 9.;G^0D_(MM_SF2]LET[0;W.C#]>]H(9PLR2A3J[$]06=OIAG7(E-Y*K1Y M\=UDT!]?LG>?:VE75UT+_K2KFP1>=Y[7X BO" :@2IL9]JY,1;I-
WX5<:^$& MC7!W@Y,,IZ**V; 7L4%O,#K!;[A6=NCX#8_P\JQ_][.C-7PA_\=TM&S&!UF M03'RQE0\$=<=!($1^DET;EY\US_O79X0<+06<'2*^Y8U_GG"#J>YI'LQ.VY7
M]@B_%U]+U&\R["20(P"9-(S7-E-;_H9%]S!A:L$&4;_7HS]6K2F-HXQ8J5C% M-7OB>2UB]DLF]O; 65=L)CROE,F2J5(PI5FAM& 4&(/-\R"MA%DIKA.F9JS
M5&I$K]*>2RJLT(@!;%@A(1B5UQ39_MP3M'MZS>47:UY9%S.A:7.0%5^\7#52 M8;2G#2\=AXTHT(3GK##B&FG(8/%DHDR$&\@GF8L%?1,YV%@M75(R;*%Y:;U4 MX"2+2AF,D*
!L(2R!$V=)S@U887M=45Z#P$M8.E^QN@PH;Q2@U5TV?P@8P(ZV M,9%Y^1)WSB%4Q&^7\]Y"Q^P,#"R^U%,39UDC4S8 Q>HK;' 0I:+5U]K"5// MC/A,3$N^L6#YMQ&YC$[-9-
(;E8X4YK,HNSREN1A-F^FQU&Q!,NNH19 MA7/T70D"V "DI4_,E51P"XAN&[M'NM!M 9_R8_$W%EO'76)YWCNW\]2BZF)Q'Y^/^ME@-^L2S!7]$3EL)=]?G*\AB7\/97SlP_0D5
MSK_FL"!V(0]Y+^]M"::)ZG[4O MJDL<&D<4[L810ZK2(14VM3<, PRDPBJ1N1$U3F%?9XS:L> MA#D*"%%$U57*D60!*%;2X#0:\3&!9'=,-Z_YEH;*>TU_XCW8V_P4M=S#]:E2 M/8-
S<& ?2-NN][BAG*XI&P>,O?=K@$31N;&UO]JXNY:.P>N$W0F4QE!I8-NQ:K*'C%=G!0[=#ROF\0)(=0 M^SLBY'LVZL7(J7\A X _W^(C%'(^']"T^%%?#'^UIH^)S+;QOSV83G:"DL'
MRA]$I8\W*@7@I$TL$B;RL.-E'/+AJF>X*?N#:-(;[D"WFRD/GL]0*'%(P;T?,2FKUGO=R8#^KYOAZ,Q^,SR:MVH7(L MHU*8C%M%-!PG). &R%V,N_&VNX^=JU%A?
76I4FM).R..CHD7%^/#>,>^X?O MG8@8U OHLNM9_KHDE$,"W_= ^F8BG-9S "J<,D-33'/V5R$OCJ5QJW1UM K M4^,B4[$EMH/'/XUQO4)63$51RKE,//1$EE#)+F>N=0N-?>)W?
LA/$ZT*I[9 M-D9PNS60UL6*JPU<[C-K4="L*;3G]2IW4!74O M[]T [5E>ITU@J02ED'M&< T:I(6@DN=.1YXB(P#()./EPO'<]=!9;3 #]T&: M.=0K$Z(%-JETP+CFN."?])FRI/9 ;V*
,7=/$24.D,8%'S0L? -E6W'EIBA1 M(C(3X1$'N7&1VG:,#4E\Z(6LVWJ[+(1>N!=:*L[]TOIGS/7L^A'XUK[];K;[M%V3$R4*6Y%9SD;B\5G'&[\96%6YE]"9LG >]YD)#H>E#5B?*V6; 1VP?
AJ_ M^1U02P,$% @ ZH%N6;UEZN22" :18 !D !X;"]W;W)K&ULQ5A;;]M&%G[WKQBH16$#C$125R>V 3M)NP':-(C3]F&Q M#R-R)$U#C4NIJ<'7! MOWVP5Q>F\86NU
WG#;]KM75X(61KSF5[>Y9>#F Q2AJZ(@03#CKU;FH%=)! >?.^D_LN_P92F=>FV*/W3N-Y>#Q4#D:B6; MPG\TVW^IU\IR_FIOG'A;Y2H_/#^";/;U1:6?43?JLP%M5
M#\4XCD0:IY-GY(U[)\+G?U\OG;<@R'^. M.1]D3X[+I]1YZ6J9JZ<&5S]\E\SB5\]8/NDMGSPG_1O#\ZR,XQ8F MR5 \%B[>_M5HOQ/QJ@RX(%W$AT)6W>*[2B
R7I5+92DT221,@P0G=#>FR)5U M0M:U-7<0Z#=*_ Q+D-F"DDY\VB@K:I5XG;F(- Q9QG&5D9!5+O0#A>/G%,). MB6CF'%%O<#A#E7**+:D:EF%(C-EB6K
,AS6I$U<$PRW]@&3D>X[MD9Q'TSB,XC@6I](%#;3)B%QZ%;'P'IY;I&G\BKTAX_D]>74V))]%_L;@0W4. MK;BE?' -"GHR2O?._]&=4' "GHR2O?.XJ),#65+,!4F>]%\]
(WWMC=P\7P2@"H3$LN/N;&YP%W UA<'!P**X10EA*^*NR+LQ.P9%3 M&%XTN:[6\,< ZW:'7*UT 9.4.PL^=$=$KF$LG'&L*(,?*)] >]6"57HM5X6 MBO"MI055= TI1
2_#R6XVRS_A":#:/,_42*'N,]4F %H=R3S59V(\ MZ8G4RB4 3C66#@G:KKH]!T/Z,5L.E#^97UUZ)>D3&7UZP%MLV^=M\'B+- : M'O2K.,+;C7H0!B"2(2.$6]T4=U?
VB0)).+18T9[&$1;9IG-%W=>:I-M M:VF M-%46_0W! -< #C$5U"!$,%2U:CU'93(-TNCLY""!F_W# M=4_W=Q6* :K3/PNBT:=W$@HS"#$BS)Z<_!K*4(_F+)K.YKPK2?I%=:]LIJG!G$*8.
M2XKUU(D(^ F@KI2%FE)$A M1<$GIE 5CHSG^S8^CHY(MP$H7H2],8R<3.GYH1TB,?C9.Q3K$V*T!3:GQ8HJ'F3A<$IM")QMVND//<6=.V: M*/*O+T^ +6NX/%
Y00=D;#'Y! S$'+)HS4X.)K?7IL0-S87^__:>GI7X%3CA M%U1M%7ZAZN-1?O?OR@\\/(]V/+,^@FCP"'LGTX^8IR5EOH*")JK.]PQ:R8F M<)I3-J>SF(K5?
(:__3\Y"=5P:LBI*D< 4;3X, <3*)DNL#?.#X7XRA=S$0: M+::)R2>#L>'KKD-C-!['_#^=4:3&T7R6\O_I(GZNK("'IL)@9-:5_ONAALPX M1,2J0K:EIJG:K^8!]FG?
HF+0^@]#S,MXD3]7IP/I[A1%@6/0R&#M3NH:>B5 MG5&")FS7>XN)&X+1#-O6(O%.J0[.)-S?E/#OM>X-ZMBA\28B1U"%6;?QW:C M7NZMD_%# 7JC0='J&UTTI.6]\C3(&
(PNH^LC=O1;R;!L)':!$^T?Z$:%7=(WHM@.-K4$HJ A#M8M$ MWM@PHG%#]/P(2)GV#B]!O#F51;V(; MV[RH=@?S[8/;50 9DZ/EZ\EIXSH(/-TK&[M[$4Z4"G4N1_^BRX=!
N+>0EIP M+5LI:_L\W9.@5R ;G5AMSP_%CZU7GDLE!;JBFEB&FJB.U$RNA+0Q7(X[X$$' MPZ(EA^MHD(X$I^_S.-Q8\(3_5NL*L76-$4N-J F=N#.<^#/\;Y&P'US SNY/A\^'7[:'C["_
M2+U&Q4 4:H6C- $-PC>%[L6;FC\F+HWWIN3'C9*(.VW ^LJ +^T+*>B_+E_] M%U!+ P04 " #]@6Y9Q,O>=:4' "&AL+W=OM\Q]"J504=Y6QX6Q2QE@_
MG\]#5J]*AIFKE<63POE*1MSZS3S47LFWD_)37WOKS4]=$ MHZUZZT5HJDKZ[0ME7'LV64[ZA6N]*2,MS,]/:[E1-RJ^K]]ZW,T'+;FNE W:
M6>%5<3:Y6#Y_<4C[>1P/'B"P*K3F#%=J>#V.J7,LKS M4^]:X6DWM-$%N\K2,$Y;2LI-]'BJ(1?/KVSF*B7>R3L53N<1&FE]GG72+Y+T MZ@O2/XG?
G(UE$#_;7.7WY>>P9#!GU9OS8O6@PAM5S\3!8BI6B]7A _H:!O<. M6-_!H^Z)ESIDQH7&*_'GQ3I$CX+X:Y_+2>/A?HT$DN>AEIDZFP %0?E;-3E _M\LWRQ\7)
_8>#O8>/J3!T70*+W?MN5J)L9JQ;M2B=J[6\W JZ%3H\C/TX+ M47E=B1J_+@]"![%15GEIS!8UCX7XNAP\71UA(2/3:2[9,"UJIV/=,B,[=ZCMI); ML59@E?7?>"2B$X5ILMA(0GT0>>-

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
[0E4\]Z66P4'2)FL=>2$\R994;\"PW"HA+N%/P5A)CE, M/7=W&*$)O N-B"2UJ1UMO >%X^XF,2(I7CI[:AV8R1%VM4=1W?C02,O=\^KZ M4MQT, /RZ!!\;&+IFDTI+IW=X 0>!\#;I(M[JT&Z@DE5R^AH76,H+C7*< F M'I%<'Y:NR'>A20M=,#G*_R\]TPZ\A+JAF9%5?/Z.U1F:B9EA)H7'IUIO-6BH M$M,,+C1<_LGDVSCF:]8. ,KZ ,. M0YXMOJ,_-
O.Y*%V+D/MI*HK=1MP0.W33$+D"BVI,/H/5F'*>)E_9L63RB,1* MKQ+B+36_*KT>*7H] JKJV%%X]X8CIBBD+G2M#!VA[@K]\I/#[\TE)S21]7&W M3%YY!SV4-743Z@4%0D69?
(SK_Z<+![O!8K"A\X?G&?+]OYN25 KT5)U3A")/ MM#[GI(X:43^6P?)='70 8I3M_,'-5V4$^^X+/N+_+FZ%]IC)/Z)'4;?B%C0. M3_*
,_VW8CD[QMN\.63O/H^FX^8NU|K0N(O;+H@1+/>-'/W+P6B? ?R*QQO|QA/00.0TC]X+F6_E@P/2 MSIK1ZT>:C+%/$Z-CSRW%*_G5O>?U4Q02KIWOA9!S[8>7CSX\P&J:E/:-)3.Q
M[WU]/OJ44BF_X0]&U.X:&]-7E6%U^"9UD3[%[+:G#U]_28\Q!H2B"H@N9D?/ M)L*GCT3D)KJ:/\RL78RNXLM225 D;<#SPKG8W] !PY>Z\W\!4$L#!!0 (M .]!;EG?"ME_22)A 9
>&PO=V]R:W-H965T5;7[_NFR;=??OGCA MBJ5>*3>R:UW#-W/;K%0+?S:+%V[=:%72HE7U8G)Z>O%BI4S]](?OZ+,/S0_? MV:ZM3*T_-)GK5BO5[%[IRFZ_?SI^ZC_X:!;+%C]X\<-W:
[70][K]9?VA@;]> MA%U*L]*U,;&CW__NG-^-M79_@\/?!WHD]GTZ C .,WV?-I.!(7IK_[W=\0]H#+3#EI:ZM?3=DNOW]Z]30K M]5QU5?O1;G_6@L\Y[E?
8RM&_V9:?/9\\S8K.M78EBP&"E:GYI_HL=$@67)T> M63"1!1."FP\B*%^K5OWP76.W68-/PV[X"Z%*JP$X4R-3[ML&OC6PKOWAUJY6
MI@4JMRY3=9G=VKHU]4+7A=']NNQ\W>3(=M?9.]A@Z;(?ZU*7 M_?4O +0 W\3#]VKRZ(;W>CW*IJ=Y-CF=G#VRWS3@,Z7]IO*OMEKXXK*NJ[1 MV7_?S%S;@-#\SR$J\"%GAP]!1?
K6K56AOW*FN)TL]%/?_C+G\87IR\?0>$L MH'#VV.Y_G&6/;S>>CK+'J?)1JRK]IC+A=]E:#$KCL5C65FZF2,\]NZNR= MV@&7QM=Y]A:. (W.8#_=Z#(S=6LSE57T)1$R2*W7C?
UL0*ETMAC MIX#N<[1$=@X*7[=]5NF," E; &#P^=S 'VO5?,)// PV_%89V+@V:I0]++4< MM56 #F!5$@S9:UWHU4PW*$N3G!!MX5F <46/ZL\M/TL@9H"NL27"TBX-8'[B
M]$;7V8H%_!DN_I%9I$Y3++,Q"?+T M^&IB!:S2R(P,5%K[_4:L6D OM$)$'P(4=Y];QK59N]751GL "6Z=]7='-+_) M)NAII(WG!<)<@!Z"NP5Y M72,\+A>,4-(:U-6UU]56?
<:ON]94<+!&J:6$"XEZF]6V!:J!.K$BKC3KJSQ$ M9"]9 9\'=?$$1D?<6?IX$?.$LA>8B SRENJR&JV*D=LG_-+]LW?67X. MRGC,)FZA"B@,<#68 D/V3TQ6B2W[5*UWOP "$"
]T5K$4:V/Q/"$/79 DE, MK2H S!'Q@.%#< 1+-:4EYQE),%O]*P!.'?T48*L5_9@3X7B/:1A$V\TQ&#T MCKC 0YU9F4HUM F0_#4H- A6$%F*!=DPY_1IM(6&+-LT/P5BPA-\U*,6DHA@
MJFCI$'_: QGB5S8:8UN"(EW];YHT3Y@O6;6M 22.F3:0M_/3_P>F#8/J[!:C M)@X&;HX\F2=/5FS.^JHPR4^O+[PJD#4"DS5X9))?]-7E.1X&TCX#0I8^1" 5 M5C,+%L2"N
;5^:MN.]N!A$5:> M@F+<=BNR-)M4'A$"I&;;=)* 5) !$3W!T$NL!2CTT1M?G),$,W F^QOD-?=+ M_4E7CBW6^,+EW=O[8+&BI*=TRF"G;[*$,]KJ&-^>YV(U4;95#4+
[%O/XK$I!5N6*F2VU!6!#2H(SK# '0KEEED9'82X/B'>GMBYQ^5N']H_ M)%O!HX+:G5\\JG?_-^9Z!%'*>EU1'@%R>U=S 0?Y269D_)-GB&V-1@?.;['H\A7^OIM-'ELT- MZV18=
(%+GKRAC[!JP=DI_C-^\C$-,3W79F@?&)L@-8@NBW82('R;P!BV/K^^ MA'^):9.7 E-R\A1AO;SNL['ON1!G)>5U1WA)+@)8E]IWE,_2N)91<(/#-^7 M\CU'.=W#
[2"Q(*K)IQ<3^GD^F?2?V:,YN>ACBXE>?GK%K#[]XJK:UG[A.#^? M3N'?Z\OK)P\6B3<0HG0E@74QO]"25Z?7 W8PX^+R^SYH6T 9DU83J[PW^GX#U#F_
S_^3(M$ZIX_/ID]^I0(HX@6Y'[JC&#A'X=F7[\GH4@*%Z>B;G\)F^)7U_#O&PZ!P"F85;<2P(NT.H816U26 M8S9^SR)&@,3J>B#XSR?_*S05.{J>:PJ001ND;1'E_@W^<@K1
G9A=G3RAM MNIR>9M/K)Q2,7EQ>9I,K81R#'X(ED%A8-3ZI?/)6.S"RJW7'GA@S5P1!1Y9/: K6(>,0@IQ?:= 95]!YQ,7#%F@ MYDB]1G\A69G>]Q=,4GP0[4B.0_%!TU/ "
<]"L6C:K%>/*S%#@Y#':WMJG*+21P7&6@^+C4 *%= M2R0+Z7A30!YO?H>3/OP(<2-$2^CGU=KTBSAR7*BP8-#9&-UBXIVLVF6?:KNM M40C?KS_JA:[SD(BV$*VVXB\SBZ%
<@RH" 1;D5.E9/IU@Z ,!!6X,.-'\>SW* M?@EY*N7A(0EB(GRRX/I6*!EA73O2'!V<;'4A!S6T>5&$6P M*V=[X! A#/7R@, MC7'=2OT3"Z@0O&N$X08X>A3X
U#3$WSVKI]+)H5<+ID8"*$EV?!I"JI[A4VQ M+DUGO-!RY0BK=QX%^($P:QP_V(93]S:KA*4MI"E9#.0(WBH['0LKN^!>8Q2 M _#9YR#^D-"3&^487"+@/F9VM=9DE
"=$H)VK%B39(+K[%:P"@T&V 9#CHNK M-?.N(5X4%=AZR'92:3HB/Q':42K!87.1&@2G8GBHY\BNM*U=T?@D-T8H@XDF.TN/Z3\7#F+U4+EB7\RVYW(KT)'\,K-#C^67Y&5
M@!*E4\Q,V"20&+)\ $'!10LHQN-P,4UYH#S?5VH7\>D_@BJ)61;\"I C!%H'I0S2<\^FQ/;0K5T?VM2JETI;*+: ';!& MV DU#Z!(]6\L8CO"THKP)6 -H&!OPT>$HCBP 6PI2-
I<$X!*8@,/%5O80:5M M+V!*R_ '*3^P9D"/7F,,(.=CT#%AGRP4S!!90#\I<:IY*]QJS[KH>D6S8<@4 M:V1D0&>H*+]U1MIN@'# =#+&:,5OQ*41=G<(5@H2:.'#73\.[@? -Q ^5H]%
MOPIV#:LWJ4TBUMZM5AV6R@H4&X@\->!8@ F\JXNH'@!#*$M3X Q"$\(KW(\Q M9-;X&*]7_(9<8S0)(@81=;M,(Y=&U#5/75K>]WRL^1C .(QH'O' J5M$M\/U
M97#N&M#\'\WMR>V[OWN?D!6P*U79F-3$.L@,5K.N@<#'8RFVF5)&W':O*NJ M$_(1&CRXW6G_I3?D?<?J/(=4F^F>2 MKY'HP2\D@#+ *,^XTAD"_L2?
T/8^6RA[F@^>1PC>8)R)*VHP K3G MHK(S&C$)_@]R![<#]F+7]P8]@>-&.^X[G+(0]:L=LL73<]#2CD(!?N8(WMS+ M8"(3O-%
IVE"8BW2]/C'&H)"K#]Y, (QV*C7@WSBP;.%#D\\O^2(=]SHWU$D M<'YY=I8D49P<)P?.T3$;[1+*K/ MT,K[R@E+BS?>O4C$V_'JZ7AK/<<<@B,JBVJL$R$3W<[M9(4V X.Y7ST^@V
MX3A,*4-D0"TP, 1(+.KREI]C\3B(@D!$R!#T05K=HZ\8@=BZ(PBYJ,Y ,N"] M0HI@<3009.%%C"0X8/(*0I3B>BYP-X_L142967(0.HE3%P9GV6:I'Y&F'#6>
M&68L+YTL(5"+9R7"A)D,1B$S'>P,[F&[UF$9#*)'79*-,$/8'(KZ0Q+ MH M%U.%U+0 "-YZX59W-R?SCD]# :K]D_JS:.$(RH9]K#LGWUB"-R9R8Y@9$X?0
M]R0_A_$M)3T6Y1#K]BZ.:1QC'J5$?P,A3RJ.?O>@1HE\>8U01!.P1%*L0B\' M$IG&B^ .I/3I069AX_ EUB+%G+']2(C8\PYDA@(M4<^\%?75S=30)8%]'(Q)
MB9B.L9DR8#P8WCB#="WHYC +-&V4A*.1.N7K_<0OS#%*TUS29^I% 6 11!2E X7A0>WE MD83W"W"F'8+ 3,8ME'AF ,F^VT;<]M0P!3?2)#'JY[2V5UKVKO+Y7E']\4H MC9
,)#!ZY%"\2RJ8_K/CB?^HIT6T)<::OOK[0&4),C[]2!]YWD)0.O8&=PB MN9M8QOKEO^(<_N0T8HU;W#@*Q=PP[S\$%L+_-:"E4^RRS^W#^YNX6:P'$+@? M 4 2_P'<#S%C\
<6$VX\/L<[V$(U0?_\PW<]9 N1W"&J/="'X4_T+*.:A81EF M=MB\19M[12;N+)HX3^D\0?CCPU&SVLGF@4P!)XR:-;V*7 Y 4K M^3N>.5W[8IXJ.'XL<18LYD.2%13^P
\TS/YYHGJ4J9B2/HX'D'6ERUJM:V)'."9HL/Z$TI (QW0H"%&I M*N\=TN9E&G/WSN1A93H4*$1&^H1/#\"&//@_6 &*Y9H ,962'E@\[D[-80$8H MI6WA\R?X)!)6AEQ7ICS!>,$W>P]W6?
VFMHZ^)FG8QB;D%QH_A_GH>=]A<+1?1 M&S1UQ+_TFC"XT]?N+ZI?T.C9?,^1)\T?!%!X /2?![:KKVR54K3KB1W=[4&@ M1ME[0B?<.VNS]XG)^Q5KFIM#@<6>A6#QD$RWGUQ-$
:'Y+XL*I7K?Z*1K^3EF2O)4+, MPOM5<;Q$U3TA>)#*>F/*QX>) +]KYX%V3Q_0,'7-UJUV 4U7."8YU&MR?V85>S4X!;<)DH(0S,UG29-]<1%I M@%W1ZWLO?@3[)TXKLC=4^,+
<'QD,/PFGP4Q,!C9F97#^HE%DY;]:I M8D5S8I9:4P#CK'-8+08"_KH$[F/%SQ>LZ78R]3AFND(472PT0F#&=TELUY+1 M"'^@F$.3D0R'NZ"@WXHLB_>)#SMTR)(QW9?
#D4N$EL:Y)!GUH_)V"G#AMS=,9 M&T]]<*;M+IT()X!'XA N6,"S!PC4IZ"IL7Q^;OH(AMWIK'U<8V),9-5]%R M/)RQQPDNA32)%WB[K+W5B7V)+4/#444/6_RA XHGGQ%!8\/ M
Y>"\PB]H9>TV*-*TV-0/D M6'5)H!W%#.2=;A:P6;_D.;Y*!C?"HZ\,'7RD>^P?2UL/9?9!X6V/3_X8<$*\ M#$F[75HB^A9K]]@P,J51W"P,A_>3W6%:_;&B.^5^]^,I0VQ?^WQ*II1(Y;K6
MM8KIC=8&P\+6 M!IIH9RP1^?0(!WP@]0;5;QY:8TLQE0MY\(#'TF/+RQ@D\VW M*?$*/M6@_9U/OI,/QK9KN;D/%L.Y3,ZMU-9U,NT!(3T:K@7HA6,CX/N&Z3TG
M%[I:87):ZCE(&@5;D .!!Z\7?DIH .?>]=%I+B=T39M4P:/[US]S2,J7 26 MX=0+P .FTDAQ^UZW;26F;,B\?ODCF6T"Q]R$3DR"@!\[,AU=Q.9PO\013KNA M8F1(-B5?12<96I\^CO?=
(M^=Z1I[%H;V&2B)P)MD^&-D/]U%6=2:!VP"R>W MUVQ-_&H&M>/NYFGP!J.DA@+T?C.%\A .UAQ:+ _GZVVZ<%B>U>'^SY;8$"D. ;L!)1N ,65HP10:'<>5:(%@K#H?
@9!FD;/*^WG_4#V3=NUF@RI*D'8"LE6^,\)?V.CK/C MV(S:KW8.M@;3;ZI_DE.ZCRNSZGVS&D3BMI MZ]=Z 5DB,4*F8*FD$EB045Q'!D!,(*4(TN=#>+%C(;<-QE<9!H$$[7Z13.W/
MY^2>WGF,I(2B6#RL+5WJBP,%?E@79W;@2\"+K]:2.0MSU*KEQ>UPB*EW&R MX7K'QB#!N.388P;Y-C'YL=":-5(7J.-35'@^F7ML>L?0\[L,&X!OPIJ5W; M^HO)B?
H<7*4_HSYB!=$;"8(Q&3I3NV0LP=\R%!I&\(;W\Q0;X(&U%2N\;RF] MU7V(5$S+*EU#Z05-UTLEE.T[6UUO,5,>Q/O9W)..G$O]S&]6&THN?7[W-
M7EG[R4F'#KO7^/*>WSIL([IWDUC2.INF+;.0^(%.VN"!RO@V),"NM$7'C$VY M>"]OUQI?7]V$*OZYN\Y88,K'(RWGUR?CZ^MK)I"<$\,,,2%P*%WPE< /GW0 M57:S,9N3?ZBY[5>
\9'@A(%V2 +?/8-P\^1G6W$>T)_C??4V1IE1.U0|<&OG M?^;+WQ!GENRI L7 /*73 6U *)6.!$]9J_B;R.-Z?*O?VF&Y;OM!#Y=]U&^4TK^NW3Q?@6^9R\)\TI"
(*1"*:4KBGY.C(:/K.JH3=9E9"[0%K0 M./:"I<0;_;FWM/1QF,<\15"'(05=2I$[S6@(PZUBOS57!IM38(&*\,Z!=641 MZ7UP84O0[$*[0T%T&!%-K(C3FLQ>1O?;J*6-=X*J!"F,%-
F>B>7FV5*:"D"U M0],3M+/4KFC,++F +FSEB?;0FD#SX5_]02&;JH @-6ME@R45#%"2/*<$^LG\ M!9!"^?L\8938YSEBHN+(VN U3Q X01RE=TZ>BN]^D-"+WY< /U0C+R"+:"2O
M(SOS=RO;Q+/R#@@B9I9Q#%&]L*)0.=_8(S527*<]82&0<5GT(@9?R6!)0V4$ M% 4!:PC>6<2'@[S(+ %37\9B@V\Y*(^@?A0AF17;RTKSM37XR!?5!(3M4HL: M#@I;QB6%
(RY94=KQ: EGV#SIU1./%*F25PG80^4OXB(D)+9ANS\'9G%S?YN= MG9_F_9?T]:>_.5+$=:1LNS!$Q%%-$=LL,2P& MG"$.02N0%)AA6U6+Q%S9VQ MA!/CU'!*]ISOJA -
!@GVF5%]K<:;P [KB_0UI7P 94.1%[HYB[27**/N11O5)&9'*#25< M*8%U?& 8\4IEB"YR\6 \=]IHK42-.S)2-YR;3[@9)L_B)1&",\.W$39[\S;4 M_*6TRO5\%D>U3DH-Z$9D^G7NWTPQ!(
+$QM; :GI;G"<<:$WZ91Z54,\+>.* M=[Q!C3- U8'BW0 % ME(@%ME=0^\))2]/ZRB^:&+P"Z?CZ);@(I_ULA4B'ZT#G:;JUV7MQG+;@_!YA+"@?O@W%8EZ.7NVCY/N&)- M-
YL+>2&?/WZ'I$ >1R <3IBN%5V&XH +"R#KG?\]I-,/=^[6'%^)\R]{XEY!4,$ET+ YBA2)0'+B(%[%Z$UG-X(I<&9\+_[O2(/("&[M/XJ2IK [B;U!YCJF^1>-/P(?
EQO$7.QC.S(Z.['GY" T'X9NA^7CX7JV73*8H1.(_!NV36"OPDX;L2:)["._=>D)%*3;P*EXYF"M;'CR\][H@WV+>]49! MTJST#3;%_6Q(G(4=*E/P#$8JN^P8NMK0+
<&8^Z4^1\:I^.5JO,\@_\1\TAV[MF\2FG3)_;MT=OCV3W$XN8YSNH %P8FR"0YD14F,'6<>614$M+E:@:AZ%8H#E7Y; M ?'5!YE#/8>GIZ/+*4NK_Z.U
M:WK+_B62GGQJ2PJ]VJP]+Y^?GSLLJ4J MI1N96E7X9&YL*3UN[>+8U5;)G%\B^/)>/STN)2Z&ER^Y&>W]O*E:7RA*W5K MA6O*4MK-E2K,^M7@9) >O->+I:<'QTGA?
\0ZNUZUT+VLG,F(]TL9>9=.K:%+_HW"]?#9X-1*[FLBG\>[/^FXK[>4+R M,E,X_BO6<>UX(++&>5/&EV%]:OPO_P4_? E+TSB"Q.V.RAB*U]++R]?6K,6
MEE9#&EWP5OEM&*26==L+,Q:U53E5>DJ^&X@?]6Z-S[3=" M5KFX"Q&C97=Z4>FYSF3EQ33+3%-Y72W$K2ETII43!^GJ\.6QAWVDY3B+MEP%
M6R8/V'(AWIG*+YUX4^4JWW[_&/MJ-S=)FIN:[!5XI^J1.!T/Q60\.=LC[!1U MUBG+.WU WJX-_WLZ<[XBN?ZS:\-!WMEN>02XYZZ6F7HUJ.G]=[J4&E]!]>_)T M_&*/M6>MM6?
[I%_>6EUENBX4Q_?:5 XVYQS@7:;^86'BPU(!79DI:UEMR#E- M)1LDC!%9A#*RH6K^ IN=.65U:68ZTI"K*R$0^8I@-T[?)@53:Z$CV(;>@BE
MIB$RF3GDI;1P_4A,BP)8(%&0P#*C$=U[E+X(3^4DLX 32[E28]94)52A :AH M3\\^+!OQGN:F &?1AKR<%4HX188T'NBH%!CKNV^?34[.7^#9NE+6+74]%+FV
MX)L"6+&0FNZ&9#_M'!V!CWD@.H6XI;7"GAMS^SH3DQTA?^&2F;)O#$[^Y2\LV MXJU614[KKAH'@YQ++B$\V+O=?$-D)ZX;]\2/JK'&(6&K#,)_\VE(O)-5,X=T
M&DO&0,S]7=76Y$WF14;V4MRW G6<4.^KlAUB,2M M5Z.@XSV26MILK6'(D%,@CD(LK$1X,WJ1TLR)D_$8S3;M)$OF8_K2VEWR.O1T"PS)2E,1ZB7AOHB*$KY2_&@L*/
I/M@(T4YEL MG&H5+!$QSM>9+H@UO2&=WH+/\5A;@2IJ)3,'Z>SR/E>9=IR8]+Q.K.*7UC2+ M)=O:RR[.9JBI3!7%%R224U\Y+T#F*&I4\6 P3)+(V5I"L4*V,[PHT.Q1;#:'
MV!AMH<#WL!MHOI\&#T!X)@ML :"@TN-&>_CJ21]50GX&F/A .KLT M\ NX.!UR?*XC#9%."HS5'!%68\0<=HQ')V2&*$)S]46"Y V,^89!$_GQ$"6 M4R
S%L"@,&98I@F3%EDD,\XVV)3C(2<_<4T'>TK+^_]M*CB T$6B"X6>9H0M M@20,%)RA*YE;4W)TM7,-YSXA(3'[M5@\' V5O'X*>M@AZNA<&U[+6'E)!N]@BF'X7DKY2!-$RMDI_ZM
;,I96_(A" M#V;L]81=%A3&.15BR\OG#75U[/N>SVOX Y0*WDW>W_(PG!N9:2LIL,0A=QC MR%5D(AKE[&/J$FA64=O-PE#\!,]\WG@"9P 3#P6P;KI0_Z1Z;V6M&]\SK$7Q
M&0V!E$SIFBD3290- M1^R0]RF8M-S$BK]'FE;OS9,E 5&P@1")BZ8X>@S8&I;OI#!"H;MEE< J5U[62\QT*Q5WTXN2N3J MC*60QH(ZPP;)B]B!@D.?
ZI?:DF66!+W@UUH39JG02X'U&9T/+-]*%Q4=)=]' M$B0SHO.#[SN;:?O=CBNGI;&]7XT2=%[D^'O-&7 D$W+FR_S3%/SV<^2&'I4 M %-.8CN ,08V/"],S111B*Q:--!NT"JT,78TR6S%-
]EGF-U,8[+R78>V'^2Z M-97-Z!64S ,G:&]+19N_G>A[?GBP:=O1L^WC8LB-2O=&HC,- 2[EI@WR0P8. MOSJ-'\RW2OFN2,9LRMLB.1*WGP,K,\IO 1)WQKJ<-=:%O" /T2;H/8X0R<(_
M[F4BI@)^H>]U%_XL.=H+3*!$'Q$?77XS%,O>@00=//#,W09_!_41Q^GJ:!<# M$FMACY;LB]TS6*9H"-U(AUY#AIH4F@X4=L-Q#%?[6HG4X%7&I\,8'COOL7G] M_[]@/FSGY=
I;X&16(,<0#/"VC0%G=?HQ2(Z(#IHB^S3%!S=2..!@B#R"ID\ MUY^H[<&B7*'?IC,>1'\$9,;9&8E?P%B*/!DPB\G5L\[S7,%2 M4>Q*G[$+6>G?
4\/7+BWSUCZJT(9X%FBX%'XGN%>3],2T/]%UO$]1Q*^=M;TKH;SUP[[G0L].'Q[&XI MXK$\[H$IF$K#0 5RZ$RA,:M0/L[O/ JD0(7Q.?HHW]=D/FN;S&=[>\)'CKMW M-
9E_2J#X!>5"N);\1^<6 M:.:/_LZQM*IW1EIA;%Y*|(2=^R4&Y2'7&6G8>QJ>%0l_G[/-OB!=M$&ZV.O3 M]XHJ!9CN!F,CM/3|:DUE*,7"UN$]\2_0T30W,"3?%;[_DRKQED\/=!GJ!OX?
MHJBMMURX+8# H8.6V8;[^;:-9D_M'1TG2X01,K0H5!J[-I.]ZY29T_E-E"- MBZOIC(E?GYD\G#>"?4FCC.9&E>D@2[; [WA%85KD[]3X'"3P0'?PA9"O9-'$ MSC!Z+>YGSZ:)M0T,
(B)/QTB[L<.+O=^]P!'I99G MQ^],P+SE VE*A7%)]S_M9"0%,P0B MKJ!4F&M/(:"CHW PL@03/&0GM1'SWH3.DKG4!Y9M$&K0%\<+'3%/:6< M4Z?
Q&M#@##IY,@Q$'+Z3"*X)O5IH.V#>5TDZ&XDWT@)T#&G>H",!Z-_@D&V; MW9(;KUF<&!FRWAK".FVCX$$16Z>3#NPHF56'[XS#%V@\..XZV*2;1M02#XK) MHM;-7"9
@XL&Z$P^WCHYUBY@GP@AXK]?@CH*B+WH_N+W&6K/'D3MV=$8D ;F MY (=2^@IB01O*G0@BG@WDL*;F-'B %.\#Y">C(,"-5?]?HVI$E_!VDBU[JQ MM0D]:V\-A97.\@-_\&
[V8#TUN_?!E& 9DCS/+:TAQ"N:HGB$T-6*1E:D'F4U MDP :;(E!=A<)<,>XJH=\$A_Z>[KC7CUWA8?@VETZ%D6I=BD8;1";KT(?I,.=-/%]F[M[[^39?
UB.HRLU_L*LW=8<'@_!G\"]$__9Z _?P3TCT QHHF[8;>%C:[&OS% M<-O5W1WW?]U2*KO@W^10%- 2A!^NM$;G_U,PZ]=NN7A-T/OI(4_Z$NL.5X= MC\Z?#(0-O\,)-X
C__9E9KPW)5\NE<0P0@OP^=R@>8XWI*#],=3E?P%02P,$ M% @ ZH%N60(O$*[K @ .@8 !D !X;"]W;W)K&ULC57;CM,P$'WG*T9!W"34I-ER6]I*VP?$2KM0;;@\(!Y<>]I8.';P
M.)3^/6.G#8M4%EX:7V;.G#/CF4ZWSG^C&C' S\98FF5U".UIGI.LL1$T.L9ZU"/9Z!P+3H3KMWV+>[U/(EXTAE*OI#=VQ89R(Z";.;.S*#1 MMO^*G_L_(]#N72TC46I@N=;S7YA
MOA"D"=P:EAX);1 Q5X_A4G_OM>)A!\(JJ/]*1;-*;ZQ>:REL@#,I76>#MAM8 M.J.E1H*"\3*(#V:YH'9Q1BYW#-9]$S*OS!Y 5?.AIK@M56H_O3/6=4@K3Q(M6Y2W E;8CN"D>
QE44YNP3L94G62\$[^@G=,[I>S%07/3^OK,<$]WN0X7FRW M4VJ%Q%G6QN3['YC-[]\=/RU>WL)V,K"=W(8^K[A]56#A^!!?D!9H[KRM(,2YL0&_3^Q8&E@%'?8QK3KWP MLDXO7;
(6?MP&-EXH!!D=HSR"<5$P(L4\1.N8;8I@=D47](^>YQ=!:O=(#)" M_B/^L5+G-_JY0;)4XL@/;^^M8?383">]?/@MWD_5:^$WVA+8'#-KL7HV9,, M?#^1^DUP;9H.*Q=XU]1ES<,=?
33@^[5SX;")_8;_B_DO4$L#!!0 (.J! M;EGT:2M$? 0 %D+ 9 >&PO=V]R:W-H965T1(GD')XYN;P:TWV_X4\#& M[KTS\F2I]3?Z^)),FR$1 @FQ(P2.PS/<@I0$A#2^5YC-^D@RW'_?H?_L?
4=? MEMS"K99_B<2ET^:XR1)8\4*ZA=[\ I4_GF"LI?5/MBGW#J,FBPOK=%89(X-, MJ'+D+Y4.>P;C\(1!MS+H>M[E09[E'7=\-C%ZPPSM1C1Z\:YZ:R0G% 7EP1E< M%6CG9@MX!E4
NWSD2PGV:M)VB$IK[A"N"D1NB<0(O95*Y=:SIN,]EDED!S:MY%- M3:FIHW33/0OX 'F+|<* =<-N_PO>KW:QY_%Z_/:BRNB,W2)7@ZF ,KN4W7]!
MP;"_YTOKY_\Y)D")WS^.3V5S;7,>P[2)=6'!/$-S|N,G6'XTQGV_9I]_QSZ M['+,"DD,+UB=\+R|=E%FM(6.67/<;X/.8?A6') 9:IL-@&##[NV4I+K%<: M#7,IL!R,T(EEWD-
%)I="X8HN+%>)O;IN/*8&X" 7&$;20;9$?2F%4RHPC?< &X6SC*DB+%A8*P!;2X[M5^R"]8+>>(AC-!CA"K3 M41&F437S"GW9O6*]"%T;1RP:ABP*QX>G>Z:C481C)^CVB?$P&/8Z?
ASCF>3- M7$K* PI(\=[C&LI K-=*_(L2 X_3*GAL@W$5*I8%:4_YCQ'$!@;&O&8 Q3[> MU8@42"TD(.<8=_[8):R%4DM=SQ*[!9I3(6M0:01N,UGE]ZVHB:AZT0>YB4
MU(YW_'.^)74K[6GC0F/*L_E.]Y;7[LL;WN9#JN)\L4MD15F8E5D(1[+4YQY! M4?X%7K,+6@C#T$]?L/'(?P2(;G/P?Q6Y#1 <)?]Q(/TQI94_96K O^/F 9O MR>P?V#K36P9U;QE\N+>:<
(SU]&\5SZWGLX 8Q#/],HYUG_.GSN-8%U1/1@8) MF (7>.3W:ET>T^]J3*S=DBUIQQ5MS(HR"I2H>_6,>9=SXY3?@;966,K1*I7+ MGD@< *CDL.!VS2WJ MEA"-VV,)A9L:=^\$/<'6'6
2#D%\;:Q1T^L.CMN^IH%T_Z&%)U !$[O.++P/+ MUH8?.L4V]<"NQ/%/@]=$*Q+P:#;&]R9!SQ^>4-%. U,8'7I=>MY>7SJ_]:\B)7?CB=^\O34CO, M+/^:XMT7#&W
]976;O=!!]2WZ=E_4$L#!!0 (.J!;EGNUNQUU 0 +P. M 9 >&PO=V]R:W-H965T=.$TM+T+%/#F8 '170:QU1MKX'+S<1K>_N);VP5&3O1 MG(X3NH(YF*?D0>&HF:.$+
:AF11$P7+BS=]CZX%=[Q9\9[#1A3ZQGBRD?+:# M^W#BM2PAX! 8BT"Q6<,-<&Z!D,:/':;7;VD-B_T]^IWS'7U94 TWDO_!0A-- MO*%'0EC2E)MORMPH_,K0SDR_4O4,
MABXXD#D$J6*&@2;GCW9&7XR;!O>P*YO!#N\ZP_,/X%V2KU*82)-;$4+XVKZ) MW'*"_I(@M5\).(>D03JM.O%;?K<"KY,[W'%XG2-X-U1'A(J0N,[MCY2M*0=A M-/ESMM!&H4S^*G,
[0^V6H]K0&>F$!C#Q,#8TJ#5XTX)?VOW6507G;LZY6X4^ MG6,HABE>T>]+9(M\I3]VH]/K*Z%=N4$[_,0*RE!S#EHD5R3;)8I?]C1HQ
M]K,ELW9DY!)EF9/1+UJ*@(=DL77K;V2<4+%UYX]C-.8RH"X\F2BN^/AAZ+<' M5YH$$G4D-(2VIR5G(34X6%!.18#[N,1U[HQEJA%77XQJJ!D#\0)4+ASR&8+= M3-O-
=&J%HPMA80J4:_] M_H%U^;&/.!ZPN9(XL\9[P*JJE7 G_KZ5,]UP^(9=/FA[*@@2<:LV6[!1AV,G*J_HO M>J?:GEZ)RNVN!TH_(3QJ=R@'$3"4Q$QK,'I$9K%4!D\'$Z74ACP)+/G8-
\H@+=*]V;P5:|P==&$0OTM]-#!NU1VF0PWNK#H/Y M_^-O8[QGJ;PBED7^GGW%FJH(ZN<1U#^M'-@0MZRT,K)LS%,"M>V4>4FY7$T.R*\>A9"K[E8,
<)K+GFI*)/^"1&(903#PA7IM)B^]+*A(3>"+.S? MS /%$]Z'SK&$Z3F Y+\=9$,@])E$!9 M4Y;FRH-I7:C[!KP/3*ID,U#Q7 M%"Q6 HK)4)/=!A;ES?T^NMI5_.?Y1J2_H0<5WVLN>]IDF?

=J-BV\Q[%.!.;C M,W).^N0B:UN[CM_>==H#G*I]08F,7*K!LPGD2KCC0#]00@*/\!@ &0 'AL+W=O.:[.S!Y?)4JD')[POID'D"*' W#H$1LLC7],0#HAH_-A@
M!GU(Y[B[WZ*_]:E3+DMF\%)J\K[RPU308!5!@R5IA[!3Z'6[R.7-XN1+&?V'= MV684,6^-5?7&F>2:RVYE3YLZ[#B,HG\X)!N'Q//N GF6;YAELXE6:]#.FM#< MQJ?
JO8DP]$GMA1HCB>A MI4C./LPW]%<=:O((U$NX5=)6!FYD@<5S_Y 8!C23+_4B/H]>'^"=]:RS0^BS>VK*HA4(JH0#5[>/]D'@_;3G%JCP%NLEZK[Z M/MP;S#?:V&O3(32[=/
/*4DO:5):PC,&*3S$T*43.8(P@&XZ!!?C@;S/&_K5C!+ M*15(5+ ^5Z26RB./5KDIW! MOH<3[O1\C7KE)YNK\VYF_#'O)N\MTRLN#:57DFMT>G$6@.ZF M62=8U?@)6LEY!?
5O0#0.T,Z+Q4RFX%%Z#_I*%?]011-^KF013"[\'NW9G:A*Z=D@;<&;)7GPFRO4.G- M91 'NXU/O,;-OZ,65^BE?7_85.?'0\#2"KK=-X(M$X)<%O53?&WB<' PC9X1@" X^[-
N117@LG9A=&;\#P:=+&"^^]ER9PLN"D MW#E#7R7)N=E[K=.-5 I$D<)-X42QEDN%,+<6G0WA(&BD'? ML'5_Z/4-?\I]N)8V4=I6!N'O^=
(Z0R3ZYU0&8:BNCXU:XL,YM*1"\#*AR+)H' M#&9O7L63Z-T+/HQ:'T8O:9_+:&%F'8'6*_B!/Y3-8^A?U'\<_=P!Y<)AOD33 M)L1;O<:DV8WI[C"$]2$JN43:./E-<)\
[*,4#@LZ&4_#L_&P>>P_&[T5 MRFTY\I[8%CK#+DS&$?"=W&LGU--DP602QJ-A\R!E29572G#>#E% 9T1>0'P6 M3J(A-,OQ-(;N4T_J_+^&T20[1LZ(%19R(C45"JKK$= .KRI > REU
MG,KZ*T\?5=V#>PTI!3R$#4(F'L@I[2@^B5X7\IN'NMU7G,O+"@*;[GE6M=HR MD8+;:'+@;6FTCR8'6% D/<84'^C&+ED2.D'+X*!])HNX[04)?TP28(=3Y[
M8[JRE/*WKR4Z&O=,Q@25>E(3I];%Q['PS%''F#A:-/?X1KKLF< <2[G=Y])Y M,9]2*[TNCN/CSL/%VSMM81,(1Y,-=R&J,Q;WK8 BMC8B]X&BEC+]35^0X%HO
MJ438FYZOL4=):,M0V Q6U/(L5'1;FJ9\R2-2S923;D]'WSK>HR&#"VU*:7SP M>G!74?]^%Q2&"Z:D^)$D@4H\,2A"M"82HN$H&,HW87^-#,JLGMZ>Z>U>>). MZ"/ $CZ(A+]VL$0]
,HW*U:Z6+I5-'H=:?V-I_,[:&ZE E,HW$(5Y6E*X@(M276SE(5WS4+/]Y3[708/&YP'\7Q;\\Q<54IM=SV**=IV#RSV=XXTUL&7BIA* ML&B3+Y<>_$YP:$)MI3D7]H@WOO&(M ZF?
N>2&R0VJL?V#@KZ-40-TX;#,*(;AK+RJ-ER<@OK&?\45%H93T9RSV6& MVE)>CV3((]ESEWA];U-#8-90[M0V;"
,!AY_7(V[2\')@IVY>X"UEMRI:VN^V/A'D]&^^/U[\P/@BSEL0DA2L2C7]GXP!,/;77 M+TZ7?E)>:D=SMU]$,'#1^@[RM-';UY80/M3Z?9_U!+ P04 " #J@6Y9 M]L.G.QE4IGLC&
<"5@IHIN]HNII"5SNYM[0VP=NV;8T M-A"DLYIN80WF6[U2N IZE()5(#23@BC8S+W%<+I,['EWX#N#G3Z8$^LDD_+> M+KX4$!KH!S"X0R?
G>87D]I$P_G>_1/SCMZR:B&*\E_L,*4 M<^_2(P5L:,/-K=Q]AL[/R.+EDFOW);OV["CV2-YH(ZLN&1543+0C?>SNX2#A M,GPE(>H2(J>[)7(JKZFAZ4S)'5'V-
*+9B;/LE$<$_91UD;A+L,\DR[R7#;" M:+*B3S3C0*@H" 95 P7YRFC&,#,,-'E_9[?UV2PP2&N3@[RC6+84T2L4$W(C
MA2DU^2@**/[.#U!NKSG::UY&)P'74)^3./1)%$;)";RXOX/8X<6OX'76];-W MRC7YNI->;W(* M/5UC918-OI73K(<|[P!&_?0)6!ZI_ <5Y#WD6'+AK[6'&=MOI M&^VT\8-_*Y=8Y-
I@%!V9$LA&R8P(AN-N?IL.CC"_H)YL/B7^"T9 M^]/)!,?(#T?A8']!N:RPNVGJ&D3D)Y.$Q/ZP17BA,KY,$":-L?;ZC:,J$)APVF MAN?CD4=4VW/:A9&U]_-
,&NP:;EIBFP9E#^#^1DJS7UB"OO&G?P!02P,$% M @ ZH%N68Y&&*'! J0L !0 !X;"]W:W)K&ULS5;;;MLX$'W/5PS419$ AB_R)7'B&+";%LTBV:1QTEU@L0^T-+:(2*1"
M4G']]SM#R8Z:B[?MTP*&/*(XPW/F#,D9K;2YMPFB@V]9JNQID#B7'[=:-DHP M$[:I-KC^7["5XDK6[.!F7_@T:#,@3#%R'$'0WR-^P#3E0 3CH8H9;)=D MQ[]B?
]>!DXI%F3E#7R7YN?$G(0U\%6F!<(G"%@8IX\[" _IV8IV@/1BU'J_#<5E1% MG)81PS%I0%O#HGG$8/S^ M76?0/MD!N+<%W-L5?3RCG1@7*8)>0
T\O4VL11)+J!@ND)C+5#I)5/SW&*CH M;S jC)%["5-AI7V-V6>*U-Q6I4!&MY^!+ MH1W1OC8R(E 49>*W/%P*<\^XZ B#\]A)92323>YF(*!>]*T.WDY6!3$;K]S +|!I]?H#09UX_V[H[3
MGCQ9>R5('S7&N0/+RI5R)756"A)S^I\@FB%@\9A?U@W7E+^86%?ULC_5NJPTVB*P[KQ MTU(?-8[Z@^KYTYKUX_S[18/< SU64%G2V<]XC81. C[W!F"B: M5]'O8I(OBG26"
[7F0RC2=" *^EX M8=!&+J4B=G1#\ZPUGS4N,8B0E?<0E0+=9!82004R1R30*:6"5.81^>V$KJ-S(ORXQXPC81ICH3G8[NV;CZ\)?/T>?I11.FFH#7?#TL
M[J=DNB:^#@U=\WZ=^A'[4!:\+I/ZQV1V-OG"S&XQLX^P?X&/F$+GH ET-%NL MARNXU:M?II>-K%4NE2-E@IN0:[M M)K=]IFP,RQ>G<]^,S;6CULZ;"6F/AB?
0]X4FG:L77F#;G8_]5!+ P04 M" #J@6Y9"?C/C:T% "#$0 &0 'AL+W=OD3K9"?E89@&:W95&ITW&F=7T\G:HD@Y*K MB:BAPI&UD"77^"DW4U5+X*D1*HNI[[K1M.1Y-
5Z>F+X+N3P1C2[R"BXD4TU9 M>$3 S/N2P57MM1J&LA/A,'Z_2T[%+'D$!B285'%\W\!R*@C2A'U]:I>/. M)@GNMW?:_S;!8S KKN"Y*#[FJ;&OG MSA=CEC1*B[(51@_*O+)O?
MLF8D\@=@\(^*V ;_RVAHR7+[CFRQ,IMDS2;-1& M#1.JD4;G\HI6Y4I+',U13B^OM$@^_W6.<:7L;,MEJMC3:[XJ0!V=3#4:H&G3 MI%5V;I7Y!Y0MV!M1Z4RQEU4*Z7WY*3K6>>?
OO#OW!Q5>03UA@>LPW_5G _]" M+MK Z L.ZR5 MAE+]UY<@:W_6;Y]*I%C5/(`3_=:0 GD#X^6?3[S(?380W:R+;C:D77%)9LV
M!3"Q9F9=64^D+V^I#7V^#VKO]_U=#1+U5AL&5]I" .HLKYC.@"4"<5"1"]A2 MHLA3KO%#:7Q13A5Y*]P*G,#R*BF:%' "@7+%K>2>\ZT1QA5;BP(9!=%J;(E&
M\2I51\>CZTP"W,,A0Q2AO15(Z6WM("'QT<$-<);P+K6Z!+CY3+)&!K!FK]! M,JL-*/Y@WMS'IQ^Y^)S-(WS._<7H'Z@PJL+,YRG6;:XT17D#$'.\,,:GZRY8 MX/AQQ'PG#KW1M=
H\&#H:-$) M>_6B!\"91[YYA['+!G 4=C@*'X>C=VN# MG49;% #S15XTM(1O<;]+91B%Y@UG%/BL"F:/EP-6NO'U36BQZXP82NQ!A09 M8/"ER6]X8>"S!>]X-
:A)V5J*LL7=5Z<186GK=(5.%^0T(NZ^3MS=C" .Y (I MT#A2DR-:O MJ&UA^)$3([:\P/&BF-"H99[84])I395C,D+78_-Z,82]$- -(@ =,%C+S'1 M^HZ!JA),!<5U4?"*?
7ICW.TEOT&E/TA^\\[E^6^F]ODOB"[NHHL?3^TF@E5/ MI'3"P27KP%)&WE M>(XE;,]U8BP@I,;)S&?Q) J(E$?OVBK:(!!(>^2$T=S,\KQN$&Y!)CGE]"DJ
M8T=6B[LW7N<2TBE2Q1IR5#--R)&B,!(AFK(BP7S?Q_M;CREO#VO9C>U<%YV< MA=3^U@\Z@AU0$#]SA;\+P) FQI,B.?:'+H3OQTELV8(4AA @QCH%,VQ7CZ:"#C=VRV=-MEN-
Y<8N\F"O5V,KCC!*. MEUVJS\0>%O"FK/+4Q,B+PIQNT%Z--M21\[.8]6':#!:FTN*@GQ#;FG4G_"Q MC.C.C(@_\<*'&-%UW)9*XMEW$.$"#[RMVUXO04SW[L4ER(VY_2L\^F&6[!6Y
MZ^W^,)S9>_77Z?,WQ!LN-[@/L0+6*$IY&#-I;_SV0XO:W+)70N.=W30SX+A7 MT@0<7?NA=Q]DH/OOLOP?4$L#!!0 (.J!;EE^?_@3M00)8, 9 M>&PO=V]R:W-H965TR@&/KL&5K
MLVM@CRX(-LNLFF#HN@#+8IM(I*HDE2<|-=WAM3:LM?K'"\4KSGY?1SJ;*WT M)[-"M/"ER$MSWEU96YT.!B9;82%,7U58TLI"Z4)8&NKEP%0:Q=P)%?D@"HJD M4
A9=J=G;NY.3\\4;7-9XIT&4Q>%T%\O,5?K\VI8?9AX+Y#L_[P;L M$..86=8@Z/,9KS#/61&Y\6^CL[LQR8+M_H/V&Q<[Q3(3![J4_E'.[>]\.^G" M'!>BSNU[M?
X5FWA&K"[3N7$MK/W>).U"5ANKBD:8/"ADZ;_B2Y.'EL D>$(@ M:@0BY[J**2E+%L# MHIS#E2]M+)=89A(-O/H@9CF:D[.!)5LL,<@:O9=>;_2$WA1N2=/*P"_E',>[M\@/R<>-
H].#H9714X3U6?8B#'D1!-#RB+]X$'CM]\4\%?BU-EBM3:X2_+V;& M:D+//X>RX(T,#QMA1IV:2F1XWB7*&-2?L3M]^2Q,@C='0AAN0A@>TSZ])X;. MZQQ!+>"^KJH<.1R1PY4P*
[@AOL';TO.6"? >I2.J7WY;!*%T9O& MIY;EF'T=IW $D*,-($<_!\A+D3NCJZL_# HOV&U:6G66/(5[3@&U^)I$/8X MTX2Y)L<6=>&NB3E#=(PQH"PC(74'E^2N@FO,FIFPYT&Z?
R@'3_DY1+TXB=QW M%$6[>[P7N10SF4M+-U2/BH/6C.?G$/:"B<=H\$VI4I4/@F%O%,?4IN.T\T%Q M\O:0WY9T;B5AXKZ3(-W#T5,1!1Q/F$XZ%UE6%[4_ 6*IMO(_?RRO8#R$$_HD
M8S@YI(9\1A=E-.$V#G\,Z,A-]_.92LKDX 8W^1CAZ5[V0ACUAT.X\Y'5_DY MKL^4/J(F733$UVT:&3R/B1GUQ_ 5A380]T>^MT_.J)]LM@3-ED?6=A#YV$S2 MC^$%M2-
XL:]^3$IY*8471\B?;.B??#?Y;VK+I?.6LE#4A66I8S/0ZUK[5[?6%6YE^=,67K'NNZ*?AQ0 M\P9:7RAE'P9L8/,K,OT?4$L#!!0 (.J!;EE3\:YW=P, $0. 9 M>&PO=V]R:W-H965T%XSL/
#4LS;0;<8%[2%&Y! MWY77$GMNPY*P KAB@A,)VX6S],ZCF;&W!A\9'-11FYB5;(3X:CJ7R<(9&H<@ MAU@;!HI_>[B /#=$Z,: -:?33&F Q^T'|K_MVG$M&ZK@0N2?6**SA3-S2);
MNLOUC3B\AWH]$\,7BUS97W*H;8<.B7=*BZ(&HP<%X]4_O:IU.)XXQ, OP;X M3P&3$X!1#1@]=X9Q#1@_!4O/ "8UP"[=K=9NA0NIIL%&0M MN,X4B7@"20L^ZL;[XPX"%
[5I!/(?!%KYG8PAQ /BG;TE_M#WVA;4#?] ^8", M/ OW6^#A,V:OX6VS1\'^CSK$[963Y1B?X.!USNA&2FNPF2RD1$2W MSG'_2F<@BBPIW*#C! MGW]XT^&
[MMCT21;V21;U1/8HBN,FBN,N]F!9B!V&2&Q)B@'3"L_[&# V;?FV MZJ1Z;3SZ) O()(LJLIDE,W?K/O#& TR9?8O.DT;G2:?.-P)O=;),)50Y\7D- MQ09DZ[;O9'IS'V2A7V213V1/0K'M G']'
M>5B]:'[05.^K-94IXXKDL$7*X> ,#SY9O5FJCA:E+&PO M=V]R:W-H965TW5/.IK$W!!2X5Z+HLF=K>8"$W,R_T]A.//,N-G?#GTXIEN$+SH5HJ M&ODM2L)+%)I+
0K3F7<=7BW"R!JX'?]PW.BC;["NK*7\; =WR,IC)@Q$B@Z4L>,Q1 MPY^PHDQ+Z@+M[GLZC9+A-PWO-P*5SGEE#]_71AL"MI:KG-')=I8;32>M-9W+
ME,7Z_2T:Q@OI]0WY*HE]_>-6S<[MZ(S;DW@00J3:[@5"28OI7V2J-4IVNMT M$W4"KK#PR+H011$PPZ\0:OI[P.$-S^#9Q(5%K1#^QEI)3>*)F'R^-PD\/6"Y M1O7IE-
N=J+;FKW3%8IQYE8VG>D9O_OI5. K>=' >MIR'#GUPCK,4FN*<[',$ MM0:3,P$?UIB5R/T$=*UY904Z1[89[8*). MZ1ZKE2V$0[F\?C6.PLLW&BHEDSHV$-M:
(=E1=S@Q:IT8=9YZ"$;%*K8EGR&L MMU"Y6)WR8H!_W)8/+B;^H_'YDLNBD\A9\Z'+EL';GL1+G58*O(MI91P.$4_JB;*
MB;BH24C0S7/JTHC(-5>*D^=VY0H&OJN8OBV9_BF1_*/.HD25N89+@WOW=_=F M.]LV===NE?EF_L8V>Z?FHZO%]?W7H34X94%R[/M&_T!IUW4^,)5QH:' E.@%
M_4NZ@-6ND=L-C*Q<+[26ACHK]YE3\XO*;J#U5$JS']@#VG9Z_B]02P,$% M @ ZH%N6>,;)W;N @ '@D !D !X;"]W;W)K&ULM59=3]LP%/TK5QF:0&(D3?HQ6!L)RM"00*KHV!
[0'MSDIK%P[& [+?$I MV4G(VA$BAKJ?Q';N.;[G^#KV>"WDO4H1-3QFC*N)DVJ=G[BNBE+,B#H2.7+S M)1$R(]ITY=)5N402EZ",N;[G#=V,4.Z$XW)L)LQ*#2C'&<25)%E1#Z=(1/K
MB=-SG@=NZ#+5=L -QSE9XASU;3Z3INS"2'#2%L&8EXKG")CELBD\5!S.LV4%KC9?F;_*+4; M+0NB<"K83QKK=.)\=B#&A!1,WXCU-ZSU#"Q?))@JG["N8ST'HD)ID=5@DT%&
M>?4FC[4/&X!>_Q6 7P/\MP*'&A"40JO,2EGG1)-P+,4:I(TV;+91>E.BC1K* M[2K.M31?]<'I\(PHJD D,).HD&MBS3V$* I0T)CJ)R \AGFUQ#9L3I><)C0B M7,-I%(F":\]7,!.,1A05?(+3V.
,"6%PR:LRL^NU?XZ:4*8.3,CM_!SV]PY@ M#RB'[ZDHE)E%C5UM!-FTW*A._JQ*WG\E^3GF1Q!XA^![?K\%/GT[/-B&N\;& MQDN_\=(O^8)7^*9$I:5?
9>,K<7!%F/%4P=V5"85+C9GZU2:SXNVW\[J-?*)R MN'R>TJR14ZX<;-'NF"HS=^/TLC>':R*7E"M@F!B4=S0RI2"K MT[CJ:)&7!II":',\ELW47&!0V@#S/1%"/W?L&=E&PO=V]R:W-
H965T>;QS#/VV,-H(^17E0!H\BWEF1H[B=;YE>NJ90(I51V10X9? M5D*F5,.K7+L]ET!C;Y1R-_"\R$TIRYS)R(X]R,E(%)]S#!XD446:4OEV UQL MQH[O; <>V3K19L"=C'*ZAB?
0S_F#Q#>W9HE9"IEB{B,25F/GVK^:^]; (GYG ML%$[S\2$LA#BJWFYB\>.9SP"#DMM*"C^>X5;X-PPH1]_5:1./:LL]M M\!C,@BJX%?P/%NMD[P<$L.*%EP_BLTG]
+J&;ZEX,K^)9I*ZSED62@MTLH8 M/4A95OZGWRHA=@S\\(A!4!D$AP:](P9A91 >&G2/&'0K@^Y[9^A5!KWWSA!5 M!I'5OA3+*CVEFDY&4FR(-
&AD,P\V7=8:!6:965E/6N)7AG9Z\@BOD!5 ?B%/ MN&CC@@,1*S)EBJ[7$M940TPJC"(?[J IX^HCP[^?IN3#Q4=R05A&OB2B4#2+ MU5 [>E \$!'T)R+S*=*#++8HA;
[&>G[8T&WQ9_I^\[MG/\W^_P_S[XG1E@OC]#RA4?X=A;"J0.X-+8+ MYN4S0LF=AE3]V9;UDK?;SFQJY97*Z1+&#A9$!?(5G,G//_F1]VN;Y.R:B^
M"$UYK0HIL%I(@M63TX60U!OOA.)"ISPU=6L9*^[E_&'@^A @"9HV.L?"-#$ M]**^?Z! "VC8';9+$-421-\A05N,43/&?O\@@=,FR ^Z!T+,FJ H"@^#; $- M=N3;"
]?!]D_&>1SOI)X()(#U8Z8 V;]Y1[2!G*9_"5H3.VR>)LUJ MV@0UJVD3TU)-6T!'JZEO6I_]D9W+M/_]F<+SE-QE2U[@_11O]SK!"[-\]&<- M#TNQSMX?:(<|),&/)#/|)2UOO&!NO 2O?-
I6M_K::*G,!?"2;*C"&SI^\#S/ M#E^00=^^7"*[RL$V=OSM$LFIMG!VX"]V;2 EOM=N(6B)'DCL"M%
[NF"E['PWZ,"CP*Z*7&_W3X>T;5AWIWU+0:YMV4G<+S)=7G#JT;J9OI$M[.'XK7\U M]5O&9Z;Y;QF_]KVK&:[WMB\^?BG;^W]=*G]MN*<2!5&$PPK=\SI]/.!EV<"7 M+UKDMN%<"
(WMJWU.@*(D!H#?5T+H[8N9H/X99?(/4$L#!!0 (.J!;EG1 M:5,1, ,)4) 9 >&PO=V]R:W-H965T?:QTD;:6A!(($TK@P^(#VYRVU@D=K"==OOW7#M9Z"/M!N)+ M:]_<?UW8(R[L1C&
[N1\5A4.F<<;B1155%0^7 -N=A,'-]Y#-RR5:9- MP(W')5W!'/1=>2.QY[8L*2N *R8XD;"<.%?^:#8T^3;A*X.-VFH3HV0AQ$_3 M^9A.',\4!#DDVC!0_%O#%/+<$&$9OQI.IQW2
+?;C^SOK7;4L[*IB+_QE*= M39RA0U0$TBK7MV+S 1H/<.7B%S97]I/U/[QL?M@!^ M> 00-(!@'Q = 80-('PN(&H D76FEF)|F%%-X[$4&R)--K*9AC73HE$^XV;:
MYUKB5X8X'=_"&G@%Y)S,<46E50Y$+,E4<"UQ2K 8G9&I+0/DG_ G1AD"L:]GH"G+U1LDO)O/R.N7;\A+PCCYDHE*8;(:NQK+-H.[25/B MM"-XQ.%+B',H+$GIG)/""]_^.PV?
08)PW\+#7;B+9K6.!:UC@>4+GW!L*45Q MS*CO5PMEXS^ZY-;\43>_V>SZIPL8,4X9WQEEI/.@#P E1WU7Y\>X;O?Z6 -
MZEN0.=C6<7_0'[OK;6,.ELZPLM@3^MASK8?.UI[K=;>R6IFL 0I(46M=KVKOYG4T]1'A/8.1 27/<_? MDWJ8%0[\Z(C8?BNV_]=BGS6CIVF/".T?KLPH]+P]H1U9.W;L"!TX>X%AJWSX
M5(GDW7V25RF*7DFZN[K))F-)1JC$6Z'2BJ5@_5)/CN,.5?S.SQ6_>C 5L;NH/F;::/N&N+9W[7Y\,)H.NN++T=2^.=P_]/6#Y3.5 MN%@5R6&)0WD7
UPRLGX$U!TM2GLM+H3&0]LV,WPW@30)^'TIA'[LF ':EUC\ M&U!+ P04 " #J@6Y922WP7;T$ 5(@ &0 'AL+W=O);L0*0Y#E-LF)]
MK:3,KVR["%>0LN*"YY"I;Q9D6*';J46MW8&'>+F2^H]F^1L"8\@G_)[H?;LAA+% M*61%S#,B8#&UKNE50$=:4+;X+89M<;!-]%#FG'_3.[?1U')TCR"!4&H$4Q\; MN($DT235CS]KJ-
7$U,+#[1T]* >O!C-G!=SPY/D #S0MY4I3_R;9NZU@D7!>2I[58]2"-L^]Z)+-<3<2"@_2,"MQ:XKP6#(X)> M+>B=&J%?"_JG1AC4@L&I$8:U8%C.?359Y4QI[3++91/ M$;]UHNF-
TJY2K28X MSO3*>I1"?1LKG9P]P :R-9!/Y#]*8FTV2\AM5BU9;?T'#R2+D^*C:O+TZ)$/ MWW^.97!?$SR*(.O2^67]IT-MJQ,VPW=VP/[M& MH ?
A!:&C'XGKN+1K/&;YSRR[(#U:RMT.N7="]%K>%=TWRQ\A5W*GE/<[Y,'I M\IYA+GO-$NJ5O-X1GCJI$S;G@ND<0:Z%8-D25/*1A&51:_]7N0)!Y(IEI"WZ M^HMBDEL):?%'QX
^5QWH=W=)]^K(F0ICY@$E1IH_Y-S2;[>03H'T7E2&NGG.H0)\S!A/B8L0(*U_!XV M?@_?.T\/,9<$)LS#A/F8L)UEH2HV9)C/XE3^L?'SH#Y"#*>[XL!,+G2;PL M[Z*+I.-R'--
QH1YF#"_@@T.2F@RK^FJZZ1=*YOF# /$^9CP@(D6,M;ZNQ_83OO?=VM>X"T*E!I'BK-1Z4% M6+3VRCBHO5#C>?^4+P17ON?L1?O?Z2Q|<^L_<)R.!'9S0%4 6 (4Q"YM#G7W"8=
(\5)J/2@NP:.TEL*]4 MT7W:OH)%S26LX^?S07+_OW4N0:AV), ,+9^9S+B5/R\T5L B$;]"^7W N M6=SLZ0/,FR.P?4$L#!!0 (.J!;EEQ_ST@GP, ",0 9 >&PO=V]R M:W-H965T"%@_$XD
)+\ MR+-"+(U$RO+2-$640$[%!2NAP)TMXSF5..4[4Y0<:^0]+68ZEC4Q&P71]_VY>A[2B MOB:PD$"#"*I*"A^ M[.$:LDPQX3V^-Z1&>Z8"'H\?V#[JY\6#9+15PS:) TE@F2V-
FD!BVM,KD9W;X M QJ'?,47L4SHO^30V%H&B2HA6=Z \09Y6M2?]$"_ :@':;$"92TY[J:(MD\$GRN] TDT&9 U1Q5.9@B"_DC5&9%SAZE]:\I&FG'RE6:5G_8CW*UQ+,_$!
ML5_6*_+^W0?RCJ0%^3MAE:!%+!:FQ/NJ4\VHN=MU?3?GF;NMH;P@KO4+<2S' MZX&OAN$KB!!N:IC; P_//_T$;J+(K=),J[2C^=P7*?WM3S0C-Q)R\6^?0C6G
MU\^JILBE*&D$2P/+A "^!R/X^2=[8OW6I>89.%(9!TMW59+=X@]N"FBK(HA MQF21"0991$5",.CJ_7ROTCW-H]05=33S2UJJ/IP)E.?6MA[H^U>FKE^]IG
M=*W"'BO;FWJM5<<[K_7.&_3N*%)6L)&=/Y7 MH5FKT.S(.U+$W5,LG DLHZ<\U;.^1L4O?F86HY)%HY$UM'2 MMAZ?R-:;I&_#>_P\L$^+5X_-Z5LD'+[?:_U7+4)WY?$I:[_B=8-
3PY\)WN- 6)6%7(^A79KK;=[)5N^IZLVY2C;5I8&PG:H2$-"1'8'M >W/2V ML4CB8CLMVZ_?M1-"2M, @KVT=G+/\;G7\?$=KKFXE3& (O=IDLF1%2NU/+)M M&<604GG
EY#AFSD7*54X%0M;+@70F0&EB>TYCF^GE&56,#3/+D0PY+E*6 87 M@L@\3:GX MTXY*92>%,F^'LA"6!Z3C?":>XW4;X.-V^ 0BA+L&WMF$VUBCJE!>52C/\'5V M\(VIC
EF0LS@VUW.5EB)3$ER\P-#R9F"5/YN2K/@[3;SZF-Z))]*=+"[QN\:I'5X'I> M'W=O5<[A.VHPZ/6JH UMW4I;MU7;=88FEAAQ"S2OQN^M8.C5UNT_4;8=X3;+ MZE6R>B^5E7
IH5%7;VM5YXFNUD6:=YVT;+A?J?=;U9I2)@A^YCDTR?:WB^5Y M _>)]I.THW&R_N:KI2E>_O:HAN<*ZRAP-JN9"-^>03D$T'L)6PM<>PG)%;N^O=M[M1R=%F1^W+O-
Z/W,=+V&V]X)YQI!+L/V-)#6$-GF37FBK= MT6*GM,#M) G,$>8<]+%"HF@2BXGB2]-G3;G"KLT,8VRL0>@ ?#_G7#U,=.M6 MM>K!/U!+ P04 " #J@6Y90S7$B,$" #K!P &0
'AL+W=O([CTTR<@8.Q+A@A3#7I#RK_NRQCL,&H--[^#7 /^]@&X-Z)9*#\]*65-F6#A4<@W* M6A.;'92Q*=&DAFT M)1;'T/4.P?^\7@M\LAL^Q8C@G1+> MW8:[%*XF9GX3,[_DZ[[!-
V$Z 5("Y>#\H> K)C S&GZ,Y]HHNIH_VT16K+UV M5ENNISIG$8X-H5.^/E3)_"^M$G^3V1; >@V >CN8@^W]\(A7&8@,X0G M9_JD H&Z-JWN3WHO'!IP,?3%+0R L^(.]?
4A6T77PX1>8U36@/874IKGB6WXS?L>_@90 M2P,$% @ ZH%N64G)#70H P 3 H !D !X;"]W;W)K&ULK59=;],P%/TK5I@02-N2)FD+I8VT?B"0F)A6!@^(!S>Y;:PY
M=K"==O#KL9TT:XO73;"7-G;..??>8\>^PPT7MS(4.BNH$R.O%RI@9O 5\);.3.,S*5++#B_-8./V<@+3) (5S& >_N-4# 4B.DT_C9:'IM2$/< M?
=ZJO[>ZUUH66,*$TV\D4_G(>^.A#):XHNJ:;SY 4T_7Z*6<2ON+-@TV\%!: M2<6+AJPS* BK_ %=X\,.0>NX"6%#" \)\0.$]"%$3XT0-X3XJ1&Z#<&6[M>U
M6^.F6.%D*/@&"8/6:N;!NF_9VB_"S#Z9*Z'?$LU3R246MZ#P@@*:0UH)H@A(M=(;F>D-FE9[]O$0[F-G/BJA?N]!74_V*4/E:DV[F4_3JY#4Z082A+SFO)&:9
M'/I*)VK"^6F3U+A.*GP@J0A=%1P M#N4YBH)3% 9A[AG\G1ZY"KG_Z+/_CGZGAE1NV4BJQ<]H>1K4$J?58H>8JF ML%!
(K]C9WR_6$@E]$GPP[4#ZABQ.X8Y'0>RQ"F,/'W\21!K\)*7+SJ]X)W+ M_N<4FSZGV.R9Q/86*FX7*CZFGGSB4B)]4R 4JR3;53I%#)1K?6KIGI4V ME\TZ.>L-_?
6NZRY(L(^9.C!A9Q\SW=X[6#E -D'1"0\A4C MOR$SQO)@P0A;/6H,DIRZCIYQ';>[D^U!S9._$>:[V[/E;TA\8,11D3U+>]TE MO:.6W###=2%#K SWPY3$OW#J]Q[>. Q+U#SQR8#H'
MF)D+$_I1XH7MK+>+<&5ONKM8Z[;/1 &H-\O.5?; M@0G0-I#)'U!+ P04 " #J@6Y9=)3BLEX# I#@ &0 'AL+W=O*/W #F3 FNI0;SK,KR74\MQS-"!*(E:(@^+.%"T@2 MC80\?
E2@5OU-G7@XOD. ,_L5C,3=4P@5/OK!8;>;6Q"(QK&B1]]\]P:]@H8: M+^*)-']KHIU+!(54O&T2D8&*F"T,=E8#4F>/WU!GA*6D8\;7DA,D#-;
M(5O]33NJF+TJF7E_8+:$_)3XS@GQ"'"]H2;_H3K^$"--=D^XWTVW4J!:*]X7R M#)[_%Z%.R'*AF6J]0+Z^Q7!RK2"5W]I*+;&#=FR]5<]D3B.86[@7)8@M6.&S
M)^[(>=E6>$](@#1G\6@:_"ST\CZ(B+1*]{,;=@A^(&"WW(^!4RX4^V4>M*E0 M0H\,M#Y?MN$@<*>X.MO#\EJB_,G$];,(.:=]#)N^%>V+LW]7&M 0;'G#P
M'/>8:$N0%PS;>0YKGL-.GGM+714B8ZH00,Z1\A6[U6-)OKZ#] 9$]\LZH1_] MLI[&B],:A5&C[C91GW*T!-80X9Q+X[TQX%W9-N6H)$; MM-
MV4C.==#)]"_BO=,.3F%RGN>!;T$2[S=H)^-!5Z@FL4?NTKGWZB&:=]BE# M3V -&5QGWTHX_=]UPFN>H*-COI9%^0>'<9/M0>/C=K(U'>N KP:%!$*E!/3K M
,_9C&81$&/H3O]VPS]TY?I":XJQ;V[=@^Z./U)>H=%6N629+ "K.2\J)XKEI[6^X MPHN"&6[P+@="!^#[%>?]:]O"_7M,/P-4$L#!!0 (.J!;EFENF01IP_M $02 9 >&PO=V]R:W-
H965T8JF&?..* MB@/.&E!9N!//F[DE)M2)%LWY;.E$ %81QR)?.A7^>^ V@L?B+P$[L72.=RBUC M7_7@E%LZGHX("DBEIL#][PY64!2:2<7QK2-U>I\:N' _LR?IY'D[Q*YA8+6+'B M;Y+)
[=(Y=5 &.:X+^8GM_H0NH:GF2UDAFE^T:VWG@8/26DA6=F 504EH^X_O M.R'V (K'#)AT@,F/@/)0- !@I=Z"#M ^%(/TP[0I.ZVN3?"Q5CB:,'9#G%M MK=CT1:-

^@U9Z$:H7RHWDZBY1.!FMN5IS7#X@3#.4?*M)I5:!/$(?U1H]1A=9 M1G0]<8&N:+LJ=77?Q2 Q*<1[9?+Y)D;O?GV_<*6*1G.Z:>?YLO4\><)S@*X9
ME5N!$II!9L#'X_BS$;RK5.BEF#Q*<3D9);R!Z@0%WA&:>)/0$,_JY?# E,[_ M\YZ\V?M C*!?%T'#%SRS+H[0NL!4#I<'^O)!F:,K";7XQU3YECLT<^O>=RXJ
MG,+24[OB$OBF.8X0*&4UE>U&J)_MCSPNFHW^ M# ,7_OG*-\S'^HBDV85_IV_/5ZXQWQ JU"=GKEQY)W/UI&PO=V]R:W-H965T??1L\^NQ$H=K87\H9:4:O@9\DA=-99:QY?
MMO*7-"2J)6(:K>}YD"'1^H7 M;15+2@=+K%/)VQW'Z[9"PJ#$>V;%[.1Z)1',6T7L)*@E#(I]O*!?KJ%;>!EX M8?NE-@/M\2@F"SJE^EM\+_&NQ;$+*28B(C"2>=7C6OW\K;C&
=K\9W1M=IX M!A/*3(@?YN4NN&HXAA'EU-<&@N"?%9U0S@T2\GC*0!OYG,9Q_D%_8,-'H.9 M$44G@O_- KV\:@P;$- Y2;A^$.L_:190S^#Y@BO[+ZPS6Z&SR.1]JB5^9>BGQQ^%"-
;,1)M&"S3B%:Z6H5DWX@J5W M#E,LMR#!83&'>@_K<'I+-6%-;A9ZY-W4>SZZEL2D&Y3M$(.+]=U-^O)YW:H]['>FTVCX56CGRC!7+?LK S M]&-
I<22TLA9%6^/6=@N_5lP'./94=^:U6;BN-]S9L0^:E2,K&A6WOM^XQU_ MR*2SKJQK(5Z=RB.AE0,NNAG7>].RKFV67JW%@=*#6A0IDUO?ZNR4-1YT9__B
MV1.T.-1%3=S=5L<=7O2V&Z*#9F7N14?DUK=$#^*9?D R5<" ;J MM!T)K1QZT6>Y@S+2 0M4H !8@)ILS8@9V3H) _*>$27/P0EN.5HPS
MS:@RWY,0QUED<;^5II(1!9^I7%#9!$4I?!&:@MN%TXD(0Z9#R|X F87-H@6- M?(0Z@[F0,$\DXD@(F/(392_91"5T"[X*"/"GK0EK"DNRPJ"$1GU\L8C8+TOU
M&18ONK$P1A',U.B(:'E ?Q\YUE3B3HFG#^_E)R9(5>>HG?V M.&=2:7A*B$2^9M#QH0JGC;PY M;9Q5I$4OB4ZIV>PB(PTGX/5;/0@Q:GN_J#!$]?>4".%<^;Q9%C&G$ISK9HF
M%16(LIO*-=/+/9FHJC%5%(^V;E9=Q2R629S!5DR9XSQZG$#7;0URVDA"$]P$ MHX59Y<;=GC=1L84DH17J!%RO-:SQP&8>8ZBTD68K 7F"B5K"G(NU@B0*,%]I M.6
T"&QJF^FB*N92A/"12IQL(F0LI!6N!=,$4[?M2*19G3%JAYY(R+>UCNK@ M,U8\E48!B;G&L:;U-N6;J&(MV8"%W FEF=;JS 1$UND,,XJK#7-M@+F(%N?< M_GKL5DT:Z?
5T@DLH9CX,G5X3;A*%^PX6(R[2&8ML:*IJ_VYOW+F&I@#,W;5" M+DFDT^NS?#2_'[^QU\@[XQ>7$]P8*[YTG,M)>]7>+J9(+^0_$[E@D0).YSB= MTQI@VR'3.^[T18O8WOK.A-
4BM(!+2C!B8X#?YP*WH^S%3)#_3(\X/U!+ P04 M " #]@6Y9ZX#+5 &0 'AL+W=ODMH'$1KL!FJT1M]V'8!\8:6P1I4B5 LI.WNW^:04A2[L;5MH;[8(L5SR',XI&;&.ZF^Z S
D&\Y%WKB9<845[ZODPQR MJKNR (%O5E+EU&!3K7U=**"I ^74"6\Z=GT+-1W+C>%,P$(1O!3S2#7,)/^;I2:;>".//+"B&V[NY>Y/J 3U+5\BN7:_9%>-#3R2
M;+21>07&%>1,E/_T6V7$'B#LG0!$%2#Z'A"? /0J0.]' 7$%B)TSI13GPYP: M.ATKN2/*CD8V^^#,=&B4SX3=]Z51^)8ASDS?29GN&.>$BI3<"D/%FCUR(-=:
M@]&OR5\8>A=DB>&6;K!;KD@SP@K'.YF HX_J UB8H(/@*$?R'>/GD" \ M=/#>(=Q''VL?H!K'R/"%)_AN%_>O:%Z\F:/$S]>SB#S<0?X(ZI]CRAJI[$F_ MT@5-
8.+A4=:@MN!-7_T1#H(WQW2V1':@NE>K[CGVWBG5 H\8$\S Q7L\OL?B MX>$]8LBM@5P?]:+7IAQ(T1\)8R1;;4;]PI8<[&4&?$D>7>-!,^ MA$<-*T$#![*W^G8:QJ,X&/O;?2?
^;]2!Q'XML=\<\: ??!_"C=/^HJA1+6KTP]?YA\4L; SK1JJ?WA,%S9A2T'=@5X_ZUVPN'+R*[>>)?%693OL.>Y^0E;,Y>\%.#&VQ M,:I)1E-B=A(57Q35;:_V;_MT[[8_\^]3XIV_](B8C!JR
P6ED2G!9H?$@VX? MDUG.7>:O24&5L1YCGDB*#2V,)E\W3#/'E5(#EELSY$HMHH/I M8G=8+QL7@3FN8&)-C'1P=T^@8VM%G_P%02P,$ M% @ ZH%N68N@.(IB P %A$!D
!X;"]W;W)K&ULM5AM;]HP$/XK5C9-K=0V(0%:.HA$2;I5;J>JJ-N':A\,.<"]$S/; M0+M?/!L)*;1I^C+W"\3./8_O[KE<.+HKQF_%#$"BNY1FHN?,I)P?NZX8SR#% MXH#-(5-
W)HRG6*HEG[IBS@$G!I12U_>\MIMBDCEAU^Q=\K#+%I*2#"XY$HLT MQ?S^!"A;]9R&L]ZX(M.9U!MNV)WC*0Q!7L\ON5JY)4M"4L@$81GB,.DY_<9Q MW/ TP%C\)+ 2&]=
(AS)B[%8OSI*>XVF/@,)8:@LIO8P $HUD_+C3T]E&=] MX.;UFOW4!*^"&6$! T9_D43.>LZ1@Q*8X 655VSU'8J 6IIOS*@PGVA5V'H. M&B^$9&D!5AZD),N_\5V1B V XJD&^ 7 ?
PQH/@,("D#PVA.:!:#YVA-:!<"$ M[N:QF\1%6.*PR]D*<6VMV/2%R;Y!JWR13!?*4')UERB<#+\QEJP(I0AG"3K+ M),ZF9$0!]84
*?;0#U6K^ZB?)$3KBJFRR:M3J[P3@<2$BEUE:VQT7'ISD'OC/>!"@"Y;)F4!QED!2@8_J\9T:O*NR4:;$7Z?DQ*\E',+\ M 7>'O(]OUGAS^#U* JG/\I/7[WZ5O)",KZ" Q?\ S?*Z M.5?
VZ$Q"*GY729^3-ZO)=1,\%G,\AIZCNIP O@0G_/*IT?:^5N7=)EEDDRRV M1+:E4+-4J%G'O93QB7YFS^1;(+(@TC8B%2E2T[9-I3Z7;(,O:ZIW$SV4XL@
M\+Q'5M%3*]|_8A4_M>H<;5IMQ=TJXV[5QGVA*C=I.CF M(1\,KRJV5X;_G9 M)(MLDL66R+9D:)U4T&M<"WYOV]7L26O-C\5&9XZ/Z9H3O7FQ&M0QO M+76;9)%-
LM@2V98,G5*&SD!P[/3CE[@:7C/ M-Z1ZZ%N3_WY'8EN.Y+EV-^:\%/C4#-@"C=DBD_E/^G*W'.+[9G1]M'_2.!XT M*O8C/?2;N?*!/O_'X +S* M$^#:0-V?,";7"WU ^5=(^]02P,$% @
ZH%N6=#.YCB7 @ &P< !D M !X;"]W;W)K&ULK55=3]LP%/TK5H8FD#;RG5+6 M1H)6TR9M4D5A>YCVX":WK8439[;3PK_?M9.&T@;&PUX2?]QS?,ZU?3W:"GFO MU@":/!2\5&-
GK75UZ;HJ6T-!U;FHH,29I9 %U=B5*U=5$FAN005W \|+W(*R MTDE'=FPFTY&H-6BI;B:Q MYW8L,2N@5$R41,)RI%SYEY($Q-N 'PRV;]J-C).%$/>F\S4?,YX1!!PR;1@H M_C8P
L7^VWM'+@BJ8"/Z3Y7H!=BX/H>[MF+TNA4&7PL#RA2_PM2E03SF@7)%?5PNE)9[2WWT&&\:HGI'R9^;#SGSX&OO3^:F:+/29;1@2RV"]RB;UX^%PY&IV
M31P'!5[L=4'/Q$6=N.A?XNR!S$2!54]14SCZ!#8L\?[:T3 Z$'@<%/KF_/0) MC#N!\9L$\]J<;TZ<8SO#0?!\I).7O*JO%NA*>\3E!QM5A0-!@>* MCH.28"'XH^Y>Z3+/QG&PO=V]R:W-
H965TTS<1"]>!*=-("^ "C'B**B7*VY%,A-XEE_XDCW?! MCSPZB[LX^59INI53D>QA$Z=EHJ]3NU7B"275I]V'1#^-*Y6-'\HH]>.()/+Z;/3:?74^<3*#O,5G M7]ZEM=3V8E4GD>!__X&
[4]&\U&9",OQ3Y0'^.[OV0Y(9[IK>,@S7^2N[*M M,R+K?:KBL#36(PC]J/@MOI>.J!FX[D#6AK08PV\TL#+)UJ,+)_6A5!BN4CB M.Y)DK;5:]B+W36ZM9^-
'V3)>]41_ZFL[M7PK_(1\%L%>DDLITGTB1]JIE/Q. MKG3$;/:!)/$UJ;723Z_35.HF(MJ0[IY8^8&O?)D6GV^(7IN/IUHG78R5GDPVI/&Z'/B;8N#T MB8%?R=U+XCDO"'4H:S
A\TOY%J:N[FY9YN/M0LK/]+*CS37\P[Z\<6]?TI M-GGD!?D4Q:M4)K=BI3W\+MKM5=8FCM;:FR(/\"_O=1?DG9)A^F^3>XKQL.;Q M9-G_*MV)M3P;Z?
3.>I*CY:^_N/GCR9G(8E9KO,JUWF0^K)P5],4"[M);I?] M/;I=TLF4SQ?CV_K8&UK-YQZO6EF#8M6@&#BH^GKFRZ/7[+V\E0%QR9=+&:YD MTK@]H&K;54$2LQS *P?
P@04TQW0=DICENDGENDG'@"[L^(& ;FCU=$!/JT%- M.P8T!0,;5&V[*DABE@-FE0-F POH&;;KD,0LU\TKU\T[!C1HUSPJTC2[TW6L MB;F.P1^G8UIX8%K LFT7%TO-=D*-
=V!I4@Y"SW(:G9[C/HYX)X!*0';-@ B M/Q"$[,D9,'-A.KN,(_F#7(KD]IY3OMUK5H?S E1B M:U'(:O;<#0.Z;&AY@NV0U.R#'(.$U!E8Z%-4F,12LUG8)*'M 6$/FS8@H80A.S)U4[Y8-3K
MFC[P9@+NM/7Z]W&81PTP4F]HZ8/*G%AJMOL,3']!$RL3E[>+C:T&HVXY-FKJ(&^"@,?$=$]@E;"[CSUBO8QUDB-0A*YT-+ M %0\Q5*SBV4&3SWXQ!
(HESG')$!#]Z<3P#/8Y\'8=VH"P!L,N/.V*XBE9KO* M0*0WM%]OAPJ86&JV^VKEXLJUX@[HUDA("$+VY S^>3#^G9I&\$8#[KQU'/1Q
MO.@9F/2&5]'V4#D42\UVG^%0KVN5&C9LDT:G"]F3,Y3HP91X7!J=BW2;7V/* M7_SY;>_?BB"__@0F$>I!)9::[2C#K=[0JN(>*LMBJ=GN,RSK=:V,EX9US)IZ
M'GT(8WVP)#,LR6'6Q$J3$[8\\A;WYCJX^R3&0AF0RND.U0PQE*SW6? F'4M MD)>&!]OEN\Z? .F[$"I_&=D$IQ/@D?8.ASZ. IEM2N80RN,_)SKFWWP,3-\ MS+J6WV'#%H#71>CP#
W"L@-U_)^1,EY#&^XT'UYS Y[\0%G_F+@^89,#=]lZ_?K M7&XPEP^MP,11J19+S7:?H5K>MXSC,F[UN]APQ:0A"!D3\X0(#_Z%D#'1()W&W#W MK2.A#YCD!B;YT.X!<%0*O5*SOV-
H*'32]1X ;-@BD1*$BLF-;U]0S_X[@,Z3 M&S]*22"OM;+S&ULU5C?;]I($/Y75KY3U4HI_H$Q20I(5HUIZ1" MX7KW4/5AL<>PBNWE=A=(I/OC.[LF!J>P$JG[D!?8M7>^F>_SC'?
6O0T7]W(! MH,A#GA6R[RR46EZZKHP7D%/9XDLH\$[*14X53L7>8&GA>Y.66% M,^B9:Q,QZ/&5RE@!$'T'D*L^I>!Q"QC=]QW>>+MRQ^4+I"^Z@MZ1SF(+ZNIP(
MG+D52L)R**3C!1&0|ITK_W+D=[2!6?$(@XW<&Q--9<;YO9Y<)WW'TQ%!!K'2 M$!3_UC""+--(&,=_6U"G\]D-I\=/Z)\,>20SHO)&//N7)6K1=\X=DD!*5YFZ MXYO/L"5D
HQY)LTOV6S7>@Z)5U+Q?&N,$>2L*/_IPU:(/0,_/&(0; V"YP;1 M$8/VUJ!MB):1&5ICJNB@)_B&"+T:T?3 :&.LD0TK]&.<*H%W&=JIP1UD5$%" M)E2H1_*WH(6D1F!)WI.K)&%Z3#-
R790IHZ5_.P9%62;?X9*OTS%Y^^>[GJLP M& WIQEO'H]O<,1Q)R2WO% +23X6"21U !=95%2")RK#P(KX"68MXD5G)/"" M\%| =O. 5EF+M'UCWK:$TZZ4;1N\\ C>4"":;#@OM2U
R#-RTYJ0;[>0ST!\ M/Q#AT(]H*_I2+FD,?0=+5H)8@S-X\X1\.T6T(K$8^K,B'!KU]A/P84A " M\VK$#]-OVNEVOYZ[WC25C=O)!$5)&(K"2P'/33
MTYE!BT=K/5B!3GUP#8'5.'UO@VU*VH;0ZM(& M.VD#:]+=P!RS#AZTK" /TK4"G$RW1(OV]]<@\KQ=*=:)['I%W]XLCC$C;EMD MB&TUV+=$.]#)A'Y'D^COND3_-;6)?J-]8E-
H=6EWG:+_BZVB_W.O>(';2N?9 MKF)WIIH!]6GD\$/4$L#!!0 M (.J!;EGAJ$ACW0D .-\ 9 >&PO=V]R:W-H965T:.4"2VV+&@-1 M/0/8ZE1^?1L)"+:$&-J]W+F9DF7Z^!NDUC?6-=/66I-
^S)6,Y^7T5Q=EU;YGG MZ\M^/YLOV2K(+I(UB_EWGI-T%>3\R_2EGZU3%BVRQU917U.447\5A%"O=K6] M[R&=726;/ IC]I"2;+-
:!>G[+8N2M^N>VONXXVOXLLR+,_JSJW7PPAY9_FW] MD/*O^GME$:Y8G(5)3%+V?-V[42]]?5@,V&[QKY"]90>W2;$K3TGRO?B"+JY[M2C$C%K%Y7A
!_^>5W;$H*B0^C]!*M+>O60P\O/VA6]N=YSOS%&3L+HE^"1?Y M\KHWZ9$%>PXV4?XU>7-8N4/;"F6^R/%F5@_D,5F&\'S?X MO3P0!P/4P9D!6CE .QXP/#- +P?
H;2L,R@&#M0.&Y8!AVRF-R@&CMA7&Y8#Q M\0#]S(!).6#2ML*T'#!M.T!5/AXYI?60_8/=^M%6/QYN=?MX]W=/K.VST@CR M8':5)F\D+;;G7G%C^]3>CN=/QC
N4OB8I_R[(1^7SQZ70Q=+@I'WX?I'RX>G;X]?]-WFX_7*\9[C1-_IVH@[/%:8O'39N>'>[*AQML MOC]R=7/WV@_7;H;[[8>KDB>QO@^[OO7T7Q5D+'UEO=E?_Z*. ME'_4I0:)&4C,1&
(6$K.1F(/$*!)SD9B'Q*)D1XL(_P0*;/'O@BE:4I6O^_M.)A__)QZ@TV/,5I^) ;D^6MU.R:V1TVW&+%(O]UQI?\Q9^K_NMA')%%321F
MM=P#&UG406(4B;DM#X>'+.J#,"%$PWV(AMU"%"=D':3D-8@VK"X_4JYK?G;8 MZ.!P'R<'6)423F-AX(#UG.!V%"6D;[M(S^T"DGS+)-_>E& MZG6-R^CDI]-Q7)#E3"1F-
<[=1I9SD!A%8F[C@?"0Y7P0)L1EO(_+^_%)=GD M61[$BS!^])B>'>C!4:B][D&5-)&:UW@>[]98./U"+* \|<8$.IE,]+$^'AZ% 5K8A&I6
M^]VPH84=J$:AFEMW4,:#Z60T&JM'&8$6]E&:&*B#5W;5[H%]N J1DYU3I;9/ M%;*P"=6L]KMA0PL[4(U"-;?NH)Q+%;*PC]+$5&E5JC1IJO[)XX*XCDCR3.9'V2N-
E]2O'.^D)H!U4RH9I7:X>I%'2CCX\5>S6:CD784 M4@8OIT>OQ,-*!%3:AFM=L%&UK4@6H4JKE0S8-J/DH3XUJU&NF? MVVHDYSLG%-IJI-
IH_M[]Y_(?;/]7.*C^^_42U.MN=]2+^W=YVU7_.[CO^^# M"]6,,Q*Q9UY*N1CS'4MWGZB]^R)/UMM/-7Y*\CQ9;6\N6;!@:;$|__YSDN0? M7Q0%II]K/OL?4$L#!!0 (.J!;ED%,4# _-0< 0O
9 >&PO=V]R M:W-H965TKADG0>P'[\2$D1]:!I2;'1?4DLF;R\Y]S+RV.2QX\)_;BD2XLMJ($^VFG*+20;8^L M" ?Q8':E"2S^/9!S$H;2DO#C1VYT4(PI.Y8_OUC_D((78.XP(^=)^#7P
M^?)D,!D G]SC='=/D$5#96EB3'U)NTMX"31#+,,XY M%=\&HA^?S7GB?3!*5 7R>*O0P*2>S!?8DH.[I(&YTDDTH?A M- "G,@ !?P9O+PC'0@3? DRV8R'
(P6T<<'90>O%YF:P9CGWQ\DWE^=CB M HITR/)RM\\RM|$&MZ?@8Q+S)0.7L4|\3?]S.(P3 T[;0U7(#A%+CCI2,XF"&FH MSS2AIA3'"R)F+P=WSZ#<[AH_IZ_3W '?_A0FP14G$?
M'%]1L?%<_OJQ8[!D* M>^1D($H2(_2!#&;__@)'!F\ZVG9DK$*56U#EFJS/OJ;E0C%,/9#5^ MF,$C"(^MAS()1C=[DC L2!CNF(2;^2T#8NVY)X'LMXV!;'AHERBPCU"= J.3
M/2D8%12,]D'!%\+:X!\U\<.C80V^T<&>\,<%_/&.X8MRVV4.C#5S +DU!G2- M2A.E@FQ2()L8D8EB"\'EC[5 V^?231':': F7SL8;E=+8GC:0WN]07RW#WR1B2_!;23ZSLWW)4*(/FE5?
R^"3G*(MX1\V MPG^(]#K@?2@\]"0>[*CQ-D9?CWY+S+/!)]4)7V=@'R(/*I4'S3*O9-P,^7#DU!$;/>J+6*D_:)9_KYWQY&D54.);!266)\M_&+:)B(FF"CB-DK@/
M=0B5/(1&265<_QN_\@Q8I\UD@':C .Q#WB$E[U!;>;TZZNQIE%9OE81*(6%$ JK;_WI^/,Z]Z*Z^-1+<=YHHR2M0E2B"IE%53/; M\D43WX5;XN(VX^).ZQK9/'S?
R:1D$NHJDRY+\$2\Q/.*>#+&/$DWA,R8FT)) M.Z/V(960DDIH5U*I%NPM:3IJ\Z/([%M?[$HDH8Y[8>VPRTP@I4QXR#)A"R'C M-O-V'Q(**0F%.DJH&R*/%65Y.D]B3K"US@$GPF.P-
";:LW8&FIFGAFT>> M@&=I#@Q!E)WQ0 1_*P>VEG:ER8&FM,51E2&@J9-=1K&"JEDJ8A\CC'-;H
M!18:;F9H'^++4>++,8NO/B2UGFC:,RJS/UV2RVRJ+W5*SSEF/7>Z6%'RD'OQ M5X*H(&:!EVW('^C$@RPZ6CZR04;E6E.K-)HF&S2D!%B/(Q#]CYB'D?
&M)1&M(9_NP#^1WIQ9RN?:A/1ZE/QZP^=WH, MDX]5^VWJ3.L3:!^BTU&BT]F9Z'SEP82C.V6=U#6GV=V^=*C-Z9CEVD[WIO.Q MJGO3C3T;LT=]$2L-Z734D#O=G,X'+P?
=/AK7;R"87>Q[T&4!?@I1X=-MN_+YV)]-M M"DAHVXWS:6VS\FI1!:+4H?N_V =T=5M\DT;6:ULY&S"6KM+M:R/0;6X$3H>3 M^A)M'KYO+BH1YW:\);>;/%\U%HP&M<#=ZK(K-
(]XXC017K[F@$O6<<\NW)< MO"VN>)^F%YLMU3R[`X14Z% & C)O>@]Y4!H-F5Z^R!)ZOTUO)=PGD2I1^7 M!/N$R@;B^_LDX2\V@9G^^ML.R)!,!DUW7?4%;.=\WIGF
MX,/T0.@=2P XNL^S@LV,A//RRC19E$".V24IH1!/-H3FF(LMW9JLI(!C!' 3M9(NK(FY$YN/L0S MPY(60081EQ18?.UA"5DFF80=WVI2H]$I@:?K(_M[Y;QP9HT9+$GV3QKS9&:,
M#13#!N\R?DL.?T/MT%#R121CZA,=:EG+0-&.<9+78&%!GA;5-[ZO W$"$#S] M *<&.%W X!F 6P/<8]%UV3@B<,A44,<0\^.(:?,&;(D)-F)QCF!;.6<(5E)?(M2Z08SF# M'GN6+X>[?
>[\/^WA?];>"H;;U(RK^-SG^!),H:Z9&_P@V@9'O.BK]@W[]LG=>L1)',#-$ MO/OM3H) MTDH6:R%)!*1))'QC]S\1D13$U.N_5JF,3M]N MJ%+8EYR*UU.\\G=H[]NN:TW-_6G0>X0<;]
(6"IX*N2//:0N%/4+#\:,ZEO/# MQOGA6>=O13@QC1)5H 'LQ>]EJI?[8X=9(%.LE"362M M_'A-?KS?W&$\G4G421;H) LUD;62.&J2./I%';;B'9XVCU&G+2R?RCA>IPD% M3V4&
(Z_37I[*C)O)?W<9-XZ/SSK^%Q1 A>NR-N>QN+2EC%,L+\0OZB!GR7^V M-'62!3K)0DUDK0Q-F@Q-?G- F>A,HDZR0"=9J(FLE43;>IQ=K% ,486KBUOW$ M'HXI/:9/RK*ZMY@>*=
<9=_M,CY0S'MJ=3F.>3'(YT*T:H9EP2]1<=4%O3ILQ M?:Z&T\[YPKY:VCWG@1SKU>3X2%_])W"-Z38M&,I@(U19ER/1$VDU9E<;3DHU M1ZX)%U.I6B: 8Z!20#$?
$,*/&ZF@^;/#_P%02P,$% @ ZH%N639V]]9> M P .PX !D !X;"]W;W)K&ULQ5==;],P%/TK M5I 02&-)DWXQVDIM$\0DQ]J5P0/BP4UN&VN)'6RGW?X]MI.&=LM"@4B\)+9S
MS_&]]]@W]FC'^)V(22Z3Q,JQE8L979AVR*,(<7BG&5 U9P!'F;+;CJV15+1%*@@C"*.*S'UK1S$0RUO3'X0F G#MI(1()B[$YW
M+J.QY6B'(%0:@:L7EN80Y(H(N7&CY+3JJ;4P,/VGOV]B5W%LL("YBSY2B(9 MCZVAA2)8XSR1-VSW IHO9(DP3[0K;1T+A;F0+"W!RH.4T.*-[\L\' 4 M3SW +0'N8T#W&8!7
KQ39^B6@.ZI, 1*@ G=+F(WB?.QQ),19SO$M;5BTPV3 M?8-6^2)4KY.EY.HK43@Y64H6WKV9J51':+K#/!+H#5JJU1CE":#K-9JS-,LE M-]JJKD^27"K;3VH)?V1"H
5P;9.JS\L8&I^XRG'KIB5,8"!32"J ;O-^/?-N!ME;4J=>X^=3.W MD7)V3GRG#/D.FZWQI_YZ7"O+IQ_FSWXZ]F/DN%5Z\@S?-WG^+3$Y3I:X =5 M222:2$R',+84A51 -^"-7GYHM-W
MWM4EOTTROTVRH"6R(YFZE4Q=P^Z=()/>V:K@%UO[0"NT>D"UVU*)8ET'5;_6"0@S#F!!,1966?K M5"D(>X90'QVV$[<_'/'!]O8PW3567]<_/+;R3^(*?L=U%'F_BKS?&/D-",E) MJ']
YL>%;BF1 KVZ6=ZJ_TU3;6GD_=-EV2:9WR99T!+9D3B#2IS!?ZXM@S9% M:)/,;Y,L:(GL2,1A)>*P[=HR?++3>T[G465Y;C/HO7U45TI[@"9IYBHCM@I-P
M"GQCKB$"A2RGLCC05*/536=J#OB/QF>=BWFG9MQ7-Z/B(O.+OKA676&^(52@ M!-9J*N=\H#SEQ56EZ$B6F;/XBDEULC?-6-WN@&L#]7W-F-QW] 35?7'R$U!+ M P04 "
#J@6Y9XLQ%RO0# "5$0 &0 'AL+W=O_"([LPTX3HL%F E"1?(A%BO?PGH>\TY&#'>-/8HTHX3E-.C%TUE)N M;EQ71&M,B/&4SFR7C*9&J%>NV' DL3%*$S?
PO*Z;$IHYHX'IF_'1@.4R MH1G..(@\30G?WV+"=D/'=PX=#W2UEKK#'0TV9(5SE(^;&5'I\]HR&OR"R(P E+/M%8KH=.SX$8ER1/Y /;_8XE(>-@Q!)A
M_L.N&!OV'8AR(5E:&BL/4IH5O^2Y%.+$0.'4&P2E0?"-0=!^P:!5&K0,T<(S M0^N.2#(:<+8#KDF]V'*,KD6\"&+,:ZQG]CM^Q9[5TE1Z1$<]+@-K(!SW%Q#RWL' M@1>TZOSY3L?-
MR-YTF^6$SW\H2+B7F(]_Z]:GF+]=/[].(C=B0R(<.BI+".1;=$;_N)WO=_J MQ&D(['$RJ=B55VX8^RC..$5ME]!^E072J5<2$K-V;5L!+N1=@/0.FD^=VU+_N M#-QM#:5.1:ECI?
3))"%%AVR1JZ0*&^24Q:!"$DJRFF =-2OPI=3L7@:P1\(% MA) 6L=B%F.R%94F[%?^N%?D!A>0TT@J8/ 6/BK" JX?YHTI"GZ>8+I#7[FHK M]J7T&P(DR"L) A?.0&$34K5$-
B95+U*JM[/BA8K*4:V+WT3;1 ZQ L?N^_ MHJ5?\>_;X] +?/CP):=RKS[;D=H!JD'"'64(R:ZA802_EWA#8&7_?,]8RWBL' M2^E 0VHUA78NUTGIYULWC-
HDJO(7$LXH2410'*Y9MQ0G784"%RHK92K10% M>.?D@^7*.Y[^]JYZ)4VK&_^79G"D&5AI_IGKO0]L69'9I2#IGAQ\ M4^0K]U9W#V)RTW>/PXL)B2OB*9@(27"I3[SI4T_/B#J!H
M2+8QQ^@%D^I0;A[72&+D>H!ZOV1,'AIZ@NHF9O054$L#!!0 (.J!;EEL M25@^R@(!T* 9 >&PO=V]R:W-H965TK)!U8C@X(X-ZR'7@WEH=I7Q3*5CK#*$8<#9
M&G%MK=CTP,AET*K A,J--95=CFU;G)(M.21:?DFQ\(K(=C?U&8W\?>W@]^7P_0<0H MW:9GA>X9M+[05]$3V*MMD?;R_ZU(IR2+#\8^/I&[GRMZZL /C>-AD) M6U)9G4#-
:M/+#,T5_FQlU.E'G9;U6/4^5:ORF]YJG-0A/"=4H!PRY*[B MYE4S4DTD*\WE.6-27<5FN%#]&W!MH-YGC,G-1#MH.L+P%U!+ P04 " #J M@6Y9-WC!%O," "I" &0 'AL+W=O\>.
[F,UD(^J Q1PV/.N!I[F=;%A>^K,..8YD7\GR,1Z[+6\ M[<0=76;:3OC1J"'!+G*.^+VZE&?FU2D)SY(H*#A+3L7?9NI@.;+P+^$%QK?:N MP5:R$.+!#JZ3L1=8(&08:ZM S-*I\B8%3(8?
S::7KVD3=R]WJ!?N=I-+0NB M<"K83YKH;.P-/$@P)273=V+!]3?U=*U>+)AROJ#>O 8>O*72(M\D&X*<\NJ? M/&Y\V$DP.LT)
[4U">S^A\T)"N$D(7:$5F2MK1C2)1E*L0=IHHV8OG#H"67JS(C=SV=P>G(&)T Y M?,]$J,-]*2";K\ /80;@YDI^,P33)[G^\: VH7VUH5)^ZC@ M'(MS"(,/T
[:G0:>Z>O3PR,X8;TIH=,+WI0I,ZIB)E0I$7Y=+I26YE'XW61B MM4BG>1'[>KA0!8EQ]GG7Z%"

]?]?J!9^:'/A/8L_\Z-1^=(ZI1]*E,0Z M +$]=:DY=0I2*7(0]1WFCEN3#95VSVG;E]HJ&K;,+JUVJSN,&81/,<^@NS5T M]XW0*>6$QW@$N5+N[N#T]H /(P;-N+T:MW<4]\I!O0VW=P#3"?9X&T):S<#] M&KC_2G]?!NL?K-H=]O?(#F."9K!!#39XA9/'_!H

**9F6\)E#; W$^%T-N!7:#^.HG^ 5!+ P04 " #] M@6Y92KWA\($ #4$P &0 'AL+W=O.-XQ_D.L 23ZF:6YF'AK*3>7OB^2-61$7+ - MY.J;)>,9D>]4KWRQX4 6)BE+_3 (8C\C-/>F8W/MED_';"M3FL,M1V*;980_M?H"4[28>]IXNW-'56NH+_G2\(2N8@_RZN>7JS*]0%C2#7%"6(P[+B?<>7\Y" MDV B_J*P$WO'2$NY9^R'/KE>3+Q ,X(4$]DAB/IX@!FDJ492//XI0;WJ-W7B M_O$3^D6L"2;%-YQW:?H!34UW@)2X7YCW9E;."A M9"LDR\IDQ2"C>?%)?I:%V$L(^QT)89D0-A+PH",A*A,B(]1@9F1=$4FF8\YV MB,MHA:8/3&U,ME)#=A"?P^8" M1<$9"H.P9TF?N=.O(%'IV*1'A^F^*F%5Q["J8VCPH@Z\&Q "X*O0?(:N0"2< M;DP]OM^H6'0M(1-_VW06P#'I'Z,+\6&)##QU',J@#^ _-_W]-QP'?]A4GPCL MH 9158/(A3XU:\ Y6YYO!2"BZB'%&$VS@5P?X\.#H91@W,[:!@% M=LK]BG+_ERCG+'>P[K=9]Z,F:TO0:#"RTXXKV&3]A>FUPDU<#C12TJ;N8UM MW" (2QCANL+4$#8,.MH.*[<#)]B/-S7IF6*JB_D*?#%KT^KV& DM(1U\/*_[# MD_)W-\VPW<5!0T([9(3M$D:5A-$+&F:Y+^2Y=AFU5@@<-6MMB>E%=J8XJ,=F MX.3ZS?@#-
>7(@^KO%2A+HTU3W><2>&:=:F[<$#T"X0(-4:8F\5H@'*(%>;2) MGST#%950<0GE6.'QGEW KZ3;C?ND>_"D.^Z6[48J9;O4UD,=.,^=E6^V"BH1M MPC_#\H%X.B0R2 X^,--_I&= M_Z@CZU!-/:RQ>UK_64T/8ZS0]\^0W0.W^B@WU+%&ZE1HA\+KD8_[K^4GL=-- M'%V'Z=UJ'V$-AM(H[QE"74,Z;2%M7I*G%M' _Q_L'=J$ZDHV_0B= .==>V M P]?
K5&=CN;H.IP([; .M7?!;O/B]%]%XUIK,&I[V:#5LNT@/!K:.S:L+4SH M](@=-QN^39)MMBW=WDC$NZ;_FA=[ZSAJT&)T/FL;+%A0/.FC7#B1TS_<7%+IS MA2BA#
[Q@.&S2M@1%S4GF[VVYZ/VNSX2O:"X4JZ7*"BX&2C4OMI"*$\DV9A?F MGDG),G.X!K(K@/4]TO&Y-.)WMBI-O*F_P%02P,$% @ ZH%N6;+2E<\O M! TA4 !D
!X;"]W;W)K&ULQ5AK;lLV%/TK MA%8,+>!$(F7+=F8;:!P$&Y!@0=UN&(]H*7KF*@D:B05-_]^E.1(UL-T(KCH MEU@/GL-S[Z5X3SC:!))I%%'Q? TAW\TM;+T\
M^,0>MRI[8"]F"7V$%:@OR8/0=W;)$K (8LEXC 1LYM9'?+4D;@;(1_S%8"O M@UE3"4L>_LT"M9U;$PL%L*%IJ#[QW>^P#VB4\?D\E/E?M-N/=2SDIU+Q: _6 M"B(6%[_T^SX1!P \/
(@>P!Y+<+#= _+,V86R/*P;]NAB)O@.B6RT9LLN\MSD M:!T-B[,RKI30;YG&J<621Q%3NBY*(AH':,ECQ>)'B'T&$EV@E5XW01H"XAMT MFZI4 +IG,8O2"-V!3A\Z)'A_
XJR4'[0P"^K&_3^W0?T#K$8?=[R5&IZ.;.5 M%IU-;?M(@=>%0')$X]22^0Z T0<,NR +\WP&_ U'.=PMPZW=:K*?)$R7R3G M.AV5\PK]7A& M/8W*1%2 M(5,
(1J:W%N%,9+6@QV70XY^]R8S/F:LSD=5R-2ES-3$ND"-M MX7K26J]DZC;6JY&YI^YIJ7MZ2O>H2_>T_9UA;]00;J3N*1P[E65P3DGW.ANY MT](^=IV&=#-W7^T'=@>?
TC[NU(Y;VKWQN*G=R-U7>V4]L+%;%WLS"O-],*/ MN>?JC(6TU_ZDM8;,D_4-IO(&V&P.LCT.L2A)%03:(BK0DZC.:-Q6-!=D.&U&
M8YRM;S25K\#&IGR\;>YQM5JTO8Z9O:_ZJN=C<],O;%'99Z2QRYJYWMHZSL56 MC[QR%[C[.880G]6,G(NMGJ7*CF!C!S_:8_>P6K-J+>T?80YPY0[P27O0V69Q
MVQ]X33MKINXKO3((^*1#Z&ZS;8O@MK;#'^$02.40R$F'T-EE2=LAD$E#NIFZ MK_3*(!"S07AMDR5MPX"'3<-@G]MO+ =G%6;#\.H>2]J.X0(WW);YLK![5(:! M]#Q-
(.V3@O:_IF;RMXJW#P[RH>62SULMEH>N=RK#,IB@/$XD;Q)#^# M6W.E>)1?;H$&(+(!^OV&<_5RDQWKE<>XB_\!4$L#!!0 (.J!;EE*"TW6 MWQH %4" @ 9 >&PO=V]R:W-H965T
:#&] ZUFX[G3*0F/N^]T5C+FB)MC6EQ4U120SDQX\6VC0M^ECJ?OMB M;JID17P.*<;ZPD/RTYE]+/^6RQ^N/LH2P?/Y^?K\8/^3Q;?5H^ MYHO-G]PMBWE6;GXL[L]7CT6>378+S6?
GO4YG=#[/IHNSZR^[Y_SB^LMR7O58VF[*[7+YY_8'8_+'66>[M1ODL'Y=;(MO\[WM^D\]F6VFS'O^HT+.7,;<+OG[\K*N[C=ILS&VVRF^6L[I- M)^7#'V>79](DO\O6LS)
<_M#S:H.&6V^\G*UV_Y5^5*_MG$GC]:I.P(HVJ!T;$+7%0+7!R[P&6UP.6Q"UQ5"UP=NT"W\[SG.F\7Z;ZWR,O./MC; M[R[RO+N[!_O[XKU%GG=XIV"/7[VWR/,N[[[=Y^]O_O-.
[QZ]U[O/N[WI=K^_M_]OQO..[;_?\^XL\[_KNT?N^^[SSNT?O_=[SWN\=[/UW%WG>^[VW>W_[IK9/ MIYOERNN;Y7P^+3+^WPQGN8KZ2_2U\EDNOVPS&:2L=A_
MY&_.G^3\S*;SE;__>6\W*S%UCH?5R/>[$?LO3-B5W(V8SRL)&4QR2^#;SVA*.?C3U+WXG>IU!222 MI=_^L_6-%3-J?
OM)ZEWMF$'+XO(QBU_N%N\+UD(1,U'^^$GJ=W9,3[HK_^L_ MNA>7?VUQ5+%C9HN-TZV<]U='.^*]K1C1>ZN+&7?Y_66K1(PA9KZN[X]:&_,# MYK$X:FTL,>-
D3\\KTQ$H]@F*]LV7?MOL\E'_KVV4-ZP M%T^:O^MZQ[NBWQ#_HZTL7OX2B)C@W[25X2FN84?;'7K9'_5:]VC$O&7Q\;_% M(B8YXIWO?,RD1W]>=R\$G__]EPSN[IS^.YZ]7*W>!._?
[; ;)47W_.SZ^UO9:?M[\.-BDD M9I"826(6B=DDYI"82V(>B?DD%!82&(1B<4DEI!8"F&-R!]\1-9 I%][CWF1 M;?-*FN79*I?RGX_Y8I6W1940.C6]2$PF,87$5!+32$PG,8/$3!*S2,PF,8?$
MW#TVVF';V?KOU[W1YK6=SI?S[Z]3B!S4)[']@"R"T(R4CHM;MN"RP8OF3'D,H.(71]=I"83&(*B:DDII&83F(&B9DD9I&836(.B;EI;/CJ M+GXB5^+H3Q8RQ6ZR);C'-I MDD_6XS*
[G;4>C@B54S.(Q.2+PX/(X<$.4\@A51+32$PG,8/$3!*S2,PF,8?$ M7!+S2,PGL8#$0A*+2"PFL83$4@AK!-#E2P!="@,H7(X?]. M/K_-B]93_T+IU! B,9G$%!)324PC,9W$#!
(S22,>Z]0(0C4%U=2CWO/MZ%?JZ!H:J&:BFH5J-JHYJ.:BFH=J/]H%J!:B M6H1J,:HEJ)926C--7MTSVQ6FB9/IG,[76K?Q",>G%&D)J.: M@FHJJFFHJ.:@6HFJEFH9J.:@VHNJGFHYJ-
:@&HAJD6H%J-:@FHII363KNY0 MZ.(E'EVT10'59%134$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C5
M8E1+4"VEM&:2U=4*VW(_P3';+LG&+TGV)&7C<;'.9K^_S#*VAID0/3G,2$U& M-075U$I[/778[75;9P]<754,U#-1#4+U6Q4U -5"5(M0+4:U M!-522FOF5%V5T15W9=R\BJ@?
T_+A(9]-I&R^7+]S6Q?:EX%J,JHI]*966J,& MK#V@T?X,5#-0S40U"]5L5'-0S44U#15\5 M0+42U"-5B5$M0+:6T9D#5_1A= MX;W,UW[VM#F.6I6K[8U?X\V!4W;?VB8H9DY).K07
]445%,KK=M]%4V=3[WN M\&TPH:T7J&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6DIIS6^9K4LP M>N(2#",VI)OE:);=+HQJCJ^C&@?%
[*E!A6HRJBFHIJ*:AFHZJAFH9J*:A6HV MJCFHYJ*:AVH^J@6H%J):A&HQJB6HEE):,\[]%HY>EI[THH?V:Z":C&H*JJFH
MIJ&:CFH&IIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ64UDRR7IUDXI:. M(IH)Q<+)R86V;J":@FHJJFFHJ.:46F'#8S-:5'SR-=9Z-K9J.:@FHMJ'JKY
MJ!:@6HAJ$:K%J):@6DIIS;2IFS)ZPON7K[^M)_=YF17;LU3S^;3="6#%134$U%-0W5=%0S4,VLM,9WF?5: PHMP$ U!]5<5/-0S4>U -5" M5(M0+4:U!-522FL&5%V L7DHO(!B78P?
MM\,O[R=3>]W9ZI:@TFHG!Q,I":C MFH)J*IIJ*:CFH%)DJI9J&:CFH-J;I4UKB0=M7U5/#JLCVK!L1L1HL-&J!:C M6H)J*:4U,Z?NLNB)NRQ>KH1827^;E@\O!1;;F@K#^"J^/@*MID
U&=445%-1 M34,U'=4,5#-1S4(U&]4<5'-1S4,U']14"5 M1+4*U&-425$LIK1EI=35%#Z^F MZ*5%*@FHYJ":BJJ::BFHYJ!:B;J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ" M:BFE-
9.LKJ:HB:LIWEP?\<%]56+LY!!#*RE034$U%=4T5-,K[>T!7X-N<_;% M0$ZD*(G+J1X>_CT_.W$K>&$EE*@FHQ"]JIJ*:A MFEYIC7/7K5]Q8J#CFJAFH9J-
:@ZJN:CFH9J/:@&JA:@6H5J,:@FJI936B*=^ M74O1%]=2:$6VO>PB^Y$5DWSRP>2>V#HUGU!-1C4%U514TU!-1S4#U4Q4LU#- M1C4'U=Q*NVH<#[IZ/+0(7U4"X[9@!
=,D*U&-425$LIK9DX=7-$7W@_[_6; M2;J/(@^DN;S\0.KPSO_4[BV[$8YV<)FC) ZJI MJ*:AFHYJ!JJ9J&:AFHUJ#]JYJ.:AFH]J :J%]!:A6HQJ":JEE-9,I;H)8O/P
ME%3Z:*9NT'H5UMMOAK@1CWIR/I&:@FHJJFFHJ.:@6HFJEFH9J.:@VHNJGFH MYJ-:@&HAJD6H%J-:@FHII37SJ6Z-Z(M:(YSLYW2^GK^*)6EY)\VGLWQ5+A>Y M\)MS*_KCL$+
[(%!-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4 MBU$M0;64TIIA5?=!](5WZ5[;NR.I_.@O?1)C)YI?0JL@4$U!-175-%334SB?
N[5M_.)J+#NJCFH9J/:@&JA:@6H5J,:@FJI936S*I>G57B MSHHHV^32)J@V,95/ZI1:B6,*+;! -1G5%%1344U#-1W5#%0S4]
M>ONS7@=!A;93H)]':CZ]!:@6HEJ$:C&]):B64EHSJ.J6B\$'+1=Y6<[VY[N. MNPI>[)T<4F@O!HJ]*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/]H%J!:B6H1J M,:HEJ)926C/'ZEZ,S4/Z--<
33)2DU%-0345U314TU'-0#43U2Q4LU'-0347 MU3Q4\U$M0+40U2)4BU$M0;64TII)5C=H#,0-&O:TG-YGY72YD%;UP=G[E\&+ MN9-C#.W6J+37)QNZG5'+M#.&DH?
1+,A:K=9$7*_%$(EJG@6HRJBFH MIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEE):,]OJ.HT! M7JP\6^7"V4*Q='(XH4T;J*:@FHIJ&JKIJ&:@
MFHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6DIIS02KRSB&??RV$*WC0#49 MU1144U%-0S4=U0Q4,U'-0C4;U1Q4A8+,P7978[RZ6LR#/IEW17;O"+R[95_2:F3HXP4I-
134$U%=4T5--1 MS4 U$]4L5+-1S:FT1M?OY:#;G#QST3$]5/-1+4"U$-4B5(M1+4&UE-*:T53W M:PS%_1K?MI.#\\U!UL/L2=I>7]B:26BI!JK)]*:@FHIJ&JKIJ&:@FHEJ%JK9
MJ.:@FHMJ'JKYJ!:@6HAJ$:K%J)94VNMSB+UA[^T9Q)0:M!E*=:/&*-&C?&Z MF)9/TB1_7*ZF[9F$%F:@FHQ"]JIJ*:AFHYJ!JJ9J&:AFHUJ#]JYE=8H/;NX M'+[YQ/'007U4"X[;A! =-
$*U&-425$LIK1DV=<7%4'CC\?7^HCQMMD U&=445%-134,U'=4,5#-1S4(U&]6<#WY'G:SX)$F=[N^2
MU.OT^JTY@]99H)J/:@&JA:@6H5J,:@FJI9363*VZSF(HKK/8S=OM[@>>+L;% M+L**]U(+;;)
-1G5%%1344U#-1W5#%0S4G4@VOG4Z;^=O/MWU%@,ZQJ+H;C&XN7"\VA]>\S%YVA5!:K]*:@ MFHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6DIIC10:U545
M([R]8H165:"C&H*IJFHIJ&:CFH&IIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%: MC&H)JJ64UDRRNJIB)*ZJ..7BYD<[\ZUSQJC2*TE.*4U1FT'D"A/12HIJ.:@6HF
MJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHII353JNZA& GO#C[E D&Q='). MH?T3J*9\\)YYX_+5!5N]UM1".R=034U -5" M5(M0+4:U!-522FNF5MTYL7GXT;2?
=+N*ZUS_H@/7007U4"X[;A! = M-$*U&-425$LIK1D\=:/$2-PH\1(\13[/IHOIXOZ(\$$+)E!-1C4%U514TU!- M1S4#U4Q4LU#-1C4'U=Q*:WYR'YPVI=!!?50+1BT-"
(>;$**#1J@6HU]":BFE M-<.G;HX8?= :CFHUKPSVB2L9#4_+989\73[F3Q[Y*]62Z[MSZN/OGPBE0^Y5.;%7%K>[1ZOGC\PM_]B[PV]?Z-O_JA8KN\?)":CFHUJ :B&J1:@6HUJ":BFE-
4.O[NP8[>^\ M)N\I0[L[4$U&-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U& MM0354DIK)EG=\3$2=WP<4] K)DZ.+K38]445%-134,U'=4,5#-1S4(U&]4<
M5',KK7%"K-=R3@]M[$"UX+A-"-%!(U2+42U!M932&F%S45=Q7 AOD+Z^R6U M-5"5(M0+4:U!-522FMF6%W"<=&EI_XNT"X.5)-134$U%=4T5--1S4 U$]4L
M5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4&UE-*:2=:KDTQ<1W%*G928.CG"2$U& M-0755%334$U'-0/53%2S4,U&-0?5W$IK7-;?&QU, .*#^J@6'+<)(3IHA&HQ
MJB6HEE):,W3[^HZ+8RHXCBB*$CLG)PY:P(%["JHJ*:AFHYJ!J9J&:AFHUJ M#]JYJ..AFH]JP0>?,'(^KMO=+EJ/D_Y%(&*W)T:U!-522FNF5%VYL7DH3*GM MY>JK]>W_YN-R>[_9?;%
<;YZ9[<]:_9+F@B,EH7QR;I&:C&H*]JFHHJ&:CFH& MJFH9J&:C6H.JKF5UCGC,Z%R-WAXHD6/Z]!8KN MC0MQ]X:=KU9Y+BT?\^UQTN)^GSW:[XG,?V2S_=USDWPU+J:
[FZ);DPBMXD U M&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']6"#S[S]OT.J[K@87=S\/Z# M;_>!MR_!^YY+3WE6M-4/A?_V$2+T'8E1+4&UE-*:"5@7@%R("T#J[T7>'HR- M-[NM+-
;CW9QA-ILM?V2+<2YMXG%_MWAK *)=(*@FHYJ":BJJ::BFHYJ!:B;J M6:AFHYJ#:BZJ>:CFHUI0::\O;O\,#OL2JY=U^Z]>UQT-#UX8H6L7HUJ":BFE M-<.H;KFX$+=<5#T64K:KK&@-
&[2I M5D5%-0344U#=5T5#-0S40U"]5L5'-0 MS:VTQD?P<'18NXN.ZJ-:<.0VA.BH$:K%J):@6DII^[Y7SWD>2EG97;]99X7 M]_GV-JC5YHAFO2EM@[QZ=G,\<[<)H^[GK[VS\X/G;[J?
G6[+\V[WL]_V?-#] M'.V>/Z^'O?[RF-WG3E;<3S?'P;A;K,*G4_:0[UB>O_P\D,Y?-S\^^-,NEV6 MY7*^>_B09Y,\V+Y@\^=WRV7Y_,-V@!_+XL_=9E[_'U!+ P04 " #J@6Y9 MMD?_1%L#
#D% #0 'AL+W-T>6QE'%1;4 MQO<>WW./KV^(VWZIEIS>'5A5WB+CHASX,Z6*MT%03F8T(^5?5E"AD327&5'; ME-,@+'0E20E!&0\ZK5849(0)?]@7\^PJ4Z4WR>=*#?QN[?
+L[4,R\-O1N>]9 MNE&>T(%_=_+ZZSQ7EZ\>S]Z]@QHB[F\1F]KFL7''6%C/$:;E-Y%@8,&Q>S&_?B#5KX&=Y>^VW+2_O_]$
M>!MDC3BH&FC83W/1]%'H6X?.3#+JW1,^\$>$L[%D$)62C/&E=7? ,5].W@)4% AGGM<".;QW#?D&4HE)< M:<-,-LY'D%>-;Y>%5CB59-GN7/A-@+GI).-
<)E36:=K^RC7LS_5RA+&A4^BUI"E;&'N1U@(P]C;.3HJ"+]]Q-A49_MM8M_^>2L4FZYYODA2W=*%6I;1(<1%X<@,CH$D0?0DV&_M_QJK4]R^BSR$2G9?
]M]I\B@.@FM';F5V2L_X3;X-?S$YJ2.5>W-3CPF_$GFK!Y%M>SKJ$0U:QF_!&6 MUXIJ$[7.Q41"%S095::CNT2A"JA/!QIT_V%,2AG'L M1@!S*PA##(&G$4WWD?!ZCT5-/_7'/X!4$L#!!0
(.J! M;EF7BKL

-8?20$3;8T.P6BP^0"X99K>]9!:G

] >@S1! %B@ \ !X;"]W;W)K8F]O:RYX;6S%FDUO MVS@00/*X^]U3LO(;I4)3#]/1:#QLI#:#]^\.;]5@/1:*,; :2JR6 T$'YC'_ZQ3C]9$V2]*)VMZ\D@ MV5?
<*1=T^5OQ(D+>RJ7O2H)NL'PLA&308?[4ZY>#WP![-]?VT!H%!/N0L-%6Y6=7B<**92QJM*P#=O M:UT!1R4^R%J:4@D$F1*0Z0DAOZ4(,B,@LY- +B(,_!1!Y@1D?D+(7D\6!&1Q
M2L@,08X)R/$I(7,$^9J ?,T+,9>/8N?%7+GNYW%&7VI?UM:W3B'$-P3B&U[$ MF?&Z4D[<,EE!/!93YZ19QQD3/")\2Q"^Y26\=FMI]%-7(;2!N--Z;93WXAK" M^
[\1$5R$>\F!^DUU[8E9@[Y>'4[HPS<:7_;76E \8D?<,LG!NU4Z;%@R^A MS)(PJ^6+=/<'THA:B84J6Z>#5GC<)911$F:E0**UA33HL1MU?\-]W,8?G(FO
MJG<[*9\DS$+Y;&WUH.NZ0YS[#/K2"''FWD,2=88Q*:,DS$J9EJ5M(:((B(C= MS8ZX4.A:B-E7&F-23DF8I?)):B?N9-T]\47)&*1_C8,)99.$62I'-[Z71*>21E[@B-B1/JE'))RNR2Y]1 O+J-
(=K_B;DH>:3,\CB: M(QREI-R1,KN#2!8B*\:D')(R.X1,&/I3AA))RBP2,F'H8U).29F=\D+"&>$$DS&+)C?U7=L^F24;[)3^D:\PIB4<3)FXY"+T?Y6&+D7=E+CX-V1C#). MQFP<&K/ F)2
,F8!'<1X+A;06M5", +F2^WE>NW4&F-2![J8#70<,TXD!\LS MO)><40;*V%F+8+6LPT;XM;3$F9:",V4#'LX[_^A9C4@:*F WT(F;; M--+AQ5=.&2JG-
A#"O%3+\&N78DS*0CFSAV$(V)G9Y3%LJ9+41C8J?GE(5R9@O1"XS> M3;JCZ3P&).R4,'^>@"UG7",.2D+%_P!02P,$% @ ZH%N69@;6I[[0 RR, !H !X
M;"]?]"2J,T(%XO*//A#P\)P/W;3O3V6W\KB MXW@XE56SFZ;A5TIEOERV:;Q^XSF M\>'[S,7+YY#_9V*_V>S7^7>__G/,I^D?@]-]/[Z575DWZ.%QW MEW39R,UYETUX].K-
*EVDS*0U@\R"++Z00Y!7C\H("CJ][40U-8/NH6@ MV_I!=Q!T5S_H'H+NZP?)$5<]L";06I!K(?!:$&PA$%N0;"$P6Q!M(5!;
MD&TA<%L0;B&06Y!N(;!;$&\AT%M1;R706U%O)=!;9P ;!'HKZJT$>BOJK01Z M*^]M!'HKZJT$>BOJK01Z*^]M!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MOL90F!
MWH9Z&X'>AGH;@=Z&>AN!WH9Z&X'>AGH;@=Z&>AN!WHYZ.X'>CGH[@=Z.>CN! MWHYZ.X'>/GO93:"WH]Y.H+>CWDZ@MZ/>3]"WH]Y.H+>CWDZ@=Z#>0:!WH-Y!
MH'>@WD&@=Z#>0:!WH-Y!H'?,/E82Z!VH=Q#H';AW$.@=]'<0Z!VH=Q#HW:+> M[4_J7:;/0R[7G]\U7O\GJ9[.Y^;KY2_+KYUXOV@O."?X=^?Q+U!+ P04 M" #J@6Y9=-+&8MX! !:(P
$P %M#;VYT96YT7U1Y<&5S72YX;6S-VEU/ MPC 4!N"_0G9K6.D7?@2X46_5"_] W0ZPL*U-6Q@^O=T $XT2#2;^-UNVMN<]
M:Y/G:I/GG:,PV#9U&Z;9,D9WPU@HEM28D%M';1J96]^8F![]@CE3K,R"F!B- MQJRP;:0V#F-7(YM-[FANUG4#(^/I@FS6+;FH6X MJRGDITM\T:.=SZN"2ENLF[0D#\Z3*
<.2*#9UOB]Z<3HYIAVF_96?G=^7.168 M9CYYZT(Z,4^_CSL>2;=ZZ%(A\K$Z_8GOB:GTV=]'W6F75/XP.VWQJ_6K_CP" MZV_G[_'',WZQ_\L^!$@?$]0/!=*'!NEC#-+')4@?5R!]7(/TP4P-
4$L! A0#% @ ZH%N60=!36*! M L0 ! (! &1O8U!R:W!S+V%P<"YX;6Q02P$" M% ,4 " #]G6Y9"%$]/>X K @ $0 @ &O 9&!C M4')O<',O8V!R92YX;6Q02P$"% ,4 " #J@6Y9F5R<(Q & "
<)P $P M @ ', 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 (M ,J!:EGVR%?"R04 * ? 8 " @0T(!X;"]W;W)K(& M @($,#@ >&PO=V]R:W-H965T&UL4$L! A0# M% @
ZH%N65/\ZG!7 P O@\ !@ ("!$Q8 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ ZH%N64ESHY51 M#0 JYL !@ ("!J24 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
ZH%N60!ZCZM# @ B@8 !@ M ("!G4 'AL+W=O&UL4$L! A0#% @ ZH%N61\,YI/Q#@ &BL !D M ("!&PO M=V]R:W-H965T&UL4$L! A0#% @ ZH%N63!&)_2 P #0H !D ("! MY&P
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ ZH%N69X^7CZR!@ K!$!D ("!=WD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ZH%N62+6]'X"#0 &"4 !D M ("!)+X
'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ ZH%N6>[6['74! O X !D ("!,M, M 'AL+W=O!@ &0 @($]V >&PO=V]R:W-H965T&UL4$L! A0#% @ MZH%N6?;'+Z.@ @ ! 8 !D
("!^$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ZH%N67Y_^!.U! ME@P !D ("!F.X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ZH%N6>,;)W;N @ '@D !D M ("!*OL
'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ ZH%N64DM%V]! %2(!D ("!<@8! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ZH%N M64,UQ(C! @ ZP< !D ("!EA(!
'AL+W=O&PO=V]R:W-H965TT8 0!X;"]W;W)K M&UL4$L! A0#% @ ZH%N6:6Z9!&G P 1!(M !D ("!@AP! 'AL+W=O"2T& !U& &0 @(%@($ M>&PO=V]R:W-H965T&UL4$L! A0#%
@ ZH%N68N@.(IB P %A$!D M ("!_2H! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ ZH%N68$;+Y3& P 1A$!D ("!,#@! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#%
@ ZH%N6?NY M^>RN P ^! !D ("!M4T! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ZH%N66Q)6#[* @ '0H !D M ("!6ED! 'AL+W=O&PO M=V]R:W-H965T'P@ 0 M -03 9 "
@85? 0!X;"]W;W)K&UL4$L! A0#% @ ZH%N6;+2E<\O! TA4 !D ("! M/&0! 'AL+W=O&PO=V]R:W-H965T^P$,LC : M " 26- 0!X;"]?7!E&UL4$L%!@ !$ $0 DQ(&>1 0 $! end XML 68
Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government

employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2133071true630false8 falsefalseR1.htm100000 - Document - CoverSheethttp://lineagecell.com/20240930/taxonomy/role/CoverCoverCover1 falsefalseR2.htm100010 - Statement - Condensed Consolidated Balance SheetsSheethttp://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsCondensed Consolidated Balance SheetsStatements2 falsefalseR3.htm100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)Sheethttp://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalCondensed Consolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm100040 - Statement - Condensed Consolidated Statements of OperationsSheethttp://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsCondensed Consolidated Statements of OperationsStatements4 falsefalseR5.htm100050 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)Sheethttp://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnauditedCondensed Consolidated Statements of Comprehensive Loss (Unaudited)Statements5 falsefalseR6.htm100060 - Statement - Condensed Consolidated Statements of Changes in Shareholders' EquitySheethttp://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityCondensed Consolidated Statements of Changes in Shareholders' EquityStatements6 falsefalseR7.htm100070 - Statement - Condensed Consolidated Statements of Cash FlowsSheethttp://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsCondensed Consolidated Statements of Cash FlowsStatements7 falsefalseR8.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes8 falsefalseR9.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes9 falsefalseR10.htm995455 - Disclosure - Organization and Business OverviewSheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverview1Organization and Business OverviewNotes10 falsefalseR11.htm995465 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting PoliciesSheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesBasis of Presentation, Liquidity and Summary of Significant Accounting PoliciesNotes11 falsefalseR12.htm995475 - Disclosure - RevenueSheethttp://lineagecell.com/20240930/taxonomy/role/RevenueRevenueNotes12 falsefalseR13.htm995485 - Disclosure - Marketable SecuritiesSheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesMarketable SecuritiesNotes13 falsefalseR14.htm995495 - Disclosure - Property and Equipment, NetSheethttp://lineagecell.com/20240930/taxonomy/role/PropertyAndEquipmentNetProperty and Equipment, NetNotes14 falsefalseR15.htm995505 - Disclosure - Goodwill and Intangible Assets, NetSheethttp://lineagecell.com/20240930/taxonomy/role/GoodwillAndIntangibleAssetsNetGoodwill and Intangible Assets, NetNotes15 falsefalseR16.htm995515 - Disclosure - Accounts Payable and Accrued LiabilitiesSheethttp://lineagecell.com/20240930/taxonomy/role/AccountsPayableAndAccruedLiabilitiesAccounts Payable and Accrued LiabilitiesNotes16 falsefalseR17.htm995525 - Disclosure - Fair Value MeasurementsSheethttp://lineagecell.com/20240930/taxonomy/role/FairValueMeasurementsFair Value MeasurementsNotes17 falsefalseR18.htm995535 - Disclosure - Related Party TransactionsSheethttp://lineagecell.com/20240930/taxonomy/role/RelatedPartyTransactionsRelated Party TransactionsNotes18 falsefalseR19.htm995545 - Disclosure - Shareholders??? EquitySheethttp://lineagecell.com/20240930/taxonomy/role/ShareholdersEquityShareholders??? EquityNotes19 falsefalseR20.htm995555 - Disclosure - Stock-Based AwardsSheethttp://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsStock-Based AwardsNotes20 falsefalseR21.htm995565 - Disclosure - Income TaxesSheethttp://lineagecell.com/20240930/taxonomy/role/IncomeTaxesIncome TaxesNotes21 falsefalseR22.htm995575 - Disclosure - Commitments and ContingenciesSheethttp://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingenciesCommitments and ContingenciesNotes22 falsefalseR23.htm995595 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesPoliciesBasis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies)Policieshttp://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPolicies23 falsefalseR24.htm995605 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesTablesBasis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPolicies24 falsefalseR25.htm995615 - Disclosure - Revenue (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/RevenueTablesRevenue (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/Revenue25 falsefalseR26.htm995625 - Disclosure - Marketable Securities (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTablesMarketable Securities (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecurities26 falsefalseR27.htm995635 - Disclosure - Property and Equipment, Net (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/PropertyAndEquipmentNetTablesProperty and Equipment, Net (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/PropertyAndEquipmentNet27 falsefalseR28.htm995645 - Disclosure - Goodwill and Intangible Assets, Net (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/GoodwillAndIntangibleAssetsNetTablesGoodwill and Intangible Assets, Net (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/GoodwillAndIntangibleAssetsNet28 falsefalseR29.htm995655 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/AccountsPayableAndAccruedLiabilitiesTablesAccounts Payable and Accrued Liabilities (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/AccountsPayableAndAccruedLiabilities29 falsefalseR30.htm995665 - Disclosure - Fair Value Measurements (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/FairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/FairValueMeasurements30 falsefalseR31.htm995675 - Disclosure - Stock-Based Awards (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTablesStock-Based Awards (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/Stock-basedAwards31 falsefalseR32.htm995685 - Disclosure - Commitments and Contingencies (Tables)Sheethttp://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingenciesTablesCommitments and Contingencies (Tables)Tableshttp://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingencies32 falsefalseR33.htm995695 - Disclosure - Organization and Business Overview - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetailsOrganization and Business Overview - Additional Information (Details)Details33 falsefalseR34.htm995705 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnersh of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries (Details)Details34 falsefalseR35.htm995715 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails of Presentation, Liquidity and Summary of Significant Accounting Policies - Additional Information (Details)Details35 falsefalseR36.htm995725 - Disclosure - Revenue - Schedule of Disaggregated Revenues (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetailsRevenue - Schedule of Disaggregated Revenues (Details)Details36 falsefalseR37.htm995735 - Disclosure - Revenue - Schedule of Contract with Customer Contract Liability and Receivable (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfContractWithCustomerContractLiabilityAndReceivableDetailsRevenue - Schedule of Contract with Customer Contract Liability and Receivable (Details)Details37 falsefalseR38.htm995745 - Disclosure - Revenue - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetailsRevenue - Additional Information (Details)Details38 falsefalseR39.htm995755 - Disclosure - Marketable Securities - Schedule Of Fair Value Of Marketable Securities (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetailsMarketable Securities - Schedule Of Fair Value Of Marketable Securities (Details)Details39 falsefalseR40.htm995765 - Disclosure - Marketable Securities - Summary of Available for Sale Debt Securities (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetailsMarketable Securities - Summary of Available for Sale Debt Securities (Details)Details40 falsefalseR41.htm995775 - Disclosure - Marketable Debt Securities - Schedule of Amortized cost And Estimated fair Value (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableDebtSecuritiesScheduleOfAmortizedCostAndEstimatedFairValueDetailsMarketable Debt Securities - Schedule of Amortized cost And Estimated fair Value (Details)Details41 falsefalseR42.htm995785 - Disclosure - Marketable Securities - Schedule Of Marketable Equity Securities (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableEquitySecuritiesDetailsMarketable Securities - Schedule Of Marketable Equity Securities (Details)Details42 falsefalseR43.htm995795 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetailsProperty and Equipment, Net - Schedule of Property and Equipment, Net (Details)Details43 falsefalseR44.htm995805 - Disclosure - Property and Equipment, Net - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetailsProperty and Equipment, Net - Additional Information (Details)Details44 falsefalseR45.htm995815 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details)Details45 falsefalseR46.htm995825 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details) (Parenthetical)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details) (Parenthetical)Details46 falsefalseR47.htm995835 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetailsGoodwill and Intangible Assets, Net - Additional Information (Details)Details47 falsefalseR48.htm995845 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetailsAccount

Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details)Details48 falsefalseR49.htm995855 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetailsFair Value Measurements - Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis (Details)Details49 falsefalseR50.htm995865 - Disclosure - Related Party Transactions - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetailsRelated Party Transactions - Additional Information (Details)Details50 falsefalseR51.htm995875 - Disclosure - Shareholders' Equity - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetailsShareholders' Equity - Additional Information (Details)Details51 falsefalseR52.htm995885 - Disclosure - Stock-Based Awards - Schedule of Share-based Compensation Activity (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1Stock-Based Awards - Schedule of Share-based Compensation Activity (Details)Details52 falsefalseR53.htm995895 - Disclosure - Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetailsStock-Based Awards - Schedule of Stock Based Compensation Expense (Details)Details53 falsefalseR54.htm995905 - Disclosure - Stock-Based Awards - Schedule Of Computation Of Diluted Net Loss Per Common Share (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetailsStock-Based Awards - Schedule Of Computation Of Diluted Net Loss Per Common Share (Details)Details54 falsefalseR55.htm995915 - Disclosure - Stock-Based Awards - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetailsStock-Based Awards - Additional Information (Details)Details55 falsefalseR56.htm995925 - Disclosure - Income Taxes - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetailsIncome Taxes - Additional Information (Details)Details56 falsefalseR57.htm995935 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetailsCommitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)Details57 falsefalseR58.htm995945 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetailsCommitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)Details58 falsefalseR59.htm995955 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetailsCommitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)Details59 falsefalseR60.htm995965 - Disclosure - Commitments and Contingencies - Additional Information (Details)Sheethttp://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetailsCommitments and Contingencies - Additional Information (Details)Details60 falsefalseAll ReportsBookAll Reports lctx-20240930.htmlctx-20240930.xsd http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lctx-20240930.htm": { "nsprefix": "lctx", "nsuri": "http://lineagecell.com/20240930", "dts": { "inline": { "local": ["lctx-20240930.htm"] }, "schema": { "local": ["lctx-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 258, "keyCustom": 49, "axisStandard": 23, "axisCustom": 0, "memberStandard": 21, "memberCustom": 39, "hidden": { "total": 29, "http://fasb.org/us-gaap/2024": 25, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 213, "entityCount": 1, "segmentCount": 63, "elementCount": 648, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 708, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://lineagecell.com/20240930/taxonomy/role/Cover", "longName": "100000 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R3": { "role": "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:PreferredStockNoParValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "longName": "100050 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R6": { "role": "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_57a12632-9a9c-4051-a8f6-855669b4f897", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_57a12632-9a9c-4051-a8f6-855669b4f897", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "lctx:AccretionOfIncomeOnMarketableDebtSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverview1", "longName": "995455 - Disclosure - Organization and Business Overview", "shortName": "Organization and Business Overview", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation, Liquidity and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://lineagecell.com/20240930/taxonomy/role/Revenue", "longName": "995475 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1,

"baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecurities", "longName": "995485 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://lineagecell.com/20240930/taxonomy/role/PropertyAndEquipmentNet", "longName": "995495 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://lineagecell.com/20240930/taxonomy/role/GoodwillAndIntangibleAssetsNet", "longName": "995505 - Disclosure - Goodwill and Intangible Assets, Net", "shortName": "Goodwill and Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://lineagecell.com/20240930/taxonomy/role/AccountsPayableAndAccruedLiabilities", "longName": "995515 - Disclosure - Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://lineagecell.com/20240930/taxonomy/role/FairValueMeasurements", "longName": "995525 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://lineagecell.com/20240930/taxonomy/role/RelatedPartyTransactions", "longName": "995535 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://lineagecell.com/20240930/taxonomy/role/ShareholdersEquity", "longName": "995545 - Disclosure - Shareholders\u2019 Equity", "shortName": "Shareholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwards", "longName": "995555 - Disclosure - Stock-Based Awards", "shortName": "Stock-Based Awards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://lineagecell.com/20240930/taxonomy/role/IncomeTaxes", "longName": "995565 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingencies", "longName": "995575 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995595 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesTables", "longName": "995605 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:ConsolidationPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:ConsolidationPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://lineagecell.com/20240930/taxonomy/role/RevenueTables", "longName": "995615 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTables", "longName": "995625 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "lctx:ScheduleOfSecuritiesOwnedReadilyMarketableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "lctx:ScheduleOfSecuritiesOwnedReadilyMarketableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://lineagecell.com/20240930/taxonomy/role/PropertyAndEquipmentNetTables", "longName": "995635 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://lineagecell.com/20240930/taxonomy/role/GoodwillAndIntangibleAssetsNetTables", "longName": "995645 - Disclosure - Goodwill and Intangible Assets, Net (Tables)", "shortName": "Goodwill and Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://lineagecell.com/20240930/taxonomy/role/AccountsPayableAndAccruedLiabilitiesTables", "longName": "995655 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://lineagecell.com/20240930/taxonomy/role/FairValueMeasurementsTables", "longName": "995665 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair

Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables", "longName": "995675 - Disclosure - Stock-Based Awards (Tables)", "shortName": "Stock-Based Awards (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables", "longName": "995685 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "lctx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "lctx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails", "longName": "995695 - Disclosure - Organization and Business Overview - Additional Information (Details)", "shortName": "Organization and Business Overview - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_87b7e28b-f440-4228-af32-94193555a9ff", "name": "us-gaap:ProceedsFromCollaborators", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand "longName": "995705 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries (Details)", "shortName": "Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_87688d54-bf38-4349-9d81-e6f4b0e71e5f", "name": "lctx:FieldOfBusinessDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "div", "us-gaap:ConsolidationPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_87688d54-bf38-4349-9d81-e6f4b0e71e5f", "name": "lctx:FieldOfBusinessDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "div", "us-gaap:ConsolidationPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995715 - Disclosure - Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "lctx:CashAndCashEquivalentsAndMarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "lctx:LiquidityPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "lctx:CashAndCashEquivalentsAndMarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "lctx:LiquidityPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails", "longName": "995725 - Disclosure - Revenue - Schedule of Disaggregated Revenues (Details)", "shortName": "Revenue - Schedule of Disaggregated Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "lctx:RoyaltiesLicenseAndOtherRevenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "lctx:RoyaltiesLicenseAndOtherRevenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfContractWithCustomerContractLiabilityAndReceivableDetails", "longName": "995735 - Disclosure - Revenue - Schedule of Contract with Customer Contract Liability and Receivable (Details)", "shortName": "Revenue - Schedule of Contract with Customer Contract Liability and Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_b540772e-876f-461d-957a-0bac41cc9cbf", "name": "lctx:AccountsReceivableNetCurrentExcludesScopeOfAsu201409", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_57a12632-9a9c-4051-a8f6-855669b4f897", "name": "lctx:AccountsReceivableNetCurrentExcludesScopeOfAsu201409", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R38": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "longName": "995745 - Disclosure - Revenue - Additional Information (Details)", "shortName": "Revenue - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "lctx:RevenueRecognizedFromDeferredRevenueAtBeginningOfPeriod", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "link:footnote", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "lctx:RevenueRecognizedFromDeferredRevenueAtBeginningOfPeriod", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "link:footnote", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails", "longName": "995755 - Disclosure - Marketable Securities - Schedule Of Fair Value Of Marketable Securities (Details)", "shortName": "Marketable Securities - Schedule Of Fair Value Of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c47b37e3-0ebd-48b0-a351-906432e10b9e", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "lctx:ScheduleOfSecuritiesOwnedReadilyMarketableTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R40": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails", "longName": "995765 - Disclosure - Marketable Securities - Summary of Available for Sale Debt Securities (Details)", "shortName": "Marketable Securities - Summary of Available for Sale Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R41": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableDebtSecuritiesScheduleOfAmortizedCostAndEstimatedFairValueDetails", "longName": "995775 - Disclosure - Marketable Debt Securities - Schedule of Amortized cost And Estimated fair Value (Details)", "shortName": "Marketable Debt Securities - Schedule of Amortized cost And Estimated fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableEquitySecuritiesDetails", "longName": "995785 - Disclosure - Marketable Securities - Schedule Of Marketable Equity Securities (Details)", "shortName": "Marketable Securities - Schedule Of Marketable Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R43": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "longName": "995795 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-

49a0-83d9-d9181ad5633d", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "longName": "995805 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "shortName": "Property and Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "ix:continuation", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "ix:continuation", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R45": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1", "longName": "995815 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details)", "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R46": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical", "longName": "995825 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details) (Parenthetical)", "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets Net (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_cae2b6cf-e5fd-4323-8a64-8f4b6ae797ad", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2938013a-5bb5-46d6-99c3-cde26cfd020b", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "link:footnote", "div", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R47": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "longName": "995835 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)", "shortName": "Goodwill and Intangible Assets, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "longName": "995845 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails", "longName": "995855 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "995865 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_495878ee-01f8-40eb-9d40-30be955420d7", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_495878ee-01f8-40eb-9d40-30be955420d7", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "longName": "995875 - Disclosure - Shareholders' Equity - Additional Information (Details)", "shortName": "Shareholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_98d88056-7b6d-4255-8121-50dcdb3dcded", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R52": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1", "longName": "995885 - Disclosure - Stock-Based Awards - Schedule of Share-based Compensation Activity (Details)", "shortName": "Stock-Based Awards - Schedule of Share-based Compensation Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_b540772e-876f-461d-957a-0bac41cc9cbf", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R53": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetails", "longName": "995895 - Disclosure - Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details)", "shortName": "Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetails", "longName": "995905 - Disclosure - Stock-Based Awards - Schedule Of Computation Of Diluted Net Loss Per Common Share (Details)", "shortName": "Stock-Based Awards - Schedule Of Computation Of Diluted Net Loss Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_457f03ba-9e3e-4bb6-8a2e-c477fd64be4b", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_457f03ba-9e3e-4bb6-8a2e-c477fd64be4b", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "longName": "995915 - Disclosure - Stock-Based Awards - Additional Information (Details)", "shortName": "Stock-Based Awards - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "995925 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount",

"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "longName": "995935 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "lctx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f03285ad-49c2-4678-8bf1-fc2e2998c705", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "lctx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "longName": "995945 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)", "shortName": "Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "lctx:FinanceLeaseLiabilityExcludingOtherLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R59": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "longName": "995955 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)", "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c8ae0e09-4626-4dd8-b215-a01f75a85490", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } }, "R60": { "role": "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995965 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_ca2bad8b-4f76-49a0-83d9-d9181ad5633d", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5d7b91cd-ab96-480b-8909-70e6231e87ad", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lctx-20240930.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } } }, "auth_ref": [] }, "lctx_AccountingStandardUpdate201409Member": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AccountingStandardUpdate201409Member", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Accounting standard update 2014-09.", "label": "Accounting Standard Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09 [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r42", "r43"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/AccountsPayableAndAccruedLiabilities"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r41", "r43", "r46", "r963"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r41", "r734"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "periodEndLabel": "Accounts receivable, net - end of the period", "periodStartLabel": "Accounts receivable, net - beginning of the period", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "verboseLabel": "Accounts receivables amounted", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r880"] }, "lctx_AccountsReceivableNetCurrentExcludesScopeOfAsu201409": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AccountsReceivableNetCurrentExcludesScopeOfAsu201409", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfContractWithCustomerContractLiabilityAndReceivableDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Accounts receivable, net - end of the period", "terseLabel": "Accounts receivable, net - beginning of the period", "label": "Accounts Receivable Net Current Excludes Scope Of ASU 2014 -09", "documentation": "Accounts receivable net current excludes scope of ASU 2014 -09.", "periodStartLabel": "Accounts receivable, net - beginning of the year" } } }, "auth_ref": [] }, "lctx_AccretionOfIncomeOnMarketableDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AccretionOfIncomeOnMarketableDebtSecurities", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Accretion of income on marketable debt securities", "label": "AccretionOfIncomeOnMarketableDebtSecurities", "negatedLabel": "Accretion of income on marketable debt securities" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Accrued Liabilities, Current, Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r25", "r116", "r564"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "negatedLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r14", "r15", "r55", "r121", "r560", "r598", "r602"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income / (Loss) [Member]", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r9", "r15", "r411", "r414", "r495", "r593", "r594", "r862", "r863", "r864", "r870", "r871", "r872", "r873"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r794"] }, "lctx_AdditionalCapitalRequirementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AdditionalCapitalRequirementsPolicyTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Additional Capital Requirements", "label": "Additional Capital Requirements [Policy Text Block]", "documentation": "Additional capital requirements." } } }, "auth_ref": [] }, "lctx_AdditionalRightOfUseAssetAndLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AdditionalRightOfUseAssetAndLeaseLiability", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Additional right of use asset and lease liability.", "label": "Additional right of use asset and lease liability" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r807"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r807"] },

```
"ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r807" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r807" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r105", "r106", "r107", "r108", "r109", "r110", "r154", "r155", "r156", "r157", "r167", "r189", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r260", "r261", "r264", "r371", "r372", "r373", "r374", "r375", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r455", "r456", "r470", "r471", "r472", "r490", "r491", "r492", "r493", "r494", "r495", "r538", "r539", "r540", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "terseLabel": "Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes", "negatedLabel": "Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "lctx_AdjustmentsToCommonStockShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AdjustmentsToCommonStockShareBasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Adjustments to common stock share based compensation requisite service period recognition value.", "label": "Adjustments To Common Stock Share Based Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc.to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "lctx_AggregateCapAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AggregateCapAmount", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate Cap Amount.", "label": "Aggregate cap amount" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r840" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r765", "r776", "r786", "r818" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r768", "r779", "r789", "r821" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r841" ] }, "lctx_AgreedSignatureFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AgreedSignatureFeeAmount", "crdr": "credit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreed signature fee amount.", "label": "Agreed signature fee amount" } } }, "auth_ref": [] }, "lctx_AgreementsWithHadasitAndIIAMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AgreementsWithHadasitAndIIAMember", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreements With Hadasit And I I A.", "label": "Agreements With Hadasit And I I A [Member]", "terseLabel": "Agreements With Hadasit and IIA [Member]" } } }, "auth_ref": [] }, "lctx_AlamedaLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AlamedaLeaseMember", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Alameda Lease [Member]", "label": "Alameda Lease [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r807" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r814" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r769", "r780", "r790", "r814", "r822", "r826", "r834" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r832" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r353", "r358" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7", "r248", "r255", "r701" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Antidilutive securities, shares", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r175" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r398" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r82", "r93", "r119", "r148", "r177", "r179", "r184", "r185", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r400", "r404", "r458", "r555", "r639", "r696", "r697", "r734", "r753", "r927", "r928", "r981" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r112", "r122", "r148", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r400", "r404", "r458", "r734", "r927", "r928", "r981" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets", "totalLabel": "Assets, Fair Value Disclosure, Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r431", "r432", "r722" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "NONCURRENT ASSETS" } } }, "auth_ref": [] }, "lctx_AtTheMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AtTheMarketMember", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "ATM", "label": "At the Market [Member]", "documentation": "At the market ." } } }, "auth_ref": [] }, "lctx_AtmSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "AtmSalesAgreementMember", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Sales Agreement [Member]", "label": "ATM Sales Agreement [Member]", "documentation": "ATM Sales Agreement." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [
```

"http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r758", "r760", "r772"] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r758", "r760", "r772"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r758", "r760", "r772"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r198"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r199"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableDebtSecuritiesScheduleOfAmortizedCostAndEstimatedFairValueDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized cost", "verboseLabel": "Amortized cost, Total available-for-sale debt securities", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r195", "r241", "r554"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableDebtSecuritiesScheduleOfAmortizedCostAndEstimatedFairValueDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Amortized cost, In one year or less", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r890"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableDebtSecuritiesScheduleOfAmortizedCostAndEstimatedFairValueDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Estimated fair value, In one year or less", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r202", "r550"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableDebtSecuritiesScheduleOfAmortizedCostAndEstimatedFairValueDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair value", "totalLabel": "Lineage's available-for-sale debt securities", "verboseLabel": "Estimated fair value, Total available-for-sale debt securities", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r196", "r241", "r431", "r544", "r722", "r726", "r881", "r970", "r971", "r972"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r829"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r830"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r825"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r825"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r825"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r825"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r825"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r825"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r828"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r827"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r826"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r826"] }, "lctx_BRileySecuritiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "BRileySecuritiesIncMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "B. Riley Securities, Inc. [Member]", "label": "B. Riley Securities, Inc. [Member]", "terseLabel": "B. Riley Securities, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r263", "r998", "r999"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r38", "r39", "r263", "r998", "r999"] }, "lctx_BaseRent": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "BaseRent", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Refers to the base monthly rent as per lease agreement.", "label": "Base rent", "terseLabel": "Base monthly rent" } } }, "auth_ref": [] }, "lctx_BaseRentAndConstructionAllowancePerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "BaseRentAndConstructionAllowancePerMonth", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Base rent and construction allowance per month.", "label": "Base rent and construction allowance per month" } } }, "auth_ref": [] }, "lctx_BaseRentIncreaseRate": { "xbrltype": "percentItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "BaseRentIncreaseRate", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This refer to base rent increase rate per year as per lease agreement.", "label": "Base rent increase rate" } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation, Liquidity and Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r69"] }, "lctx_BroadwoodPartnersLPMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "BroadwoodPartnersLPMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Broadwood Partners, L.P [Member]", "label": "Broadwood Partners, L.P [Member]" } } }, "auth_ref": [] }, "lctx_BudgetaryCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "BudgetaryCommitment", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Budgetary commitment.", "label": "Budgetary commitment amount" } } }, "auth_ref": [] }, "lctx_CantorFitzgeraldAndCoMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CantorFitzgeraldAndCoMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Cantor

Fitzgerald and Co Member [Member]", "label": "Cantor Fitzgerald and Co Member [Member]" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment expenditures in accounts payable", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r20", "r21", "r22"] }, "lctx_CapitalResourcesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CapitalResourcesPolicyTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Capital Resources", "label": "Capital Resources [Policy Text Block]", "documentation": "Capital resources." } } }, "auth_ref": [] }, "lctx_CarlsbadLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CarlsbadLeaseMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Carlsbad Lease [Member]", "label": "Carlsbad Lease [Member]" } } }, "auth_ref": [] }, "lctx_CarlsbadSubLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CarlsbadSubLeaseMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Carlsbad Sub Lease [Member]", "label": "Carlsbad Sub Lease [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "lctx_CashAndCashEquivalentsAndMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CashAndCashEquivalentsAndMarketableSecurities", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents and marketable securities", "label": "Cash and cash equivalents and marketable securities", "documentation": "Cash And Cash Equivalents And MarketableSecurities." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Included within cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r19", "r114", "r690"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r114"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r968", "r969"] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "At end of the period", "periodStartLabel": "At beginning of the period", "totalLabel": "Total cash, cash equivalents, and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r19", "r65", "r146"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r65"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]", "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH:" } } }, "auth_ref": [] }, "lctx_CellCureLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CellCureLeasesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Cell cure leases.", "label": "Cell Cure Leases [Member]" } } }, "auth_ref": [] }, "lctx_CellCureNeurosciencesLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CellCureNeurosciencesLtdMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand], "lang": { "en-us": { "role": { "documentation": "Cell Cure Neurosciences Ltd [Member]", "label": "Cell Cure Neurosciences Ltd [Member]" } } }, "auth_ref": [] }, "lctx_CellCureWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CellCureWarrantsMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "documentation": "Cell Cure Warrants [Member]", "label": "Cell Cure Warrants [Member]" } } }, "auth_ref": [] }, "lctx_ChangeInRightofuseAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ChangeInRightofuseAssetsAndLiabilities", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Change in right-of-use assets and liabilities.", "label": "Change in right-of-use assets and liabilities" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r805"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r802"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r800"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "lctx_ClinicalRegulatoryMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ClinicalRegulatoryMilestone", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Clinical regulatory milestone.", "label": "Clinical regulatory milestone" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r806"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r806"] }, "lctx_CollaborationRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CollaborationRevenuesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Collaboration Revenues Member", "label": "Collaboration Revenues [Member]", "terseLabel": "Collaboration Revenues [Member]" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": ["r398"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose

reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r398"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 13)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r47", "r83", "r557", "r626"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r73", "r266", "r267", "r683", "r915", "r917"] }, "lctx_CommonStockCapitalValueMaximumAuthorizedSharesAvailableForFutureIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CommonStockCapitalValueMaximumAuthorizedSharesAvailableForFutureIssuance", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Common stock capital value maximum authorized shares available for future issuance.", "label": "Common Stock Capital Value Maximum Authorized Shares Available For Future Issuance", "terseLabel": "Amount reserved for future issuance", "verboseLabel": "Net proceeds" } } }, "auth_ref": [] }, "lctx_CommonStockCapitalValueReservedForFutureIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CommonStockCapitalValueReservedForFutureIssuance", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Common stock capital value reserved for future issuance.", "label": "Common Stock Capital Value Reserved For Future Issuance", "terseLabel": "Amount reserved for future issuance", "verboseLabel": "Equity securities available for sale" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Shares", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r743", "r744", "r745", "r747", "r748", "r749", "r750", "r870", "r871", "r873", "r966", "r1029", "r1030"] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNoParValue", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, No Par Value", "terseLabel": "Common stock, no par value", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": ["r50"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r50", "r627"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r50"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r11", "r50", "r627", "r645", "r1030", "r1031"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, no par value, 450,000 shares authorized as of September 30, 2024 and December 31, 2023; 188,837 and 174,987 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r50", "r559", "r734"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r811"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r810"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r812"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r809"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE COMMON SHAREHOLDERS", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r16", "r127", "r129", "r136", "r547", "r572", "r574"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total", "negatedLabel": "Less: Comprehensive (income) loss attributable to noncontrolling interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r4", "r32", "r36", "r127", "r129", "r135", "r546", "r572", "r573"] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "COMPREHENSIVE LOSS", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r36", "r80", "r127", "r129", "r134", "r545", "r572"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r150", "r400", "r401", "r404", "r405", "r501", "r684", "r926", "r929", "r930"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r150", "r400", "r401", "r404", "r405", "r501", "r684", "r926", "r929", "r930"] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand], "lang": { "en-us": { "role": { "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand], "lang": { "en-us": { "role": { "label": "Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]", "documentation": "Disclosure of information about effect of change in parent's ownership interest in subsidiary on equity attributable to parent. Excludes change from deconsolidation of subsidiary." } } }, "auth_ref": ["r10", "r37"] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]", "terseLabel": "Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries", "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary." } } }, "auth_ref": ["r10", "r37"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [

```
"http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r33", "r691" ] }, "lctx_ContingencyWithheldAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ContingencyWithheldAmount", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingency withheld amount.", "label": "Contingency withheld amount" } } }, "auth_ref": [] }, "lctx_ContractLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ContractLiabilitiesMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contract Liabilities [Member]", "documentation": "Contract liabilities." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Contract with Customer Contract Liability and Receivable", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r933" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfContractWithCustomerContractLiabilityAndReceivableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenues", "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred revenues - end of the period", "totalLabel": "Contract with Customer, Liability, Total", "periodStartLabel": "Deferred revenues - beginning of the year", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r301", "r302", "r313" ] }, "lctx_CorporateCreditCardFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "CorporateCreditCardFacilityMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Corporate credit card facility.", "label": "Corporate Credit Card Facility [Member]", "terseLabel": "Corporate Credit Card Facility [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Revenue", "totalLabel": "Cost of Revenue, Total", "verboseLabel": "Cost of sales - royalties", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r57", "r148", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r458", "r696", "r927" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r63" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r274", "r924" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r274", "r924", "r925" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Available for Sale Debt Securities", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [
"r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Amortized cost And Estimated fair Value", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r94", "r699", "r900" ] }, "lctx_DecemberTwentyTwentyFourProspectusSupplementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "DecemberTwentyTwentyFourProspectusSupplementMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "December Twenty Twenty Four Prospectus Supplement [Member]", "documentation": "December Twenty Twenty Four Prospectus Supplement [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred income tax benefit", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax benefit", "totalLabel": "Deferred Income Tax Expense (Benefit), Total", "negatedLabel": "Deferred tax benefit", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r101", "r869" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r362", "r363", "r556" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue", "periodEndLabel": "Deferred revenues - end of the period", "periodStartLabel": "Deferred revenues - beginning of the period", "terseLabel": "Deferred revenue", "totalLabel": "Deferred Revenue, Total", "verboseLabel": "Deferred revenues", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r860" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenues, current portion", "label": "Deferred Revenue, Current", "terseLabel": "Current deferred revenue", "totalLabel": "Deferred Revenue, Current, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r859" ] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues, net of current portion", "label": "Deferred Revenue, Noncurrent", "totalLabel": "Deferred Revenue, Noncurrent, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r860" ] }, "lctx_DepositsAndOtherLongTermAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "DepositsAndOtherLongTermAssetsMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deposits and Other Long-Term Assets [Member]", "documentation": "Deposits and Other Long-Term Assets [Member]" } } }, "auth_ref": [] }, "lctx_DepositsAndOtherLongtermAssetsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "DepositsAndOtherLongtermAssetsNonCurrent", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Deposits and other longterm assets non current.", "label": "Deposits And Other Longterm Assets Non Current", "terseLabel": "Deposits and other long-term assets" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r7", "r24" ] }, "us-gaap_DevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopmentCosts", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Development Cost, Period Cost", "documentation": "Amount of capitalized development cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes acquisition and exploration costs and capitalized interest." } } }, "auth_ref": [ "r990", "r991" ] }, "lctx_DirectFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "DirectFinancingMember", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Direct financing", "label": "Direct Financing [Member]", "documentation": "Direct Financing ." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r312", "r706", "r707", "r708", "r709", "r710", "r711", "r712" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable",
```

"presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r312", "r706", "r707", "r708", "r709", "r710", "r711", "r712"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/RevenueTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregated Revenues", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r934"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwards"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Awards", "verboseLabel": "Schedule of Share-based Compensation Activity", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r323", "r326", "r354", "r355", "r357", "r717"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r759"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r793"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "lctx_DonMBaileyMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "DonMBaileyMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Don M. Bailey [Member]", "label": "Don M. Bailey [Member]", "documentation": "Don M. Bailey." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r804"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Basic net loss per share", "terseLabel": "Net loss per common share attributable to Lineage, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r137", "r158", "r159", "r160", "r161", "r162", "r163", "r168", "r170", "r172", "r173", "r174", "r176", "r388", "r397", "r428", "r429", "r548", "r575", "r693"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Diluted net loss per share", "terseLabel": "Net loss per common share attributable to Lineage, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r137", "r158", "r159", "r160", "r161", "r162", "r163", "r170", "r172", "r173", "r174", "r176", "r388", "r397", "r428", "r429", "r548", "r575", "r693"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r463"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "GILTI income", "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount", "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": ["r719", "r964", "r965"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r356"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "unrecognized compensation costs", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r962"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r757"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r755"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as

Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "terseLabel": "All Entities", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r755"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r755"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r843"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r755"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r755"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r755"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r755"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r798"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r839"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r839"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r839"] }, "lctx_EquipmentFurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "EquipmentFurnitureAndFixturesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "documentation": "Equipment Furniture And Fixtures Member", "label": "Equipment Furniture And Fixtures [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r11", "r107", "r130", "r131", "r132", "r151", "r152", "r153", "r155", "r162", "r164", "r166", "r178", "r229", "r235", "r261", "r300", "r371", "r372", "r384", "r385", "r386", "r389", "r396", "r397", "r409", "r411", "r412", "r413", "r414", "r416", "r427", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r473", "r495", "r570", "r593", "r594", "r595", "r615", "r668"] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity securities available for sale", "label": "Equity Securities, FV-NI", "totalLabel": "Equity Securities, FV-NI, Total", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r120", "r431", "r457", "r552", "r553", "r722", "r740", "r742", "r970", "r971", "r972"] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableEquitySecuritiesDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Loss on marketable equity securities, net", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "Loss on marketable equity securities, net", "terseLabel": "Loss on marketable equity securities, net", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r578", "r898"] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Equity Securities, FV-NI, Realized Gain (Loss), Total", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedLabel": "Less: Loss recognized in earnings on marketable equity securities sold", "negatedTerseLabel": "Loss on sale of marketable equity securities", "terseLabel": "Loss on sale of marketable equity securities", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r576", "r898"] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss recognized on marketable equity securities held at end of period, net", "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r577", "r898"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r808"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r765", "r776", "r786", "r818"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r762", "r773", "r783", "r815"] }, "lctx_EsCellInternationalPteLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "EsCellInternationalPteLtdMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand], "lang": { "en-us": { "role": { "documentation": "Es CellInternational Pte Ltd [Member]", "label": "Es CellInternational Pte Ltd [Member]" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r814"] }, "lctx_ExpectedConvertionToRevenueBy2026": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ExpectedConvertionToRevenueBy2026", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Expected convertion to revenue by 2026.", "label": "Expected Convertion to Revenue by 2026", "terseLabel": "Expected convertion to revenue by 2026" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r431", "r432", "r445", "r722"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r436", "r437", "r438", "r439", "r440", "r441", "r446", "r724"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent

financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r436", "r437", "r438", "r439", "r440", "r441", "r446", "r724"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r436", "r437", "r438", "r439", "r440", "r441", "r446", "r724"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r284", "r316", "r317", "r318", "r319", "r320", "r321", "r430", "r432", "r433", "r434", "r435", "r444", "r445", "r447", "r507", "r508", "r509", "r703", "r704", "r713", "r714", "r715", "r722", "r726"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r440", "r442", "r443", "r444", "r447", "r448", "r449", "r450", "r451", "r542", "r722", "r727"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r284", "r316", "r321", "r432", "r445", "r507", "r713", "r714", "r715", "r722"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r284", "r316", "r321", "r432", "r433", "r445", "r508", "r703", "r704", "r713", "r714", "r715", "r722"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r284", "r316", "r317", "r318", "r319", "r320", "r321", "r432", "r433", "r434", "r435", "r445", "r509", "r703", "r704", "r713", "r714", "r715", "r722", "r726"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r284", "r316", "r317", "r318", "r319", "r320", "r321", "r430", "r432", "r433", "r434", "r435", "r444", "r445", "r447", "r507", "r508", "r509", "r703", "r704", "r713", "r714", "r715", "r722", "r726"] }, "lctx_FieldOfBusinessDescription": { "xbrltype": "stringItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "FieldOfBusinessDescription", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand], "lang": { "en-us": { "role": { "documentation": "Field of business description.", "label": "Field of business description" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": ["r478", "r483"] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability", "terseLabel": "Total", "totalLabel": "Total finance lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": ["r475", "r487"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities, current portion", "label": "Finance Lease, Liability, Current", "verboseLabel": "Finance leases, Right-of-use lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r475"] }, "lctx_FinanceLeaseLiabilityExcludingOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "FinanceLeaseLiabilityExcludingOtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Finance lease liability excluding other liabilities current.", "label": "Finance Lease Liability Excluding Other Liabilities Current", "terseLabel": "Finance leases, Right-of-use lease liabilities, current" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities, net of current portion", "label": "Finance Lease, Liability, Noncurrent", "verboseLabel": "Finance leases, Right-of-use lease liabilities, noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r475"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "verboseLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r487"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year One", "verboseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r487"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Four", "verboseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r487"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Three", "verboseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r487"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Two", "verboseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r487"] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r487"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Finance Lease, Principal Payments", "terseLabel": "Repayment of finance lease liabilities", "verboseLabel": "Financing cash flows from finance leases", "negatedLabel": "Repayment of finance lease liabilities", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r477", "r483"] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance leases, Right-of-use assets, net", "totalLabel":

"Finance leases, Right-of-use assets, net", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r474"] }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "negatedLabel": "Finance leases, Accumulated amortization", "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease." } } }, "auth_ref": ["r845", "r847"] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense for right-of-use finance lease assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": ["r476", "r482", "r733"] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Finance leases, Right-of-use assets", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r844"] }, "lctx_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortizationMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "documentation": "Finance lease, right of use asset, before accumulated amortization.", "label": "Finance Lease, Right Of Use Asset, Before Accumulated Amortization [Member]", "terseLabel": "Right-of-use assets - Finance Lease [Member]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": ["r486", "r733"] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r485", "r733"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r236", "r237", "r238", "r239", "r240", "r242", "r243", "r244", "r285", "r298", "r417", "r452", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r571", "r699", "r722", "r724", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r735", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r894", "r895", "r896", "r897", "r967", "r970", "r971", "r972", "r973", "r974"] }, "lctx_FinancingLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "FinancingLeasesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Financing Leases [Member]", "label": "Financing Leases [Member]", "terseLabel": "Finance leases [Member]" } } }, "auth_ref": [] }, "lctx_FinancingRelatedFees": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "FinancingRelatedFees", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Financing related fees.", "label": "Financing related fees" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life", "verboseLabel": "Estimated useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r118", "r245", "r254", "r701"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1", "http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r247", "r249", "r250", "r251", "r253", "r254", "r257", "r258", "r537", "r541", "r687"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1"], "lang": { "en-us": { "role": { "totalLabel": "Finite-Lived Intangible Assets, Gross, Total", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible assets subject to amortization", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r245", "r254", "r541", "r701"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r247", "r254", "r257", "r258", "r259", "r537", "r687", "r701"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1", "http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r247", "r249", "r250", "r251", "r253", "r254", "r257", "r258", "r687"] }, "lctx_ForeignCurrencyRemeasurementGainLossBeforeTaxAndOtherLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ForeignCurrencyRemeasurementGainLossBeforeTaxAndOtherLoss", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency remeasurement and other loss", "label": "Foreign Currency Transaction, Gain (Loss), before Tax and Other Loss", "documentation": "Foreign currency remeasurement, gain (loss), before tax and other loss." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency transaction gain (loss), net", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total", "negatedLabel": "Foreign currency remeasurement and other loss", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r459", "r460", "r461", "r462", "r665"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r769", "r780", "r790", "r822"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r769", "r780", "r790", "r822"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r769", "r780", "r790", "r822"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r769", "r780", "r790", "r822"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r769", "r780", "r790", "r822"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r803"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r60", "r649"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r60"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": [

"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "totalLabel": "Goodwill, Total", "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r117", "r246", "r543", "r697", "r700", "r723", "r734", "r902", "r903"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/GoodwillAndIntangibleAssetsNet"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets, Net", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r901", "r904"] }, "lctx_GrantsAwardedPercentage": { "xbrltype": "percentItemType", "nsuri":
"http://lineagecell.com/20240930", "localname": "GrantsAwardedPercentage", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Grants Awarded Percentage.", "label": "Grants awarded percentage" } } }, "auth_ref": [] }, "lctx_GrossProceedsFromIssuanceOfCommonStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "GrossProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds from issuance of common stock", "label": "Gross Proceeds from Issuance of Common Stock", "documentation": "Gross proceeds from issuance of common stock." } } }, "auth_ref":
[] }, "lctx_GrossProceedsFromSaleOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname":
"GrossProceedsFromSaleOfCommonStock", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Gross Proceeds from Sale of Common Stock", "documentation": "Gross Proceeds from Sale of Common Stock" } } }, "auth_ref": [] },
"lctx_HadasitMedicalResearchServicesAndDevelopmentLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname":
"HadasitMedicalResearchServicesAndDevelopmentLtdMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Hadasit Medical Research Services And Development Ltd [Member]", "label": "Hadasit Medical Research Services and Development Ltd [Member]" } } }, "auth_ref": [] },
"lctx_ITICollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ITICollaborationAgreementMember",
"presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "ITI Collaboration Agreement [Member]", "label": "ITI Collaboration Agreement [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r758", "r760", "r772"] },
"us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InProcessResearchAndDevelopmentMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": ["r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914"] },
"lctx_InProcessResearchAndDevelopmentOPCOneMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname":
"InProcessResearchAndDevelopmentOPCOneMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "documentation": "IPR&D - OPC1 [Member]", "label": "IPR&D - OPC1 [Member]" } } }, "auth_ref": [] },
"lctx_InProcessResearchAndDevelopmentVACTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname":
"InProcessResearchAndDevelopmentVACTwoMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "documentation": "IPR&D - VAC2 [Member]", "label": "IPR&D - VAC2 [Member]" } } }, "auth_ref": [] }, "lctx_InProcessResearchAndDevelopmentVacMember": {
"xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "InProcessResearchAndDevelopmentVacMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "IPR&D - VAC [Member]", "label": "In Process Research And Development VAC [Member]", "documentation": "In Process Research And Development VAC [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "LOSS BEFORE INCOME TAXES", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before net income tax benefit", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r56", "r87", "r92", "r549", "r566", "r695", "r696", "r874", "r875", "r876", "r877", "r878"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": {
"en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label":
"Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } },
"auth_ref": ["r262", "r263", "r265", "r437", "r441", "r446", "r588", "r590", "r652", "r687", "r725", "r1000"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label":
"Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [
"r263", "r265", "r437", "r441", "r446", "r588", "r590", "r652", "r687", "r725", "r1000"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] },
"us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock",
"presentation": ["http://lineagecell.com/20240930/taxonomy/role/IncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel":
"Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r149", "r361", "r365", "r366", "r367", "r368", "r369", "r370", "r376", "r378",
"r379", "r380", "r609", "r719"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"],
"lang": { "en-us": { "role": { "negatedLabel": "Provision for income tax benefit", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense", "totalLabel":
"Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r95", "r102", "r165", "r166", "r177", "r182", "r185", "r364", "r365", "r377", "r579", "r719"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r688"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r6"] }, "lctx_IncreaseInBaseRentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930",
"localname": "IncreaseInBaseRentAmount", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Increase in base rent amount.", "label": "Increased rent amount" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r247", "r252", "r256", "r701"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r247", "r256", "r259", "r701"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-

us": { "role": { "periodEndLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance", "periodStartLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance", "totalLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Total", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Intangible assets", "verboseLabel": "Fair value of intangible assets", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r245", "r256", "r701"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r247", "r252", "r256", "r701"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r769", "r780", "r790", "r814", "r822", "r826", "r834"] },
"lctx_IndustrialMicrobesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "IndustrialMicrobesIncMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Industrial Microbes, Inc [Member]", "label": "Industrial Microbes, Inc [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r832"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r761", "r838"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r761", "r838"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r761", "r838"] }, "lctx_InsuranceDeductable": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "InsuranceDeductable", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Insurance deductable.", "label": "Insurance deductable" } } }, "auth_ref": [] }, "us-gaap_InsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceRecoveries", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Insurance Recoveries", "terseLabel": "Insurance reimbursed amount", "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses." } } }, "auth_ref": ["r59"] }, "lctx_InsurersMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "InsurersMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Insurers [Member]", "label": "Insurers [Member]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Total intangible assets", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": ["r117"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r247", "r911", "r912"] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating", "terseLabel": "Interest income", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r696", "r865", "r875"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r141", "r144", "r145"] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecurities"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r89", "r104", "r192", "r193", "r453", "r454", "r992"] }, "lctx_IsraelInnovationAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "IsraelInnovationAuthorityMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Israel Innovation Authority [Member]", "label": "Israel Innovation Authority [Member]" } } }, "auth_ref": [] }, "lctx_JanuaryTwoThousandAndEighteenLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "JanuaryTwoThousandAndEighteenLeaseMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "January 2018 Lease [Member]", "label": "January 2018 Lease [Member]" } } }, "auth_ref": [] }, "us-gaap_LandSubjectToGroundLeases": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandSubjectToGroundLeases", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Land Subject to Ground Leases", "terseLabel": "Land subject to ground leases", "documentation": "Area of land subject to a ground lease." } } }, "auth_ref": ["r977"] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r489", "r846"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r489", "r846"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r978"] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease Expiration Date", "terseLabel": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "lctx_LeaseModification": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "LeaseModification", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Lease modification.", "label": "Lease modification" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r72", "r488"] }, "lctx_LeasesCommencementDate": { "xbrltype": "dateItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "LeasesCommencementDate", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Lease commencement date.", "label": "Leases Commencement Date", "terseLabel": "Lease commencement date" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity:", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Legal Fees", "terseLabel": "Legal expenses", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": ["r848"] },
"lctx_LegalFeesRelatedToReimbursableUnderInsurancePolicies": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "LegalFeesRelatedToReimbursableUnderInsurancePolicies", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Legal fees related to reimbursable under insurance policies.", "label": "Legal Fees Related to Reimbursable under Insurance Policies", "terseLabel": "Legal fees related to reimbursable insurance policies" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r480", "r489"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r480", "r489"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Commitments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r979"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total lease payments", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r487"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rent for first twelve months", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r487"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r487"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r487"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rent for remaining twelve months", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r487"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less imputed interest", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r487"] }, "lctx_LesseeOperatingLeasesOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "LesseeOperatingLeasesOptionToExtend", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Lessee operating leases option to extend.", "label": "Lessee Operating Leases Option To Extend", "terseLabel": "Lessee operating lease renewal term description" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingSubleaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingSubleaseOptionToExtend", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Sublease, Option to Extend", "terseLabel": "Sublease agreement option to extend", "documentation": "Description of terms and conditions of option to extend operating sublease." } } }, "auth_ref": ["r481"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r13", "r42", "r43", "r44", "r45", "r46", "r47", "r48", "r148", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r401", "r404", "r405", "r458", "r625", "r694", "r753", "r927", "r981", "r982"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r54", "r85", "r563", "r734", "r868", "r899", "r975"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r44", "r113", "r148", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r401", "r404", "r405", "r458", "r734", "r927", "r981", "r982"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG-TERM LIABILITIES" } } }, "auth_ref": [] }, "lctx_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "LicenseAgreementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "License Agreement [Member]", "label": "License Agreement [Member]" } } }, "auth_ref": [] }, "lctx_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "LiquidityPolicyTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Liquidity", "label": "Liquidity [Policy Text Block]", "documentation": "Liquidity." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r268", "r269", "r270", "r273", "r359", "r702", "r919", "r920"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r268", "r269", "r270", "r273", "r359", "r702", "r919", "r920"] }, "us-gaap_LossContingencyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualPayments", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Payments", "terseLabel": "Loss contingency accrual, payments", "documentation": "Amount of cash outflow reducing loss contingency liability." } } }, "auth_ref": ["r918"] }, "us-gaap_LossContingencyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyReceivable", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Receivable", "periodEndLabel": "Loss Contingency, Receivable, Ending Balance", "periodStartLabel": "Loss Contingency, Receivable, Beginning Balance", "terseLabel": "Insurance recovery receivable", "totalLabel": "Loss Contingency, Receivable, Total", "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable." } } }, "auth_ref": ["r923"] }, "us-gaap_LossContingencyReceivableProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyReceivableProceeds", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Receivable, Proceeds", "verboseLabel": "Upfront payment", "documentation": "Amount of cash inflow from the collection of receivables related to a loss contingency." } } }, "auth_ref": ["r866", "r923"] }, "lctx_MarchTwentyTwentyFourProspectusSupplementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "MarchTwentyTwentyFourProspectusSupplementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "March 2024 Prospectus Supplement [Member]", "label": "March Twenty Twenty Four Prospectus Supplement [Member]", "documentation": "March Twenty Twenty Four Prospectus Supplement [Member]" } } }, "auth_ref": [] }, "lctx_MarketableDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "MarketableDebtSecuritiesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Marketable Debt Securities [Member]", "label": "Marketable Debt Securities [Member]" } } }, "auth_ref": [] }, "lctx_MarketableEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "MarketableEquitySecuritiesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Marketable Equity Securities [Member]", "label": "Marketable Equity Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Included within marketable securities", "label": "Marketable Securities", "terseLabel": "Marketable securities", "totalLabel": "Marketable Securities, Total", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": ["r86", "r858"] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr":

"debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "verboseLabel": "Marketable debt securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r858"] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "terseLabel": "Schedule Of Marketable Equity Securities", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": ["r269", "r270", "r271", "r272", "r322", "r359", "r435", "r535", "r587", "r589", "r603", "r617", "r618", "r675", "r676", "r677", "r678", "r679", "r685", "r686", "r698", "r705", "r716", "r726", "r727", "r731", "r732", "r737", "r931", "r983", "r984", "r985", "r986", "r987", "r988"] },
"lctx_MaximumMilestonePaymentsToBeReceivedUponPerformanceConditions": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "MaximumMilestonePaymentsToBeReceivedUponPerformanceConditions", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum milestone payments to be received upon performance conditions.", "label": "Maximum milestone payments to be received upon performance conditions" } } }, "auth_ref": [] }, "lctx_MaximumPercentageOfMilestonePayments": { "xbrltype": "percentItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "MaximumPercentageOfMilestonePayments", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum Percentage of Milestone Payments", "label": "Maximum Percentage of Milestone Payments", "terseLabel": "Maximum percentage of milestone payments" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r806"] },
"ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r806"] },
"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r269", "r270", "r271", "r272", "r322", "r359", "r435", "r535", "r587", "r589", "r603", "r617", "r618", "r675", "r676", "r677", "r678", "r679", "r685", "r686", "r698", "r705", "r716", "r726", "r727", "r731", "r737", "r931", "r983", "r984", "r985", "r986", "r987", "r988"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Noncontrolling Interest", "periodEndLabel": "Equity, Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Equity, Attributable to Noncontrolling Interest, Beginning Balance", "terseLabel": "Noncontrolling deficit", "totalLabel": "Equity, Attributable to Noncontrolling Interest, Total", "negatedLabel": "Noncontrolling deficit", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r53", "r84", "r148", "r225", "r275", "r277", "r278", "r279", "r282", "r283", "r458", "r562", "r629"] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand
], "lang": { "en-us": { "role": { "label": "Subsidiary, Ownership Percentage, Parent", "terseLabel": "Ownership percentage by parent", "verboseLabel": "Ownership percentage", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r825"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r935"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r833"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r807"] }, "lctx_NealBradsherMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "NealBradsherMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Neal Bradsher [Member]", "label": "Neal Bradsher [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r143"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r143"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r65", "r66", "r68"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss attributable to Lineage", "totalLabel": "NET LOSS ATTRIBUTABLE TO LINEAGE", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r58", "r68", "r88", "r111", "r126", "r128", "r132", "r148", "r154", "r158", "r159", "r160", "r161", "r162", "r165", "r166", "r171", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r388", "r397", "r429", "r458", "r569", "r647", "r666", "r667", "r751", "r927"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total", "negatedLabel": "Net (income) loss attributable to noncontrolling interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r35", "r81", "r126", "r128", "r162", "r165", "r166", "r568", "r864"] }, "us-gaap_NetRentableArea": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetRentableArea", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Net Rentable Area", "terseLabel": "Rentable area", "documentation": "Net rentable area for properties owned." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r806"] }, "ecd_NonNeosMember": {

```
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r769", "r780", "r790", "r814", "r822" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r797" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r796" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r814" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r833" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r833" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTINGACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Deficit [Member]", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r30", "r300", "r870", "r871", "r872", "r873", "r1030" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "other income (expenses)", "totalLabel": "Total other income (expenses)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r61" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSES):" } } }, "auth_ref": [] }, "lctx_NumberOfBuildingForLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "NumberOfBuildingForLeaseDescription", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of building for lease description.", "label": "Number of buildings for lease" } } }, "auth_ref": [] }, "lctx_NumberOfRsusOutstandingRestrictedStockUnitsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "NumberOfRsusOutstandingRestrictedStockUnitsExercised", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Number of RSUs outstanding, options exercised.", "label": "Number of RSUs Outstanding, Options exercised" } } }, "auth_ref": [] }, "lctx_NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Number of RSUs outstanding, options expired/forfeited/cancelled.", "label": "Number of RSUs Outstanding, Options expired/forfeited/cancelled" } } }, "auth_ref": [] }, "lctx_NumberOfRsusOutstandingRestrictedStockUnitsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "NumberOfRsusOutstandingRestrictedStockUnitsGranted", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Number of RSUs Outstanding, restricted stock units granted.", "label": "Number of RSUs Outstanding, Options granted" } } }, "auth_ref": [] }, "lctx_OfficeAndLaboratorySpaceJerusalemIsraelMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "OfficeAndLaboratorySpaceJerusalemIsraelMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Office and Laboratory Space, Jerusalem, Israel [Member]", "label": "Office and Laboratory Space, Jerusalem, Israel [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r92", "r695", "r874", "r875", "r876", "r877", "r878" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r976" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease expense", "terseLabel": "Total operating lease liabilities", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r475" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current portion", "label": "Operating Lease, Liability, Current", "verboseLabel": "Right-of-use lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r475" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Right-of-use lease liabilities, noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r475" ] }, "lctx_OperatingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "OperatingLeaseMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating Lease [Member]", "label": "Operating Lease [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r479", "r483" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "terseLabel": "Right-of-use assets, net", "totalLabel": "Right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r474" ] }, "lctx_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating Lease Right Of Use Asset Accumulated Amortization", "label": "Operating Lease Right Of Use Asset Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "auth_ref": [] }, "lctx_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating Lease Right Of Use Asset Before Accumulated Amortization", "label": "Operating Lease Right Of Use Asset Before Accumulated Amortization", "terseLabel": "Right-of-use assets" } } }, "auth_ref": [] }, "lctx_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortizationMember", "presentation": [ "http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease, right of use asset, before accumulated amortization.", "label": "Operating Lease, Right Of Use Asset, Before Accumulated Amortization [Member]", "terseLabel": "Right-of-use assets - Operating Lease [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r486", "r733" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ],
```

"lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r485", "r733"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverview1"], "lang": { "en-us": { "role": { "terseLabel": "Organization and Business Overview", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r40", "r79", "r604", "r605"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on marketable debt securities", "verboseLabel": "Unrealized gain on marketable debt securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r123", "r124", "r125", "r570"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustment", "label": "Comprehensive loss foreign currency translation adjustments, net of tax", "terseLabel": "Foreign currency translation adjustment", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r2", "r570"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss, net of tax:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on marketable debt securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r123", "r125", "r224"] }, "lctx_OtherFinanceLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "OtherFinanceLeaseLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Other finance lease liabilities current.", "label": "OtherFinanceLeaseLiabilitiesCurrent", "verboseLabel": "Other current liabilities" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r43", "r734"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r46"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "verboseLabel": "Other income (expense)", "terseLabel": "Other income", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r62"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r806"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r767", "r778", "r788", "r820"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r770", "r781", "r791", "r823"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r770", "r781", "r791", "r823"] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesScheduleOfLineagesOwnershipOfOutstand], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ParentCompanyMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Parent Company [Member]" } } }, "auth_ref": ["r150"] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1"], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": ["r78", "r905", "r906", "r907", "r908", "r910", "r911", "r913", "r914"] }, "lctx_PayCostsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "PayCostsPercentage", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Pay costs percentage.", "label": "Pay costs percentage" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r795"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForAdvanceToAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForAdvanceToAffiliate", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Payments for Advance to Affiliate", "terseLabel": "Upfront payment", "verboseLabel": "Insurance deductable", "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)." } } }, "auth_ref": ["r17"] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Payments for Legal Settlements", "terseLabel": "Litigation settlement amount", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": ["r5"] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Payments for Rent", "terseLabel": "Payments for rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": ["r5"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Financing related fees", "negatedLabel": "Payments for offering costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r18"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Common shares received and retired for employee taxes paid", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r140"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable debt securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r882"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchase of equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r64"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r805"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group

Total Shareholder Return Amount" } } }, "auth_ref": ["r805"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r797"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r814"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r807"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r796"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1", "http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1", "http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r798"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r842"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r797"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r743", "r744", "r747", "r748", "r749", "r750", "r1029", "r1030"] }, "us-gaap_PreferredStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockNoParValue", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, No Par Value", "terseLabel": "Preferred stock, no par value", "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r49", "r932"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r49", "r627"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r49", "r287"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r49", "r627", "r645", "r1030", "r1031"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r49", "r558", "r734"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r861"] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "lctx_PriorSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "PriorSalesAgreementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prior Sales Agreement [Member]", "label": "Prior Sales Agreement [Member]", "documentation": "Prior sales agreement." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollaborators": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromCollaborators", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Collaborators", "terseLabel": "Amount of grants received", "verboseLabel": "Upfront payment", "documentation": "Cash received from collaborators during the current period." } } }, "auth_ref": ["r67"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of common shares", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Maturities of marketable debt securities", "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r138", "r139", "r882"] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from the sale of marketable equity securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from employee options exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r3", "r12"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r186", "r536", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r689", "r706", "r736", "r737", "r738", "r739", "r741", "r921", "r922", "r934", "r997", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r186", "r536", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r689", "r706", "r736", "r737", "r738", "r739", "r741", "r921", "r922", "r934", "r997", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net income (loss)", "terseLabel": "Net loss", "totalLabel": "NET LOSS", "verboseLabel": "NET LOSS", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r111", "r126", "r128", "r142", "r148", "r154", "r162", "r165", "r166", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r388", "r397", "r399", "r402", "r403", "r429", "r458", "r549", "r567", "r614", "r647", "r666", "r667", "r720",

"r721", "r752", "r864", "r927"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r8", "r488"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/PropertyAndEquipmentNet"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r71", "r97", "r99", "r100"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r72", "r115", "r565"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r488"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "terseLabel": "Total", "totalLabel": "Property and equipment, net", "verboseLabel": "Property and equipment, net (Notes 6 and 14)", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r8", "r488", "r551", "r565", "r734"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/PropertyAndEquipmentNetTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r8"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r72", "r488"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life of asset", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Purchase Obligation", "terseLabel": "Purchase obligation", "totalLabel": "Purchase Obligation, Total", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r795"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r795"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r269", "r270", "r271", "r272", "r315", "r322", "r349", "r350", "r351", "r359", "r435", "r510", "r519", "r535", "r587", "r589", "r603", "r617", "r618", "r675", "r676", "r677", "r678", "r679", "r685", "r686", "r698", "r705", "r716", "r726", "r727", "r731", "r732", "r737", "r745", "r916", "r931", "r971", "r984", "r985", "r986", "r987", "r988"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r269", "r270", "r271", "r272", "r315", "r322", "r349", "r350", "r351", "r359", "r435", "r510", "r519", "r535", "r587", "r589", "r603", "r617", "r618", "r675", "r676", "r677", "r678", "r679", "r685", "r686", "r698", "r705", "r716", "r726", "r727", "r731", "r732", "r737", "r745", "r916", "r931", "r971", "r984", "r985", "r986", "r987", "r988"] }, "lctx_ReconciliationOfCashCashEquivalentsAndRestrictedCashEndOfPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashEndOfPeriodAbstract", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Reconciliation of cash cash equivalents and restricted cash end of period.", "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash End Of Period [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash, end of period:" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r762", "r773", "r783", "r815"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r496", "r497", "r498", "r499", "r500", "r610", "r611", "r612", "r650", "r651", "r652", "r672", "r674"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r360", "r687", "r696", "r989"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r763", "r774", "r784", "r816"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r764", "r775", "r785", "r817"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r771", "r782", "r792", "r824"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total", "verboseLabel": "Deposit assets", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r856", "r867", "r994", "r996"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r114"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodEndLabel": "Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies))", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency

on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r96", "r857", "r867"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Restricted Stock Units [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r51", "r75", "r561", "r597", "r602", "r608", "r628", "r734"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r107", "r151", "r152", "r153", "r155", "r162", "r164", "r166", "r229", "r235", "r261", "r371", "r372", "r384", "r385", "r386", "r389", "r396", "r397", "r409", "r412", "r413", "r416", "r427", "r471", "r473", "r593", "r595", "r615", "r1030"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "totalLabel": "Total revenues", "verboseLabel": "Total revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r90", "r91", "r177", "r180", "r181", "r183", "r185", "r186", "r187", "r188", "r311", "r312", "r536"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Total revenues under collaborative agreements", "verboseLabel": "Collaboration revenues", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r90", "r91", "r177", "r180", "r181", "r183", "r185", "r186", "r187", "r188", "r311", "r312", "r536"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Revenue"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r103", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r314"] }, "lctx_RevenueRecognizedFromDeferredRevenueAtBeginningOfPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "RevenueRecognizedFromDeferredRevenueAtBeginningOfPeriod", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized included in deferred revenue", "label": "Revenue Recognized From Deferred Revenue At Beginning Of Period", "documentation": "Revenue recognized from deferred revenue at beginning of period." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligations", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r98"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Total revenues", "verboseLabel": "Total revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r90", "r91", "r133", "r148", "r177", "r180", "r181", "r183", "r185", "r186", "r187", "r188", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r458", "r549", "r696", "r927"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": ["r484", "r733"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r484", "r733"] }, "lctx_RocheAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "RocheAgreementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Roche Agreement [Member]", "label": "Roche Agreement [Member]" } } }, "auth_ref": [] }, "lctx_RocheAndImmunomicTherapeuticsCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "RocheAndImmunomicTherapeuticsCollaborationAgreementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Roche and Immunomic Therapeutics Collaboration Agreement [Member]", "label": "Roche and Immunomic Therapeutics Collaboration Agreement [Member]" } } }, "auth_ref": [] }, "lctx_RoyaltiesLicenseAndOtherRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "RoyaltiesLicenseAndOtherRevenues", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "Royalties, license and other revenues.", "label": "Royalties, License and Other Revenues", "terseLabel": "Royalties, license and other revenues" } } }, "auth_ref": [] }, "lctx_RoyaltiesLicenseAndOtherRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "RoyaltiesLicenseAndOtherRevenuesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Royalties, license and other revenues.", "label": "Royalties, License and Other Revenues [Member]", "terseLabel": "Royalties, License and Other Revenues [Member]" } } }, "auth_ref": [] }, "lctx_RoyaltyContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "RoyaltyContractsMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1"], "lang": { "en-us": { "role": { "documentation": "Royalty Contracts [Member]", "label": "Royalty Contracts [Member]" } } }, "auth_ref": [] }, "lctx_RoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "RoyaltyPaymentPercentage", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty Payment Percentage.", "label": "Royalty payment percentage" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r833"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r833"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "offering price", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "lctx_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "SalesAgreementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales Agreement [Member]", "documentation": "Sales Agreement [Member]", "label": "Sales Agreement [Member]" } } }, "auth_ref": [] }, "lctx_SalesCommissionPercentageOfGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "SalesCommissionPercentageOfGrossProceeds", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Refers to a commission payable to the seller as a percentage of gross proceeds from the sale of shares of the entity.", "label": "Percentage of commission payable" } } }, "auth_ref": [] }, "lctx_SalesRelatedMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "SalesRelatedMilestones", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Sales related milestones.", "label": "Sales related milestones" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/AccountsPayableAndAccruedLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an

entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule Of Computation Of Diluted Net Loss Per Common Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r23"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r398"] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Stock Based Compensation Expense", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompen { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensatio "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payment and Postretirement Benefit [Table]", "documentation": "Disclosure of information about arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": ["r26", "r76"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r968", "r969"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetails1"], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r247", "r254", "r257", "r258", "r259", "r537", "r687", "r701"] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillAndIntangibleAssetsNetDetailsParenthetical"], "lang": { "en-us": { "role": { "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": ["r247", "r256", "r259", "r701"] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/GoodwillAndIntangibleAssetsNetTables"], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill and Intangible Assets Net", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": ["r901", "r904"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r8", "r488"] }, "us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Fair Value Of Marketable Securities", "label": "Securities Owned Not Readily Marketable [Table Text Block]", "documentation": "Tabular disclosure of not readily marketable securities and investments including, but not limited to, description of security or investment, fair value and value as measured by quoted price." } } }, "auth_ref": ["r993"] }, "lctx_ScheduleOfSecuritiesOwnedReadilyMarketableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ScheduleOfSecuritiesOwnedReadilyMarketableTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "documentation": "Securities owned readily marketable.", "label": "Schedule Of Securities Owned Readily Marketable [Table Text Block]", "terseLabel": "Schedule Of Fair Value Of Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1", "http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r324", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation Activity", "documentation": "Tabular disclosure of employee stock purchase plan activity." } } }, "auth_ref": ["r28"] }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "lctx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental cash flow information related to leases [Table Text Block]", "label": "Schedule of Supplemental Cash Flow Information Related to Leases" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r756"] }, "lctx_SettlementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "SettlementAgreementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Settlement Agreement [Member]", "label": "Settlement Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment

Arrangement, Noncash Expense", "terseLabel": "Total stock-based compensation expense", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "verboseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Number of restricted stock units, forfeited", "negatedLabel": "Number of RSUs Outstanding, RSUs forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r343"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r343"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of RSUs Outstanding, RSUs granted", "verboseLabel": "Number of restricted stock units, granted", "negatedTerseLabel": "Number of RSUs Outstanding, RSUs granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r341"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value per share of RSUs granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r341"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of RSUs Outstanding, Ending balance", "periodStartLabel": "Number of RSUs Outstanding, Beginning balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r338", "r339"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Ending balance", "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Beginning balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r338", "r339"] }, "lctx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsToBeVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsToBeVestedInPeriod", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options to be vested in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options to be Vested In Period", "terseLabel": "Number of restricted stock units to be vested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of RSUs Outstanding, RSUs vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r342"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r342"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1", "http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r324", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in shares authorized for issuance", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized for issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r718"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r27"] }, "lctx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndExpectedToVestWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndExpectedToVestWeightedAverageExercisePrice", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options, exercisable and expected to vest, weighted average exercise price.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable and Expected to Vest, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price of Options exercisable and expected to vest" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of Options exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r332"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price of Options exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r332"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":

"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r345"] }, "lctx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedRestrictedStockUnits", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options forfeited restricted stock units", "label": "Number of Options Outstanding, RSUs forfeited" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total", "negatedLabel": "Number of Options Outstanding, Options forfeited", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r942"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price of Options Outstanding, Options expired/forfeited/cancelled", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r942"] }, "lctx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRestrictedStockUnits", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, RSU granted.", "label": "Number of Options Outstanding, RSUs granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Options Outstanding, Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value per share of options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r344"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Options Outstanding, Ending Balance", "periodStartLabel": "Aggregate Intrinsic Value, Options Outstanding, Beginning balance", "terseLabel": "Aggregate Intrinsic Value, Options Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r27"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options Outstanding, Ending balance", "periodStartLabel": "Number of Options Outstanding, Beginning balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r330", "r331"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price of Options Outstanding, Ending balance", "periodStartLabel": "Weighted Average Exercise Price of Options Outstanding, Beginning balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r330", "r331"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options exercisable and expected to vest", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r347"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "terseLabel": "Number of Options Exercisable and Expected to Vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r347"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price of Options exercisable and expected to vest", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r347"] }, "lctx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingRestrictedStockUnits", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, RSU vesting.", "label": "Number of Options Outstanding, Rsu vested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfComputationOfDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price of Options, Options exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r335"] }, "lctx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePriceRSU": { "xbrltype": "perShareItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePriceRSU", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award options forfeited in period weighted average exercise price RSU", "label": "Weighted Average Exercise Price of Options Outstanding, RSUs forfeited" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price of Options Outstanding, Options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r334"] }, "lctx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceRSU": { "xbrltype": "perShareItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceRSU", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": {

"documentation": "Weighted Average Exercise Price of Options, RSUs.", "label": "Weighted Average Exercise Price of Options Outstanding, RSUs granted" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r27"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Team (Years),Options exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r27"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Team (Years),Options Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r27"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Team (Years), Options exercisable and expected to vest", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r347"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of the options vested", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r345"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "periodEndLabel": "Ending Balance, shares", "periodStartLabel": "Beginning Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "lctx_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureBasisOfPresentationLiquidityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Policy Text Block]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r50", "r52", "r53", "r107", "r130", "r131", "r132", "r151", "r152", "r153", "r155", "r162", "r164", "r166", "r178", "r229", "r235", "r261", "r300", "r371", "r372", "r384", "r385", "r386", "r389", "r396", "r397", "r409", "r411", "r412", "r413", "r414", "r416", "r427", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r473", "r495", "r570", "r593", "r594", "r595", "r615", "r668"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r151", "r152", "r153", "r178", "r473", "r536", "r606", "r616", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r641", "r642", "r643", "r644", "r646", "r648", "r649", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r668", "r746"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r151", "r152", "r153", "r178", "r191", "r473", "r536", "r606", "r616", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r641", "r642", "r643", "r644", "r646", "r648", "r649", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r668", "r746"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r766", "r777", "r787", "r819"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued, shares", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r11", "r49", "r50", "r75", "r607", "r668", "r680"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares", "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r11", "r49", "r50", "r75"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options Outstanding, Options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Shares issued upon exercise of stock options, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r11", "r49", "r50", "r75", "r335"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued, Value", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r11", "r49", "r50", "r75", "r615", "r668", "r680", "r752"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Shares issued upon exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r11", "r50", "r52", "r53", "r75"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Equity, Attributable to Parent, Ending Balance", "periodStartLabel": "Equity, Attributable to Parent, Beginning Balance", "totalLabel": "Lineage's shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r50", "r52", "r53", "r70", "r629", "r645", "r669", "r670", "r734", "r753", "r868", "r899", "r975", "r1030"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total shareholders\u2019 equity", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r30", "r31", "r34", "r107", "r108", "r131", "r151", "r152", "r153", "r155", "r162", "r164", "r229", "r235", "r261", "r300", "r371", "r372", "r384", "r385", "r386", "r389", "r396", "r397", "r409", "r411", "r412", "r413", "r414", "r416", "r427", "r464", "r465", "r469", "r472", "r495", "r594", "r595", "r613", "r629", "r645", "r669", "r670", "r681", "r752", "r868", "r899", "r975", "r1030"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [

"http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/ShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Shareholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r74", "r147", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r300", "r418", "r671", "r673", "r682"] }, "lctx_SublicensingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "SublicensingFee", "crdr": "debit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Sublicensing Fee", "label": "Sublicensing Fee", "terseLabel": "Sublicensing fee" } } }, "auth_ref": [] }, "lctx_SublicensingFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "SublicensingFeePercentage", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Sublicensing Fee Percentage.", "label": "Sublicensing fee percentage" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/SubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r502", "r503"] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL DISCLOSURES :", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r813"] }, "lctx_ThousandTenAtlanticPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ThousandTenAtlanticPremisesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Thousand Ten Atlantic Premises [Member]", "label": "1010 Atlantic Premises [Member]" } } }, "auth_ref": [] }, "lctx_ThousandTwentyAtlanticPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "ThousandTwentyAtlanticPremisesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Thousand Twenty Atlantic Premises [Member]", "label": "Thousand Twenty Atlantic Premises [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r879", "r980"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r805"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r812"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r832"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r834"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesValuedOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r285", "r298", "r417", "r452", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r571", "r722", "r724", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r735", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r894", "r895", "r896", "r897", "r967", "r970", "r971", "r972", "r973", "r974"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r835"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r836"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r836"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r834"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r834"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r837"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r835"] }, "lctx_TwoThousandAndTwelvePlanAndTwoThousandAndEighteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "TwoThousandAndTwelvePlanAndTwoThousandAndEighteenEquityIncentivePlanMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "2012 and 2018 Equity Incentive Plan [Member]", "label": "2012 and 2018 Equity Incentive Plan [Member]", "terseLabel": "2012 and 2018 Equity Incentive Plan" } } }, "auth_ref": [] }, "lctx_TwoThousandAndTwentyOneEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "documentation": "2021 Equity Incentive Plan [Member]", "label": "2021 Equity Incentive Plan [Member] [Default Label]", "verboseLabel": "2021 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "lctx_TwoThousandSeventeenSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "TwoThousandSeventeenSalesAgreementMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "2017 Sales Agreement [Member]", "label": "2017 Sales Agreement [Member]" } } }, "auth_ref": [] }, "lctx_TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1", "http://lineagecell.com/20240930/taxonomy/role/Stock-basedAwardsTables"], "lang": { "en-us": { "role": { "documentation": "Two thousand twelve equity incentive plan and two thousand eighteen inducement option.", "label": "Two Thousand Twelve Equity Incentive Plan And Two Thousand Eighteen Inducement Option [Member]", "terseLabel": "2012 Equity Incentive Plan and 2018 Inducement Option [Member]" } } }, "auth_ref": [] }, "lctx_TwoThousandTwentyOneEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "TwoThousandTwentyOneEquityIncentivePlanMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureStockbasedAwardsScheduleOfSharebasedCompensationActivityDetails1"], "lang": { "en-us": { "role": { "documentation": "2021 Equity Incentive Plan [Member]", "label": "2021 Equity Incentive Plan [Member]", "terseLabel": "2021 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": ["r105", "r106", "r107", "r108", "r109", "r110", "r154", "r155", "r156", "r157", "r167", "r189", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r260", "r261", "r264", "r371", "r372", "r373", "r374", "r375", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r455", "r456", "r470", "r471", "r472", "r490", "r491", "r492", "r493", "r494", "r495", "r538", "r539", "r540", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r398"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "US

Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r692", "r713", "r715", "r722", "r995"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r831"] }, "lctx_UpfrontAndRoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "UpfrontAndRoyaltyPaymentPercentage", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Upfront and Royalty payment", "label": "Upfront And Royalty Payment Percentage", "documentation": "Upfront and royalty payment percentage" } } }, "auth_ref": [] }, "lctx_UpfrontLicenseFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "UpfrontLicenseFeesMember", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "Upfront License Fees [Member]", "label": "Upfront License Fees [Member]", "terseLabel": "Upfront license fees [Member]" } } }, "auth_ref": [] }, "lctx_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "UpfrontPayment", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureOrganizationAndBusinessOverviewAdditionalInformationDetails", "http://lineagecell.com/20240930/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Upfront payment.", "label": "Upfront payment" } } }, "auth_ref": [] }, "lctx_UpfrontPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "UpfrontPaymentPercentage", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Upfront Payment Percentage", "label": "Upfront Payment Percentage", "terseLabel": "Upfront payment percentage" } } }, "auth_ref": [] }, "lctx_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "UpfrontPaymentReceived", "crdr": "credit", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront payment received", "verboseLabel": "Upfront payment received" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r801"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "verboseLabel": "DILUTED", "terseLabel": "Weighted-average common shares used to compute net loss per common share, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r169", "r174"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Basic", "terseLabel": "Weighted-average common shares used to compute net loss per common share, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r168", "r174"] }, "lctx_WeightedAveragePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "WeightedAveragePricePerShare", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average price per share", "label": "Weighted Average Price Per Share", "documentation": "Weighted average price per share." } } }, "auth_ref": [] }, "lctx_WeightedAveragePricePerShareIssuanceOfCommonStock": { "xbrltype": "perShareItemType", "nsuri": "http://lineagecell.com/20240930", "localname": "WeightedAveragePricePerShareIssuanceOfCommonStock", "presentation": ["http://lineagecell.com/20240930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average price per share issuance of common stock.", "label": "Weighted Average Price Per Share Issuance Of Common Stock", "terseLabel": "Weighted average price per share issuance of common stock" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r799"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-11" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4M", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4M" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",

"Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r236": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":

"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r491": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",

"Subparagraph": "ii", "Sentence": "C" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r898": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "932", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 74 0000950170-24-127077-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-127077-xbrl.zip M4$L#!!0 (.J!;ED:L;9WH1X" &>>'P 1 ;&-T>"TR,#(T,#DS,"YH M=&WLO6E7&TFV*/K\] (J\/]O5[WGI&,>
[*]ZB*XF]6>&O YI]\7KQA!74*B M,R7;]*^_>V=*(###8& 2DL-R]"I!RB(@]S[.\G\^'P^ICKIO!>/3KG]D3^N_O/_^>W__CE?Q%2O7BY_:9ZDS]5&W$R^)A?#)HX'#?3 M.E<_[;
[^N=#>#0>C7/W/ISNOJA?C.#W,HTE%JH/)Y.C9TZ>?/GUZDLI@U(R' MTPF\JWD2QX=(*T)F#]^LL\?/JQ=^DJMGG\))&"-.IC'Y3(AGPCQQEKK_C]G ME"[<-CXZK@?
[!Y/JI_ASA7?!NT>C/!SFX^KE8.1'<>"'U>[\K8]AF?%)M3$< M5CMX6U/MY";7'W-ZTCWT8 +G 6JKI+)XN7#LXL8/%J\13.<0);R_/KX>3_ M^,KE^'7PS6C\>@-0+X>Q(MO2Y/Z
MZ>3X*#^%"\FHN_)D5Y$-/SF\]Y7.GW^3X9'_\\2E\ M\1018G[AM"'[WA^=7%Q\$]H7S+XX<_&@&4O.S-= T%TQOR"'=/$RX(LS3X83 M('@"S3<.".[AA HBV F0X^04&'CP?C]'P/26DO
5U EZ"K<)@26<>SJI_:@IX_JP)3Z$]B+4+KP4ED^:;;AT;_CEV9/[/+EX9U][*VZ5$Z;G#VGJ MR9=P@@_/ G127PH?]Q2^??3;?U2_'&?2%&?URV0P&>;?&"5__^5I]SM^>I@G
MON51)/]K.OCXZZ/-\6@"G(OL 1 >5;'[Z]='D_QY\K0E_*?XU*>SQ_X2QNFX M:B;'P_SKHT-?[P]&SRH_G8S_U^#P:%P#IDZ>'_F$[/1998\^/\<^S MBCU_U"XB#3[.GY$&S='0'R,A9?
CVE\'G9_BJ7'>_#E+*H_;74TJK!H!Z+S\H MY:1 ^ 5;,I$V,&*9T(3ZP(OAQ3$F'E4C?XAOR8-GF].ZAJV]!#;NA__(OMX: M)62^LTU_GNSD L?QH5#!K?*)2!N7,V&JH>_48(XX VOSP]
ML[2+5^IYZ%9J4I1$"JF(+56';+\^ M NQ\5@:?SBJNY3RY[_EX^NMD,(_:[20EZWT9>UC*^-G!PJ0=!+@,4H'!RH M=8OP0 3.9-#!T2CG2YWQZ&>;X\/#P02/M=D8):15H"Q06 ;YBV.-
@&8^V4!D M,1I6[O$DDB/),_O-]] :RE&3P;#89 \/4T ZU?O'2M M0DQ)1I*C*T0:G6#I29"E*3&\$S@..'QFB7BE/&$!A\EB]*% M4*Z[],RE5=+?U?GDH%;!/.[Q7WXX
M_8)+W.9IATBYS=;#LQ/@-+6N'^44.D]/5;T1@@=,A")7TEWK<-.]'H.4/! _.Z17\]7L&KISW_.?SFV0N MVVR T^)/(D/1(,E@NX5IK6(R-!P[4U2SWQ(F@";%("G.@#X#2.>)0-4K6B*
M^DXV>9O81[7P7II(HM.P24-ADI$$PK.S/D@/[%QILHR%RI:Y.-M$E("TJ+R11$ JBB(3D09C8" MV3@CW)=D<_6%:^L"S4"3)2/H"YQX @6)!0N*LY;):WO=A7,:@?TQ01S5P/XL
MT+OE!NU7$[S+)02?K[UPQH%5 RB)4@)/'-B*=0I5&*T+ \TC6'_=A:LDBHX" M]6\/0C0RU,4<(\%%PY7@!J3PM1=N0XK%2M#L(W(K"QJ)]S$#%Y1:9<,\13%Y
MO847S215\####*!*X()8RRW0M0(IG%A@XOH++UIPGXHCQ0'V28_@9,"& N"X ME9E9*]I-@4ID(,=B02SQJ*<;H"0P@+1SBB4I@3%)H3M%, 2H"U\S!X,,M
M$)#ED8@,_.06P8O(UT85Z9D301-!"QQ*B*"Y <$3;J6S@KDDD2U?<^%:.\ W M"Q3#M8*' Q4%K0 M*:R<@TX%3/JZ"S=11%FX)EZ"M@,Z+&AKVH ,%8""Q3O. M]?47[J,##<1E
M8!0QP"A! TH-2A=S*@5%S;50!$2Q24(Y$!A$%LM :RBM=6 M-9/(R3 !3P15"J)IV-#&R2!%*),^&%OP&.@V&CI98D*U"KP$H(Q%M 1JDX
MZ'5)F,2OS0XY&&A!P&@=Q\"1.;#*"%$L5G+F3@OGK"R %$B8E0!"!?%Q9 MT Q5441HQ41@H&KX:W,5=.,\)!E+9VP XCHCN*9B:($BCR]3QEGZNN?!DG8_(MN).1:+B"B0D""%!>,
2PS/;Z LA9Q[T&D99S L*7*:&6&HA6(*&-MC[SZY\X M[!Z *2+1R<'"R(*R"4* MRJ+QZ=H+-W F6@0/:BT'/ 2T)$[2"-:F0DIEW.5K&RB@7P')@V5I\&0D$P9T M%2%)U"&#B
8YIZY_XAEH!(2,)5D&T"= W02Q7 (!*!0#)CUCX=I*EBM")>-! M\PSP N ((!0:Q%49CA^JS*[_HD]D)4"&4J)*):9L,1S)@D5/HL4E=/*77?A
MDI>D#*J:"K!$*MB"!7E,..BS8$9P#C+IV@M7('Z8D90X2P$/8P3MD(-9#ZL7;>W^/(JY^>T7#&0\:]JX 3RB:@,;S]"[_NNC9G!X-.0@ M0OO908UO0
<[F3O2GWQNTOSQB\!L_VS&T[K]JPW4/)OMJSTTT'H% QW,*6)< M "TO6T=]OEH.(B#R>M\&. 5:0#?MH&_$^"']',!QYU>#CSEMCR9^ MM#\ L[>#Z._'K_T_Q_7FT#?-
QN=!\^BW$U^+1Q]YTSWUEZ<7ONRW^2I/UO3T MH@,X:MVD)\?1QGHFOP%,Q-R_?/:;^=_S^YZ> **OX\'QI_PQ#!^"YN2B[='1=-*T5[!O .HZ MBVE19
$UD)06'%I;_YK"*9[Z3%8'50ICQ:*"*<&<2KX0#RHTK MJNQ.@"SQGN[P-\>'1^-1ZWT^@R%OQB/< B?@(2 M]\8HO4#B'1^U(/U\[$_+RX<20**>8!2P(R0X4WI"2*??
G9QG6KC4+8!T_LVU M0 JZLTV@ZX8"]@S&B(A+EI$,EF.@V;"L2M] VM239V_C7+=' R.%CC@9AX. M-T'U>9.G]:B)@U:'>#5)MPPX(#!V1<#)90(NF,PM**(2E+I6]?=%<-#_F1-*
M*>_*K0/N>T^*7_VDSHF5&YV4UR8ST! C'% 73PT"X$!%U,;H$G-_<1W0S]Z M PK_I;O?1KO'8RGC1^EO4]Y^'$F]H&_X>L^9KQE [\[N#P+\)QR'FV/TC2V MW._M$?
^ATD75_&"]Q3:5U?QS@;%;D'%O+:-^*Y:VF'D^X39H+'6;W"\I9N^ M04&-/Y $/OKAK=M%Y_#T1KI4,I&Z1(FPF(]AM"?!>T58 794?)32[=8N>E>/ M8:N38V0U$P !'G^K?
U^C(E<"QC; 3&_RK[);0KHV_*^Z4S<+E:[$,_=.!S7 MD\&__>VPIELR60I5K =<%@80SH?0B@$7,'7P@GBC=]A>+N-#2#-/#U,8;9 MWY8V=V,!=AN3O8/]R AS;0)99@6T8(-OWWG,
<\0[4_.EX6+_XV]ASB%W&?IU;!>/V58NK M(LP258LKA0EZAC _DFK1&ZG@N*5"9V ER3 BO0/SVDE,/]*6@KWFP^W;9@[" M*ES=6EP>D7-/LQ.6%,_ ?I
Q$ENR)2)YPRA+BF/V;3]AUZI9F.N*<:6I'^[E M^G#1/^+K81-\ A"W5ZZ*JHPID9XI!:]50G+BB3C@Q22E&$,0.H'VW%>0?-V M;^UT>.#QV]%%9OR#--
"=PLP.$*#648LJ.P8B@3F",B8TR]+R?.M.Y&NP(GYU M5L0)MTLY*>-RRJ(0S30%O/>4!)8285G;;(*1-/4V'H)VX-NR4==^M)I/;?>6 M +;WMC?'PZ$%X[KSP=^1ULBPV.IJ4&1=7=92H
A&A:5*$Q-T(I(#'[,.7H#) MSRD(^$].78-B3\V,=W#]]6T;&F=E&-"R6XH,<]D:E8&6!5-$&K X@U98$]*% MROC :'$X/5T9S\ 7,> U4SVTA$K0&XIA)A(<,EC]C M+HO>!BR_Z?
K_P=2&P!0/0(_*8KQ+@\80,-DG2&&%C\H6X?H&RIZRT3OPUMP2 M.5\E^:YG.+!,!PA?&0=(2MX7HS#9$$LOL-A4ITR8R,;9K'DTO=5<5SRXL4QR
M*S'*DC7A*3+,FP\D8&;I]0SSCTOW/<5BE?,QUJ T-O)0:[QNCH?X-,^YBYE M:%62LSP565CE24X\HM/1$A<45E2HR&RT!A2?OD'K_C-Y;H=R/*;U8_&CI@Q[M+G '8* >C,IH?
2Q11]M;O7-U*&=IT!*! D^C ",+E)-#),&*3(1.Z'YQPI3> MIHQ<*:WQ+QE(S]!F&VD0[#@F@DZ7C[FAYS8Z)7/1BJ-U1,!:\N !+& -12P M&)++#LNK>ZHH;Z9_3IFM>\7)LD,)EP*8'V-
A$4!(!6MPFK&7O7>)+:W#7XS2-D[?U;JX_#N*B.K\S/O9# M-,]?P>? %H%=M]D)M!P SFMY&&44/\3(;=AW<4S/B^Z+A84C#@#RE?G%8D@:X$BJV(Q)N<2(Z)
MJY2D'L3)K'G1^]%@TNSLOG^8U.YC$I%18A+% MKG4I$]>MQG9@*5.M6 Z]M4LVZYP&DY<^#H:PK$5C<5P?820Q=U=L I3G5ZV, MVA-
EXCD9DC58B=A;BCB@*R*B\E06,$1H;_UE/:M\ZP.57:5)24^AV:\2@'Z6 MO"Z3\)/FH#*#A+;8'S" (F93+@0,5!X=E0CAOJ%*O]7H>_(V8,LDC45EF6(U
M'HO$2NV)L?!/JR04C7V#XWJ4"8 M=2X9XY51JULF>(>Y K?#* -5DC%E2"G8&Z5@PF!.@G@AF+81)*I<=0WIZ@1V M]3?W*9G['MARH&"01L:(RM@#3#E%O'*.
#5[GF7$SF8KCC7W$H?I03Y08)9* MSCEQ!36G2+%?) #9:A>2X5HZVEO0?LV3~->:KNA&NI*V=CZ)SW^^G22^.VA! MP?RY(EJTER['014XXY%)31)7'!4Q;,D)#"!)RG44R7/36]OK$@?
5UN'1<'R< M<\N\'W#E_I5Z--\RZ.XMGA(T#UYE2G@1F"5N_& N-@>&%#6*.M2;W-M[KWL MZ#SR7K56XUQ^]XV0U]-DM2U&&89=H]N>C& *8F=PC%QRXWMGR-]_8.-*$NGR
M\$U7(3+"%H;U'?@*[J&L)WC+]0N&>(M\#@BP5R*V19661*ND]3;+P%C?1.#R-A]SU,PF(@3'M)6@&XO MD84&8;E0(CG15[KX&@LJ89S-?P\F!W_UR3<#3"S>WMY8&;Q,"GV:E
@9<,"* MP"[Z21$MI9?2B6Q4;S/D5L:.OI]Z]Y!T%B("LA07@>6 (',.:*D$B58K)+] MK33J,VC(\AE)7F'K)0V01+%/<6N49+X[",H)P7CBC+1O))>CYTQ+&EI&B:.
M6GN5]_VP52T7@[0CJ)DA43XQC-AAF0!%==;9]#PUU^?*L_DA-U@*'WH!X)9)21:RBJ9W, M5Z3)I>3>95%^5YW4&1?!P7B8MH'UCC]VZM"]:#]12!N9=L1SG)!6L)V/\8E8
MSU)AB65O>U=9\YUDM -&VV $MKBO1T!'*],R/.)X&ZZQ8 ,G_Q7ND<-A9F(I M8#191D7O"&BYZ:O+<9?I*[O+3B^]D622)@B303/* 6V]@--N0.MT5$0!,Z/! M]5:/N24?
2'_8G56,&6Z)8@Y@DP0''9-CNBCUWI;,)>MM!ZSOFJBQD*YT/'=? MKQ"4?*89'B=U.URV=6JC59="9J MDQVHU-B50G#,\A21>$4Q&F"\OOWF/O=FC%YI"G&O-
K],R/M$50%CP,8(O%&$ M J0G$PZWH30Q'4/JG5)X6;GU5H,%UZWQ-&K-8C]\!UQT=>]M(PBHH&,A696$ M9"A .6\GO\B@?38.AZSU#!C7%UG;([*]8FZ:B\>5_-?
&YMZG\/M.LE.:QC3H5K;+1>,-)N M) YXD ZT51#*%'KZ(J;>IU@^_H"&6$'5BE+B($ZZ!'Q,GBR"% SD;"P9$Z*U: MV]'24B6>F*2UG$WOE6>IN2=_ Y=(EJ
MKC1C1&>'DS&QV#.U548Y,!H3-_G6DPFN;2'>=0>,*Z_LDBC6:1+_26/;CWGA MJE7AWV"Y>.M<(+%M?YY8!J0).!G>@;'#,N]QYZ*K=VX[^>;EM ;M>UICE=K+ MP6?
\;65$;1+4,.TX<1J;3.4$FG,.^'2O610A>[ZNQ>]O;4K2P(2C8Z1(W'^#L\ND+Q,\EP+'<<=$I%0XSX-YDD+)8)I*171O M66$_PWY+\SPF:V,4B9+BG (I922QE 82;(!<).
[AH[Z"IN=Q\R4&9Y-U/K*B M"<"'8]:@PE&,E'#!L"9:9KL>Q7B%]S_\=L$IN!P"C<18,)0DEO\XQ8#=TBAS M-([1_CH->I/Y>T:E80@<9JZBTIR["8J3>99AL@U80D39;AT)(@LB0)R#S+
(M6&QOV?**Y)(N,?DL*QH4MV Z),R8L1$][T&13!F.EJ:9QEZ.I/A*[Y'W1Z6& M/NLSR:ZT>1E82Y2P %J&K$$Q%:9W&1K?@-R9@4!WURKF
M'A+NLW5*!9<(2#P#=I^BQ(40B1)!6<^+\7E=YG)UCLC,6?EU(X[H:&!M+03' ML05:&G1^@6TAHZ0EZV1,[YIA][F+S^UHASEF;FP&,\(*;,\-5&.+ML0DIG B MB ->V%>HK$!
[[OL)3@!0==%;@LD>P#8LUA$GO"%1!AUR3,S2W@'UWA-WSX\F M.\W%O1%])9:29PK$D.!8NNZ(-1ZT=LVX$(E29WKK1^X9UUNBI$%G([S-AA@C M-8[0\01,*T$T!;T]^00LL+?
NX2MQO8N3E^Z,Y]V'VIZ#RU19DK2). D2=,!L M',E*T\B],VN'\FK(KN*D-,;2+ ,E$KNG.UT"B4844Z1+/2V9';=W_5N====2 M:%%&N$&U N9'8X,?
[%$CR(G,)ND\][JVY1W&D,:8GSL@H5W"]?B'01HQ- SS84 M1DKDF3MGH[G]0>^KP>*E2R[Y G/ OB=Y>W$;D<4!:'%%"CPN7=(W.\FQ?<% M1VM
UX@D1R[LN1/0JUP4BM49UP8BPRG';F$ M=5T!.))S6,7 N;'."Z%C[^CL^W.O5K/0JS#%:;29Y& \-B?"OI(\$I%=#+8(M7D1OS;$5U?
E6LWJV<&]9Z#GR5B(E"$2*T0B8"78:*T.7/>.R5[>+^7WG<$P M+^C=8-D_X&J6^Y#)7"C)LR;%1D&DD($5!W3R1R85$R0HOMKNBT$2"I:2$@$:3-WH/,
[ET@KZ>5:^_@U.L[G$G/EF?A X7J("DE MN>!(+8VE3PD,2EYD4%&GP%/OLBAZ9^'W(!V[R,@=QA:EQHXD5!L2E 5J-M9P MZ8U/L;Q*C6G"?BL-
<;DFD!UW(8M)P\$%:F9FEHK=1D766\%V2N V.47B< MU9CUEB4#1 $;RU 9LU2%BOYU"EB/ +IW]F*3+=PD=%GC@&,?B<.JJZ#A5U&$ M=?T-NC[\^%CQ*O!
<%.$!NP]'CUI74$2%"-2N8V'EUM. 5@2/ ^71:TUTD063 M!RBB<"*.L0ESO^A+ 5092TI)6*B<B@5D=N9$BN]YJN'W@!X?3:H'R)#WHHL1I M;%,2O,
(!V8Y8'Z135&2N>N=8O4OWV'46<]Z8GU_R&G#FN#/]7TY':65R'BA(M4!8R)8PRT(0=SO!4W! =:HELGKWNHZJY+%M/+$;!25"B=I1TQ@PLE!P3E/P+[%<6\^)[?J31SNNNW1 M\D
3K-0V$*T4YI9AZUO7SJ5Q16,4VO97G_UF<I7AQXLZJV[@=R>7;0WV#R8Y MCI9';=HU@+RM_*+;<??3*'G)/)$,W)8 NP78&>D)@\]S<$S3_F9I73W#=S:D M=9;ANSJ,+U'#@C D%*J(I
(83'R('X(@$*F]BV?XX\<6;066)76IH,I%AR /E M$O(\BR,6X 59*I9,9DKU-O'ZI88>]BV5Y'[F'=)"?1+ $S"]B_Z>0FP(8)8H MY1)HMY*O?"7[_?MJED:9C
KK0S"$6P;:#";;66,3*=QS+SC0=N@MM/K57YRC M$+PRM2W+N\H8TU')2#SSD4@,1@/8&-':"Y6YCR[TUC/4,WFY1!N!<<:=>3I+TUWS;KG :3ESX.AF?+4#;']1&&E'-W!9!7FE^U
M.G")Q4002TH)I*-B]II3P.V\UH694D)_\S=^A#3'JR^FLV[\JG4G M6.P;3*7&'\A=/OIA7[$B5"9]H2!_06G"<"A5D;A@*4X8SXP)FP+OK17TNP?; M-_;=@YS/)1FU:/HB'XV; ?
#X6;'WJ_%HOQ7<;9;\LO#CWE6#6\(+Q;23+A,6 MD@1M36,,Z:^/_\>NC6 *9$M*.&*W;4)B!?&J*"*T8B(P+XWO MK0F]]OK?D3&F*#>;-1"B)R &4>GQU*"$2DK$-(5-'8NQ;5L
9;RP6DL,DH$(S&8Z(AA3 EGC%>NMYGU_:W'>#&H35,=TD-;$0)3)V/V.2X_GWCH8OJ6;Y^%P7#%]O*9YGP^]VI&@ RK5>POHE%II(R#H"1T>L#%&,#P$;QD%SA6DG16Q_I
M0_#ZL-5!E!RHR6!>*XG%K?";+SBL4PDF=!9<|Z\2:)7F+BX15)Q*[;P%< M2?,#X4A_P"(9V!B%$ASS@;-7(O$98*,Y""E@0U[66U6I-[-7SM@@C+"K&I#M MIZ6=:ODP I90&9:1BF?
8O.0(#&CMH2YR& M2U_[SX/#Z>'*T% (%+ML$%Z\)Q(KH:QAD8@D@7R\Y#&M6ACI/GH^WD,,B:?@ M'#K.$K4@N6A,Q)98B(U9Q<)<8/S6+805.:D2!8B"0DKBC%__&@EQ'NC8;_
MN>AX?V="K&S)WQ*9E&!&*&\PT1?+:5F2!$< D.QC!!U !]W?+(FON9QV\V0R M[#Z\HRP7T8Z\O"H! HG891"@ '/(VI)(U +SZ0480AE'9%]?K*!12ML[(=/O
MDLTE>I[$TS9))HGW%#0 C>%5)1@ IX#BA?&8U%LW>R\GYBP5-M;17#*0+/8V MQ B9C4$0IY(P(-0"5[TM>.AS,5X/VE8*2;TM.A&5,*&8,4M" %N6R^945HE
MVEOW>R_G#RV3[&0.T61."@LXE80CQ2E*%/><4<^]RKWUWO6A*J\'W@2A6-8X M';A$)H@,VA"OC"=.ED(#Y93V5V58VP9"V5"<&"U%<5%=-HGVMN6KNN4O;NT[$T6$1@U
ML8(#F1M=L/X=S$/-BI+*B!QZ&^;^N\XDE\6G*6IO,YI$/UP'LZ9^42;LV&= M5Y-TR\SF?C]6B,@X$]&0DI,CDGM*!.22)<%F$Q6%-';AE"[T];N9S"#B%PY
MZC0)U(*V9G(@@8'>%H(%,S>68$OOVICT>SKV/<$QN9)2MD04I0BHVH)X!D3I MF:>IRS!E?]L/7VG QL4!\ZV[&]]Q'ZI>;_?W4^AO0!K1^ MJ&&48-
\7*H('74)@T6W0Q']>293&E*0EZ!:]]?'U9F[[_42OI'+>\,Q(B!HC M^@H40B\28=+D%R1A&Y3J;(A(6E'G (ZE#SDP'L;1NX-#[V?M$2IP:XV MT1)&$UAGB0/4'#-
$>4UM2:QDVEOKK&_UKLA.*OWMT^U#BA^HI06[STAE!#ET@$?02K>'1QQ$J32"@Q)RXR MU?UU4BTM!+B:D3<)MC3\OP"%>;0"+ 6H\4"LHD)*JAQO?,-(ZO<&TS0';P]
M2H./@S3UPP6PO)9!*/(1N&C9=8;Q-Z M;JU9Q)5XS6J7!X*N"\8(!1W*I$)D4)D$ECUA+$64)2Z+WE9N?$TX;^]MG^DV M>5=R&H2TO'*K%
[AT2=3+0M:F9&S4$XF4OA"G>03]M5HJ,'%,Z&V&S%VDPUUG M,=_(#>RXR1VEOB^3X#E3C'% $.M 8#LOB0LAD&2-B,J7I$IO&7W/O8/WX&)2 M/)?B
CQ16:SM4H58YCC6X1FC%,N*]DY! \X$@%N/_J/FK);D>U=@*!F;X8E) M"B*9=,318(@3)5NC,BNW#X_O9BW+FH*NA/8!:]7!K#*>@0R:+!>N,<# 1QE+R0BK]+)1J%";Z,,O?'1
MM*DJ5V[SQY=D@2OC&=<" .8=#J50C&#=(1CD2FL79+&W/XKZ^_!VB:W:E(F% M&4E!F\%LJQC!;.4I$."T2GIA9.XH5P\W;9@0R:+!>N,< 1QE+R0BK]+)1J%";Z,,O?'1
MM*DJ5V[SQY=D@2OC&=<" .8=#J50C&#=(1CD2FL79+&W/XKZ^_!VB:W:E(F% M&4E!F\%LJQC!;.4I$. "T2GIA9.XH5P\W;9@0R:+!>N,<# 1QE+R0BK]+)1J%";Z,,O?'1
MQ@9^L$[F7_]66:!,D$QV(B/N!6L#L1@?,S1K+A@H+O[6&S.MB)IJP#NOF]\$>)]*:)UF MQ$ID01%;CX&11!+5*HK$"^UO-EH?RHANQVC0%"@GZ0SZ"LO8!%P0&[TDP8)D
MU\%Z6GK;X^^2_!8P"";U($YR:B'Q'BR+9F?W_8-,3](\!LFS!NW3%^SS#]HG M!?LW^&Q]486E=9/IZX#RJJ.JEPE*[0Q7%DT3K;"C@B9!*[!H)Z1^R*-Z:UG ML%_#;Q^\$UGK&
(SED63J*9'&<1(BQSD!&8A>:1%];[.#O^8NF)=RWI'#@%9Y M#^HN79(>9)0RB7NBI,4RF!R!>0=)8DD!5/*T<7?_*]7LX6.Y^+!!M)#C<$N4$SK3$ MR;@*I_X)%XBW$4LE=5 MD(%+\
[%%+:7/ .^$(<(8%;%%&%*$X#[Y8LSM=]_Y7CF#$]/LGTKA M!!XX!S!3920\%>-T\33DWF)G[UO6W)/3,06C Z48Z,8Z(.9)X/!;2!3D D_* MR-Y-$NFES_A^RK@,YS)3S%@(BF&>$
.5'/Y3A).11J\TZVT4[1SX[KPO_!(5 M<,.U4T(H$I3+!'BD(XYQA<4]D=*4C'5]D HWX#=B21XSP[W6V.?"&HX-"#FJ MH302$Y5T/#/,DN\KPJZ*J7*?GO$EZL)&&!JD+L0*T(
E=88$WY9'!4D+EUZE M_EHL]!T8M^.C?K@-.*BGIPZ/KR?BW)R/OR^O ;G_SIJ"7<16%IH&SG20E1* M(D6I8H_KO7I3MW=+H)%4*N89R@)
UEK!CA_,8A.78H)HF^'V+B/B6T6W+\:C MU[_[P3 ?/\@2=V.$S<%FPB)F06 \P H32-#1L>(C5_WKH8D@>_L)2Y,/!D<+ MH-IJL']]Z^(8M=:F'[Z;Y-

OO+7U/MHB1F:OB24R.$RFC)D'82!0-QNDLJ4B] MS4OM33RM5;7I\MU'8?I6OG'9:_6;YRNFE-P)=$)A_ M+HAA!F=W*DN Q@"VJEW22.JM M/[?/
:3E>35R9E)9H$^/XWZL15=8,41;&D%; C6I](Y(ORN&\I<,BC!8+*.T MD0X'HT$SP:R*C_EA15&FHT$'T?^C3X[NM/&WQ^5N=ARR;0.*Z 9?^Q.QZ>95UXPY-QO?^44RJ> M
F//3_&Z1Y6O8_WUBV=7/"U@MY$R'D]&XTE^5$W&.[DTOSYZ^6;O0] VT)+ M+N4XE2/@T%Z:)0AF<]:.GO=B08W8N.^(5>C4Y VO>*T8$'$1A28EL"ERF0+N@F*^9 M0RA$.B-)
<,H3:"8?0VZ#/7"9=U(8)P1)1F8X40'/Y3S#B=ID?1!6N=B3$W56 M%>U])DIK"H<$6K25R1+FI/5%X(_^?29$C?,Z90O"!%LT2*TC2@6L%849)6TV M7D8X ZZ=O%,!74R
:I9H(D&'0+))@0O*N7 2+@. ,I,E(ZYD !(UV/K!15#C MX R+"2X9A(^)7@FM" JPV?3E1;(6501W!/:-C*,'1 M6&9@J5(K 83&9#I[HC0;EB.31&/\1T8D63@K[/V1 -^MR\;!&11'$XU< U)*
MC\@OB-5 K,X$Z6G01AD/E[FL="}5CX!R1FE!,(G MYN*8!RC >:@RH@]+QF#D% MI3VWT&9<4\,(UP]>IG#>%Q)1C$[+$D&98:(GT"Z RXQ[8+@E0C/9X!
MTX(4[QQP,6\"MSTY@PB*O."2 FVC$]N6!AOP(10*C-8+OS_'%=V4;"4@7M; MBWR4!^P7" \ (]X8[H'))D07"9C(G5&$&@QH,(I-&@!1@],@KP1S.9J>G$'A M1@'P-
6$>0"NU!W**0'6*8Z/ O]3P&,UDA)P7@>:$Q.J8!L MF8/6Z(".0@T"GOR1FP1(62V)X/VZU)AF(V@(S00"$E S)H>4Z9 M Q'B9('-I=:A";P;IT@!DMF"(I2EY%M&#,R&>CK?7@E?
DN[IXH_' R/G^V! M9=]4; *G:F=\Z$?S"\-X,AD?PK5HYQ(_'.R/GF&A;JYO7KN=KN>Q|\+)/@S0Y>%8&$](:UJ,)O.-_ R?3]/DO3_%5 MP_:?OO^>5[_=3!,HR':?'H[35W__[-]M[6BVIW;V-O
M:_=''/83=K/-7[:JS;>O7V_O[FZ_?;/J)\.O M>3+_[8'EC08GX]'CZL63S2<5ITJZ>S^--2NX!2IX^7;G=37?_.)ZON/9CUIQ M/1J/6E?<(+;.'%
@2RJ>,JXI)A>X;I=:%M44<34Y1F^JB:.3M!A*++NE#! M+5@W(#PC3AU.BS04!NH!S]PY&PT%;7;DT2&-;=Q?C&.;<8;AN'X<*.SW|R?(M=.98?KMW'+M+"FHS#L_I%?
AF8"RX5/R6#/WQ>#J!IWW.Z7GW9$;I$_JGY[,; M(K]0CYK\K,E'OO835%O@X?#T>O[HCX-F$;#P>3XV?$]V45P53K9>?MP@0_^_MC)O%5M?\E^,'%
M^/CENC_F>H(CY&=@[4"-8+U-Y!GF,KDZZLR>_^?=O#_.U?OM:O?X$(CISX\; M/VI(YA?KHXY=[ZO*V_A$B8']B/+&L=86IRD8 0#E1\L&QN#*HSFHHM?%I/[M^]370-7#XYU\-
XG8'N,ZT,_^?71 +;8Y CH,1X&/QR.)X"?W\\.+5Z,U(_M_S97 U)(_47A&YS W]IO[.QMI;SZ1{6S]>[MSE[UOW.[On---WO5WML%,D] MT!8K)JJW.Q53/Z6?]TKF^]]1*&Y*T4 MR6-
Q%K/ 7"*-O*$2%IEC/J02A)++8DCOVNUL==='L,^SH&;6D$-XRP'>1I(_M)L?9UR2/[@44N_EHTN4:"(KXEDX^ZZ!\L E+1RB<(BW$TTBQ-:>U17%T#B[K MY%\,&F"I_X 3?0F?-
/=RIIA-]"V9\ ,KP ^5J[W=N?>-KNV8M1US>TK@C:V: MR^7+#0P-(81RQA3")4H740*6%CEBM?!*JDZ>@*S6/J^U1 M?-)7I+X;%OK3UF"Y6B]5'LYZZ;1G2YG@ZFM3'F^.4O[1>&[SB
MJ!Y_Q.=N M D\U/*M"@SY,5CR=?7/:3UHTB"VOORXW%62Q-+W-5CDS>WVZGT_&ORI_?OG MU>0"_>!_J[#-G[9W=]NMPZ/A^!A+L5<4A\^RW.K-^,F%B'O7#M7[-PSNU15P
M32^6S892PSGALF"-8"XD'!JP@Q1(:RZTDGHYPGHCI3HWS>P'&N&L'^XLSHRH M=OWPCVJCG;KS#@Q7?5M)&]-1*C3V(O+. #)21X+',,]OL$F "%^&VD('W M
QEVI_"B"BRROK]!EI 4I81ORYN9Q+I\6@QO6,Y&/5/*1ZJD+$N%\B;\^K;> M&W]:AG&YC##!K*O0Y$%[!HI):&>)?
P05^$Z\$$M!E"LZ+'JPUEO"%"ZH42E:;$O'@%E@#;^.P#MT"45X'(VR M7)'P;@RH,/S_!T>MMZH71^M '-B^RH,(,Q@:,.;2'APY(=5_ISC% MH MX6.P!W+S<_430 [0(>4?
*R;P8.%^&L#[W_]I05-^WE23/,Q'!^/1/+[^N)\ M&$ZQ)+KR=?8=^*N?;HDSRABD9E;0W-EA08=F MG=R !=WLV*7DMR!Q;K:FGV\K4]Q%Y[3%X:T"=)'B'0'EA!(JF0I!VJ+3C=51
M])@W?(R,/\0WM3&NPF5!O+8LUO[P->_)DQ,0LEI[KG*JC:=U,,:@^&5=P M1>M'8_RG\#/*5TQ=VXB3>S^Q'SZF_LU@]U)BZDS?R6LD7X'0_0R0&A%RFUF;K7S/JIYB^4?,WGKRJ?
UH+*Y M:)*&X2<"}BY9B,\=(@A2!:*:84C%$X6X<*IA)L4ZW2)@7F MX*&S)3E$A8U+';\:>W\D[!5* M&*&S)3E$A8U+';V0%X.'lZ:"<^TN&+ !>*UEO/L'WSC]VM M6PY52
=VLGTT[&%6O7FWV(2GH@5=97K*]N_%GXI3$B%F:X;B*!SG^4<%* P"] M,,"CN.N;61&* ;'BQ-]1,\#^BS M:J:@X38'8ZQAF9>(3@[\Y/S:/_FS]VR+!"]N;9WOX^7'E1ZGZB7=
[#$#E\'WX M)^P KV\OA9MP%:/G8&5YTRZB7:1O)I6C5?+'S9,+_>PW ^DU^Y&=Z71U]PAV M6UE.+CN+?8:CU#@3(6*3^Q)(88ISS4Q,X<;- [J0]N:TQAE:7=\ 5' F?G)/
M_6G^\4VlO2?PO2]$E_>)Z&_&]R\TUC+QSF4BR@H0$X>#R00$2QZ"N*C'(]2M MA\=5!CW[N&K'K/G8)EF\\!-?83'X>9%Y^HS%P-+.%*Z45*%4W,G[TZZ!?+5+ M]JJ?$"KF.1?
\R>R"R<&@+>:\PG+,VY:?W7I/Q&)N?EX+O5L6>LF N:,$)E3 MC++K0B0Y5GC@>DQ3"9,J6E.>]@+&(L#,9N!9Z:Z&W%GIKH3>I0,]=2)BID+XX ,V0%X.'lZ:"<^TN&+ !>*UEO/L'WSC]VM M6PY52
=VLGTT[&%6O7FWV(2GH@5=97K*]N_%GXI3$B%F:X;B*!SG^4<%* P"] M,,"CN.N;61&* ;'BQ-]1,\#^BS M:J:@X38'8ZQAF9>(3@[\Y/S:/_FS]VR+!"]N;9WOX^7'E1ZGZB7=
[#$#E\'WX M)^P KV\OA9MP%:/G8&5YTRZB7:1O)I6C5?+'S9,+_>PW ^DU^Y&=Z71U]PAV M6UE.+CN+?8:CU#@3(6*3^Q)(88ISS4Q,X<;- [J0]N:TQAE:7=\ 5' F?G)/
M_6G^\4VlO2?PO2]$E_>)Z&_&]R\TUC+QSF4BR@H0$X>#R00$2QZ"N*C'(]2M MA\=5!CW[N&K'K/G8)EF\\!-?83'X>9%Y^HS%P-+.%*Z45*%4W,G[TZZ!?+5+ M]JJ?$"KF.1?
\R>R"R<&@+>:\PG+,VY:?W7I/Q&)N?EX+O5L6>LF N:,$)E3 MC++K0BQ5GC@>DQ3"9,J6E.>]@+&(L#,9N!9Z:Z&W%GIKH3>I0,]=2)BID+XX ,V0%X.'lZ:"<^TN&+ !>*UEO/L'WSC]VM M6PY52
=VLGTT[&%6O7FWV(2GH@5=97K*]N_%GXI3$B%F:X;B*!SG^4<%* P"] M,,"CN.N;61&* ;'BQ-]1,\#^BS M:J:@X38'8ZQAF9>(3@[\Y/S:/_FS]VR+!"]N;9WOX^7'E1ZGZB7=
[#$#E\'WX M)^P KV\OA9MP%;

[NJVY>_%V_^_[A^_VCY\W":*MR0V^-XFZD>>Z,?NR8^+NRBK>K"X3H%L,X+"#EZHUT*EHO5WC<++?MU.CE]6=ZL?HC_-YQ_>'D^ M*X*GZ?ZGBRHA>
[-9*O^/#^]U^9T6F[R5'@9/M_CQMC1R##EVJQ)$-,HE;\ [M4CAFI(>"(@)1BNA,X)X2>1,HE"=WAF)4; M*884Z^)4(L4:HAC).0EJ>?'!? 3!+047>0(:N,E*!97#"L5R)#$]PR&YNBHF
M*R@SFI7](7-"&):42;8[%),#I2ER##G6Q:E$CC6UJQ0BZ@*F B[M"L2V^H*"> M@/76@<^!]V:/SD+W)K$.0) 8A^?3IK>M$B+L? UYV$L5@[TZTA#!^6(^1+$M8(HE 4V28IPFH]U*
MAY^GS$_5>M=/$A%?NSZ5/<67I4P3:C.0*"0(&1CXQ#4$?S;Y1MAH@[V-+Q9] M@9V)${DIKRS%9":'#"8D&3*UOKQG=_!%!TQ@>5WCB:[>GL]?X"CEFG8T#+QD# MP5S9C4M3-
N(^2Z]\#(FO]%RI_CR-.G@E8$0J2\\HA:\R@H",YYG(\N7E+ Y8[E$ZO!F;GKP7=%51\XB+(8KL8^)#)WQ;1[BB$<1%& MO^A9MW+V_Q5+$O9839=M.V7!]HFQ=E@W7)\K69=EP M?
6ZU;%AD> ,YVR\GLWDUR=7,C3!EN^JB4SL-]A$%5X002SM]E3V%$O<*T*99,!]T""4*QNLH,H7 M2XWC,AJB5U,4U\BP;@5+IL7"$'U>RXBEWDQE3['D5.&2,AE(\8Y 9*?!V<1!
M%E=),Y58LBL%&]:)G&X#2X+*'<<2%N;=0(#O;9HE-PT?%5X8UG!H\G9:?D1 MVHE>ZQ;:B>MVPDA!R@Y9@G&JN*^2&"'N:)A%DE[K%+3G*[OJ]RIZ"B@10<40=
<60O"F@361PY9:A:3\(2RE8HQ MZY5<:!]4=D!VODD.@FK7I[*OH/*,$^L24SMY\:BT!9N4!:)]B$08[L5*9;[U MBBNT#RI*!]KN.JDP+7 #4;\H!;$@&>.+6BF)^DE[9TJ\3>
[Q0V6)_]FXH;+,F2 P$ MQ3X+Z$\C$A&)ZY>;-2X[QAGHQ(M/3H@ RV.$Y!VWS!@35_ONKA/EW!0229MQ M3D0B(A&1V'I4+'X!M)L-P,$FG=+0#=1&0B
M,A&9N#X32?'X@E:@DJ[[#P8)3A0Z4N\%L2H+*4@3H=N-,9%0@4SL5EKHXAT? M&^%=O,FVA7B7W;HF9ZE>[./W55JN=KP$CF8*S=2#DDN-$HF*8J%$S"!\,3Y6
M2@*,"N>BIMK3E>X3ZUXDGQ4C=6&69@W9)3U0%-N+HZN.#$0&KN^J!^DRRP9X M$'IR2,D1JH8TX:072TC5U;;X6!5F(("QF(#$0&KI]IEBA/-I':!0P@>+9@
MXN*+RIG[S$1HI M92PQD;&#;3"Y#"'($$8)]AV!]S9)%YB 16H!F50)GBDNH M: S4)R78_Z/IZ,IM5>3HYO0R\3L88 M<$4;@S;F[C'[Z7*K6K5906L:$F%03)<&H8T'1TT IYRP.15/G-(F
KA'EV!&D.5C%0JNQ(A62=*O '0JH$F+=;O0M B:!&T"-HU0:N\)RX5 M5"9!!(@4-'CN$CAMO:>9>\9=$Z'H#8"6J@%7NQ>10=
(B:9&TW2/!F;^QJ3NEX2XA'LXJ;LE+2JA'DJ[;DF+2[B'D]I# M:1N^ZJCT;N*ITV@6G_;7 ;%? ;3_7V_V#X_W MC__V?-=Z)F/?:Y2M\[+A^D39NBP;KD^4K*\#, _)USVUZ_,I^-:?
<7\ES5)ZZ@QE0"BW('*P8"15=1Z0*6\;@]$K=;/6 MR6>_U+'ED?3%3:S#R?BJIM!AFC?52\KJ'6]L@+3:I;GL*:V4HBQ$E\!*%4!8 MEL %HH$2I7UF5'" DD&S3E+X!FDE.$=;
(;UV>BI[2BO)E R1^?* TA4_R3!P MT9CR5V]LY)H%OM+-8YW,Z@W2B@XX8\@KY-5.3V5/>>6,4Y842LD8. CN'-A@ M'6BK96;>F[#;^7R=_,2-\HJQ%J_>;<4BWVB-Y%V-(2Z*=11-
*I_XCS1W?I2J M],_SX?QS-4OA?#]<#]-L4(W3'"U*KY5M5RW*9F!0Q,@35U(!U;2XR)0)<-0S MX%X;3FSP@IQ8'6BE?L+U3V-TMQ?/QX.?W/#<2NWPWMEGO N(E(0*=AR2[PL
MI#+2%@K61',D@N$]0)(J4:IUB-XV$07=* 5;K2&$0,(@9[AT$B%&',$;!! M4A!).S#"!/!2,Q&IU9ZL8'"=\.HF,4T>I"V@P M3\![7CR[1 CS)'@=5^OWK!&UW20&:9L-
0;>+@Y@!NH'H[:^3:1G2<576]C2- MP^=]/G7CV86:O2^+O/II5);YWS""NVV:A];JD1E7+-:M5148P@4(9HMU$28" ME]'GS)E5*C41<;W0P)<7"GCR1?\N;MV']2IK' MR -
B$;'8\FF\2T&X^B">6 \B%]_06N? >RM=^2]&%YH(P#XA%ID1B$7$8]?G M%+'8+2PR*9E7W(,.AH*(0H#7)D,@DGM+HC'!-!&0?4(LTH&VF+>$^;6;B] >
MS3^DZ<4%_>JGM,P91SN%)>VQI/V#KOLS&A(M3CD481MF+G2M CT%>Q"'BL+G3 M+1I"3H0"#9Q '<@%&XP%9A)G2C$;Z0H.UVHRUP(.5YURI"'2$&F(-%R7ACE*
MHEGDQ='3'(33 4Q*&11W7G@1DZ/-=(+;" TMXA!QB#A$'*Z+0^VLU)D8D%+6 MK=YC05MF%)3M)"0&T%T(^W:-H%#*5H\R.H-#UM/METG=-O]X.S)9.Y&U>2N
M$.T,8[1H=]#N/.C\D*2DB2EN>*Y3;G-R8$D6$)DH5D35B;>BB1AMVR;'<'3! MT05'%"(*.Y.:H4GFRI_$S#L#@@@0*UB<&U#G+9>8\TT;JQS: UOLE8@C98O78
MCC(6<]@0M@C;5N(=R1.F@=0I:X([7_S..OP; J/,2B*";"+\VWKD=T!XB\EI M':4B>IX(0X1A9SW/X+PGBF6@PKNRJ8\!++,4I/4J9)^(B*NUP-<()F_,\Z1M
M=EGI*&,;3A)^8#3YSE7XB(:IV]+:.^FZYOFF-MD4T[-J]R]+B$N[AI.Z6M+B$ M>SBINR4M+N$>3FH/I6W]FN%VYZ8L/NVOY7CXR2A^O5/'T?%Q]N$&\X M=M//!_-T.CN4-
FO4IT(4@0I@K1=D!IK72*1@>>" M@\@D@>/20(Q$RD 8+9!MIOGRUH"4R@'G_>K>C"1%DB))VR6IH)(XZW@1F/FR M3T^%I%Y9J-
,%E:7.VCOZ+*W5%GI[2&H&4]%/BKDM>"3UB".I7HB)HFVC:+@X M4;3.BH:+$T7KK&BX.+=8-*QOLM:^^,UT\G$XJW?$95=X6>%D[CY5/HU3^54,
M+^'M*KQ=]9"KIH9%004!H[BKNPHZ<%KJNF-"\%X$YT.#Z2(G[M/%):A?EOJ* M]:<[KQK(0>1@_SGH(@_2FA]_6P/Y.#VJ09R M$#G8?
PZ:0(.QSH,2UH!PT8$A5$,N(-0Q<,;DZA'CVLD:R,'M4PWD('*P_QP, MAHEHN8)$$@61"@P],QQXW5,PRI!"7&DTO7ZJQ2,X>-\V@8;L7GVZ9L*RF$"Q
MPW%Z/&E!T:HM&BY.%*VSHN'B1-$Z*QHNSBT6#8MP-%.$XW#_I*H+<6"$:(NN M'.#%G&Y=S#%&TA3,XF*.!I$2!9\H 6:5Y$SDG$1N(HOBS712']>^F(,U,O!" M(G(/N?
>TW",AR,RB ^VH!>$)!QI|!F]2SHP;1XUJ(FNB/>YA20OD7O?G%+G7 M+>Z)++D.)A>!>0 AZQ:!)O'BN^7L?4HAVY7:0.MD2;3':Q @>#;@CE%\'4+ M?#))+X04H(6I'3XOP-
E",I6X(Y$I+G(CG;A;!)\::"41?)CO@&%U/!A!T;9. M-%R<*%IG1YCFU4_+.A% JT9E/UFY^7PZ].=S MYT>IFD^]\8TZA=7PHE AAHGPQ@S>F'G"4%,.-E F(EAJ!0CM1=T$W4.(@G#-
MDM$T-9%340CQI=[IWC4XG$P>6\+TVQD7NWZT94(BH]ZZ4:*G@H MSB5(YS((95,A:'9 HT[9)LN<7\F 6R<3Y*F\5+%SP$4G%E)&[4)Q4 M 3*HXG
R38J3*C609&P*1F3F7!.I(T_NI,K=8R86VL#S#3RAPAGLM6BX.%&T MSHJ&BQ-%ZZQHN#BW6#0LM~%LH8UJ[^3D[<$O[IV?GF]7YT<5:\/#O?W?MO' M@%(SFV+VC-6[XC@YKQ-
\GC"D=+] XK^V%ENZ>R"V/K]TF;B^94I8FBEX8C.(M;!DXD@1$(B)/,2=EF\\^::&H!]]8,.K6+*(*(RRH.*O/BXFK!" MSTQ 6J-
(IC*SW'SN2BN%3!0B%Y&+R$7D=AVY241B!)$T3HK&BY.%*VSHN'B MW&+1L-#*VH56%O55SM*T*,#I:=GSSCZX:5HIN//Z.$[N??IW/_WY8AJN?_5N M-@R5&\R[Z7@X?C]
]DZ;'-45^]:%P,Y!5ODWQ>.[F:7:4]T[3M$S\]\EHY*:S MQ4NNPESD>IB+W3?*]953:DM(H#Z#Y50765(ZYP!QB+AFF833&Q#_E=+&&YT M!,@S%> $[X4D+&BHT5-TV5,
(;F[++D"*E(&ATX(FQ8+V)-BBK ULY:5DG MG:BKALD)[[CU$3*E D2Q.N!C,$"EMU*ZF(PT;NJH?(L:T^I I6(I'*WLI+(8"RD(E3CD7:2 &K M;ABJ.Z^OH*':ZHR ;3-
WO33ECTR.V!HY4;;ME W7)\K69=EP?:)L798-U^=6 MRX;EKM8*&?R_Q1"E"Z(XMZG&RF L^I\EF*=^U?^]:QL9JLO67Y?20.\2/ZK MQE]+*\388,]B@T]4@;VG(<&OU&
/UG#"2%U>A=0]U0*8S!FP2#EQ1G!K&JEJ M=4F#O24,#L!/?9H>Y45D:G9T/[_-B^H/Q^]70WM+7JS9K.)NH8-U00LA(%$1 M05">P%M2OA/,.V\L=68E;M>@T!?
ANQ79FQ.;&C,P7&*\#KLEH(M";\!F:#$P"L,1T&;@S4";T7A#TAB$358 C[Z@,!0>&]\EY$B3YEZ0 MQ%9NR:R3T]4IFU%83T,P%AQ;M (,(%POG: L)SE')DRT+0JB7V&*C8#\P+0
M9J[#-0)O1M,TH?K4+@C"(@AD0PDGPNFX2Z(GAG-E4/.\FTJLZ93,DL2'*0GVJ M/ %!=09'=(((@&^F/ '6M<&A#U.J7*A/I-UX\\%^]5X,B\OG$^[^8?Z
M!'<A&Y5G+C\X+6\Y>W9KX.+P8Q5& M;E8LQ5DQ.S">Q'3Y^47B^L<7 O\O#,NG?7H,_$4>I4\0A].T, S/RU""FD<7YQ- M9L/%>1 T_3R,V'U,Q&I_JL2SO^?S*?
GRZ82064U8_8WDC)NK&N[=GX-IJH.Q[M,]+-!:%N6*$R/1=?ZJG\<)4.>K17+QSI?SNM"HQ1Q>6Q)L,FY[F;CNTNMZV[0&QN"BD5KUV_VWYT5 >'+Y]5 M>X>OJN-WOQP?
O#K8>WNP?_P$E%^X_5=@_?,Z6/^L.3Q-'I*XK.0_ZYR7;HSJ MRZ/#5VO>+VKC6ACH]>'[S:.RE_.3XI?_RQ?WAR7!W]6G[TQYNW M^[^7WSOX^_ZBX][66/.&A^JG@\.B!D?
OCLO"/_[;SH["N\.]=Z\.RD)Y^Q8+A MJ->Z++AWTV;7KO32*%_8Q_I9:G-9'K[^=2@NUN2N\$K#3RF'6'X4)>09^?'R M!:&^9'8V2\)GZ'[7I.XYFNTY&'G+JLRVB7=V 4-^Y 7$S5$OJ376U\
(?O.NNX?.H![D8O MMN/=\ER^-G8G'Z8I57^4OW^85?ME(Q"KXW0V3W5 ON)DL-Z"^<9(7H6\NS&6 M3ZQ#S8F'6O2$6G0X'*,2M7G7R: E1TM^_[N,33&HJ8%IGT",,/'4F&EWM%!'
M4$<>K2,<=01U!'4$[0CJ".H(VI&GV!!A\8]'A!?V3VZ?'&,B_X.R<)|\ 6RB MN.S69^)OJ.EYS/4-6 23#!:O5,Y>IYI M>P#4 RKO*A;0=V5! /9O3A& F_< #7&<)PO*J5!
[@!F\=A(TTT9'SPT/C?2X M:0^ 5 XXOZL;9M^U!0G8OSE% FZ<@#Z36#,0A*C+2!FEP%H1@!KAF3*=-I-OR8%N5!IXM" MOY-F;%|<(4]>6! M=3(MKE_RK=_C^GN2;]2YZ,KNX-?)M
SIN KGTVD:A_5?.K&L[JV1]E'NUB7 MU*C+S&!$:HOVV!LKG8B!]/N=14;%>. 6I*ICZUP(L'4W#,JT-(QY8<)*:=YU MDC$6._V7US?Z!^.R[T]U:.I"SU]>J/E)K>7+A]P;QY,O.K]WI?
*':7Z43]RG MIH-: F/Z2-".SRD2]''$,YGY;"@%)7(X6,"$YP#)QQA7'%CC6\B^^*IB?=- MT$G:K_0-+,"-?$.^+0MG$R9U)@&(BX55W"?PTA7(*2*TU+S\KY'DBD[SC6]. M?$.^[?
14]I1OR29+)4V0L^'%?\L.? H*3]"<,,4M8W4R.\VWP:> M:AW\2O?VIH/#3\#-%N^I(#>1FC-OG.SH*]PTBMPI'P169:->K01;%0L!ZU4 M6-VH-QUT?HJ-
NKRK52N2<\/)P#M29NV;K;K03O7O!&=7#S8WD]I+:'"1Q@A9 MQ>*WYQ3 ^>! .T,"I5)1&IH(+M]AKB[-4/G;Z+QNX?EF,EV MG4P.)^/ZTZ>3T:C\RD$]DVDV;[Y8FV!8K
WAV>TY17AV"YXA9<$*)8"1 L(MLP6;RAW9Y3A&>WX.D8T]QG!9SY"$(6 M]].'XD\[*3A+/.D[+I6M$V7N.#RI'% ID)Y(ST[/*=*S6_3TPJ<@38884YT4 M9NO:<,%
:\2:NT]/IOMU2ZT[!>8PV?FND7^=9K/GU+O]Z'X: M+C3C;XNZ=)6[I@C5?%+]NY_^? '*ZU_'-S2D&EZH")I%/';%8]>G+#PMRP[# M2 '*&0>"$@E6104Y^4A#,%J2E:A.PR'Q9DWIMR/?
+=Z![.CA+>Y/$,0(XN;! M*0OL@K'UAD*6_47D"3P)'KR@(CLNI4HK/9L:#H<_Q1Y$M+C_Z"A!,7$0P8G@ M[*P'2UW4D3H%V@D/0A@#UG)"}+FHF$R4.--
R:'V#'FR+P?..XA<=6.0PR7>R]\OK_>KDJ'I[<+B_]]O^U^+FY1W^.#]LCG_?*^]SI/K5_EM, M 6](/]DS5BMHG)S71Q=/;.LVWY/L/@.Q[69O4]L/A47%H+UMIC1\EVAHX-,
MDP_:>4),VSGE+>2';\Y*WEI\N-_ G9SWI&_G>2O4SH1SQ-010V(Z#@XR1(M*PV1C!JQ&JE[LD'^JH$T&SNH1/XB?Y&_R-^UST&M9221Z#L:G.I3..7A)"7 5 MN8W%R;5TM?
ALL^'W5K+4-W;.B0!& ". $]]WD,%O._1U>/$/4ZIA&Y9G+#^H*?;-G'1BZWJ^-C0H8AQ^K M,'*S8O7/W;L$XTE,EZ\ISU7_^.*Q_G=Q&^K3<^ O\BA]@CB3 MV7#QWM-
4=R/YF(HG*F6O[SG\RNGX-,-RW_]QA83]9'^-ZYMT2U5:7W#HRC3 M<_&UGLL/5QD %P_'(^&X_(4=/W?G\\F+FS\H{W\Y\74+|, 7"ZR/7>C MO]SGV8L??KY,)!?O?
#FO"^@OYO#:NEB9W\=.8YE%SG]L:1HO%M^3J=^7B=N\ M@5TG=:*!,;A,H7BY__IU=?+[_MN]-_OO3@Y>'@^J@\.7SZ]]PU?5\;M?C@]>_M'>R]/=@_?
@)'9+%7NVX0__QB_OZO]@^/]U]5Y;OC M-?>P;3S8T>N#5WLGY;F.3\H??^P?GAQ71[]6+W_?._QM_[C,]8TTF7_[%\.H M?E'M_^>[@Y/_?G+G\XG&
[*_'[T[+DIP_+>=*85WAWOO7AV4M;/&$&RW M*[:\F'W3@B^NHR],](6UK)^E-I[EX>M?A^)P37KI\K-7#Q<5P^ M(^K'ZX;]0LZE9?_Y*R^C&WF)><985Y]MC9?
H9UIT]=E0'!2GX^*T@:EO)&"; MA]\C*\9U9,/TY2J/\K?/\RJ M_;*!C-5Q.BNNNT_3BI-!Q4A]5/'MDXFFKPNT.WP-G9!N8 VO>@\/.69N:A0W M=,K<1]&^D.8[H-EN,5&T;10-
%R>*UEG1<'&B:)T5#1Z]..]XIJW> MRNZ%<'YZ/JJ/G];;IRX,""YR)'#?9Q C)[@\[]W@:@NLV,;F=*>$[>,F&A'1V";Z055B M>P&1EY/3T\FX.O[@IFG67GY3%X8-E07M*9Z;X"+?
Z45^L_HVKG-Q$!# 6@E]"6 M?#=8<%HLR'?IFJ.6H);LLI:\2GD8AJ@FJ"::HJ@F]":H)H1IDV4UZNKGZJ?7 MD]GLN_7I45U077997
87Q0912QX7,MQ<(1IOZN/6]$+]9>_UWN'+_0JJ_WL^ M3O./]JS1-9F3=B]U;7)9D<[S.57-9"@XTY M@% R@@32;W!]IT3?Q)Y0>6-9BMSC$'^(/\=<+$-""BN3TN"XE!
8C=Y0*FV0M_F:ZNVH+&ZETDZ#D*GPU44/T?'$A#<^ M9OO4?+UG5WJKVVW+N3W:B1TX=V"2$<$=1##1-AKJ+' J2'%7K0.C$X-D!0M2 MFO!3NHU@PS.EV20P4KBZ0WT&1Y4
D^L?R,@8)]N!8#H03"* $< [,@+4B "=9!!$3TS+?!K#-(8B<%+ 8;'D-\^"E]. (<90Q MQS)SVP%@-A":((1P#LQR0C@A_/1B>25+[ZIT3D59U,(\ 5_0$VR*5)B+*.W M^2@Y<;K\'$@4'
05%BSQ&BS/R6B9:"9/'B/X)A:5&I3G[!47-Y&]\,WK3:NI M"HLGOFBA6K?!71.Q%P.QZ$%7O\WUM[T8PDXD-GS[&DPUG,W.4ZS.SXKJ14]I
M&H:S5$UR^8"B&-7DK%Z!WITL@U:J0^)BG4|K M@Y.FPTEN12$/AL->ML%<5%O M46]1:W$J46]OLE%O>S256Z^W=^_P8_)9Q*S!&15 B$#!R()Y-S'92)EWT?*5 MH[&HO:4A@O-
6@3#$@['E-9HDQ3A-1KN(._R.+/?6+^OB"=CR!*Q>Q.!=6;I% M74[/TGCFZN6&UJ37ZK6KU@2]0-3;]HB+>OO(8D#SG?=442X[?I4;CWV.N*BWJ+>HMSB5J+S25J+<[--
FHM[V92M3; M'9ILU-O>3.76Z^W=45:3F?91:? R&1#,$7#*+.I*4>&BE-ZZVU%6SHTE*2<@ M-&H0)@DPP7.P,G(=N/=,KM3J.YI_2-,ZECI-'])X-OR8E@WAOD2>?I^,ZLI4
MO[GAN.X0=S0^OHHX[4V'L *CZYGZAVE^E$_= P26I025+A&;)R+!2\6B=&T4(N&YK!5X\VLQ1T]^3:1G5<566 M]C2-P^=]/G7CV6AQ?EJ']^-6M$&]UK9=M4&X.4:]
[8ZXJ+>HMZBW.)6HMSC9 MJ+<]FDK4VQV:;-3;WDSEUNOMNAVA:SS3((]8D%83@%$8T"(^MVJD(EY7,6 MV<'C$]GX-I03O5^SVYG+! M[E%
(4"1HXW7THJ+!^;K/!RLTY,H4@FH,A"E"E611\4==GD*";BE!\4;59H[! MRE*N1D4)T(JMJU>^K*\TO7K49V455+/):!BKRPGILYW[OO1;;PF;C@%\8\B6 M#".\UTL&^8!\0#X@'Y
/R(==X,-F=M)&1DZ<9:"#-B!43&"4C0L:#(F%AX:5[VR*P!T5V4D9M,LKM9F#B"O%#4D1 M!X)]"=;I!#Q(1T3F*A+2! ^_C<$6VP)WE('H6B+Z$'VX]7SR)8-\0#[TB0^;
MV7IZ;VRTB17?REL04K*RC0R^.%!*TA"HI7DE#6:=0]O6MYZ$[IS;M='CV0?> M4NPVM.^A0HM/^VLY)'XRBE\=WU_V7N\=OMROH#I.9_-TZM.TXF10,<($FK9F M5(X]8[7.Q-RSR2
MYEXH(Q-AP*B((&RFX -EP%,.6NCLXF]@1G-/DBTN,[/!%IIG#HZ2##)&'H.0 MP5/ZU#2_9W8](0-J6\RP[RS6U]1S3#I X"/PMQGX(;L<0DIUU=3BO@>;P!K' M(#+FG?
D&KW2H#HJ2D*P%+)0'NH6U^#"HBYAI"KRQ!1-VP%\.N"(>\0]XAYQ MOQNXI\DX+VD&MT!W@3MX&Q)PQHRCTNE0YZ_=RGDC7CN2*"A"1<$]LV "<4!, M,"[DH()9R0'N)N[9P-
@6&Q$B[A'WB'O$_2VKPRAJ5'"_-*@- ^@*$%R9H* M9TQPEND5&@=7'/-H"KRS5B"L(V!XM! M-=1%]3A?28OI5.Q_SJ,W.?)^;R_:<47RP_BA+RC/QX^8+"JI$[FZ7GLW3F
MIFZ>+@=A0;;E>_]P.QWKXW V]_-1P<'SRI??E6>U^#@NGQ%5?]RG>DSJ9[N0 MLPSSIQ<__/R5E|&-O,0\8ZRKS[;&2_0S+;KZ;"@.BM-Q<&K U#>R6K9RW06=N0__B!B1^NX-
UHOKYIR.^YV[XVZ4F??)BF5/U1_OYA5NV/ M8XJK6;'\>\YDTTG8[0Y?0QO9#:SA5>_A(=& ID9Q0\& /HKVA33? NL:+@X4;3.BG;OQ7G',VWU5G8OA//3\Y&;I[C>O'=A M0'"1(X'[/H,8.
<'E<6\%5UM@Q38VISLE;$\6)#:X8;B <0'C L8%C NX#QOA M1>\E7-ZXO+LSIXVF+$SF;K3SRQLWT8B(QC;1#ZK,V0N(0)R MAB&]":H)]@FJ":H)]LECU.1@"':GJ?]Y^]ENQ??
=,H*H+J@NNZPNRY)\]"6/ M"QEB5\EUNTK^W_-QNG?IG&X/T%/6?'T"<3?6C6F3T+K&2$-,=2LR0@(([A(8 M815$P;7*6A.B^,V*K(1&SX4VD'.L&Q5+ L8$#KXNJ[TX,FZ33:"U&
(@N&VO MP&]?USDB:P=*4,*S)1EV?/@P>]"(T$I Y-- $=8"@51PC+5",RZ5%Y:"#-@ M O&'^.OD5"+^6L#?$S53*2R-VH<(61I7^)HE6&,T.">S,50DF\5*[RSM'1,\ M?DUYH1 R@(_40?
0Y6&6F$E&I+FJEPS096TUZ!%ANE(((1P5N$8$6-X9D%*(ZN M :']7BJ<*U#%?0V.I.3-2K]:Y0NS9<@U@BF(*$SQ;I,#IUSV,:K G[[[^'W; M%PK2+T\7 8P
1@!O$8!)TC)I8\[Q$!H1<%)+T%8$PCU)%.9;P/81Y4X#P)(MM@%$W?O*4DE!"LFS-X12^N0QAOLV%%04/6 $\&Y,,@)X'0I37OCH MO +#? !%K
A:[>NU7VGQ9W50.EG05I"ZX;H&3W@H8"5&F:R=2MUN\:?I@$G3 M*RYN(E7AF]>;5E,5%D\\',?R((L6=6LBI]F(@%CWHZK>Y_K870]B)Q(9O7X.I MAK/9>8K5_$,9TO1
M<9JY\2N)"YY(0:G4D+.L^\F*!#9%#HYSJDSPT@MRIYTY6.C:[_-I;5W2=#B) M2R4LXI'XT:RY; ;)=IV.(+)V?2I[BBRQJ5&*$="D3D_P1H'U-A=X:69$I"%H
MVR*R_NY&Y^CNSW\%4M=K;N\QI'7/5F*K<>5XOZ' PG&_6V"^*BWJ+>HM[B M5*+>XF2CWO9H*K=>;[]RXA48S2$F<)Z5+3HE!IQP&2PCDIE('"?A]K;>9")I
M%A94YN4UP5NPP7-(S)8?<,NST[BMWZ[3K =>O,73K,4, #H.UW]U]3X@8MH&>NE(CL+\T_,K>_MV:6Y_ M30]Q&N^9)=]O(^R;$XT9HT8 8O>6FXB1&(D"!(BF!PR MF)!DR-
1ZRC3&")XL1H#WIC9STG3SWM3Y6=&I]"E-PW"6]DDN'S)_Z@F9_52 MQ/.G;=(]M%&/M"F)B6(]+!!&-0AM+1@; W#M',TF2$G88^+.][I*M?CAT5+[
M]B_4,C98));TRMR@AXWT0GHMBQ+F8(/3#G*]JUOIJ,'%XA8'R9@L'K%(4;=(MKT7ZU??AM7XJ5K_\9 07@FOGP(4A/=3;[HB+>HMZBWJ+4XEZBV.->MNCJ=QZ
MO;U[@\^XDDEX#H9'#D)Z!MYP!T'XP#*GCD3YF",OW.#C3:N=./^JUS!X5U9N MT9;3LS2>N7JYH3'IM7KMJC%!)Q#UMCOBHMX^S@FD011/SB;0V='B!%):'+I$ M@9/,
(V&:1;92=O_!=Z/VXO^:=D2)FMI'H^^/(3!@$ZK1%X6VHSIT7OQF601N4)8_7>#<=54<+RX?](BW9J M9='Z>35+X7Q:%CF6Z^NYSNVJ%4+O$?
6V.^*BWJ+>HM[B5*+>XF2CWO9H*E%O M=VBR46][,Y5;K[=W1UD-5\[]Y$]JET!0R<#IK,%&E[R7,5NRDF^?LS19\0B> MA0A"B_*=# RX$83::!31YG:^_='\0YK6L=1I^I#&L^'':=# ,D!/T)?+T^V04 MA^/WO[GA^/5D-CL:'U]%G/:FPUGYT?5$_<,T/\HGIE-#P=9=#[0BWW9!GO* M-TN\\81YB+X 2]#(P<1@0&9./*$%N2*Z:N$^$?.NT4N"UH\T<)/TZF991'5=E
M94_3.'RNYE,WGHT6IZ>5NSIL11/4:VW;51.$6V/4V^Z(BWJ+>HMZBU.)>HN3 MC7K;HZE$O=VAR4:][WAUB)<0R&P0"KD#X9P")T0"XGFD3&?%Z6I%
M^0:/D.IHZD75%V.FDCCHM'W)O'$^^Q*"^/Y/LW'&"5=-\HW MQIWFH:XY'R@'(:@&[S2%H+@A223F^:.Z,"'?MD(I\"[29HZ0RL*M1F7)HXU9
M5YU\65][>O6HS\HJ|&:3T3!6EQ.R%0JWYF1_7_IMMU--[Y^_,61+AA'>ZR6# M?$ ^(!^0#\@'Y,,N\&$SW8L5LP%JHX$(ED!DFL#+LGDVVAO!5")E7[T2%V19 M>4$(I$S*:Q0E8&-
@P++P,JCH6FVQ7I VVPEV5&L/J*[M,?(5^8I\W1!?HW1!6I=!DD659!G!B6R!$*.E#L8%M9+:+AF5E+(,UMCR&NL$ M6.\]1*-YD"Y'F5=Z8;;'5]%B3!'ABG!%N/80KKBYQZC0XM/^
M6@Z)GXSB\?WE[W7>XLERM|-.M"R;.C_EL[L;U_?8;9FJV^.Z7[9"U M&%BC-V6B;JT7|/T1D$]B6>^'M^/^*Z&P%G2QKE8-@H -G("C7X"1-H"PE7AL> M@X^-H+,N-
/^A/%^:SO;_>3Z>D]OTYQH281,Y3=#R"!2"N75U@&32@GA7(KV[H;R&Z3Y M_8(\W) !,70'L;ZFGN()&P(?@;_-P,_** Y!1&Y :&-*4YYH;Z/3#,=DE;2
MW@:^,I+2G"5P$8O+7QQ_,+S.5XLJ<^>H3S1M!_#I0,A=#)D@[A'WB/L=Q+UV MGJ>D+!C/BE=/E "CJ07+J5"<4.:(6ZT^D$/RY36$VP2">0E.>@8AAEB^2%>]>
(.X1]XA$Q('T8N=4BX)@%R%Q'@I9#0,C+0?+% N99*%BN$UC M!VT(3"6P)A4:RW;#C^)^4) ,%(89Y+P="4GN5.O_/WKLWMY$C^X)?I:+W*]X[M@E 7'H4"[',V0BW+W;IK2SZ6/'/O7R?
PM&J&8G%8I&W-I]$JDA1HBSK04I\ M8"+&+8F/ I"9OWPG..]Q_FQ(FN$PH\?H@# ,#82)/]YCU01^?>2ZK\3MITAZ M]7S^L^?==^,OM; [2OK5:AZSW5/G,F5,?
0%/O@2YR@;U&#XXKK/QN0M2;MV@ M<3;\%$N_U!A^]<)ZJXO.5P,U,)7]PYKAA7@'\]Z-H[/5U\ST50-2.%1?'!K4 MUDV?#SL.+W<;_G<<#-[9]AGUU^3]\^F:H M;
("*N>]TJMUE5_5_B&,4JG\Y?2!\;/(#>R;8=W$ZYY?CUP8N_+5@8A^#V<) MW_EZ)JW?KXGD_]@.PD(YW!VS./"&,H2X)O- GN[?0,OS6=%ZWZW]1E\^:7WV=,TGWSE*X1Z2(-Y_AB
M@;Y/)2-0D=)?5T3&COD>"%R/IMPMD#TEW"]URM.8==6<(9O#\Z/MS_\S [M.'S_/CO[Z_#3_L?#SV='!Z>][.CX8" ;/WZ;G7[^X_3H[='^IZ/#TX?C_':<
MT\')\=O#X]/#MQG\='KR_NCM_AG\'QVFIV\RP[^VC_^_ 43BX[M_6O_T^%?)^_?'GXZC=T;Y9OL\+_YW]G^P5?,/9T?'GP[>_[>HOH(3.OOK MY/,IL-?
I[I["Y^/]SV^/SA[%",]M'BX/9<,&HR5\0S?&Z5U1^75Z**PEJ"58 M?'@[E.FGH!)4GUW]DW[*)SG>_FOTP\'?MJV+C7C1NJ$1A8TU.(GF'[W;_< M+&?_6C65KOK@3KV>?
OZV.O7X,%KLY?S7>979[/;F;__X&/X63XB]@A9U[4] MXB/E7LG6=6UI.VD[:[Z=5<#4'=U XN'3(&.(O1E]E:X3N##OFO7PCJ90;> M2^UW%&MG9?QP8*0XB]D'^/6\R0[!,
[.+347L9[&X9?>PK?;TEI0'> 867C0> M'I),6=8I/E,N91NW=@4T/\&9S=YFVMHF;BTQ9[K:VFXM,6?:VMIN+3%GVMK: M;NW>S'G+FC;:D]TW9G(QZ8/HO@3KV?DI@\(?"V4S!%3A)

[W%O ^09HL6>C MZ4YM=DL8>!/,L,3 B8$3 R<&3@R\#8YPO HSL7=B[_6AZ3+9^ZP>]_[.LW=R MHA-$+,V)?M!@\ZT D8/ZX](>9.T UM75-ZW#L25A2?HTY4T2D^\TDU]O84]\
MGOA\?6BZ9+L&/G3N!DWUU24V3VR^/C1=)IM'N[V;8-(UQ>X\LZ>(0 *,I0'& M[D4$4B@@24F2DI\&"RY @XR3E"0I25+R8REYZWQEJB0F24R2F"0Q26*2Q.0I
M8G(T,/6%RW|/7H6;C'\ZA3F)2Q*771:7=J)QDI*GA0S3I=R/O93[K3/=^!R< M[N1^VNSN%]CNLUUHN2M#[:5@7!@F4*%5B1B3%BFO&")%43AL9$&5OSG4WLE<
M8VH8RDGN$>.L1-)DA!0^+/>.VI*4VW27]C;S>8*L';C@5UB? S.'2,K"!$/R# M 9@P !.E,2JM+7->4.Y*LA0P6Z<;.EB!>Y31'\)_M:1E G^5@=I-M-EH7R*K"
(4:%0${8BG11:B]SI[04-_'54"8,YA(I'N S7C*D2V614-AZ;+%3 MPKXTOM[WOFG6$P7?*]!-=\TE"$X0O$D03$@A9"Z1+[P$""8,P==S9 O/3$&9 MQL7")72EIIHZ99"7VB*&L4-"&H(L-
X876CAB-P2"P=*5"8 3 .\&D1, KR$ M<^%Y09U&UAB!6)D'&YAP1!5C)94%YHLQAMSGR@:HID+R<">S1T+K'.&BD)8S MRTCXS"8 .,WE7"0 3@"\$T1. /QP?-2,
!0ZL"Z)*Q#+C4+*2HRP=84!#"24 ME0NW)!?HUSA MSA:GQ7*%N.+N?M)PQ>PC(;8[B'@-72B:^;_MCG MBAON;H7J)J:9.)N-S^%(
MOYQG(_>E:@)3VZR!'WAZ"?'/^ZF3JEJC[:8*A_O2^G;]@YW S J&G&(6,68- M N"1R"JB");><&=OZA\X644%A\^4CB%6E O)2R4J,2ZH+$M52'VK_CF*,OAV M,@I:QXVJVK;"">
<17VJ66.5 >XR3'5O:TP(Z3PB)O,$5,\Q*ID ^3S/M&$,90MUOU([QAA%6CB! M&!$%TH7RR&F."?$V9\7MK6W/F-;:LGZ*9/@FQ$J(U2;BC5,YM085W'HP8AU' M"L.O.7;484:<<
N%LDM$K)48ON6N&[T)K7:=E!N/5BF\EN1V?;;;Y#;);9+; M1,HDMXG826ZWB)0;+[>W>_7,TK(HF4"$\APQKPA2I2X0]GGIM724B87V+NI(
MSHD&AU[EP:NG%"DG!9+.%KD)+C|)7OUFI;)2Y]9C1.K=M",K&[EXHVOFW<\O M-4KZ8XVVF_1'EA&&OC$(&?$*-6(&$Y09(7E##, M-
24+,$XID4>2H")V=N2*[<&YJ1_;-^/OKF;|U*K;=^XA M-N,!1U+A>K[OTI[-/XD@=\N@5\R6I+8($4F'%.0?*I]%F9?CBH34E!- MR+1&?F]ZV7_JT>\=W,W_.W#C*FVTP,^/*
["G,%QG0W59>8NAOWZ$J0F*O/R M3396WU-6:Z/D.2F^IRDJ0DQ>2,$08SSH 20@J>$^F*Q0D(CP#'??N/23.^@*4TG2E_5I^I[W^OQN=A M3CB@)0!AA,H_5./L07TQ=(-
&A94NJ9!LRT: IU1@ L?=!<<4FDQRNS[;37*; MY#;);2)EDMM$["2W6T3*C9?;YPDBD#P7'!<684<)8>YC<*(X-1ZZ@/+>%H;E[M4BHP!1'6+XB0VM)>+%7HOKN1J1H7LWXQ05@/
RNFM-XFR5Y28D^,7&-EN*0" MN3+>]AQPJPN58E*Q*UX[9$RA0EV+]<"R,H|IRN$+[BK(?H]<3+&4B$W0EZ-II M4FX\=*6P7Y+;]=ENDMLDMTEN$RF3W"9B)G=(E)NO-S^X)
(%65I&C44Z+\,= MX$0BB;U$KF2E%9Z5V/IEI,62B[\YLQE3O]RCDF"!BY$,25V0EZNL;E(G6RU> MNZI.DAF8Y'9]MIOD]HG5491B[;1&3($AQICA2!7*
(4P\YR]PN7+C]X&F)*0BPUA*16J:>)UOT>0"'U(<5 MVNR+]@89""$_)NK'3?. =/[<=8X,0D!DZ=1B%LN<[NJA9+UF.1V?:;;Y#;) M;9+;1,HDMXG826ZWB)1);G>
(V$ENMX:4&R^WMT=92TEEP;1'RBB,& ME4[9T MB&DC"",Y<7YA)MC)%CPC%'AG$:LD 52A92H5(4B+MQKHQ>:ZD_&YVX48]DC M=^X&3?75'0U,?>&N(D]_M?.H_E35X'W=-
">#TUG$:7]4-?#2?*E^O G@3'U? M4K U3?]/^+;;I-Q2?,NY1]*X>P:D.,N#LD1N8RVP\4H.F'[.GF9HE6Y,*VFIIVU45E%SC)+?K ML]TDMTEND]PF4B:Y3<1.+G]0:&^-)0(X1 N"H$8
MMCF2+)?($UUJ6TI!\WR5*:003>WB3@==V.DL1)W:1>X/[-E5#.JJWG_) 59< M;M<!)PG?$KXE?(OXIIVSNC04<44 WX0W2&,M4*FIDE8)2FEQRA12PK>U$(K4
MB_0*21@W*P/+)]TS&/%20-_N=%LJ7O !5E3]RN;30FR$0+W2&+_?/<;KZ>6 M[3_?<60MAN5TJUDFX4/"AX0/"1\2/B1\V 5\>)X[CH4N:8X51591BIC5$GQ@ M;9$LP/ -%QZ[P7 BF ,
<2< M,DA(J1&VRC,M2D+RA8E&1&I3B-(C7I0$/L,PDD;DR!//"N"U(KDNQ#$"\$P?9 MSD%@,BT3\B7D2Z[GB[-,PH>$#]N$#_C>A+%]<*.(ZT50\Q0%L9&XK?>]'T/&8I/^]8>B:[[]H?
G^\?^ M^_WC@\,,9=.N.'87VHTRFO;*H2+WEF]*:9DO!SK#'JAS M6)\:-8?_FE3CRZ.!Z4\"B'ZL1[*857H2AV2?U6R1[A8)O -H%M 5L5@.UC S-/1'/'6,$8I(+)$@!OU*])>,&C'IS$_
MQ[DQ M$B//N$:,2H:4802YPF)NJ2,<+W2+KB?@XQY-<)_@/L%]@OO=@'MA>6'#P%5M M,-CWWA DK?)(B!);8Z6U;B%:HW)=]MQAQ'/, .Z)1,+D"N7"'&6\X48L% &O
M)IR3GI!Y@OL$!PGN$]RO0>S<4>.I*0G27G- 5D&1YKD!P+),*BH]74P[&D6T ML@+L;E_"9Z3*D:!6(BNQP,H6G%+[TFA\)PASUBOELY4PKQ$*/WI& ?PW$";^ M>
(]5$_CUD>N^$K>?(NG5\UDH5[K[B??=^IKND"]WA^T]KE.VF!L0H2;C>LK M83$@?6'UX>VHKR[KR1B^_KNS;]I'X3S?RW^=?@#PJJ^&C7O=N*$;J;&;'D-$ MM_:[?
[E9DO6U:BI=]0$27D_?UNM57P<+?9R'A[W/9Q*6%NW3SCH[V^-?T' M'\//\A&Q1\BZKNT1'RGW2K:N:TO;2=M9\^VL J;NJ&@5+8Q\X=*O&6;0@9FN%
M[PPZY+]^(>R7&7@OM6A?+,GVN5W#+M.:/]X&+OL OYXWV>$ K.7%PECZ,WMR MV778JSV|)?FRS\#"B\;#0P("RSK%9XH';./6KH#F)SBSV=M,6]O$K27F3%M;
MVZTEYDQ;6]NM)>9,6UO;K=V;.6]9TT9[LOO&3"XF?35V]G%T7X<#24R>$'C; M*9@B)XD][BW@? .TV+/1=*!D:R;^W824^3WR^/C1=LEUS=;3;NR[<>"]' MF>*Y*2*0 &-I@+%
[$8$4"DA2DJ3DI\&""] @XR0E24J2E/Q82MXZ7YDJB4D2 MDR0F24R2F"0Q>8J8' U,?>&RW|-7X3J^GTX23.*2Q&67Q:6=RI>DY&DAPW2Q MY&,OEGSK3#<^!?Q.22-?
KUCPW?.GWR!!3[;I4R[,IA5>>/+0DADKFK&XSGR?(VH%)U+L"9K3 4BN;(RJ41(PQBQ0U"NG2"D*(*!A;N.+E46"V M3E.F&ZDX5K$O'9(&L518QFFLD:&Z0QH4P/G=2
M,GP37TG!E&,%0[X$8&:%ET@J0I$K+7&N=,*:\]7Q]7YWJE!.>[3<+J!-]Z4D M"$X0O$$0K W.2UIRA+$&",,.((E+C63I+3:.4\K\PD4J.:*:9\6)3;.!>4>($P F M=X+("8 ?
<I'RK(*ZX&%A;R.MQ2 M]TB([0XB7D,7OF;^:[LC7(OBAKM;8;*[:2;.9N-S.-(OY]G^V8>DDK9:OK9= M\3PPV%TI3:']J,3&(R9#(*24.:+,Y=I2P2Q?L,.]T!+GN42">[##'0/=%#Y=
MYLPX5OB(E!LOMS]HRITH7.C M$=5<(B8+<.P)%4B9/%?&.^,6'7M)1$ZY,TC;$B.F)$-:,H=$F8O<,Z:T!\FQ MW[2??S<6])A:S1=I,*2:9?,OT2*;=7 M;A|:I"#!RP4)4O_4
M\^2:KO=/388@5%]=,P()II[GH2MP5)F0@FI"LC7R>]/+_E./?N_@;O[?@1N' M3[4M'_#A<34*35EU-E27F;L8]NM+D)KN$K1LK+ZGK-9&R7-2?$_M>,@E-J1
M0A4.,8D=DF7!DWZ;#?);9+;)+>)EEN[&3W&X1*3=>;I\GB%!2 M3+E0!&FL,&*>Y$@Z8^$?Z@WGW!=\(8CPD%1@"B*L7Q AM:6]6*K0?7!E9,;;U-DKVDQ)ZF=*PKBM*
(!EFAUZZ3.1*0;\DM^NSW22W26Z3 MW"92)KE-Q$YRMTBW 8Y_4%\DBIBT3 MIR0(*J4@.5*>$\1DR9 6E"&L&""8E)(1]^11BG-U46?U07UQ40^BTKR]%.J3
M^]>D:F!GIV[TM3*NM1<_.5-_;L0WA!-QV453/4*D>^XH9C ;==)N?'@EHR2 M)+?KL]TDMTEND]PF4B:Y3<1. 5.3)HQ)3$&"M)2+U2SU/MNCS ZI#RNTV1=5#3(00GCX/]U8Z;X#
MIM7CK%F,@(E3W,0MUSF=E4+)>LQR>WZ;#?);9+;)+>)EEN[&3W&X1*9/< M[A"QD[QN#2DW7FY_$&55BLF"Y4%]@U(=RNDW)+8$YH
M9:3P%#E/"6)$ETAAQI&AV#DI/<:^6$9+44*X-1>+U'KT/,FD=_4(3G60 6^/ MW,!<9N.1&C3]F$'-U"SAFI305DO;KBJAY!XGN5V?[2:Y37*;Y#:1,LEM(G:2
MVRTB99+;'2)VDMNM(>7&R^WM05:M2T:%5X@:Z1$K0L#4N1(99;C QA"AV2K3 M2"&>VL6=#KJPTUF(.K6+W!_8LZL8U%7-_()#K#VZ95>=)(1+")<0+B(<@)(P MUA"$!1>(,6X
X:1 1DAEF%%*+R+<,M-(">'61"Q23]+SI)& =;,^,'W2,H\5 M)PW\Y4:SI>X!%V1-W:]L-B7(1@C<(XG]\]UOO*9:M@]]QY&UJ?"<;C7+)'Q(M^)#P(>%#PH>$#[N #\]ST;'6WCO"@M-
,,&+<:B04\T@0HYPO/<[QPDQW1K&W M!KQM30EXSJ4HD<0-<75)UQTG V 6P"V&<"6,IH*0O/5TA!D91DI2B20MJ<=4EX5;&)?, M"FF-MAYX30O$E,)(LSQ'GA3&*=(@9\18
N6P#6!:P+7!*[)NTW>;<*'A \; M8WP5/%=<2XRH,QX\U9R@V&V8A^YIRCBW?"DWEJW6N^4KO)=L37'U"0;8RCL) MUQNU[R%#\6G?VB/1==_^\'S_V'^_?WQPF*LU W'ID*
[44;S7D9R0I-N6X](MD3T29,[6DS#-<_>TV^W[WQC]=F]9^H&"@B_F,B]!NWB,&#CX2++2(V]R4FK/ M16GE306%,>:F8 8IK$!!\=PB10E&G"M:,**,U,7"E9IA9')S,ADW8S4(?>[7
M]%037WULV5')>E*LL/#H3GY)QG\"R!?1K/<6 /](T+D2Z"2*2D^-0-)QAAC+ M%=*2@)5O&;=Y >"H^5*@,XR]UE]7 _"0T=UOP]O.0H4<,UX236>K,A[1) $M@EL$]@FL%T!V#XV,/-$
M-.0O#2:WR_*0T7>R\6S%3&L$:P_4LY3ZBT!?@+\309\YD7NE:((\ C MEAN.E&,**>)SZ[DQC"]$/K@H,/:^0)19@EAI*![4.Z0M]U0IK-UB7<1Z C[N ML6(70R8)[A/<)[C?
0;CW."^D]@9A)AUB!=5(&N4052[/2P8 +OQ")M9[XS27 M**?A,^)H)";1<8:"S\X(IW?#+@G8-T_6Q5=@OL$]PGN$]S?%6WASGL&EC.S MS .R,H-D@172SFI=*@^0O'!]J];2&,
(=DL(%!#?P$V=AQD+!A!*.;8Q?&HWO M!&'.>YRO<,[VV]+PX*/]U@U@5\?N>XK.I/(E2%8V],?PP7&=C<]=D'/K!HVSX:=8_*7&
M\$L5UEM=9+X:J(&I5!_6#"_$^YCW;AR=K;YFI]\:D,.A^N+0H+9N^GS8<7BY MV_"_XYB+[Z\1?>/[[CNRUO3W;_W1T>/IPG'_R.45#RZCF_'|\
MO_[6K,>Y'9P<+\0[7\)WAX>GQZ^S6!1IR?OC][NG\$OIV?PGP^'QV>GVX<9KI[-EFD:1S?@AED0AY=%O=^IX+"4H)%AY>'M"*RX>@+66/7=V3?M MHW">[^6_3C\ A.NK8>-:>-
VZH1F!;3H\@NL7M=_]RLY;_:I54NNJ#+_EZ^OG; MBO3CXSC?DY+^.F\N=!MM[87??_ YO%>(1WS]$1\A>Y(\9H&[N*<[.CO*AS=V
MW"H^BXQTP]>_J*SMNQ1X\6*$@H/V1K>D*T!Y<,K__4+_^7N;3ZHQVZZZEL. MIEP[A?O#F8W@JV4?X-?S)CL$Q\A>[^IY'+?6@+UTESP'6$FU4C>$6 A]2#7__HTL=RX=
(86[@"N;)PB.'2 M(UURB1@I,6$88\'*A6+PG!)1*(N8- 0Q7@HDPLP4;X@C4@I3Y@NM^R#G5_B%XJG\ZRI+#QU)^(A(U:X;Z8-K30)MF;)KQLEHWQA1VK'K
M3E>L+W)KG,Z508#Q&C%O&9+4.%06BBBL2TH6FWF>;$T_YRLR;=F(A+)9%IO M"2'?"L,VVJ+65EM#A$/2.T
[+2V2QE'$74DL%.I0=#'>\%2+^B7ZS%=Y5U<1;WUDTV:V&J8U4/X]#@8](%QOU;CRC4I[[PK::S= M2MH]MKHKL?!F$G4+=[OJD-9\^VZT;!\3XYIO5(I?,O^M^4V#=?
T4B,,N(?;7#:TYG4O?NZW'UIZH&JTB=D*U*F[SPW/8$7!M'R)T M+ES@PLN<(4HT@)#R%&E7.$0*QI!W2N7%XCS$1X2DGA.X<+G"Z5J;P/"K+L9, M1G&(4ADS)6# M>E\Z'?!R
W<31B:,W#V,=#1G6(1;Y@ I$6-8(>%*CZBE0G#FK>)/LO)?"",Y M6^:=%1N%D2D, @P6_UL';S&5BH*E!C93%V%X]+_;/[COPS"\-FFPC9&W'=-@ M*I8QM%-<.F60=Z E6$%#
<1/12)46RX+BPE*VC!#XO!3N#^S^G PNJ!SNJ]I M4N0[X57"]\4K[Y467]./'<4,5L0I$R>(Z.,TH40#-.EM#<] UYAN=MXE>+= MSV#]'IRKP1<72B2CM*+:HTGC,M4T;MQ$<[A?
J3@0-\6ZMUO<-EJK;'018=ROH1X-/X?AJ#T*^'V46Z0E%PC3!RW5%..\Z448,]+8,AS3N6OU2Q+TB6$[+8N28BUVX3<"<3R M%"O'F(#E<@?F+,=@ H--6^2.E4HXG'.\C/CSLR"6%+N-
6"D" 0S6;[S%&VG5 MWA!\$]Y&[H\@=P=S8K5X"3N4 /$:$%FE, M$99*%XI3C,E2ZBU6#%:%2,V%*=["E)C[T:C.)$J-A:.U?=,NX&#=R4%LL7" ME13(CQ4(*;T%X"
<(S%X6YI&72%B*D7;2$^:-MZ5:3H%Q*WMM$\N9^G[85Q:_MT2>^)D":"WG KF)0'B/<=W]$1.MPDS;ILHV1NQW39:ONEV&YL(3E2!44S&]; M%DA)*E">
<\]$61"&GW196BS9ZT3QH)/$3_."_!T7]8<#!1'4T/[G@2Y7,4, M*9KO>$]-PK3=)N1.8!J6C&EE&5)*@@7-N$::Y3C+TC]S&T=?3-C=L1;NWJ2S,JKV'R67*NMMB>3,[5'?G;
(I:Q&U0RIQ!S8?P@QB6RA&K) M3"%$R9>1KST:&,"EQKUU[7^/!E,I_#03PJ6'AV@*#R4$VV%"K@>";73ZM@ (MU#;'@(I*!ZSC2)="($UM*4OI2_C/,M*WR\'7'NR-,+$WQ2%62SV9M?
QRYH:KL M=/1J,Y>];7.YX]06OVDRMV,;:,4Z1I34Y44A$.="(D:U19*#22J+SPO!&;D M20.C?JQC.MFJ@NXJ5E\78*8T83E\;Z
M]HJD:;3.V>A($%*8>$HXM0J,+MECI3S'!7+X4>%)6A"$H!F&C&0!A09!6&'R"PF!9YA2,]<5[M9Y8:1G]*0]MET>08JQK[=K),M$,')?W6"2RED>*UH:F,R-9DO=*X;CK*G[
ME)SQ^<3SVLI"*B!)Y5X9$!(M,V"XKRDAD;1?TG[KJ_TX$T V1Y"G1(+VXPY)["223)18*T' \UB&-P(X<0 P M\7%4?ZVLLW]AZ[[]\9"G_=,_LG?O
M3_Y^FKW]=/(A.SK^V^!V='QG]G^P=G1WX]L.C@Y/TW2G9JFAQAZ0K$I&5("*:0*)@MG=)4EHLWOCTB S05 MRW<@E:7 MX5*+YJS>-^
%C]P*]9;HE7RKICVENJH$D0DB7PHBI6<8D% @2L)0*>H]4F#@ M T3*'.QRG!=^*<-8GQ,B,>^Q=)-F"I_GYG?>:Q5LO.3$MM,);;JIHB\X"(H
M%TVT1DR#PI%:AIE/1>&$$SK73[I$\U[1I/VO]NH'L7Q7C*+2U<\K ?'M4UZ M)\7&$YHE-%LTFDMM+6<*Z=P*,)H91QH#FO%2::,YR\DSQ,97CF8%[3&YPF:"
M39""%"1_QB!YL)U#%(I)N:0^NH>3.O71/4=JF-O"%HHB*91$# =%R(1" MQC+NN1#>$[.2L#KHPR&0_?)C7PW&H_P/IV"Q)(U'5FF!:UWO7$+CA,8)C5\< MC0M1<,X 3W-I
(VE=^%:"(DP5H33DN-R11'\5:-Q(588P|\Z-$ZSEAXA4;-9 M2Z^Z84N_9<.N:$_3E_#[5]>DR4M)$R9-N F:D$O"']\I\YR8B+2?1D08AI2DR:8K,SN\V ML? 6$G6;=IL&(?W,77_,(*1W1\?
[QP=I$%*:(I-VFUAX*XFZ3;M-?1I//@C) M70S[]:5S63T,084F<]_=R%2-LRD6N<4UH:DR^L=Q1,6Y$Y(RA)GBB)58(!VN M1]:"$T6%47Q)I6'SE='CVOSSI!7!PZD$+]LBC,C=+H!.J+7;A-
P)U&+$"5HR MA;BP@%JY9$@I7B)KG6*V, K3?.G]'"M$+;'C]I2U8SV,(']<4%2%!SKD:P M@I$SKOKJ;*8&XV>CR)\PLX<)X MI#VEB"DPH37-)3*E!>%H2IQ>N-
GM"6\>B1(66A;.E%OONP0^2]! MB_9N':;%VRT3$=)S%33!)$ MA"T1PUHC);4(N5U:%]0PUB\F:YQK3PE/K%T,,38MVKQ$6Y555Y*:"]WC;\ M)S=L>3K$L7TU".R<]5V86-JOE*
[Z;3!0FC^QY?,G-EKUY5([QO(2&4O O"/< G>M=CP/D##1W#T3354_:D^7-8= VE$:7(;$OXF M_-T@_"5,$V:81H7U'#&;BS!82"+//,MM:<";6(KK\2SXN\++%[<.?U>=8MCN
MH:3SHTA;MR.-(DT:;U)4U\NNII%+93D+*A)0KZNDWGE PW)V7 'V8:Z0]=X@Z M[+!QE #ZK7 VZ.]0DO<8Y0DH7WJRS%8:\8?>.Q,3!NZ[.5>#+RX;]:'+VI^;
M#*0KV/B|UM(/MYY]!0X.A4)M VTS'E5F#+9_>#VIKZ2^ME=];79HRQ92$<,0 M*#2%&,TQ$@432'$N7"D=\7HI;D2+)R?^L$.33P F)X.@+\/_#Z_PXL,,.L(+ M^P-[_0]S[USVY028I-
1$2DTD_$[XO4'X+8DUI0%O1A@N$6/2(U%2C;#V"G-A MI"]6'GPZW#\]_"T[.FY_@A^R M,)*Z%__-#O_[\]'?]M\)'I^=9OO';[/_U*/?.\B=__?3X>G9IZ.#L\.W\6-)
M\6Y,$60])=X*E88R2%)'"@@/#:!F<'HJT*844S'CMEN+T/$DI?G2CJK9' M S,*Y0!O7?M?^+T_"3,WYA5QJYR7K4_+'A!H:![HIAL7#> M<4<],CCX!3I72-!2(FJP407\5)9+*7-
:5UB\>VQ;WLLYVR8X3)>L/3^6IANJ M(@&BFW!GTVI=4)58>">)NDVI76X5P++5V)I6 =P1P+H1J4HWJRU#D#;AHJ:= MNIJL?!.$G6;=IOF9#V#IMP?9LK!LP:AQ:7VV?
C<9<,8JDCAQ%0\L;W%$RL. M26HJ5.F$059A@EB9YTA1SI$J*>66V!SG"\,P=,'RLB0.B9)[Q#BV2!:E0CD@ M'=%3\]=*V%(C2\)/!-XKF9LB+7<4^T1%=P"$-H2">8I
MXE)C1@MBK"B*#A\CGDARW4$3XQ[,C7#O'PS M3'(&6F? #6QR U8@>62/!-&S]43WW0OJLOO5DOS'RI3:[>>P$VI-6FD<+G.$ M;2E K2F,I&,$X=
(+4B@BU6++BE%$*RLT8K[DB$F5(T&M1%9B@94M.*5V'=4: M$3V;/YM:N\%4&Z78$I8F+$U8^N#>>%-HQXU#E#G 4E-JI!D!7,QS7C#GG>8+ MDP6UEL80[I
4SB%6P*XMJ_.Z=U/CZ>>/'|\??C@\/MM_ MG[T].CUX?V+Z^=/A:2KS6H8<;4+5R/)08\-WFUAX"XFZA;M-F9WG*(B.-
]B%5@&=>,4SSRH2&33OY>VDA:::SQ@1BST7%$;3FFGCG$2V<1TXH@246! MA)2Y+(]",U\LHZ/^]).XCR"'QVY9O9VK2+"\&(>GU$F"]@15=PW_\ !5+D=$ M$A\N\R!(\2)'4CKA*?
=,XH6JJ,=TN:\&JL1N0U7*3*2P;FK?W<'VW<3".TG4 M;=IMRDPL/3-Q>O#7X=O/[P^SDW?9\Y6 W!BX9TDZC;M-B4WGB&Y\37

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

*H\|<)D<%4A&;Q&WFB CA$-1,BZ)48D$ M?Q,>:7#&,!U0P%H@C@$H=0)(U3X*GXC)V8,;A4=<\+'@XY[-,<''S> C,09C MD5!TG"*

*>&$/.@E%HC"4,)\X9%ZM(2UXG/M(7/Kf\M6NHX./^SFW!Q\VXU!G> MTU8A'XG)# \&62(H(@YKJX4V-BVXU\D*1V,2B'KC$?=PMQ-.(,&\!H<;3,BD M-XF/!1:4#81;'X%5KQ)E@]^4!!R54'BY4'RD<$05M"RH&5!RX*6]T++0)PC"EL4@F2(-M4P]&(K<,$1H5QY%;0=)+A8Q?&BU+ 9$"E@4L"UBN+GZ,M5088E0\L7L=VPS<8A"^N0 MJZDD*1=^_,*/O[6|LO>8RS2'.%$8l1{$MX0 *SJ"A)WC#U4M'L*0+M:-KS MUC+NE^26 LL%=E9XG<8EF/>331,(\\%1PENCR15!ADA:5 V13B2\'7/7QZ6F2JX M7'"YX'+!Y9W#918$F+X>*8YICM1CY"SVB&+L->&* LJ^5*3^Y7&9%%PNN%QP MN>#RSN$R%]GR]1PE1CQ@;+1(,ZL1\48%QHA58B&,L:I-@37@,B__O!0P/Z&&MX)}OE+,X7]/*%]M71V!EY3UN5%FZT<'[?O'+]44YG$K1XV20U3+'!ATXKLQ@ M1(3%/(IH-%M(_%K&0/]CU[T"4,[^HVT[_:-.R OS*I>F^]BJ5:.C M&DUS##$?]QS:Y]5[RF%)1>F-U/%9V!\Y7747YPBE M3@=E6! Q%T%\K8fM^%OHSUTZS24^N)ECW!:@4H^_6_69/+&^16>\'EX-AO<60 MJZ;XUK"N3GZX'1:R;KXXK'*AE7Q7447YPBE-

M"YF4!L\PDU'/E;I[;47!IF+?]2B>MK+B7+2N6V0$&LSSAD7M;/$M9:R@8/A M.+M-VM)YPYSW7#|579;*@M<&FK\]1[*U_:-\;^0GYSGKK!0Z;#KH3G74H6]Z MT3:.-8FWNGI=L/:;3H'A6\P+Z<_LH/3-6^XT;JGAFIHTE4XPO8'/]\+:-'W1-MFLI^Y_:?.0ENG LG%L(#^BUU% ?P@%Y=A#O,L.G[N]#9M2TQ &0M8_-BL/M M5VT_RUY^_ML-C@/2*8<;Y-9"QC5"O7NC$8>W%A2,8HIF /TH4%7L?7D\7L>-K%?E+ MQ:O&\@6K;]<\)HZ*8 1SB$]7Y,"4YP8LZ^G[!$KH|OT0L@TVYOQ M1M/'>WA1FB7L53#U;'V-P<8;75[_L:? DS\P1+_=OKABT;Y\C\6?2 (?#FV;C.<7_>%E]@.\FO> #.LXO<*F MU.0WBGZ3[ZTA_#*M3%;QT! WNM#Z-TD?>]B^S.:.NN;SI:R M.Y+8BGPXF;C_SCW@<'L\[4_ 29+H!-<|<9,6]55JC9CKPS?E;[U^VZ:FQZ*2\ MPNQR[:]P>^'THV6I[ST@R]R/(_[PL15*]>0\C_FJ!WKGP%T2J9(!C%8F'<0M M-!)DN:(R3I@3@9"-.2RN!Q9XC%RWD5%B({K"E\^&-S7#NF, M]R*DS_6X>=7KW='9I9ZC^@*&LQXV5Q1YHR(TU8,(7:T'+92,*)?-2Y"IQ MSKEJ9]7WW%)FD1%<|$!D,]V7F:!DH7S.I8],=IU* `1&Y4>-P7T MQ `?J.?|ZJ29JL\P D)X=,A1|S/:G?*\^]P^62!H:(0(S36'ZU;*V+]V8R-D2 MW%S)=*KEDHPAR/"%CEE+5B?P2)#K$.,R>BCLJ#C+H6SV629$EX#%N1824>! MPXUPB&AC,C ()>*F.'PNL?P?>3,>'O%+!A15>XKM5"S$E-$7(B ;I6N%6%DX M^EAK]T_%I?+1,L1YQ(@;Z9!QV6>2N,'P?$_24DT-PYBV1 ADO"!9: 1D#)8H M!. ^=8S)PM1SD[<|BF()2HLY6$7\,I_LM4NT4B'IE9YE:=CO# [\7_3@KQI,:T!BP,"LI%^.YR&U[/IR M[OOZS6/Y(&|8Q4=SL/X?5?GG[^/"A(N'3;F49G.:U!|LY/?)YSPP@WPYZMM+ MD(+PB!\QO&T>9_ ^_MOT>I|CMR_I^*:.8#R _)JN1+&*FJ%_F[X"O,/LM.M; MK^XY,%C&EV^F8\Q=*%>&V4*5IP]\3\C?YH^BVBDW9U&__^36Q[W-[$M)'_=% M]^GC/E#O&_[(4^RV<-U3)'1J3_S[[^/1*K9O3YJ[SI0_1^OQ#@&C@%/)DLH_M;W-<=7.P_;8YWLY?K)8SJQ'C6AW8!1O>5Y1;YA?597X3LKMBN.C<7A9\P,Z MR+_^7[^\!?J3N<[*$*:1*B#BZV&_%ZJI6K+BS5>LCMZY,^0:3I8;$_GO:O3[MOX-"\+%Q2#9_SY5&+W\OJ$"OITI1/UGEAE4QVXEUW@$V6I<$,R[,*I=-LQL; MOFIS')L_#G_$D<^NFI+RV/#9S*KHF*QCLH|)'LYDGTO>S%2.E08!8/I/;+_|M?1I'Y|6KRVA'G53K&*YCN-LRW,'L^.\H1_T/ZIZO2GY>IRT^C/!^8>46VVO9 MS/6P%,G?8.;>X . ;1;N3\UX(_;@-,_!)SI_V'Y,L)C)'TN-\FY#BK=9F.=<C M'Z|8=0>D)AK)_X;Z'-1A85A$B1F",#,:.19-ZK MH ?!>YKR&X\S.^H &|'IKS(_3?-]=|ZY+L-\@6CA+8<(QE10-PJT)"(D;A(MRB7!7B6R5*QBR\AWK2#6U%U4O$1WK7W50B6>ATI:RB;3#@H[*.RV=&<0\(90 M(V9%8LJBR(S)|?\),@G0S#)O>4C):\N6"]LEYV4@&!EO3WSO. MZ,!NIZ;9CY8?%/HG-WQ0TI#2=IDP,Z@?1B M.*V30PN==HC'P6&/'#$@AWRD2),$,B51IW%B0>NE5!)C4\)4.H1IKH!@#*CR M1 5$7?28$&(B<^N60R5OI#[*===ZPU JK]W/IRKWA+PYDZ1CCP|Q=F3*G0]^ MUY15G/G&9+)+1O\1U",A@YE *7"]'E71)'E71DN?2A!]"OOA/V;=-[]^JL6!.3FEG9/-ME;$ZK'QD\-'+6H!NTEB1AVIO{!)/UJ,6^>*67#%O%:3Z9PQG0;UW"V25_15%RJ);P5#|X4]W;(B<.?'VYV-DYGV7:[WDVZ(_5N MU[MXFFTY<7*IS_ f:!\I9M7E=Y_3'?O|S]WS<)WJUXGYO(^[GSP9')KF,[" <9G0I(\PL MJ?5YDD0.QM^D272;>@$[ZY+HW$U/T23NWUKQS*B0PN&,!,PP# _-"B) @-F M^F OK41L(/4*]+;FGL7Y.A\\U"MNFRZ<3Y9VGI_/T_"0US*?HL39(. +X M""_A8YQ$7&F.C162Z:74L"WCXPI[K-5W#9QH5>+]H(H@XGNRW='7A<7;+8"6"- DH]6.N M.&B0DQ(CJ7 F3+>ZK@V+_8S+-G%15>RJP.[H[&EG5*XSN._A86F&B/'J,]* M(4':>8HBL\8%3HD,9,>4PIVH4[.JR_Q_BY+U'B.&S=?)>R_PL[5H|AV_G\.T< MONN679PPS)TWB-KLQ@@T(*V41SY:3Z/P@8B=7B'|NAV^8H^,#1<5[_R] M+Q1=MRYV.|7^8:H|"|Z#+1H^XY/D\K)0DEPSI:)WP,FDGEA))MPR/V_?W=BT: M.ISLMG2'X'&UOS=H@#*A.!*&,L05|X!M(B))!../!($W05_[\W8=I_ESR"MOU?M"|7Y>SNP>QI;VBF%.U0*91*:4!-0D!A ,!"%C(T&61$XH0H[|?G(UT/ M<"[Z>\G|'+Z]|R,&|^\X&F:VT)30MYVB]P";Q?6^PN/[R#DM/'HU4R'7&:'$K:(@"60)0R@,V M?XR'KCD:-@B6.3L.+F::B0!U^_CN)7T N[^.-'\D;#Y[SPFWWU_Y[4XUZZO!7N M77O\3Y]XVIE/YUJF.EN[YGU+X50[&0^G+I3\/B#"'|PSRY:AO+X>3\G#C;?.X MC??QWZ.7^YRX7-3O31TOI AH=|H2A?F.H7]\Y?S_UJM[KM?OC2_?3.>XR:M? MGBKEOM'YL3_R^N17;*<;._[C[6^__^16LD_D/>^\YVULGSWR$_Q]|&_A!2N 'Z_Q'+\;P[=Q&\VXC8F(TP3I$C;2($^^0-M2AZ$R WWS"8BE, MD7*2*#<"69X\XD%A9+V72 GJE&$.1|)6YC8Z_)\)&,=`@WH\FH1F-V1"9W%T M>F8'K4/\>#CX>6Q#CX$Q#ZX[8D'+#X1K/G64Z%.R|ZS#,#KW5F"1LD<)2(VZP0E9] MA1*G/I<|\C* (ZW#H!,=*T8BTD@EQ20(R0EF$01T#0/7&N[0%.+OV+%ET\JR. M9VU\A4-]4^$8!`X/T2!|WJ*W9?!BEVMUGDBL$VTOAM%>]D1{G-9?CG-CL0& MDD(B+B)%QGF%G)641"OI"K\Q"?GG%!/6WP2,X,<7?-@U^'J^ -O9#FM$ M1B:=P%9$1$JQ9X8-X7%HR-C;OVU$]8#WJ>=]?#({JO_.>KBR'AI#NI-L7>?AKO/PKI@?2B=.!$5) MNGQ>$1TRFEO$/$N)V]R ->'UI QL1LDT |/IM#[GAIIA=_^&7#>(|N[=>>27FM$ M@C3I>XY-#2VH E,#*^>04&"]*ZP#FADLI+IWTH[9YLHB>;&8NW4!W-D%#P)-K 5W#QB9@)#$' ,4.@=!*)*45"7#-%L* M>? *6.AMRA;^D.M!:C#0+!@5#-+%|2 ,,"RPUYRH<9R|)?)S'S4BF9?+3+2HX_BY'2CQ_3:LX|/+_H#R|C/!D/_3_34;^ M#*[X!.;- 9#\-^#8T[S?|_2?_3ABM^]"-QTD4^81L" (7NZR&];+M$N7/ &9@_1%:Y,7;*_5,VZ|T M!:LR\046]K#[U!S)E7\4?T$Q@[5L/)N.Z% M6)[6[U>Q@&AU -<^H7^_!O97-T?'|_O!{7;W]#>"9PTD-#Z_W8! /MFF5\|2* MSEG9<{#GQ_7K-_-$?0N.7?]>==4"NFH!7>6 KEI 5RU@??/KLIMO6RU@6G[\ MK!?_GM!B-PJ[

*({BRL_6>8'I1EV:WSJX[U:]+=4"$*9+|4Q1I'CV8 M7\;PD#M7\B4;S5OJ;- .\;0DXG _TBP8% S18-<)R5CXN8TV2Z)(U_#AFHPT MLH=UUZZR@[°=W]*

*(.PM;9_Q!+E8B6""&^\2UN!,,VZ)BX/T9B[D^,:.",9%Z]- MY1.;!A[_FSC@Y\XO'4AV((ER0-)J%:GEH,*G%$&C5P9I;PPBRG&E@U-1A@UJ M]'L 2;/I,C_/"B2WXBRGZU#]Z5-4_4^':;=\N)@L.;_]=!*L"XG]0J+64M4N M2ANP$Z"[4P,J/ Y9_>"*

J9D)S;N:1"ND;U?VW!4))LN"+G,PN&ZI"R0\H. M>_DU1( ]1@H]=Q+@IPQ"]D8+;?8TY"6#B;7: .L#2DU?E3-_\DCY>.' MC=XZZ?DIA9:]^,BY\UX(_?CLXLA^LKDO;\8=.3_CS7VF,]I L?;++O!QJY8P MS];4ZG]Y=E/N*/JE;.^SFW*7(M&5"MDU 'H"T95=+/$;O8Y2<"H-9TCP)!"G M.1,B;(R4D3Y(*5GR_+K7$7M.4Z0!188EXL$;9!6WB,#WT1F@,QWG.PI= M2UC_(Z;A*!YX/SF?E)K>!^=#V(%_E3K?ZW)+X@WGLC\9=V,';3N\I1VTK3/3 M*T3)L>%(.J<1?,]'(RZA@+4E'&.GDURJQD%5T#J!LB69SAV-X1Z -*0UH"(# MX,/;fQBT$:,[:-N4IZG3IV_FNCFWKF2+2IXL$[B*!?TDWK29+ME$A-+7B MB4F.5*(@'13!R%H/JGL,PA,F!95ZP_K]9L6?XBh|RSOAVFN+K#HL[+.ZP>$>2P M.'!+K5$>$9YR:53/D,8XMWF.CAOG'1%]PP;)9K%8]@Z+[X[%W3' MH\!]H! M[++*\NTCF+1)Y/3D?6I.D0D!6LEPVG&MDK+!@3L@4$XL&NZ5LQC7;'.ORK=$-M^]:>62QSAY4=5G98>1>L=-P&IBA#WN46"Y)BY%BNEA$HEU'AJ)G;L$VP+JQD MI,/*G<{[Z,]%=V'U=SSR?2I!YB^OOG)'SB]Z/X+(X^7"'G>NOOB@V?GS\9>ZS^M!W>T@[3UAGS3VVRD7.D@^.YW(@! M3/;>&2$HYQH;3I=JG^2VBE1,T+!G^(5MT=+7YZ5W2XU6WI"\ M:;#ESEOD MG 'JE^.;.)@1C4)PYQT,+B U91W6^Q\$ML^&CVB=#Y%MQ.[_TPMMIOH)15W;[-M%I-N0Q_*ZZZ(O^^BCNZS4EU0TDW"CA'F//46R2! <&$5D.7>(-"\^?_/WILV MMXUDB:+?WZ] >*KFVA$$"RL!RM,3H?92[9GR\FS7=-Q/$PD@(:$- FPLDMB_ M_IYS,A, -VVF)(K,BBA+(H%6]+ S(7UGX4CW,VQO Z NP.A8 MXY4T$=9$6!/A1_0\,E I$L\W+3ZQ3"]P,#/R;<=,?- V7,?EX<1],(UC5T38 MNU^K-V===#HWM' HX^R> Y,U=M($MO3@'H VWL E 11EP/ .SV#)9A@=.2 M,&MQ6?L;SHVJ]!0#S3-97O3$:>U5[U_I]W_C2L'L3^GKcGQ5HPU]"77U>[N2] MFV+-L-&GJ8>QFRNKUJ9WQ*HM5.K0?V*D=^F;H33W32U+X+8X<<\IX"+NQ);-M=]\N5,E0IT*$^]HD*/KR.\A/J!*=RZQY?)*TU8*S:G=.[(R#[EZ7C]:SF.UH M(@%#N/B?0)3], +KN9T$NW+&OR<5SRU?=E1GCZ"0\W?3L, @V\UV?L8EOVEX0FIX7IR;C MOF.ZCA;CIW8KKM6D_]G(TOV@EP[XXDFUU]ZT]+-=7:2[,&9Q9%N@_3F _5-W M:DXM'QND^Q-0!%.6>#N1IO:.6+AC2Q,+ _9/M'L=BY\U-G/-TD,5SV)XN9:1W M?-@[UA!^-#O6++T?.(8CR>H8CJXQ*M9P;>W8?P5FK\F*WO*>;UD#^1%M6=?D MV?O8D*-,,SN\Y'Y=P6*YTWOHI9[+3!:PV/1"CYO3.)V8B6V[OF>%<+6DQ;RM>)=K9CK#9+,,FX^-[Y=KML]P?[NU"%KN.[°0_6&M[N//"3H027+QV,SP?CP2EMJ:5H3.4WD[F8T"!B;,LFTS .-+\5B_[@=HYM,;CKX.U_U;?WK/W?Q[ULX M%&[_U]FLG7M;X;YD:W_B\X;.(5X9KC05'.M<, R'401#K$T. V*3W7V1U M)F#^1(VQ1:$7LT|\<> $,.\5G@^N4>X9SOS]]8O?KGG7'D_N~5K W-1ZWP5X4/F;TTK6"0OC85H_A^/_G#;P<5=E_G_&0%_]\T:%GZR &^\[7 _M6P=Y+)CWFH>+?>A_[*5 9WW?-V77%'O?A]/8@>EXCUW$@MES+7;]3:AU"M^TL*LRQ)$*6>LQ8U$3)N<6MJ>A-G8GI)$IJ18_LFL^PT M\%GH>U/K3JZ0+VQ!UOVW++?\$TWR_Y/D%_PASGM<[:GSA3 \O&/DHVP8]@D5T MG^]Q:UF!ZP=1D*[2OL!Q/&ZYCCF- M?-OTXL0V60# I.[4BZV8^1,[OE5'GX>G>?9$D[R';AMIV?HFV=H_4 9TV/Q% MQ^C(/%M) Y>';#+|>#N0D0,[!+;B)[9M^5-[,HFF<,0>B/R (C6:>+|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

*!;ER[3!UK4>'?AQ$BD&99^H=2/; .D&E1*L+R0$' MY85!*P1QDE+% <;1@K|R:,/$! 3E;CI LENLJ8]6I+373N7K%I:TT!\Q$+C[M@3KY+^+] "NE2G%[68I9GAS>9#]&7XV)'* {"P:AY{JM4$YH5M%ZY/=AJCBW* MS\|f $%Z;6'! F>Z...1EMTR@[+-N 9MS.3.K5T3A-0*JIV+J$)<5RL18)T M%[-*T$2%D;LW!PU^MP$514QD78V3_@D"- F'12M1#\$RCON]+N,CU+4% =R;K M"S%S$'Y\+5\[O!3HP1HZ7;L;8P/R M+"7/%?I\Y%12M-CL#;34RU"UVT3#9X7.I'0NQG#"(\!(=<6R;YOT,J'2 KQN M!]M'0Ul56YDV#5$4P&YLEHOCR9;"Q1&>#,;)XEV!3QHLPONCP@2/#6]^$ MNAUVBO21?D6]U&1EMV1*:N:LL8P4E7E6"7'(MU'TD%F,R@P2P.#&\K98DAS M93RW4$_D*>&U]'[:W\[Y#R266'H,OZNP I6HN 6@W>2(A2]-=)NH-P#\04C? MDFBVS%\V"U\K5=BQ_GO354\16T.%9%BG>;A-(D1P[E6))42PFRV+?]1]JRU& MW5^5V%*+? GR4EZE{DE*5[BHCX>QWEX]&EA_#6>F&P!.P 0.)("04Q6R.C! ME 8=D*1\H>BAT/3H&)%_];WDUKE]=P/]O8@EG6.PS1]@;]5E@X5O]\FXAE-= MN3I9;]VO4:@#VY]W8+NM]N?? V#[<4@GVDX,_^"%_E:V1CEK206(N^CEV?+\AHS;PM/(2VV%2(O&_8D3WH". M9,.0Y@1<"UH78/7XN)FS!88),/P53UYW0:-CZU?U D5\S&M^4G-L6=ETL;74 MUTZ,_0+GAP5T!A:, {A;VXQ/UOGP{GDJ68U1==YPCM1B8/N1&A>WCMRWOV8_R-MBCIVPL>92>_G?ON96'N[N&\[^_B#@\2#FT_OK>WBPO&WN3&U_[CMZ9:Y0S2 M_HVU=K$(QEF%+09,*96D]- \P-4(8W?&#S;+*.E-9*?4KF/46"WKPV ;T.UC% MF^266|NPC@?IT>IGT.[1)JW-MJ(!4F&F%AF:NH4%O=M\VNTMP_R(L(!K>M5!Q.X!9M_YJF>* ;8V6*;1,H4'_ M\#?IV#*%- O8<"V0Y;[M)8HI'FCECC;IS16*.QYBY8_{M%Y+=M^BQ=EB;V,+7.H9_3\[@-MS/8W B>]MN\R8HS(ZW*F=' $QBV[N?G<.XSFBDNZZ;&^2)<7MQ6U6#DK%Y9 M!E-3C'<",),.KFY/06=SC6QCQA9&FK=QT\+1BI.?\RHKZ3[E;Q' 06+ 6_$Y M"\[$G6RXC;J=S\NJP;?2LH*UQ-PH(|@Y35F/C>]PX1M:A" *;C)O$7(O,IA% MA,"4T\VJAUA#@!-Q.-\"X:1,# <[BP),EP$_|&_M5M"&\;^M0#;,NIF,)Y/@.B"SPR>#LF$5^SN G7@4ISK) %NS>"L@?H9+8G1; M_&J.%U$?-5Y^!I LUXZ$@#.K&X1Q1##\6;,9F\=4(M59;.HK7 8H&IG%<-3(Y*W?.QL M#B3PBB18sBKI21KG/&AO@)RQ99>TEQ(_"U4O>30)N5\&*UM+14P5R!QS MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+{)E@.N(R0N)WK"36"SRLJQ^X!HHH.Y=W!:\ M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_U!>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\!1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_\\UXOHY M-NHN)S7!_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R78E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+{)E@.N(R0N)WK"36"SRLJQ^X!HHH.Y=W!:\ M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_U!>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\!1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_\\UXOHY M-NHN)S7!_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R78E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+{)E@.N(R0N)WK"36"SRLJQ^X!HHH.Y=W!:\ M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_U!>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7!_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R78E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+{)E@.N(R0N)WK"36"SRLJQ^X!HHH.Y=W!:| M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_Ul>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7!_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R78E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+|+O}E@.N(R0N)WK"36"SRLJQ^X!IHH.Y=W!:\ M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_U!>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7!_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R78 8E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+{)E@.N(R0N)WK"36"SRLJQ^X!HHH.Y=W!:\ M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_U!>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7!_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R78E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+|+O}E@.N(R0N)WK"36"SRLJQ^X!IHH.Y=W!:\ M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_Ul>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7[_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R7 8E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+{)E@.N(R0N)WK"36"SRLJQ^X!HHH.Y=W!:\ M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_U!>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7!_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R78E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+|+O}E@.N(R0N)WK"36"SRLJQ^X!IHH.Y=W!:\ M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_Ul>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7[_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R7 8E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+|+O}E@.N(R0N)WK"36"SRLJQ^X!IHH.Y=W!:| M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_Ul>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7!_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R78E+7/&X'0BXU1PO@",CJLNBX/D(M27*7%<8=Z08O"P[TK'F>]DORZOUBVPUR'MX%4BMGD+5MX60*%K7.."7M],\7'*=<(^DO=^"7>;PXM 3G'6]7GBCCO\N@G MF %? 4HKA35<$4-5K&!M%]E!']&$ E%L W0 ;A]C ,GM%=P6K.^.XL.%<2-%H MY)@#.*&*L/D"CP-N=C:"=^7+|+O}E@.N(R0N)WK"36"SRLJQ^X!IHH.Y=W!:| M+P< M4? J'HHVMK#.H9ZSPCJ3[$(<_Ul>S&'A9E$F7%%M8&[XM603_R+&>G5B MNJ_3G%^9@D0B"P/"W,Z*UTE6SW.V.,%O7\|1 2G.!BDSF> -,N5 ?"#9]0]0 M7C5YD;R>ES6I+R=$0P$97T?E%7(@&/.D.XQ>+5G&ALS?\3!"YX&8_||UXOHY M-NHN)S7[_Y'>P5+8W G+ M+|FB?OWBMPY*Y,CJ8LE,19S6)MZ'; /V]Z/E5'E&O}^L M_NVGI.IG\|QO<<"%^"@HHA=4;)+ ^>46R7 8

KN<{QB1)8E,B>I:'0MR6S-PK!M,M7A;=:9N:A;9PQO/JK4 M&0L(JXF;2Q1FIT?+9H'$:H/#=+!|CV:,D,1#BTBXX41L3C}\|DM#M6;E-HP MRE&)\|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}Jf_2;M0/&KUGZ-MHGI:3^-ISI.'$ I33;$6!QQ^,%_*S/(FJ*64#T?N7+&;%YO6O2<4#P\0D0}) M 0=3Y1D:#8V[1R,TBM_\O'>PMYS>'%328!U4 RP*C[34B.8,_PEGZ'''*@@YY M%]?++=Z-XK/(}4$WY0,,%G;YO-E\?FEY_XIL)8\^>/XE@M0G>X>I^4BIG]>3 M-4M6>D#_-5K;N=8;EKG5DT'O*2IV/.4T-JQC6&?+Q.?3T_/4 G1'UM_LBT?R MT;D?E%,?&#XR?+0V'UGO63!7'5#,9)AI6;">XCU%35+,E]O4K6$;7H)G]$C M6*Q5=U9D,I11&P\7ZJ#$C=K4UGIAJIDU&#'<8YBFX^1H?__V]K;><+=^ M'=WLG\3NT+_AR3[WKEF\[&4[?<.NJUV:Q^FQ6D?MIQ.LI[JM!N-3F^?W15L MISY.1!G!RH:&,.@5*PX><0%[%T_T8#!_HFG<'N:,(H//$<4NB'''W!4MPR2G%MMF>=X$S+&T4Z1:1_*?;D,?)T!\;Y%XIJHU%H4I4]^P_*DEW-5?[M)+N&-BVGB0C;..SD'!B$;1#VDL//]}T[0/7Z"+MQV&DX!XUFNW'0:APT]P,W MO;.!9G]SV'/A[*NL5NI9)|(N3OFW*:D#<6HZ.2I%>S04W MH+M*5^K'S$=LZB77,D9,)+;0.!%(IY]3=_ZYN]MB#,F;A&KL+9"RLZW%[!(MRTSXB^H@ZM46SR/,?K6,D8-Y;O/'KT2V'':O5;,)C]B+>%8O[M+,2)_>DNX!/VH'?-!N-YFYC\U?/K0:IF"4V2 R:EM@0NW%BMR4MSNJ$&2A] M#Y1N&BB]O<3.0NGF"T/IF9+A!DH;C7$&F(-L8980^P6P$$#G)\#.#?KS@^[MR_S5L8),(^CF%AJC]=+J]"UTI.^UJ_JI_4<.#NM3N->=*W8Z+YV.%T=?C94 M&ZH-U89J0W6EPD7F4F@@^K(1+CU0Z.MXT<6)'J__GU\H-U$28I@&AN MO8_1"5)/1#-6&:D.UH7ZJ\60C2@>BU0 M?77ZNP'5W:.M;A>%'A)3+J+OK.#[4=T3S'1;?__#C M|]__^ I'K#"U^SLT!SRT@1\BUBFX^1H?__V]K;><+=^ M'=WLG\3NT+_AR3[WKEF\[&4[?<.NJUV:Q^FQ6D?MIQ.LI[JM!N-3F^?W15L MISY.1!G!RH:&,.@5*PX><0%[%T_T8#!_HFG<'N:,(H//$<4NB'''W!4MPR2G%MMF>=X$S+&T4Z1:1_*?;D,?)T!\;Y%XIJHU%H4I4]^P_*DEW-5?[M)+N&-BVGB0C;..SD'!B$;1#VDL//]}T[0/7Z"+MQV&DX!XUFNW'0:APT]P,W MO;.!9G]SV'/A[*NL5NI9)|(N3OFW*:D#<6HZ.2I%>S04W MH+M*5^K'S$=LZB77,D9,)+;0.!%(IY]3=_ZYN]MB#,F;A&KL+9"RLZW%[!(MRTSXB^H@ZM46SR/,?K6,D8-Y;O/'KT2V':O5;,)C]B+>%8O[M+,2)_>DNX!/VH'?-!N-YFYC\U?/K0:IF"4V2 R:EM@0NW%BMR4MSNJ$&2A] M#Y1N&BB]O<3.0NGF"T/IF9+A!DH;C7$&F(-L8980^P6P$$#G)\#.#?KS@^[MR_S5L8),(^CF%AJC]=+J]"UTI.^UJ_JI_4<.#NM3N->=*W8Z+YV.%T=?C94 M&ZH-U89J0W6EPD7F4F@@^K(1+CU0Z.MXT<6)'J__GU\H-U$28I@&AN MO8_1"5)/1#-6&:D.UH7ZJ\60C2@>BU0 M?77ZNP'5W:.M;A>%'A)3+J+OK.#[4=T3S'1;?__#C M|]__^ I'K#"U^SLT!SRT@1\BUBFX^1H?__V]K;><+=^ M'=WLG\3NT+_AR3[WKEF\[&4[?<.NJUV:Q^FQ6D?MIQ.LI[JM!N-3F^?W15L MISY.1!G!RH:&,.@5*PX><0%[%T_T8#!_HFG<'N:,(H//$<4NB'''W!4MPR2G%

MR8SOB,I;_EH .IH_&L]+G0? 63{&%MG:1/ 5KG2R')6&SC[_=6|Z(X8Y-D;_ M-J9Q=/MV7!"9BF@H<(D6@..E,'&0NN%?'I.2TI1/$4-5M\7U=#9B ?;NZ+ M4N-&[&D\IFBV(^HX3R>*1*$?M^(MZ^!H0,(C Y1G<]'UJ5]"6J52%@53 MBO!K:FG8QDW/J,ORC,!KVF#D+C6="FZB,!J(L,V(IN@U>9:X 70=G.$\GG35 M@ACM?YK@S\42JJ!:,834851, @AVLPKVIS-=_T-*

;AJ7(H!P5V>"P01BZ#N>) MX\8@P8;,1?%R/I=[0YHJW+K^LU5;G-_GT(\7^A46XWHB H1R/7"H"Y1J,- M-BV%PC)G;XZA1SNG1D\.QT)T:W;,J$VXS8JBNI>Q\PX,HUBZ!XGTI3;=IZ*W M+'.;T(=*X'V:O)X3L5U99YC M4527;S'VZP(NGT|26.'S0XY(3YU#E%Z:.ET$33-U/9W0&M^2V145@\QDW@Q_UY6YZDAL/O*E+%=R6O7P8#;,9A54,X7[_?>/QD11LIZ> M0OR4JA(T.+5-16G]3+59,JNBD:,76QZ\95=>\+KP-T&XE8&:U@$]\)0[_1!2$7RQJS]4C.CY1,28B&DV()0!97AV=V1-YD>DLK;Q@\%U3(NY.21 M^X:M?4-9^:IVT\K!.7:E-WXR"48.]2K3@'!UM,]4=8F M&S1_,SW+2)K:FV=^%Z22R\%^W)'8=2 M&=WQFVV(6QPW*YZ-GTS>DCO0B! .W5BUD0K]WE>6=)1%[;$LA9 M72O#<.KS_5KT!]17?Y<]3M,1-B(GM$H(%:)?$M-SEYNW!06RK8 M=U-5.Q$ONO?/+/\?8;*+]3V?:,BF2)&ZJA_H0[\=\>Z3TH_AY86HI%^>R5VS M7![Z1#Y'%B/7<;<>E:!OfQ-V=;ISXG6]IT MT%&NL.6XWCY32@YRFQU&:VS(V#]-+/WS:_-\N%^-'&%VWV)8[_#(>+)3;2[:.M%\OU05]D'I;Z3+==#*(QWUX3D]HNO+)O*>PWES"H::K(2DJNFHZ&PT')$-%\UR M(4"$'G8N$D@.9Z%)3(,-0KY1,O\]2H5,"4BI[@4>3-=DILPA#LRAU$9;:M#E M*P(/.2;(3&./0@=7_QW;|T^)3E"BGH?'|+B;$^W_KEG15%398MY W);ZT>3QF03/_8A-)\,)G)X-&VP@O7ME=\3[^'ZV?0QH2EI M#:!0=4TG&9M?7^E/"8[*0>1'|^WP-+QN7IU"XQ%M1%';\5- 2-%*H8A.HH;>M1W[RG_[Z#?9/'NZ_R7%..-*8@"6L%T6)%0 HL'_WF7T5O:$.Z M0T 2$2$6B1Y1L!$$0H8&RCF8H'<0)49Y.X)M_^9AQQY5VKW!.SM ;:.NN(?ISBV U)DSA .VN',$?$B'Z/8NM-_QME M8N8][H[OSG6,3SQW'-(FNB-"M.7|7W<'D.DICQHCB#C%&6(T$2&*@*KN?<"= M@JG63Q14F@\(=:+38IR3-4Y[AE+J2"(O71-$%']"4?)K'PQ9(SN)$:#E+,V M8UV)P:\C$P'J@ 6J9HDZ80Z[>#W@K8?^$1T K#JG2D51N1OT=I]'MH@AW 2M$0L7%<]AH$(4W],3F2,\0)8{(:\@[,')ZVVJ(i5U%1A91NC.44I[! MC?N($53].#;69&V):CF(F; T))'AL_+SA\#-*+9PR.1#R)<$,.>R4B}'=! MR(&QT^38'.?XKX#%U3W<9BAU#>%.(X/H&@T6B&4]LRCRX$V=4?MK)XT*_"XGK(L!:CE?!70+8WDC-A@=1#BPV#','7,H4P|'F67Q O_:=C)#'NNX&M/E&7_7+$7 Y2=/=:'MI.GD<^<._#4)9E7%)]170\W%.MRC0\>7QR8H^>MRC2EL C!*N.-#I.N/O2D@TB(B MIH)*;U&>;\L@WZ7LN]%;_))206>6|_S-N/7F2-@@^EP8(D-9O FY,T2YE5 Q5 M^K+^3FB'*,N1*?81^I"9RD6OW\Y07EO\,J9%5B)[3TQ)^SSVN9%=<;UGQ4BD MHNZ9| 9-PK%S+U_[$L<6I7[LS.7]LU1C?J$&BV #WC.SS%[5,WJVO[%^#<(T M5;"_/<=I^F':#:#^&!2&/)$FH)#7=V7%.%^)^XOKO2Z+/JH*:&M2P\;LKM<+ MLJ!OS5V U)SV114DF)4T5IR:F@>$9G#Y*,Z!3D:/S%@&8S>T M\9L+|'\YXN[N^O+F\7<^OT? WY3Y<7#|>7;'F%,I>W)^?S^Y_0U>)V?GN^N/V" MYK<7;"[\^7]FOQK?KY>_+Q8+R[O?]1J,[G NR!RX[2N\G7@/T&NIEQ8N;?2 MPDA+GG.@?*

*@+DQ75NQ"ZD@\>"86P*0.8P/2#VFNQ#5H/N-HBQ.H,/HVG4G*,- M15(P/N_D]XAUH]. 4ZK3,4!]HK3HYKL+6,UKS:)1ISB@IP\2Y,4':\7T@,2?1B](76QFT]* MH'UHW9>#RW4SE(0NM;!7]P\#+ZCNH5^KXN3D@6DV*,6'3AYY@-M^9AUQ@!D,"W5,.L(KE1E(!'V5\TG1BBPV#',!

67$>S4)S'MK>A,D-PV"ZV|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}>T&PBl;6S\0&8MP5\L7KN8R7(Y>Y M0FYR>,[CL)0K L$R,B^7 6@5=FO)IW^?);-5 T#,?C=&D?!LHFZV%+V-XH M3"P'&&7D4X]?1,M,E4V!9)8B!A+F67&#P0ANO%LND-I[%,H=TZD(M>,*_HHG\""AHWYUQT* ,BY^#Y9#P).B&\J,57,R'% NR-6V*&GNC4>+FI MB? G49'M%>U),.3YDX?.@@COPB0>^7")K'4#U#TBG)8(2:4)N, Q5! 87'\!N V MH)@YGN5,FUM0^RP58' M^"9%@,WPG?K*FYPVW!B<.LK(2P!8O\5D==5KTOTSH%/# DLHN@Y ?47&.'4W M7B#*GABX)$>6'*@ZR'0%@.8'3OI;@Z$SROG+76CKGRY7:'%[OKRY)-S\Y]WE M[?WE_;?Z0Y_2\A/5D?DI9A8\?V*C@0K'C:U](&UDF);Z+(@9$F/AQ7_$:*A& M,1/6W_T(H#8C'3<>*?!+>K4Y[%W?C7)&GQ?(@48A(9"-'E=S=*Y6Z M_-Y0C@NIXQ_;\^D>&|&5]13Y=&G#S>0(!C I>&)RF.(%I+:5DIA>9[&'(%1+:/4ZI'KC' MSSC--F2 I0;DWXJ#,IRM6KA"+O#&M5USP(TJV?(J.*&Q<_EFDZ8,?5=C%KO<)6)}&H++\-3(3>4)PIN[W27LZC)CF]3+9755(I-\ M4E?-Y56U^~@ M3EY%[L #?95;Y7(8__BH^) (NG*%D2C6,YBU"]S6+IU_">[(\R$H8A- & M!"8[TC(L&S\0^B-0!V(2+9,XBBT:I#*Y F'2V&;'5OE+V;R60%7;JWOEYLUP M -*TIBV'GWK@Q&4Q3(^_L;D[L)B? 1Z8T,O:1^72&Q>H4A]518;M8XW/;UOQ>*]I72RM.>N$X%?!TBGM>,P5;..8[\64@1OKUR \JZPH@DTW*)\]ZPH@K#RU>D#+N$.V/ M/G(S>O\&=A"_&F#)Q@H.%%#IC{J6967O"*I';LTXQ)"%D3BR\+*E OGE[Y-P0*#Y7A?F+I[MWJ^P%TY ME:JY -*WW/#_W.+P"0"(P^ U?H9C;_D#L]X%2<1H M(D[4:!#80OXT4835QO4'O;1TV(IPU!(*#&> ^(.H M.6-!6&I=X25'MS%4)@WN;,,.P&?RS*'C%12@VP1V A>/9-LO$3]<6Q64(^LE M%8**G+HZJCYEH7U/LP.DNBUSD%>XO*UK1"NS\1=BH9=C=''%(B,,.]@.$MB MG(<9EIL2R=?$O%3E5PY,AZA,'#68X@" $U"FG*PF]FW2]__/WKLV-XYC:<), M1=%OQ$YW1%9W95;UI79V\BW:L,`:EE=65L7L?.B@1++%3]>M?' D M01(0?$"B'3L;%=F"@!Q#H"#@W-YSIT7H-L$[4\.!X#U*8VX^"\8HZ4*@=%P<8$Z%AV[1QH :'N'!&HTJ*Q? 8U1KO4O_-VG3P8UW'B[8F5+-"7C88&Z{)9:8CDZ0^+87E1" MS7U:I/$7\(&1:-PBY,8W4;CO!2^_?$<",.Z!?8)6J€(%D=\[H<52(V+W +XV)AO^ Z+R#4\)*T8=M2("V@TK3/[C3NB MJI.G7M\&AS2)!Z!XW^=.)N4B"1T"JF%0K.:!LO/(Z%,XW_QL/]X1B_@<1L MX[WG8W4Z#+K&/V4C+Z)\Z,4^&WM83T6/1&6[3T7,\$^H.00O@"M$_WL,++'2PV|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fQ.LRIW&R&l;)IM75H&D>[K1+ jQ;_+"2M*,N=40LV?B$!d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f",]96GF;=EIZ]$+%-P\9Z*UBA M8X=5Y=L\?8[1?Z?X<|=O?>01Y\,MZ'ACA7Q+(@$T!X;5?7-<\8'\+?T!OW1M34OT,$"")Q_X#N@N5- 6."2+)R8E%M#AX0$I2Y^^/X3C5NF0 U;]J^? MR; ^ <&6|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f",]96GF;=EIZ]$+%-P\9Z*UBA M8X=5Y=L\?8[1?Z?X<|=O?>01Y\,MZ'ACA7Q+(@$T!X;5?7-<\8'\+?T!OW1M34OT,$"")Q_X#N@N5- 6."2+)R8E%M#AX0$I2Y^^/X3C5NF0 U;]J^? MR; ^ <&6|ZO,8IZ'#(2;L,$X+],>EDT:$8 .0)L]YOG)&LTLL,UP:C(@"]9IU(QB#%H5-W'3-T%+%3=^,EZM ,@(WSK?A1=+EPKEMD 97[YJH/C/"- 6."2+)R8E%M#AX0$I2Y^^/X3C5NF0 U;]J^? MR; ^ <&6|ZO,8IZ'#(2;L,$X+],>EDT:$8 .0)L]YOG)&LTLL,UP:C(@"]9IU(QB#%H5-W'3-T%+%3=^,EZM ,@(WSK?A1=+EPKEMD 97[YJH/C/"- MQZ,PG^X9P1_ZCGRI#E#]:<%];<%_[HP9(-0<>#J=$>@$6\REEQR7$7(N0_?D M$"MP3,,8"QAD4#&[>0\WKV$:XX."5;?:._+?$!BVR5_XGZZ)QQ$%UZ0X%3ZQ M$&=!V_9RI6*9^X4<5_R'ORWH5Q;Y9XC]?YR+QQQ',,S#-WM.\+)<@QV#ATX7 M3K7+3H6;2\5V+L>I6-Q|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|CN|S2F*1*|854-PD:&.1!EY2WKK#X^UB?11)K,456*#->]B%[C7!(3", M1CD,5$*B=1=[+/5?AP=*'I94=L#H5R#?3^X#] $_X<^=.?4U^* <_#WK6RW14 MS-X]9:E4+]I*@B{1Q>KW:)P!?XR=L#(:*\1^K7FPP(J4'>T<|[%900C&5&<=GJ188Z M@UX<]MVU3%TO 6=DM+\]59=E8RQ@D,7MU5#3C?%K\! [K*_MTWZUB(1UCS$)\ M&1!YIWGS4.KG,WD!@C]-OQ*3H3G9-U JTF/WG,M^?C[QK?T3Y^RYZVJM MD\<8UWF7U:ZK] !2G\L',)A&'KFU_N#'QX1>D+1&[Y))%>BI%=;EG,%X;\O M 02ZT2N/Y)G==0Q+%FH0Q3W*?/$4 0JEM0/19&9\+%]S;F >IR$AQ9=P3PQ\'F<#+GSY3&??=B> MRT4JXL",)@:;3AB#*U>/E*D"]Y,K9>PTR')0+DWOD&%H6B$#8KC,WEK]RD@",%*,@5+KB M27.5R/#SCN)U$1C8Q9Y.A0. S2%AL]D0W\^.S(? PL*$AO7'FF*;R'"2P9M1 MR<^FP%50SVNJY^RZ+ e,.695.UV6V\1{HZEQ?53I M*N9#L;/9C$BL/ FO=Y(D]+4O'R^H^X M!70E\/I3(-(!PMR1Y>23_Y!SX+0O9'(^&1(? 7HHUAY])8!L4O"V^_U7RL<__M<%[N8FYC5G8N.[6?TF>2A$0U_DUX_2U!P:G>A;HC/OL^-M-N+">8D0*R[%;FK.MRC2)L:L]CPZ0TD)NH0KVUIV M$Y^T-+C(I 3G"%EWS)C\"&DV(;W)%BJ MET"LG1?%B9U!6%WIE0IQC6BL53'XF6LL-M3'LGXE8<%<9Q5 AH-&ZBHE/B4'@X^N1<<'Q3>&S|\OPVPE-Pl-"N -!'MM0G)4 M.]9.K(;$25B&CPT+YZATU(59;+SSR M%8JZ'+(6*;UOS]_ M+R[4%K(6ZJ[O/O_M;Y_^]L-?R<^?__KC!Y_^M=LU%ZJO7X"]R\4TO7>D#!X M9% [7!?!+O!^SZBNYLHLBWF64TEZTCV+P106 =IRPEWZ)8RMED*ABS_D^#2W"M6Y0/&U\&++E'*Q3|S(%^=_^=+4RC%I'*0:.[O7&ANN=.8D?.*VZ&ORX ?A|;@ MBVG(4L3?"KN2&CC.'3$0\?JJP6B)O$MF#D:7SH&& G4M@9H-"/%7+.5CX**G MG4E@ZU),?8NG[I"AA]IZ&4.H+/P'#"!8=0"IE =&%%XZ5DVM\QJ\L$P?_@?O$ M)SXLNOC,X- 'FN25;3+FQ6/=,*!/6#QT #>R+ ^E$#LL'&BMWN.G7&_&G2.E$ M?OSLN2#[F/W82,RH(5SH2+?^]/.O@'SO#@!;WKF4IPD3PF@VM*!{6Z!FA M*F+?- -4J)X_365CU2A.A$HYBTJQBUZ#F8,)*X9&A'Y_5!N45=/6J#:KHTB!%E"0T-G"9I;3TZX"PD Q<5>[*\]/DRR]LGO\= V'H<#>%=6#9E|_M<]KV4W@: T:*9AN8#Q5TK-N[KYOKP4 "QUI; ;;C=PY;VRWO_Z>YKDE(4KCP MMXO\V0/-Z\[;?EJXX^S[#'VIN @>4-)#;%;.ZA1Q-PPF]YSH\2ND\)>EL\/4 M+(@!+]9VH"&!*N(R0ZR6+.Y*1- U*05I_T5G59V1HNOEL@B";9+9)?QS#\SX]. M7!U54/]I^X+P;?0LC)8=V9^/2)1*.N2PI. ^!!L9^T=Q'"K?!LS*U+'+&BH2=GS MF'5-ANYD"2(C.#2]$"$9/ C^FY_",.1I];PV6R;L)S_U3%A51,_A6 RT3DM MV*1LR7US=^1UVN[A_7UW^_?GBZ_>5Z<;=Z>AH>ON!I[_C^11I[58[NN$5 MD*$6V5@FD3Y_65YNWL/>D4SQL%^L0#+M0E^?E@ABA"T(A8G)_QS%FIR/"I3"K M7!\]!W.$A<8C@[_KN&AKM(,H0"Q4'K%DZ^!BL)&WAFQ\CW\;/4P>|S>'*S MF8#$>HF(Q8Q- 9K&+PCWMX3"X!FIK8)U1+;_P#4&!VC-3XO*V.9$"_#(Y]SR6'$UZW _;ZRN^-X^K]P"Y M3^ES[+D>UL'9G7]H]VZ%M$]IVEZ^0GP(P:%U#U4ISPKHSGA5- M=[\S6I")++8J9? 5K0N2WRR?$H%71^<'38#*GN,WZLFU6L+@?'-Z_K&(D.D7":B(M@G)OHOH MYQ;[_'L#WRXCT>U7-L-JQT:<.T3//KG@HI', 1T-R@WA^< LX7)B\-^$45G# M%R@BB%RGJA- 9=UNG689%M'RN-9-#9/E,!<'MH|WYZ],&L%#3Z-A3WO#7IT4V MHHF),.') $>=OW@2COQ@\X6V*27G[S3HY(IP[U;*3%?\%8XV0/ M8A5]@#1(/*]}5,ANQ&2+,3X1N34%X$@H"LD5OK"'"%XH73A]5Z[SV)&E&JF@1 M@S<^$SOD03F+D\LRDI(G],,+^N6\=O,3@Z$F!P<[,CQ%*O(A&^QV52M[E:- V*.0'O#!SR(_%A1DPL)'YJ5 M!S]$K^QL= @\DY0_H,ZZ_LI^ZP/G75'4)O^@^E:(VP[,AE)6Y?K[XN9N]>O3 MXF.]NE_+"!WM[_<,FZQGP.O!W%RU4)6YY.S&%<"*^_H6CK MQ>@1RWV#)6_SHK;E=(M:=D8VVP69[DRYWEBRMLPEXC&@$RIS]TP*UX[!3&5M M6DUVCE:A-K'<5&^],RSQI+]^AN+),]J MF/3DPF..QM_GXR^R#PR>4#\$E>7KY\3Q M!^\=DC<0CXC=XOS%<=[W*1?14]A6;? M)7E*U8?B;('6(]*E5 .P#*\U/-!I=N/?!@>L>MQ!G.,/G7"HH2MM6W MGZI8C2(*0)#€WA=[#11L?F MZ$:%$%5EI,R/GB@0X4J4%V.DG749Q@1C\HHB1_<0\%G'3,TZA&22[O1P,X% M&88<[.N1)E[93I@$_ "]1BMR[(C.WW[-.*Z?0CRSN^)IB9F1 GR2K! .AVV%T MCYCW!"2YU9.G0!D\!U>USMY%=|SMJP\"$FW\RS(8G_!(C%LN[#.Q61&&]E163 MQ[H9A)*C*T3_>QO4<8A$Y.CTLX+ 1WRH'YP|HF57A7NOU;**21Q=&!E+"#JH!0!POD)V)R?:VLHL=.T'$ M:,,!A D7MJ&/%81EB6=9IH)OBH):#X4Q//.NB!OB[!R2<=Z6)T6D3V_(Z/#H^ M+1^PA2<:/LK$JI0QF+K+>%):=+-B5;K&.+%(*1!GJA@MH2(ZSJ>M8+.J7]4X M4+E)0.F-8@7Q-8AGZ6ZHX4";GCH7<)?]_|>|>WF3I!O5(O.80-;^4%10|C:L MR]3UDC"'"9T?UJN=^LFLMN%"(+W4)K-'<"G).%G_JUWWG4\,:M7@ZR-%:MU!,!P$030@8ITXWSC M'K42=;VABQ5D-4"FU>*7Q<^2=F-80?B-?,(7QWOGGV&4)P|(5$W=[E:02[&Y M=YX+2)08E75$N[-Y5>(*'<+8(^M"# AW8? "_:'T M($]T!IU.5]PB23@'NS^*8B@&&GQRAX*6F;]#=V;A:L/$2!M[IO7ENZM2>C-)& MYC=@DR6KM>G+BHW')@, ^7E JX:R#"^HRC1,L^"/EOM/M:W[M&I^"<8.!C<;" MW@84.TD8UL_?:WMA'$_;\6^@IB UBYO\"K;'<]2EW^S;WLH*X BD$4O'A M/8;__Y+W#<\?+Y3X7^5Z1Y?QK&"(NG9Z$3@,,9V/<"/C!.O$=ZT%#(-+X_O:8_"MU6[=V;C%F'] +Q' E*=I)[D[]0*)H5S)CHJ"I%604J,K7#*B, MF0XKH.41U;I\3$XO!_R7 ' +Z.,Y"SDJ7:\ROT"K.:P@O$C\R^7V!:B MP<.4MS!@V,FYY1_%U]_P!@PC+/ZT6CCWG"1';S)+>;X^5@F3- :!G=11_.D/J7/K'+0J0|0HH,1MK2BO,_M1ZL4#B!5>,4MS:\$Y&4AJEA3*;.*BF(F9=-/W5R@W]<\H=HZC=6:3,%?=?J8 M]}WY-;C=W+:,*.VIH;\6*G!SHEKUQ"J,;-0|CYW$S? M8@7S/^8+@,WU D>NG4?C0O%\H*F408B!I9L66O-MG0BRT&)\561'S|N*=INPH7GN7|>7R/>)8A\X5#0\)N@N<24+T=#>BC6IN[D M3]PB28$49BV<6&!4SLO7"*.4^AC8"A;EYRF#?5"91;2-K2"%MP4|8BF|0YX MG3S%)0)/QH-;|_(GLFI'T PTH$YE+VX='G/XM*_8&#;^C5B%\5@$OI>)44IL# M=7N;WS5+W!DCUU'=H?4FY]=-JF:S+/Q[#_.\Y"0/!8U/)5D\KB.1%9B4&"H((=(1(9PI39>[E)Z#;/8'YC%N;.(P&&0+Y,#]H6M[1B MY=:(0A)GZB>G!%RAG;?U)+G,3;YL(" [#*1'E#_"_6S'A'HM1T"=]KU8"V4>L M8!VU8S,CMNK6%C8T+U!:>++59O3/DKJ)+$)]^W\U++AK/BC655%3*WQM%1271 M0NOWMH+8DX\E53IO {RP!.DX)OZ=S:L3L /+U<>K7*TD/N(*B^T)\K-7@=\K MS*Q8)-A0E6#?6HAP^1^XEC0DJ1ZYPS+5LIH H.?0-"^5&#,S&RL6H8]7*=YH M%!QS2_"]X)\X> ^UPE2?NMXTG(!+$<8/ 7L^B[N)X=H&QHQ5[A- %,5U'(&HRQ4 M&-H-8079>%'P-9<<0"(%%PABBRYS^1$]V$]?#LMAW# M"L+UM1AE.FGK4\&S]%V"KB"Q72G:FB=D\QYN7L,T=D!" M0N$,A)BL6IR<>MV-$]BIDK'2$UM#9 VM.&M%X'E; ^,0"+U&=#]SG M!\RON@+J2UG?6++=NPUGGAU$.Q"%GA: UG7'=7,?\X2QF*_ E6J M[U#?LH*1HLSX7!T4/KE5':P@*4]-6.U W;OQPW>E6JAJ;U!LW.:1@_S,(C? MZ"N.\J,E1UES$H+JJ%2M4SNVY"|\=N=U-UM8.0MA[Z2.;IM"+XS^A)/&<1-*A" MT=QX-!Q-B.E;-ZJ_6<%W+(3BT/=0!J8!C>K6)E+/VJGAGLN# C"E,1? MJ.Q@R39FF5WL/W=>4 YN53:T8E5$;=V9MXQ?VWKJG3;OG80RM1,%K>B?BQH M=[*"M.$\1F6\G7&!5>5OV\'HPJ @QT+42+1OZFU>&;3!>("(@'!#6[P#M9T M0\$S*]9*:F_ 4V$E-_*H#QI8RM(M*0[T$M_QKN>G !5:W(<4!1.Y-.-W?T@3AIM1S3[0M&+V]17S6YCJI[M;E;L#2Y: ^39@\|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|$F?)> E]>: M6;%&NE75Y)$;VIVM()4>*U4^7[F%|>VU3%TO":.,5:ENJ\K/5O X0\IZ!*+V5A T>-%54W=(|?-6L%OH.*[4!-R\A]HH^ZGI7*\@L@*F])@.(M8ZTM;+'<,.A96^9H$V\ ,^LAO7""P&6*'+;$>IXV]0M!=:WNR9 MG16+!= G,#$\/Q1LCPQC0(5SH>YA!5$GA>RS.H.P+\1 L-U'M8(Y12A+62*S MT#DB4NL("4WA&5V&- "^L2:&J&X1B-N--N$;>_CF-R(^&K@HPGI.&A'C _,^ MU<3U*8-8L2/Z6D"A:UK9C6$&X(*Q/"<*C:F]^&V;64]D9U0Z>BRO?O44{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|*98KF5I##8 UIF2OJW@:# MSF4.)^$>17D!0Q#[^/| <2%OZT?A416#S8KP9>4LKS@\U46?N:;GF+FIG?NI?(M_\@A4]MH#0*XZV'IXB/ 1#4B>>7WED.8]5Q[>{F+#P\>_?]@[G8DJT%HW=VL(*7BXC M-41_GU^P@VF[E%3/O#:YC6+ \NWU;UG!2/%:RPV-JO96$*1TA'X-7%8?&+G7 MW|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f$$T>EH M!8EXVX:968)&9K&P+"5B5%,G*TCQD "$]ML\M -. ^.F.*GQVX!<$,3HMAADN! MYT\85V_8"X `X-72+:C+FMGO;IS2(E+]PV>_?@[G8DJT%HW=VL(*7BXC M-41_GU^P@VF[E%3/O#:YC6+ \NWU;UG!2/%:RPV-JO96$*1TA'X-7%8?&+G7 MW|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f$$T>EH M!8EXVX:968)&9K&P+"5B5%,G*TCQD "$]ML\M -. ^.F.*GQVX!<$,3HMAADN! MYT\85V_8"X `X-72+:C+FMGO;IS2(E+]PV>_?@[G8DJT%HW=VL(*7BXC M-41_GU^P@VF[E%3/O#:YC6+ \NWU;UG!2/%:RPV-JO96$*1TA'X-7%8?&+G7 MW|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f

*6W,O\AKN'&Y26_:+_>Q.F$9YX#*&&:5S@ TENXY;|K5A->!U$Z!4_M$+!|1Z7< TI6.TB5/C'ON..05K#E,6+V!+&TOM+|'%42QZ%*0B2(DY3Q=#]RR M^/]<"2;[\" <-8$I((D!8TC(JG2_2[%>LE]%U5+EQ5KV15M*3FC[H_C"U.!C6] MQO?+!6Z'Y#[=\69@!=,;=K>Z;I-65RO(+,>]'==HB_"Z8;&<:4[- 6Z"3G:0 M!MNL8D"6)W7(6UM!3*X D5^;XR0HO807?,RB*U;/OO4CS1NNM+,$XUHEN77PZO9VW MI058%&)D1+$5ZT]^$K[5JF%)?QGB0)K=(# A_%Q&5:@X97M;6"^UTJL5Q_MG;8G=A#LB!.F807[=8IT@0U`!F?0W-<*0@M/D4XX7'1O4H?;6<$0J3E+$VRL M37\K"Y*GV/THWR?x5;D_=9UM:\A4\2HPP1V>]6C1%T5^&<61"5$%QGAVL6PHE+X7!- 'X6H0,%:F@:OT>Q@//P5ZF",>1'S6_WBRATW/ Z"?KR_>R$%.),@#$@VWY2C&{\Q+* (6(>$0*$7W=9] M "M(SE-S&?0:1?QW5\$:'N 10T6)OP;A;6+':U>C?55 M(2(I>UA!5 71;/6<./B0X#="%A&"5'TAH'1?&7)PZF!6L:(C?EV>4:76T@D0" MT24("00/?]5R"Y=. F\-^)M/E;L\<3T+)!1N_4&^9 43UXANZZR6HWQCB%M: M0036!@^.Y[*DQSBKQ,-$4W:+R@C3[VT'L=7Z*:UK>OW-]H6E%5C&A-6#]%5-M-#/^%,O<'T0&=#1'$OS\,C=)M9UY_IL&_-EF:>TP.U:;?FLQIO@DO4+FL M0VU5Q_RX%>>Z507ZlU!H:FHWA/D=I@2DU3{GSR(%2O>,2<|RSDWAR_3:@;& M1?(R=;T$M/9H?^M6Y7#11Z-3C;'PO_<",Y_NZU1+[4$^097>9'R?(!.9OR30I'5FN>8T/?0ULA60J 4EF_@Y(\BT:,1M0 M5+X^?P04Y>N5]0,#?,<*!E:>@$\I7FI(4SG0H,7K;PD*A&%$6AVM(%%EC4)-2^LL2]B@J. M5MK2BO605#»^\OPTR=Q@#>EE+8>P@NPL(*84@\H43S]5>VM($C75M_%SF_^ MU!&U#%XY5UC'W"95N2%K8W[B%ZG[@@5S="RNG-K$!6VLV%K:24#V)O@HL+!S M(-S'D# "W?T=W[!(8ZQ#Q!)MJ1;+\G+S'IY8QX7K M;YV0>#7$1^$3$,=Y413+T:E>]O5!?2#0[6G%R"W/";>"B9IS+1,,@H3,"\)>?M:P@G^%:6'9'MDJP%)9#GTI4!1:=G5BK4M(4> $@(QB+^^8D%X7+T'6'5,GV// M]*"-^,C I,$?{W"#94*2XI?]TERJ3&%7!/E$WS0#UH@$0KO;_[Z(W2MD>-Z M_K%X'>J[D5L-9,6N8LY^X?LX^\V*B7Y[VD0$S>"HYEA.5]2&168BSK=(S)Y696)ZX,"$0 M%[E7*0" T$A#:F@HTD]{,Q+P3O1P#GM0J"5T'=3\RBI3^[3]_QV'LF*\@&U& M$(J,L*ATPY[;CV(%\5U!..N5EH;MG2/;S:2O8G#MN+X[D5%SZ3AQ+]YG+&EM! M2O4AA#=^7ID^BX(54:73S|Q8S*WN,433L6+$1NY0AH3,U$+!=*!W6KA> M.PQG!3OR(T;0U- Y[V!?\3UD/M:&/LA'4]-#<0UMX0 "JR\3)-7?,Q^0|6B MRYJ=K"+F-HJ35H2P#E81(;MK|O+!L":QN,A;FO#U#4/AJJ'/60HCX2LM3W3 M;SX,RBZV:%^GQ;_)++YQ91.+WPl;Z:9Y%+*%R?S,MDR"P"&OIDG*AJQ;0I-;=R M3ZQYS,1TV9EG4B$W=;-&3YRK2+A^K0^3Y9JP*,_PK+/-<)/_&]JV+!P3_WJF M1AL\-W2+_RC#"Q,T-(BK16+ F@":/:\U;3_@&'T<(-(+) .HEKY=IG(1[%.7N M97 XX_|SY1B+IXS4+]EQE' DX[\5Y.*_ +Z$FVZ35?2$HC=0BY;NO.J6DC8S M,5'B=Z%$B* "O>,%\MD*VAH$!X/ X_Q4-AP%66O54.P;< 1TR1S:R#5B*XO: M;1(\|08POO0:9)!:5/@V/4,77X0^_EQ(+\E,,M\C6]*Z-)W&!.8^(!5 M@VQIZ8G*PKC5^Z&YGTF.0>* *TV+GZ^\E(=65X-7:HRP:@P86U=X^_@A 3EB MLY1>KJH^/1^(=7AT?'#\W^'KA$L%:#X;FCV-L9ZZ@0MPC)NW!^]G?%E"EHR$ M\HNYF!_48"WL@\(8^[>"SPXK%#_6;V+FGJ90|<-(^2|L#3$[7$3.4$,|:W# M(&/U!=KA-G+ML\T(AC4CF$RF)?M!BL51\42CD\Q1J5!_0VO$7{QXE=Q="2/-MFU8(AD-^T:C& IOIL,HE(92.[.HLM*K5J:JJ3L9WL1XJ"97&"AL1/B18BZ/1"MS+>U3\-HJ=D9K>55S"<:Y"_SR@IEK1#=&S[<>P68<<<@_H: M2SMZ1!&Q]UXXL;>5*6[*MM9,_\$\N[!F4# ;#T$V@<,])K29;_(-M.H%__^5LG>?.D@0[, ![]4.YE\=4,!{]],&CMH$;F75G)OZ,4U@G#P3)F#>"_MV=#FC- -2&0H0ZU\#)W4]+MKJ/#)0SSR1[2SB+77]EF#Q[H50]CD">/S_BJY9OP>XXV81C]5BP_:Q>K.(AAA_F[?31F;Q""TV=N!]S"RJ ?;#X%8, M[<>!:,^<M NQ^6ENKLMIX1.H$+RB^#8AlK5)RXIRL1v>7]9?S00)H;T.,HXY M^(Y>|2@BJ+/!?^044R%_5XN./4.X7'D1VB8.2S%XD2.VB!N:!}^B^P/D91B M8!" M>GU,8PUD\|&N4'$;2VI 2#R,.3L:YZTTJ? M8_UG.C(B3[5$9:V-T>"9IVW?[4N)*)\F6Q>T;T3_0LE;V1#P02EY*BW M,ZOU4,#E*_P"Q^H(>><3Q.\'|$Y^D=|^.GT- @LV5" 8]ET32V+9UH4?NQ(6I M=C;)Z"/0;I7KH^S2L|C)5<(U(N6=;U"-T_)VQIC*U:.66=Z4'-;O;X[$W#88 M,Y9OPHWS#; F0&7!*P'F1!8P!N_L/<2RDE>RC.@.(]HI&];X6$3>-F%]Z? += MB5QB:,&${)"7I-%I8D-K7-M80[XB\MN*6)'BZV\HVGJQ%'RH_3BVD4Q7JP>: M50/UK><5IW 35@L;U-[>&N%W2>PEB"4*T^FNT39\"4C9!%&AL^&^8UVTQ[<@ M0HX/A4? ^3D58EB:W"C@W2X1)\"UIX!3\Q^J/SYZQCX$>LT51"[,[ION/SS^< MX4Q_YI]_M,0%1?/W'-!Y%Y#+ [TNDV<*+')MZ=O\L^A.22FIUG$I6B9[^LH M'#4C^=2Q@Y2^ 7D)OR'WDDWL:67&GS- 7J_=O<0<#5DV>8;10IZ(1=AL&*36 M).2Y3Q[*@4@I$#AQ9A'/IWW1":Q&LP&:DLLBN7B?#7,.7S3-CKM9X'"%[*S69 M2W (+EFY14Z:NYL^5TXY:#5/["PJBFN?-+6+=PA>G<_,4CB9APB$MHDQVONG MA3=[7F7IE;*JDX.\5V0C>W,6>I#Z>C[V>96O/UE9E;BJQZM@?Z{<4WKZ/Z"2 M!G3Y?X LC1 6\(''-%[*>+^P318F\[^,|_BYU]?OV7*FOUB'G+&]/OZHN?PZ M.$=-4U)1;D7.IUU>-G$M6I\4Z}>N-'[X7W#N+)%@X GCFM\$;WOE0^RYP\$<_MV0P-25GZ_:GWH[2!59TEZ'- GJ;X!E6YXQW:10=\884!?RTZVL0 M,.!P\(DL)P[V\?K*6O[CLR5/D0X)?^W",7>>G2.[6)9; MQ @1:I,(;_4U"_O";S%@/"%R19-VKSO'/8ME@Q4NZ;9!44?+M"SXF4[ZV[M&]]5/8%OG#R<17=*9N_$M,!*07U?O)(I=WYKIZT5GF/KQ+S Z=39.V70OLSI M/?#42S#W/=#U5=:GAD[&B*&F3'0'6^HQ\H*M=W#\|"1+:%'W.8N$I/MPM>U9 MJF]H[FRJ-OGDH.HH-8]LG& ,Y;' K359,*SJ5??T+'E6.PUVN-]GD;$09>Y M-B[0#K>"4C+,6"QPD7.IUU>-G$M6I\4Z}>N-'[X7W#N+)%@X GCFM\$;WOE0^RYP\$<_MV4P-25GZ_:GWH[2!59TEZ'-GJ;X!E6YXQW:10=\884!?RTZVL0 M,.!P\(DL)P[V\?K*6O[CLR5/D0X)?^W",7>>G2.[6)9; MQ @1:I,(;_4U"_O";S%@/"%R19-VKSO'/8ME@Q4NZ;9!44?+M"SXF4[ZV[M&]]5/8%OG#R<17=*9N_$M,!*07U?O)(I=WYKIZT5GF/KQ+S Z=39.V70OLSI M/?#42S#W/=#U5=:GAD[&B*&F3'0'6^HQ\H*M=W#\|"1+:%'W.8N$I/MPM>U9 MJF]H[FRJ-OGDH.HH-8]LG& ,Y;' K359,*SJ5??T+'E6.PUVN-]GD;$09>Y M-B[0#K>"4C+,6"QPD7.IUU>-G$M6I\4Z}>N-'[X7W#N+)%@X GCFM\$;WOE0^RYP\$<_MV4P-25GZ_:GWH[2!59TEZ'- GJ;X!E6YXQW:10=\884!?RTZVL0 M,.!P\(DL)P[V\?K*6O[CLR5/D0X)?^W",7>>G2.[6)9; MQ @1:I,(;_4U"_O";S%@/"%R19-VKSO'/8ME@Q4NZ;9!44?+M"SXF4[ZV[M&]]5/8%OG#R<17=*9N_$M,!*07U?O)(I=WYKIZT5GF/KQ+S Z=39.V70OLSI M/?#42S#W/=#U5=:GAD[&B*&F3'0'6^HQ\H*M=W#\|"1+:%'W.8N$I/MPM>U9 MJF]H[FRJ-OGDH.HH-8]LG& ,Y;' K359,*SJ5??T+'E6.PUVN-]GD;$09>Y M-B[0#K>"4C+,6"QPD7.IUU>-G$M6I\4Z}>N-'[X7W#N+)%@X GCFM\$;WOE0^RYP\$<_MV4P-25GZ_:GWH[2!59TEZ'-

*$4?_`3!8;R6/=V/0SR3WE#T'-KUQAP4![ERV4S]Y?D!:3_5C=R'I)KZZUZH-M6?:#6*A28;(P_#]L=VAR/QND&ERP"P^^6W_?%/ M2]?U*&VWP2Z,]M0^>(ZF*ZV75D]O)$G)V99%QDHS/&$ >Y_&<{02GCSW# ZU-M.(JD7;Q,DUDE%8?&ZOF@?8QB^NK4Z/KDT]U,\=W=W#K3Y@WK%>2=CY+DG+ M;DNF3C;6Y]P#4+E>L%Y 53]_<;-=/$N*TM<<;VZ2*S2LK3B6SI-^?]DN+2#[M1_)T,'Z_@G.KDH]<;PNW5;.A39)[4?=WHI4])OF_4'Z*]^L^-'1,&LG9WUX> MM)7$P*I+_ 4^DW0|S8TR?A'M;7Z;D/ZV"]U#!,'$6[L&M]#;.OA#;Y^?>$K$> MJ0%PC IW.@VD/IT76#/+D'2D-9R"DN"&_L<##4N'\A+7 M"$#(BU65LYU%2X\0!*K',)U1)M88#S$EE5$X/CL$+8\-ZDX/QJ*C66K(@TLO M$=(NR1!^$HM67@6%I5998L&EVL2]+_O4!!6GKCDO !{:CN0675Y-MZ*YC^V. ME^+39] M_ATG%_E0+]#ES;&)"V0D@J(QJ+RX\6;FV1)WH%"0+\!7K8"_O<M;I%/_#GM|)ZQ9"?]5.R'45BB_RF,\U!;_DUU%'M98/5,:N=95X2\0C':ALPT M+T$O&-)/@B-[2KGJRB\Z_F$BB$) ^TNI!^GL%6ER^?#-^H-6FC"<50\;\|M_'M 7E]+,ZG(^8DU"V;IC@$BW>,2."AJ&[@CI H(\'XYB>)&;I$<>'T0>=LI&2EYX<(M1-*")D5OE#:%\85>A!X1Y MI.*#&Y3Y;5BN.J_,$*'<'O4I>:8*%1GXD.2\YB8?3Q$>*K.OH$Z'3s]K9-&Q M'AQ"I5;HX>RR=8R;&GUQ/9 ^5PAO%[3R_6)?E+MEM4_2//R]W `#^>9]{&CSN M(QSKQ>IT=/HD,@QK ! M=E{VL6$?(*2T*MQUD1+]4HJ642=HQ#PFL3^%GDX_:"2I$0+#.'G&B7[V-HEZZM1N"&NV; M_*60Z08+>+6XH9P^@]# 9T2N%)82"NKCRYBH/ , 9+F.=ZE2MDS&!+KZD@:.31K$QC/L5]!"$^DM@G%5BAF[5K&E,Z.":.9#!D:^EI,_9?B^NK%PZ>HH'A5!&+KVHAM9#0G0\S!)8 MZIB08]B0/T0PB@+S29JN382?Y"1%:5&PCJ08\K=<.M\$3>,$:Q"XW#J[J)^.+;J!<=EC[F:RGN2RZW/IYDF]M:ZV\XG%,]HHY&<_V,]^V^V)<(=KHYF3UQ>9Q>.O01>S,\!%QPNIA@<L]XU[_)9*Y+#7-YIAWM_^T. MO7]<'$?,>ZPZ&'}>I{tX8U!4_#0M2>9K.E%";,W!L$*?3-518*\[_A9+SLKW MA_N>YD(?9YIW*W!X1'V<2S*FY-,Z2PK64^_2W9W@+PZARL-<\C2E&&0B7\'G MIS/\"-B*?8F#VB2&@MMO/B:"6Y14.0R8:ZE(\K2Q8*VRBQE1&O-Q%U-!6\UL MM_1X:G7;GM!IRK4VF, 3H /:PEMNBV71*7;V<0[%-/8!V'6LS-2+@\A6S[3 M5*3XTC->S)YHK='1!(P 98,KCP8NEIWG.OT^&F//("8J@^P'J9A[>19Z"0+ M',N"""XHS_?BP.,5=\X/#D)C6O'2MW!$?)*lQ3AE@#MB/*0+X">|_OLB ;3+ M4!%W:)D9<^W\#P*G 9YDN*T)D'#33,URJ{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{Z)TKQ8F"A4%T&..4>E 8OWPP*M(P%NN?7EQXZ1&/W.P5\fD)6=D1 MQ0(50;JOYCD_%F34]?J"'-23OLN28=5+&G3E>EFCYDP>OC>\6_DYYOD4XIU MB%&S!^3H&7;2;,T\?8FX++Y0%+!-JNS&FF>%J2VYD:\G M4EKIUK:*8(=R?($^N9NIBA6EF3W95.3^&SXTUZ]1N*.I!)R&FN'fE'K$/T]2 M[E# 7TM64^WQUO+7D+DN'ZO=+BW35ZZ]WOO45KI=AX4F!&(%X<87D85;:E- MS,Z OSSLQE:4HM,'UMN1/L/1?2C|(-Q>5L$[4;PVR6JQ6KVV(8AU\>$$SYX M"7>Q1UYEP4O,VQR,MKJ{2]RD\I'OR/.427!L5Y1Z7G*;Z]XZ\A[X&95O9K8? MH;(EHR4$1BP]^2>W)%/;Y00P5\)&/T&!8624]W95%08B7'D$%$IRW%)1D$JRZY4,5A5/2T5\)M>O829>BMU2|?'SNLR%R\1 M;JDX4?/H&L+^'BE(B"'''ZQ09.*?+IHEVD5/(`32 'IJ]+7*YS1RGJ)R\N MG:O$*9!=KAKE&BZ:=>03BEOVH>9!+IV'SJ[_S[K&+1VX' "$F[BPXPJI3X<+&PYQ*[:L7B0%'1N M:AF1I0-TKE#B%#PQ\2P&).C%47%81Y(H@_/A.(JZ MQ=A1*5I?.G$'!8.P"I79 *B1>PZ;AFE#\=8[//2#@N;>.X%-$H"T_?44E8? MXM$AA3VJ6#WKPH8ZGK7^ZX7[%$MZ&4'./<;3KT=6X_6WCXV71+FS&JB_+WM+M*J$E>G/NAP_ND!"4<&M06K@+7MUWTZ\LU\"T6">% D+L>G<-2LM^ UL=*FX9 MO@:TA=N_5"P6$C4!&]06;K]0EUOB^H0-=)=[$;7T80./5NV=]5BM,RB-:BXV M,&E5VEW>@)2"D UL6O5U!W;::XTOA&/W$1U@8QK7]J\YPE M*O7.H+9P-X;\2< I/-M@]<$-\4:&WB9K\(H[KR)P]%X"XH M0-PB=5'?>>63&Y0^N&;.+.CRB>LM6\FXATZ]\.WO'$Y0C;\"ZJ;.. " NE-NL '5\NY]=H;C!9;8VE&RG!H7 MAV^P6GA:LTJB):.5:?8/213.?6D2_0? 2&L,OM|\"==-'C94K[MW M/+'BG/0MUK,##?0SZ/3_^_T(.4S!;YT&Y>\!VF+5I_FU!RP]}WUZ5[(-+?X7A&\N/HJB M/_K)_OOFY8_O<^]+$B?[8S6W%_QE5/FM\%!QAH)NVF'[:[;>UM@1?ZFMMR/:MZ8R6.JK6@=0'VH,7I5PVG(J;?'_*@@B1DD%@?_+]AXW_@T*8VDE*PLS3LDX[^=R"W+*4)T;I6 M:5VVJ5NUJ*:%V$5G<#>WYU8])Y^]C M=GMK)!"OY'I;,T;&M/MMM+]CK"YM9?,0G?+.T!S$^_IN, M& $_B/M9?+$+]U$HRWO3ZL[W$;&HDNI]VWZLAA?OPA?F\'$.*MX?8R\;5H] MV%6EKKIDGAO2/:T!OWM?PJLX-<56_ T[H%?PT[8D).K!0-Y;A=KA'Q",6;E M"..[*O;XND V;QZ^(SX7B7I9(^UH:D8',HY:EJO$[669BS"KU3*ZP4-F& M? 8SAC/+3EA.CR@04H/\?\|@[32CXOS_D:6E{J?\1BQKT+;^MG-W_]X<,I:K8 M9KJ#IO5FA'''^?1#N6_^,T5TMPS,1M^KDCDPBG,<+9.1.^.,B:T7G4Y(;5*# MTKCWW;YWS9U"]-BXJCC9+&\!A6@:U SUH7,(]":!,XN^'GH7X|+(.SU#?QJ9@ M-C@[0GQMZ]9+?6M"AXV">&L(+?'=/3*P>3M*NI0?I9.GQ3&S.XJ LOF|'_DB M8^"&C,P;'CGUBU?T72LF!,XQ78"8('RL*UG6$#A2PW'ZE>2AP"7B*!1J M\E'6Z^(H&&>)2KI?Q@0B/T*3%!*X.8Z#DL00.L>"4S^#'-/41R CE.QM!^H,D3' 9BT)6;>#?\- M,3=TO9HF"/X+-((G>$A-X)?T+B8H?EOT&AF^&--T/YWZ+2W#ETC%W1POBU% MA[14,"9\Y1=QW*PU)EC_3:5I<'O@>]'"LI%0)>CM\1\|IAEJVI%"\1\W! M_S=ABOS\+HRI\/,?8L6/JZ0WM;Y.*/ZZ3_2&)B4"B9,W)],&!\WLICOL=\GL7@[CMO9U8;NLZQ P4V1$C4%84T_^-F+ MR+NH7\M?V*>23%^+Z8LYWDXH.:Z_W"5A-(:V+M66F[@PP\XV\7^Z*<2.G](?H*OM62:*?WVFW(15B^OST2 M@W\765GQ^E3.:N-I*ZNI)\TKIXU[S[|\3 7]=_1A-]QH@P91>5O53FE[/8;2OTP8Z:S[(\#C>1]M330 MS!M(MYYWVH6;I*,|\+WL2S,41VG5DV75&7;56;%;FN{3-X]T2HA4QR!A+M'-M]&+BQF;1D(DF*6,<3[^1U$*F1]K I5M=H:."X21P'0?]\H'A<0.N<_>SI:?C M&44*]P^QX\IQ+*0W LO9Y7CRRUF\"6.0Z&-#/P_6N.)W_P68+CP'<;NG5 M5W $?HC$EI\AA\B4T:#0 _%#9,Y,\#)^B.R:*:[(1:?>&/1J?HRD'7.^S8^1MWV/*M6D$/7!W2_5461B)3UBX?/=*!$MY2&>E[<#BFUA4.;=*4Y)U1=;@ZGAJ M4C[|64Y\M#:TN./S!K87M>,_H:H#38B*C(6&=PL*VWCVXLLB+R8F#ZY'!"9^!4C[@1!/M39B1=2M2M$YW7AS^[M4&^:LBPR-DV?]=^(70UU40 MA!4)|_$V2?=ENQL2_1/9,_5VGLQX1{UM$@=E, K]YX|K(1,9?;5^L#U4@,] M,56>U25'Z/|S(UI9TUZ#=X,"R03T!Q MC)(TMA^+:TS93[\<\!$BHIOUB>5-3:&>-:#/KU4J9X[;HTQK)!REST4#$RET MGZVW3RG*, I>[<7_%'%FAR-Y_;_8[[WTN-Z^A+LXW(:^AZ65[R<%>9)]IY1$ MH1^B[*0V'ZKO+9NO4,$M_"PWG;R<>L$W>U|GC49BS|8-%,UA>)52C+-F]> M_L,7M(CF7UPRJE\PK..\Y:D)H7]=KM%?J=T_",2UFDW^TV+I4[UD\659YG[MGEX(LS3OP(?_=H*.O++93HMB1QG_KKVN)8J"|:.Q*-^@S$_#0QZ.JB.*6MN! MC!K&1FNA&,9K+%FOI=O\1$6:9%CXX=.S>\@#M@U/T,V?/;K3W\.X_)0;;9N M.T&LOA#_)SYMKNIMSI 6*B-HVI;:C*Q^^>'8JU2!IQQQV474Q6%3T0SG;;|< MA+%3"?)53?JR:_S4;EY*'YQSD,&3NF#,Q,?"8]I1(#D'44NVZ)@%33K77,E4 M_$:[90%Q<*K$FCG&F?FP4U*3' 571G (-:X;:Z2!&2OD96^8 O)^CQ MW8NG[4YHI4\T@A#+10YVB9) .IZ]&T^*%_/ c>7X88:[C91%1F^]AR?I@1A> M4?6Q:R\-F@]RKN+"3KIG25U)_"]5@3ZRH]>81NJ,E08 PARPA^,]0\;=^&;263:^\0YEY45B;|'T7I.PKNDO2N{$6!2#T8XFBB MF[TK%,=PU@8E_\G:[%.U(U?KM*X[RA,H#:S.5&BZ]1SR)@N;79,,WD9#_@+<89(G6&V*8+95GNF MT=&+B/I7?PF#4)8#;/8_;6[''/A9OO.4JMBl.$\]/R>5>ZC^+++$_V*&T?G5IE M&<+._']@OL$T9R3,9+&'(6QS+6D=T6X;#D">\&]<91P2"}HO MWQS*lF%(.$?:0B9?^IXKHT<.6&' +I;AD-#]562"Y%'G^$UOBI2<=&(Z?A\|| M R=']H_CKV<-T\5[*055*05QNJ?/?4MTLFF"FU$8 M^EF'__'I)5N/8\I@2S(U?.1"(O5T@H1=?YC;5#,?G,*\7DB.G9<&7PZ!EZ,? M__0#;LGF":E^UD"^\B)B=W\Y0RA_]"NK<5B$V1P4 =P $TZ')1!A/U:F_[._M79(^H]^=$DL'?$?_?]{8O.9VABNBBA358N:Z^=#Z+T2/VS(.[/8C1=62\G- M2F#U??,9D1H),]9R3:HC1MO;TL M_^.@E>XDR&\'5,8.)/$[2LGJ;1+Z4U=`W/PO-`X7=]*[$1NV+-]8^[T]+3I M9I5?H5T8$Z=;ZNWQ*Af==)0SKIO+E7 +@XB]TJ@3;O.(K<1W"M7->&TS.F4O8&T$A(<8G(-M%E%-X]V1$B>"&V>]!PHU"@"\-LB50"@ .MHHC MP/!XQ0@RCK".6,**#6J=$&6FL00R')="FPY7.%QBH4UWBB7K @78%F1K#8Y:!'M!%!G5-+$ZGBHUAGJ4]9@"QDA(OMUWAC2.3/##&_2D7W=!%X_+8O9)MX5("-KM6VF3)+"8@_/"X%OLNO'Q5!A6FF TX;_\|*T3(9=;VD-;<<2T^8T6M=A^5=N M'WMU;2G3X@?MLMM;(Z%EE]LC21_(KR,OX\?/L-O;)Z&<$-8R/;)'@G?\3$!. M\6XO:Z]HB9-7DAQ.\+Z/#T5.9$5,R@F4:GD?'FZ$E+'/:7_A]V&V&.2:GQB. M'9\BZ&$OG-(>(H54CTF/&.]R-5A1^5)!+[QH]WN=,Q9N=.+.)Z+EF-BQE]0!T7M"B>%N[$E4D=^KQ{J^V"%,/B5OIT)%8'OU?N9D69PUI#8@O+YNT%-.B M6ZA$!VBF%$ZQ;W.'"TMJ2K8[/S&2*^M7^R3-B4OD.LGR4JU@@*.\#%2"?;_8 M%Q$ID?DI33*L1>%|&)&I?\+.O!?.)BEB5Y73.I9ST#$@OYF"IC\V&&BZZF"7 M$$GJF=V=M=-=:MLS+ADZ3IPN:CQ= C14<>6873]5#, ^8 .J*.N1PZ>#QQ:6771=/F4 MEB E2\?$D.1(]1(E)6C$:V+9;-M-ZBLC[<)VDB4R7$AT'6^^9LY0S8 JZ M6R.0.:]2Z*BN6-4)'C%71Y(KQ[ER?2$1Q;9&C>H2:,G.LDR%7:5?NJN2/%Q M@.4U_OY=^(W\B1-Y)=/-GO'GI&K\#8\O7V2U;% 50*,X>5NBS#WG=GCZF9QKLP)BF.&BD\,YU9DT>Y.-4%YO\HFSR>&]#MB^@AW+)HD^DYZQ-1SZ14!=5X M,?QUUFE]|KZ%^V+/G%C_]D18SSY=?H-YB+:.#_?M:L<#I9BQ97@]YN5)?'QQ M>;+WN|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|KZ%^V+/G%C_]D18SSY=?H-YB+:.#_?M:L<#I9BQ97@]YN5)?'QQ M>;+WN|VT?/:1+X&V;.^+6?)BEE0[UEQ%AB%@F]IU@Y,*-)'"9QU&9UM#90\M1VBDF5%EB;P80X=0+=4NQ95K7&W%441$\]ROY2S5T,1==FD5RD7SR*GXESS @AWOA5*G\OBI'?KC:<_&#-UUMP;M?5R?Z'1.OOWF1T40QCO!$B@/,_-2>?[T=6K[0A18O/\Z83=[G@DO M%X;^]MM8W" 4Y.2WA51GI8\E'ITH/S;/(W"'RM@3(ZPP.LSQIL@ J=R>Z%5Q\-8%L-Y.LOZA^1QD8$=2484<0XQ9.G\6RQ1H92_^MDMB-H8>,ETP%RFGWS#8[2NE]MURLN++^=$ Z;N>>B5GZE]7E8L5E%O7+KN-^ M!=-,:=:ML5+ADZ3IPN:CQ= C14<>6873]5#, ^8 .J

,]FFHM..|=6N\YV,PA%FU$'&Q*Q@BA.0>T"HI+&YR@P"BX4IG)#Q-M,7!%9]N3D($XZXHL2I%UE' UQ4 A%]=1/.3U 68RKZ.43S2D4G.#78=_;0< M)B,[7]|ZW -3(B<;,D(&CDR&?0XR"N>!7]<\4"IV8$9&0T-M2H:!OP8RU=HO5:.*&ZY3+R|-).I\0'X+0?,&8#NO(8.@]XQDU51Q'8$)>X); MQ<7QAQU4S4Z07I"

*<$R9YME&L)V,"F+^ZSC|&G^F;$QUYMI&O;&,"D{]!XQCY MRCDFX/@[-#@DZNX8,?Z#C10X\T$A11C ^H$858",@ #;H-LO.V0$)C&+';M M(R,@@+N]2Q=7,@('U,N;1 TG(WB N|HH5HHR @I8?Q08@\H(]>!T2V;1*B/D M@],E6;6RC#A*$2M>6#1H*D7D>#+8! 0]=*=*+*AJA'9RF*"KG; 0;%<,]A0OE((X" TQ EBT\: 0.FHLBN(IQ$(P.F-4@5!C4 !4WVDUAXU0C],S7%:Q5,C (3+;GU48U M $[%E*BU:@0(<%]F8L56.5#^]_L!)OC3OW5^+G_%1[9/#NSZYQYF]/SV/T7G]:9!Y;XMPH%09?.?O8B4XG6$ MPL;E'99YXG+T=OJX2*>)-=X=+"SQK21(!\2 H7_CZSI.U:QB6$RO ;2](C% MI%L,.V;1^]B/"A(H_I2DY3SR/ U?BU}=W"2/24S*8>/Q\6"[^SA*%:Y5T"'B M,;\CH-#8ER*#?9]QB!,FB2GB^0?@Y$T1SR>/ M4U9%/ZT!O?!HHMBPM=;+,^\L>T;O*\"X0(7;PP;$3*#S%&L7S9)G"?#X48]"IE)/9=V%,3#)\B0V=5+;,$ M[A])@S#Z;NTC7(3)B:EGK'B%,0INO33G%&<<=$8IW;.B'[A L$$$,18,BBJ 3 M*A1%_2K[355=NG42.K%R&FEPOKA&Y%@6,>LBYVU=9,RY0SK_#)Q.P1:EGBN4 M#>H0F;R;3]FD;*L4="K9!RC67KUX%Q+S6\6I*+_]5BN_GY(D^]2-_=.%9)

MDRDZ5@:K2&%7Z!2R%W*T6'1](V6>-RS|\Q\\4EG_:'ER S% G6/3QMI4V1KC M8+Z4AO;>%;;Y):FSIK6T]^ZJ!$EA^.2]J!L$@L1S!S%-_IZD-+0V:4GG)I4. MN;Z 9,XY=G:AG)HTN+VS0\6723]9%$:PQ]XCQR6=DX?-K$Z8Z7QDSIW5PQH9 M0@R1,?+WT>=<^;&9MPB(/'G7Z@DX6U4F>MXZA5W*Z MV#P[U'QQK(-#:13KLHSB8.)*L7%

{ZZ<]W8'$/=Z!?;P1PG>)* M^,Y)/2AGI>AIG8ZRU="WI^,UM;F!+<=0H=(BU17,NHA% M+[N#-2($*T!#NU>0W'-\<22%

M"NKZ_6VW&W+,.1IF/$#*LJ&*H]\X;"M,_X2QQ@B(B*C!68;S[*LB;MWI'(?]E7 M)6B(R=*$\=$LMMO>>KA4POS57HLBR3(U*UZWGZKC/Z#J8R MZ4^_?

1)G3&@#0J]A=X1N[A%XRE'>7:\QM4]IL@USIU:S.V7:\AG<%HX@1-VK M8ZAJ&V&#$WF,CM0COBZR'/=*6U,),9{@_P7=M#/H$)2EA8E#L=]_5/I)F_6V M1L$9RF:6^QS9ZR0_AU(

MVF5.:I!2A:X0C';A@2]RG:Q^+/%0)E!/D\1F=M2%9+#H*D7D>#+8! &8983P-Y'AQ!T6I46 MNW3TB)-Q22GN=QUQM63D9?/W!?M&UO&0H<+6/%49]IT[%

MD%N\/O9\;"IW);KG36$$>Z%7HJI1E311+[OA<*KZHZ"3P\[&7K8(X;@OL8>5 M -P*@O.1DLLRS(895!QE-3^KLAMT6[UVNA?AP-/'/LR7<_ +;Q$-/:AAP^+ M\F\U&,&_|

<6D3M+K%Z.$;G*UC/#JW0LC,B"&FCQD=-+:..9@J6C9GR^(6;>%Q M%C>S!T0R-)92T/V5BUEFXIJ:64/8.V9*XK/5FC!7ADME>)?O.5[V M=A0X5 U?

%+1HIUM"Z6%>;?=V8YNX&!W1%MG$%S%7PL M\IEW\Q>$ M2=;65ZF>DLKN_V&4C_"!>YC<-]_(!EMQH.7EDMZ#-YKC3,C^1M MK5.*,[0(4-85L)XQ(FGHXYU<5\CJ_T.GY1-

PX24NTE%//@-JOZ_U7INO_EO M7KQ#SU@>W&ZWR>'H"GL2D=_U2AHIMZ!7<)%5AC5R2WM:YCX;"2.-%+&C#RP MC4_2-R]%5UYY'NV)C;"G5\O$M'B9G MG7G\U?

1NDI6(&2\Y%W",//!A@MQF5)UT)@3OKS),*S/X).F,95#+9%T9G2OG; MWW;5+ ^MMM_4Z/FM>SJ_,?^6-7U(851$AE]O*\5T'9\,@!OTFE.8|<^-.[M4)

M%^/[+"N(CE!Z=9LZK,Z\5:!9,V"6?/PPG%$CLMZ6?-P1QDP1WOWP"D)>$ M&W1(D1!ZM?EWM2?M4[_]ES"%]Q(<0:"4E!?EX7(ZEA:DVU1ES@D!9*TM!/_MND@DFM{=Q2?

G1[]F5PO"WQ8-@L P\?=%$E_NA8%?Z!GML=Y6I*5_8!1M=RH: MV$W"!^?/%=8#JJ&LY(7'=4D)&$8J_;C$KXG+/ZZ;)X8@U"7,&V8A5K+] 3/

MWSX;/#*O.9S@6:;\9:,S*!M[LBDL.E)FRRY0I'Z<5B [(P4"IGT'"#KP;D/-MR:T';0";P4\B3S>5-G$_;.O&N=G+K1MM !CK)N>9%Z^CU#A6W[R:WXY*>3QK MQDG D-,?

{!5MN!^=OK.F#@>BBB/%YTN@=

gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0000876343 lctx:AccountingStandardUpdate201409Member 2024-09-30 0000876343 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000876343 lctx:RoyaltiesLicenseAndOtherRevenuesMember 2024-07-012024-09-30 0000876343 srt:ParentCompanyMemberlctx:SettlementAgreementMember 2023-01-012023-03-31 0000876343 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0000876343 lctx:CorporateCreditCardFacilityMember 2024-09-30 0000876343 us-gaap:NoncontrollingInterestMember 2024-07-012024-09-30 0000876343 lctx:MarketableEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000876343 lctx:RoyaltiesLicenseAndOtherRevenuesMember 2023-07-012023-09-30 0000876343 us-gaap:CommonStockMember 2024-07-012024-09-30 0000876343 lctx:TwoThousandTwentyOneEquityIncentivePlanMember 2024-09-30 0000876343 us-gaap:CommonStockMemberlctx:AtTheMarketMember 2023-07-012023-09-30 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000876343 srt:MaximumMemberlctx:LicenseAgreementMember 2020-05-012020-05-31 0000876343 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000876343 2023-12-31 0000876343 lctx:CarlsbadSubLeaseMember 2024-02-012024-02-29 0000876343 lctx:InsurersMemberlctx:SettlementAgreementMember 2023-02-012023-02-28 0000876343 lctx:MarketableDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMember 2024-09-30 0000876343 2023-09-30 0000876343 lctx:AgreementsWithHadasitAndHIAMember 2024-09-30 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000876343 lctx:RocheAgreementMemberlctx:IsraelInnovationAuthorityMember 2022-01-012022-01-31 0000876343 us-gaap:NoncontrollingInterestMember 2022-12-31 0000876343 us-gaap:LeaseholdImprovementsMember 2024-09-30 0000876343 us-gaap:RetainedEarningsMember 2023-12-31 0000876343 srt:ParentCompanyMember 2024-02-062024-02-06 0000876343 lctx:MarketableDebtSecuritiesMember 2024-09-30 0000876343 lctx:RoyaltyContractsMember 2024-09-30 0000876343 lctx:OperatingLeaseMember 2024-09-30 0000876343 2023-06-30 0000876343 2024-09-30 0000876343 lctx:EsCellInternationalPteLtdMember 2024-09-30 0000876343 lctx:InProcessResearchAndDevelopmentVACTwoMember 2024-09-30 0000876343 srt:ParentCompanyMemberlctx:AtmSalesAgreementMember 2024-04-012024-06-30 0000876343 lctx:MarketableEquitySecuritiesMember 2024-09-30 0000876343 lctx:TwoThousandTwentyOneEquityIncentivePlanMember 2023-01-012023-12-31 0000876343 lctx:CarlsbadSubLeaseMember 2024-01-012024-09-30 0000876343 lctx:AccountingStandardUpdate201409Memberus-gaap:CollaborativeArrangementMember 2024-09-30 0000876343 lctx:EquipmentFurnitureAndFixturesMember 2024-09-30 0000876343 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0000876343 us-gaap:NoncontrollingInterestMember 2024-09-30 0000876343 us-gaap:RetainedEarningsMember 2023-06-30 0000876343 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000876343 lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000876343 lctx:AgreementsWithHadasitAndHIAMember 2021-12-172021-12-17 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000876343 lctx:UpfrontLicenseFeesMember 2024-07-012024-09-30 0000876343 lctx:CollaborationRevenuesMember 2023-01-012023-09-30 0000876343 lctx:AgreementsWithHadasitAndHIAMember 2017-12-17 0000876343 us-gaap:CommonStockMember 2023-12-31 0000876343 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0000876343 srt:ParentCompanyMember 2024-02-06 0000876343 us-gaap:CommonStockMember 2024-09-30 0000876343 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0000876343 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000876343 lctx:MarketableEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0000876343 us-gaap:RetainedEarningsMember 2024-06-30 0000876343 2024-01-012024-09-30 0000876343 lctx:RoyaltiesLicenseAndOtherRevenuesMember 2024-01-012024-09-30 0000876343 us-gaap:PatentsMember 2024-09-30 0000876343 lctx:OperatingLeaseMember 2024-09-30 0000876343 lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000876343 lctx:AtmSalesAgreementMemberlctx:BRileySecuritiesIncMember 2024-01-012024-09-30 0000876343 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000876343 srt:ParentCompanyMemberlctx:PriorSalesAgreementMember 2021-12-31 0000876343 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000876343 lctx:InProcessResearchAndDevelopmentOPCOneMember 2024-09-30 0000876343 lctx:UpfrontLicenseFeesMember 2023-01-012023-09-30 0000876343 lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0000876343 us-gaap:CommonStockMemberlctx:AtTheMarketMember 2023-01-012023-09-30 0000876343 lctx:MarketableEquitySecuritiesMember 2023-12-31 0000876343 2023-01-012023-09-30 0000876343 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0000876343 lctx:CollaborationRevenuesMember 2024-01-012024-09-30 0000876343 srt:ParentCompanyMemberlctx:AtmSalesAgreementMember 2024-03-31 0000876343 us-gaap:CommonStockMember 2023-07-012023-09-30 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000876343 us-gaap:CommonStockMember 2023-06-30 0000876343 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0000876343 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000876343 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000876343 us-gaap:RetainedEarningsMember 2023-09-30 0000876343 lctx:TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember 2023-12-31 0000876343 lctx:FinancingLeasesMember 2024-09-30 0000876343 us-gaap:CommonStockMember 2022-12-31 0000876343 lctx:UpfrontLicenseFeesMemberlctx:RocheAgreementMember 2022-01-012022-01-31 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000876343 lctx:CarlsbadSubLeaseMember 2022-09-012022-09-30 0000876343 us-gaap:CommonStockMember 2023-09-30 0000876343 lctx:CorporateCreditCardFacilityMember 2023-09-30 0000876343 lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember 2024-09-30 0000876343 lctx:DepositsAndOtherLongTermAssetsMemberlctx:CarlsbadSubLeaseMember 2024-09-30 0000876343 lctx:InProcessResearchAndDevelopmentOPCOneMember 2024-09-30 0000876343 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0000876343 srt:ParentCompanyMemberlctx:PriorSalesAgreementMember 2024-01-012024-03-31 0000876343 us-gaap:CommonStockMemberlctx:DirectFinancingMember 2024-01-012024-09-30 0000876343 lctx:CollaborationRevenuesMember 2023-07-012023-09-30 0000876343 lctx:CellCureLeasesMember 2024-09-30 0000876343 us-gaap:USTreasurySecuritiesMember 2023-12-31 0000876343 lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000876343 lctx:EquipmentFurnitureAndFixturesMember 2023-12-31 0000876343 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000876343 us-gaap:MoneyMarketFundsMember 2023-12-31 0000876343 lctx:AgreementsWithHadasitAndHIAMember 2021-11-012021-11-30 0000876343 lctx:TwoThousandTwentyOneEquityIncentivePlanMember 2023-12-31 0000876343 us-gaap:RetainedEarningsMember 2022-12-31 0000876343 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0000876343 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000876343 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0000876343 us-gaap:NoncontrollingInterestMember 2024-01-012024-09-30 0000876343 srt:MaximumMember 2024-09-30 0000876343 lctx:UpfrontLicenseFeesMember 2023-07-012023-09-30 0000876343 2023-07-012023-09-30 0000876343 lctx:TwoThousandTwelveEquityIncentivePlanAndTwoThousandEighteenInducementOptionMember 2024-09-30 0000876343 lctx:SettlementAgreementMember 2023-02-012023-02-28 0000876343 lctx:FinancingLeasesMember 2023-12-31 0000876343 lctx:OperatingLeaseMember 2023-12-31 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000876343 lctx:MarketableDebtSecuritiesMember 2023-12-31 0000876343 us-gaap:CommonStockMember 2024-01-012024-09-30 0000876343 lctx:DirectFinancingMember 2024-01-012024-09-30 0000876343 lctx:CellCureLeasesMember 2024-01-012024-09-30 0000876343 lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0000876343 lctx:RocheAgreementMemberlctx:HadasitMedicalResearchServicesAndDevelopmentLtdMember 2022-01-012022-01-31 0000876343 us-gaap:CommonStockMember 2023-01-012023-09-30 0000876343 lctx:RoyaltiesLicenseAndOtherRevenuesMember 2023-01-012023-09-30 0000876343 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0000876343 lctx:AtTheMarketMember 2024-01-012024-09-30 0000876343 lctx:CarlsbadSubLeaseMember 2022-09-30 0000876343 lctx:AgreementsWithHadasitAndHIAMember 2021-12-17 0000876343 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0000876343 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000876343 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0000876343 lctx:InProcessResearchAndDevelopmentOPCOneMember 2023-12-31 0000876343 us-gaap:NoncontrollingInterestMember 2023-01-012023-09-30 0000876343 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0000876343 us-gaap:MoneyMarketFundsMember 2024-09-30 0000876343 lctx:UpfrontLicenseFeesMember 2024-01-012024-09-30 0000876343 lctx:BroadwoodPartnersLPMember 2024-02-062024-02-06 0000876343 lctx:RocheAgreementMember 2022-01-012022-01-31 0000876343 lctx:NealBradsherMemberlctx:BroadwoodPartnersLPMember 2019-02-012023-07-31 0000876343 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000876343 srt:MaximumMemberlctx:TwoThousandTwentyOneEquityIncentivePlanMember 2024-09-30 0000876343 lctx:ITICollaborationAgreementMember 2021-04-012021-04-30 0000876343 lctx:MarketableEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0000876343 us-gaap:NoncontrollingInterestMember 2023-07-012023-09-30 0000876343 lctx:CarlsbadLeaseMember 2019-05-31 0000876343 2024-06-30 0000876343 lctx:InProcessResearchAndDevelopmentVACTwoMember 2023-12-31 0000876343 lctx:RocheAgreementMember 2021-12-012021-12-31 0000876343 2022-12-31 0000876343 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000876343 us-gaap:USTreasurySecuritiesMember 2024-09-30 0000876343 2024-07-012024-09-30 0000876343 lctx:CarlsbadSubLeaseMember 2019-05-012019-05-31 0000876343 us-gaap:CommonStockMember 2024-06-30 0000876343 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0000876343 lctx:TwoThousandTwentyOneEquityIncentivePlanMember 2023-09-012023-09-30 0000876343 lctx:MarketableEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0000876343 lctx:LicenseAgreementMember 2020-05-012020-05-31 0000876343 lctx:CollaborationRevenuesMember 2024-07-012024-09-30 0000876343 lctx:CarlsbadLeaseMember 2024-09-30 0000876343 us-gaap:NoncontrollingInterestMember 2023-09-30 0000876343 lctx:ITICollaborationAgreementMember 2024-09-30 0000876343 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000876343 lctx:RoyaltyContractsMember 2023-12-31 0000876343 us-gaap:NoncontrollingInterestMember 2023-06-30 0000876343 2024-11-08 0000876343 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0000876343 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000876343 lctx:FinancingLeasesMember 2024-09-30 0000876343 2023-01-012023-03-31 0000876343 lctx:MarketableEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000876343 lctx:MarketableDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember 2024-09-30 0000876343 us-gaap:RetainedEarningsMember 2024-09-30 0000876343 lctx:DonMBaileyMember 2024-02-062024-02-06 0000876343 lctx:EsCellInternationalPteLtdMember 2024-01-012024-09-30 0000876343 lctx:CarlsbadLeaseMember 2023-03-01 0000876343 us-gaap:CommonStockMemberlctx:AtTheMarketMember 2024-01-012024-09-30 0000876343 lctx:RocheAgreementMember 2021-12-172021-12-17 0000876343 srt:ParentCompanyMemberlctx:AtmSalesAgreementMember 2024-05-14 0000876343 us-gaap:NoncontrollingInterestMember 2023-12-31 0000876343 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 utr:sqm pure iso4217:USD shares utr:sqft shares iso4217:GBP iso4217:USD iso4217:ILS--12-31falseQ30000876343 10-Qtrue2024-09-302024false001-12830Lineage Cell Therapeutics, Inc.CA94-3127912173 Salk AvenueSuite 200CarlsbadCA92008442287-8990Common sharesLCTXNYSEYesYesNon-accelerated Filertruefalsefalse188837375277500003544200049610005000040500074500012850002204000344010003844100020130002245000236200025220006060005770001067200012890000-3068000-400192000-384856000661860006341900 0-1392000-1396000647940006202300096594000101019000338600095700056710005949000393000289000960000908000377900012460006631000685700038000169000180000415000338400000-6705000-16368000-183710003970004330001322000122500 0-6000-60000-21000-170000448000-827000-284000-179600001000190005440008390000-4530001036000-197000-3001000-7158000-15332000-185680000-1803000-3001000-7158000-15332000-167650003300 0-480040000-54000-3034000-7110000-15336000-16711000-0.02-0.02-0.04-0.04-0.08-0.08-0.1-0.1188835000188835000174868000174868000186860000186860000171880000171880000-3001000-7158000-15332000-16765000-432000518000173000133700012000900050001500 00-3421000-6631000-15154000-152780003300 0-480004000-54000-3454000-6583000-15158000-152240001888240004679280 00-397158000-1425000-247000066875000130001000010000133000013300001200012000-432000-432000-303400033000-300100018883700046926800 0-400192000-1392000-289000064794000174439000448249000-372971000-1409000-261100071258000538000784000784000-28000-280001000080008000012690001269000900090005180005180 00-7110000-48000-7158000174987000450282000-380081000-1457000-208400066660000174987000451343000-384856000-1396000-306800062023000134620001400000014000000560007000070000-113000-113000450002300023000287000229000229000376200037620005000500017300017300 0-153360004000-153320001888370004692680 00-400192000-1392000-289000064794000170093000440280000-363370000-1403000-357100071936000477500066250006625000-221000-221000530037000370000660005500055000358000035800001500001337000133700016711000-54000-167650001749870004502820 00-380081000-1457000-208400066660000-15336000-16711000400 0-54000-21000-170000184000647000436000419000-31000860002000980003762000358000 00-1803000-309000-1892000-339000141000-891000-56000-1778000-3456000-5201000-6036000-16746000-225470001800019600087610001640300040000005349700020000058300 0-494300036707000229000880002300037000140700006625000113000199000400004100014123000643600 0-120000-532000-768600020064000359920001193600028306000320000006000800011000800027750000031474000556000526000283060003200000 1. Organization and Business Overview We are a clinical-stage biotechnology company developing novel allogeneic, or "off-the-shelf", cell therapies to address unmet medical needs. Our programs are based on our proprietary, cell-based technology platform, and associated development, formulation, delivery and manufacturing capabilities. From this platform, we design, develop, manufacture, and test specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. The cells we manufacture are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate

cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages which are relevant to the underlying condition are transplanted into patients in an effort to (a) replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and (b) restore or augment the patient's functional activity. Our business strategy is to efficiently leverage our technology platform and our development and manufacturing capabilities to advance our programs internally or in conjunction with strategic partners to further enhance their value and probability of success. A significant area of focus is a collaboration we entered into with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (collectively or individually, "Roche" or "Genentech"), under which our lead cell therapy program known as OpRegen®, is being developed for the treatment of ocular disorders, including geographic atrophy ("GA") secondary to age-related macular degeneration ("AMD"). OpRegen (also known as RG6501) is a suspension of human allogeneic retinal pigmented epithelial ("RPE") cells and is currently being evaluated in a Phase 2a multicenter clinical trial in patients with GA secondary to AMD. OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. Under the terms of the Collaboration and License Agreement we entered into with Roche in December 2021 (the "Roche Agreement"), we received a $50.0 million upfront payment in January 2022 and are eligible to receive up to an additional $620.0 million in developmental, regulatory, and commercialization milestone payments. We also are eligible to receive tiered, double-digit-percentage royalties on net sales of OpRegen in the U.S. and other major markets. On May 7, 2024, we entered into a service agreement with Genentech pursuant to which we will provide supplemental clinical, technical, training, manufacturing, and procurement services to support the ongoing advancement and optimization of the OpRegen program. In September 2024, Roche and Genentech announced receipt of Regenerative Medicine Advanced Therapy ("RMAT") designation from the U.S. Food and Drug Administration ("FDA") for OpRegen for the treatment of GA secondary to dry AMD. Our most advanced unpartnered product candidate is OPC1, an allogeneic oligodendrocyte progenitor cell therapy designed to improve recovery following a spinal cord injury ("SCI"). OPC1 has been tested in two clinical trials to date: a five patient Phase 1 clinical trial in acute thoracic SCI, where all subjects are followed for at least 10 years; and a 25 patient Phase 1/2a multicenter clinical trial in subacute cervical SCI, where all subjects were evaluated for at least two years. Results from both studies have been published in the Journal of Neurosurgery Spine. OPC1 clinical development has been supported in part by a $14.3 million grant from the California Institute for Regenerative Medicine ("CIRM"). We plan to apply for additional funding from CIRM for continued clinical development of OPC1 for the treatment of SCI. In December 2023, we filed an Investigational New Drug ("IND") amendment for OPC1 as it relates to our proposed DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study, to evaluate the safety and utility of a novel spinal cord delivery device to administer OPC1 to the spinal parenchyma in subacute and chronic SCI patients. In March 2024, we received written correspondence from the FDA, advising us that due to significant workload and conflicting PDUFA priorities at the agency, its review of our IND amendment and the DOSED study protocol is still ongoing. Since that time we have been engaging with the FDA to aid in their review, including through an informal teleconference meeting with the CBER and CDRH divisions of the FDA held on November 12, 2024. Based on that discussion we plan to submit an additional amendment to the IND and final protocol with clarifying information to the FDA by the end of the year. We currently anticipate that the FDA will complete its review of this amendment in Q1 2025 and we do not expect any further feedback or additional information requests that would delay start of the study. We currently plan to commence enrolling the DOSED study as soon as feasible after submitting these updates. Our pipeline of allogeneic, or "off-the-shelf", cell therapy programs currently includes: • RG6501 (OpRegen), an allogeneic RPE cell replacement therapy currently in a Phase 2a multicenter, open-label, single arm clinical trial, being conducted by Roche, for the treatment of GA secondary to AMD, also known as atrophic or dry AMD. • OPC1, an allogeneic oligodendrocyte progenitor cell therapy which we plan to evaluate in the DOSED clinical study, to test the safety and utility of a novel spinal cord delivery device in both subacute and chronic spinal cord injuries and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752178649237472 5%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"> continues to be evaluated in long-term follow-up from a Phase 1/2a multicenter clinical trial for subacute cervical spinal cord injuries. • ANP1, an allogeneic auditory neuron progenitor cell transplant currently in preclinical development for the treatment of debilitating hearing loss. • PNC1, an allogeneic photoreceptor cell transplant currently being developed for the treatment of vision loss due to photoreceptor dysfunction or damage. • RND1, a novel, hypoimmune iPSCs line being developed in collaboration with Factor Bioscience Limited, as assignee from Eterna Therapeutics, Inc., which will be evaluated for differentiation into cell transplant product candidates for central nervous system diseases and other neurology indications. Other Programs We have additional undisclosed product candidates being considered for development and we may consider others which cover a range of therapeutic areas and unmet medical needs. Generally, these product candidates are based on the same platform technology and employ a similar, guided cell differentiation and transplant approach as most of the product candidates described above, but in some cases may also include genetic modifications designed to enhance efficacy and/or safety profiles. In addition to seeking to create value for shareholders by developing product candidates and advancing those candidates through clinical development, we also may seek to create value from our intellectual property or related technologies and capabilities, through licensing collaborations and/or strategic transactions, such as our business development approach to our VAC dendritic cell therapy platform. 5000000062000000014300000 2. Basis of Presentation, Liquidity and Summary of Significant Accounting Policies The accompanying unaudited condensed consolidated interim financial statements were prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2023 10-K. The accompanying unaudited condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of our financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts in the condensed consolidated interim financial statements and accompanying notes have been reclassified to conform to the current period presentation. The reclassification of these items had no impact on net loss, net loss per share, financial position or cash flows in the current or prior periods. Specifically, our reclassifications are (i) operating lease right-of-use assets are now presented separately from property and equipment, net, on the condensed consolidated balance sheets, (ii) cost of sales are now included in operating expenses on the condensed consolidated statements of operations, and (iii) foreign currency transaction gains (losses) are now presented separately from other income (expenses) on the condensed consolidated statements of operations. Principles of Consolidation The accompanying unaudited condensed consolidated interim financial statements include the accounts of our subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. The following table sets out Lineage's ownership, directly or indirectly, of the outstanding shares of its subsidiaries as of September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:32.46%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:37.98%;box-sizing:content-box;"></td><td

style="width:1.74%;box-sizing:content-box;"></td> <td style="width:12.32%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:12.02%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Subsidiary </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Field of Business </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Lineage
Ownership </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Country </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Cell Cure Neurosciences Ltd. </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:top;"> Manufacturing of Lineage's product candidates </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 94%(1) </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> Israel </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> ES Cell International Pte. Ltd. </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:top;"> Research and clinical grade cell lines </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> 100% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> Singapore </td> </tr> </table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Includes shares owned by Lineage and ES Cell International Pte. Ltd. Lineage consolidates its direct and indirect wholly owned or majority-owned subsidiaries because Lineage has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholders' equity on Lineage's condensed consolidated balance sheets. Liquidity At September 30, 2024, we had $32.7 million of cash, cash equivalents and marketable securities. At September 30, 2024 and 2023, the Company had restricted cash of $0.1 million required to be set aside for its corporate credit card facility. Additionally, Cell Cure has restricted cash related to its lease. See Note 13 (Commitments and Contingencies). Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities, together with our projected cash flows, will be sufficient to enable us to carry out our planned operations through at least twelve months from the issuance date of the accompanying condensed consolidated interim financial statements. Capital Resources Since inception, we have incurred significant operating losses and have funded our operations primarily through the issuance of equity securities, the sale of common stock of our former subsidiaries, OncoCyte Corporation and AgeX Therapeutics, Inc., receipt of proceeds from research grants, revenues from collaborations, royalties from product sales, and sales of research products and services. As of September 30, 2024, $39.97 million remained available for sale under our at-the-market offering program ("ATM"). See Note 10 (Shareholders' Equity) for additional information. Additional Capital Requirements Our financial obligations primarily consist of obligations to licensors under license agreements, obligations related to grants received from government entities, including the Israel Innovation Authority ("IIA"), obligations under contracts with vendors who provide research services and purchase commitments with suppliers. Our obligations to licensors under license agreements and our obligations related to grants received from government entities require us to make future payments, such as sublicense fees, milestone payments, redemption fees, royalty fees and patent maintenance fees. Sublicense fees are payable to licensors or government entities when we sublicense the applicable intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments, including those related to the Roche Agreement, are due to licensors or government entities upon achievement of commercial, development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of milestone payments and royalties received under the Roche Agreement. See Note 13 (Commitment and Contingencies) for additional information. Royalties, including those related to royalties we may receive under the Roche Agreement, are payable to licensors or government entities based on a percentage of net sales of licensed products. Patent maintenance costs are payable to licensors as reimbursement for the cost of maintaining license patents. Due to the contingent nature of the payments, the amounts and timing of payments to licensors under our in-license agreements are uncertain and may fluctuate significantly from period to period. As of September 30, 2024, we have not included these commitments on our condensed consolidated balance sheet because the achievement of events that would trigger our payment obligations and the timing thereof are not fixed and determinable. In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided. Significant Accounting Policies We describe our significant accounting policies in Note 2 to the consolidated financial statements in Item 8 of the 2023 10-K. There have been no changes to our significant accounting policies during the nine months ended September 30, 2024. Recently Issued Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and does not believe any will have a material impact on the Company's condensed consolidated interim financial statements or related financial statement disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 expands disclosures about a public entity's reportable segments and requires more enhanced information about a reportable segment's expenses, interim segment profit or loss, and how a public entity's chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. We are currently assessing the new guidance and we believe this will not have a significant impact on our consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The purpose of ASU 2024-03 is to improve the disclosures about a public business entity's expenses

*and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development) ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently assessing the impact that this new guidance will have on our consolidated financial statements. Principles of Consolidation The accompanying unaudited condensed consolidated interim financial statements include the accounts of our subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. The following table sets out Lineage's ownership, directly or indirectly, of the outstanding shares of its subsidiaries as of September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:32.46%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:37.98%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:12.32%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:12.02%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#fffffe;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Subsidiary </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffffe03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Field of Business </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffffe03;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Lineage
Ownership </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffffe03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Country </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> Cell Cure Neurosciences Ltd. </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;"> Manufacturing of Lineage's product candidates </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> 94%(1) </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> Israel </td></tr><tr style="height:10pt;background-color:#fffffe;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> ES Cell International Pte. Ltd. </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;"> Research and clinical grade cell lines </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:left;"> 100% </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> Singapore </td></tr></table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Includes shares owned by Lineage and ES Cell International Pte. Ltd. Lineage consolidates its direct and indirect wholly owned or majority-owned subsidiaries because Lineage has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholders' equity on Lineage's condensed consolidated balance sheets. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:32.46%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:37.98%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:12.32%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:12.02%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#fffffe;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Subsidiary </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffffe03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Field of Business </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffffe03;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Lineage
Ownership </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffffe03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Country </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> Cell Cure Neurosciences Ltd. </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;"> Manufacturing of Lineage's product candidates </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> 94(1) </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> Israel </td></tr><tr style="height:10pt;background-color:#fffffe;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> ES Cell International Pte. Ltd. </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;"> Research and clinical grade cell lines </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:left;"> 100% </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> Singapore </td></tr></table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Includes shares owned by Lineage and ES Cell International Pte. Ltd. Manufacturing of Lineage's product candidates0.94Research and clinical grade cell lines1 Liquidity At September 30, 2024, we had $32.7 million of cash, cash equivalents and marketable securities.At September 30, 2024 and 2023, the Company had restricted cash of $0.1<span style="color:#000000;white-*

space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million required to be set aside for its corporate credit card facility. Additionally, Cell Cure has restricted cash related to its lease. See Note 13 (Commitments and Contingencies). Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities, together with our projected cash flows, will be sufficient to enable us to carry out our planned operations through at least twelve months from the issuance date of the accompanying condensed consolidated interim financial statements. 327000001000000100000 Capital Resources Since inception, we have incurred significant operating losses and have funded our operations primarily through the issuance of equity securities, the sale of common stock of our former subsidiaries, OncoCyte Corporation and AgeX Therapeutics, Inc., receipt of proceeds from research grants, revenues from collaborations, royalties from product sales, and sales of research products and services. As of September 30, 2024, $39.97 million remained available for sale under our at-the-market offering program ("ATM"). See Note 10 (Shareholders' Equity) for additional information. 39970000 Additional Capital Requirements Our financial obligations primarily consist of obligations to licensors under license agreements, obligations related to grants received from government entities, including the Israel Innovation Authority ("IIA"), obligations under contracts with vendors who provide research services and purchase commitments with suppliers. Our obligations to licensors under license agreements and our obligations related to grants received from government entities require us to make future payments, such as sublicense fees, milestone payments, redemption fees, royalty fees and patent maintenance fees. Sublicense fees are payable to licensors or government entities when we sublicense the applicable intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments, including those related to the Roche Agreement, are due to licensors or government entities upon achievement of commercial, development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of milestone payments and royalties received under the Roche Agreement. See Note 13 (Commitment and Contingencies) for additional information. Royalties, including those related to royalties we may receive under the Roche Agreement, are payable to licensors or government entities based on a percentage of net sales of licensed products. Patent maintenance costs are payable to licensors as reimbursement for the cost of maintaining license patents. Due to the contingent nature of the payments, the amounts and timing of payments to licensors under our in-license agreements are uncertain and may fluctuate significantly from period to period. As of September 30, 2024, we have not included these commitments on our condensed consolidated balance sheet because the achievement of events that would trigger our payment obligations and the timing thereof are not fixed and determinable. In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided. Significant Accounting Policies We describe our significant accounting policies in Note 2 to the consolidated financial statements in Item 8 of the 2023 10-K. There have been no changes to our significant accounting policies during the nine months ended September 30, 2024. Recently Issued Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and does not believe any will have a material impact on the Company's condensed consolidated interim financial statements or related financial statement disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 expands disclosures about a public entity's reportable segments and requires more enhanced information about a reportable segment's expenses, interim segment profit or loss, and how a public entity's chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. We are currently assessing the new guidance and we believe this will not have a significant impact on our consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The purpose of ASU 2024-03 is to improve the disclosures about a public business entity's expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development) ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently assessing the impact that this new guidance will have on our consolidated financial statements. 3. Revenue Our disaggregated revenues were as follows for the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Revenues under collaborative agreements </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Upfront license fees (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,386</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,671 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,949 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenues under collaborative agreements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,386 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 957 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,671 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,949 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Royalties, license and other revenues (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 393 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 289 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 960 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 908 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td

colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,779</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,246 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,631</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,857 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (1) All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement. (2) Included within royalties, license and other revenues recognized for the nine months ended September 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively. We are recognizing the $50.0 million upfront payment under the Roche Agreement utilizing an input method of costs incurred over total estimated costs to be incurred. At each reporting period, we update our total estimated collaboration costs, and any resulting adjustments are recorded on a cumulative basis which would affect revenue and deferred revenue in the period of adjustment. We believe the input methodology represents the most appropriate measure of progress towards satisfaction of the identified performance obligations. For contracts with customers including collaboration partners which are within the scope of Accounting Standards Update ("ASU") 2014-09 - Revenue from Contracts with Customers (Topic 606), the aggregate amount of the transaction price allocated to remaining performance obligations as of September 30, 2024 was $28.1 million, of which $24.3 million is reported as deferred revenues. The $28.1 million is expected to be converted to revenue substantially by December 2026.</p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:middle;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts receivable, net - beginning of the year (1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 676 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 297 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr

style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accounts receivable, net - end of the period (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">392</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 676 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Contract liabilities (1) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Deferred revenues - beginning of the year </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29,501</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,146 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Deferred revenues - end of the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,300</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,501 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Excludes grants receivable which are outside the scope of ASU 2014-09. Our disaggregated revenues were as follows for the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Revenues

under collaborative agreements </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Upfront license fees (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,386</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 957 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,671</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,949 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenues under collaborative agreements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,386 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 957 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,671 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,949 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Royalties, license and other revenues (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 393 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 289 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 960 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-

align:center;"> 908 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,779</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,246 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,631</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,857 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement. <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2) Included within royalties, license and other revenues recognized for the nine months ended September 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively.
33860009570005671000594900033860009570005671000594900039300028900096000090800037790001246000663100068570005000000050000000300008700050000(
style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accounts receivable, net - beginning of the year (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">676</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 297 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accounts receivable, net - end of the period (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 392 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">676</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:middle;"><p style="margin-left:2pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract liabilities (1)</p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Deferred revenues - beginning of the year</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,501 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37,146</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Deferred revenues - end of the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29,501</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"> </p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">(1)<div style="width:100%;display:inline;">Excludes grants receivable which are outside the scope of ASU 2014-09.</div></div>676000297000392000676000295010003714600024300000295010006<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">4. Marketable Securities</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table summarizes the fair value of marketable securities held by the Company and their location in the Company's condensed consolidated balance sheet (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Marketable debt securities</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Included within cash and cash equivalents (1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,856</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Included within marketable securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,949 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Marketable equity securities</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Included within marketable securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"> </p><div class="item-list-element-wrapper" style="display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">(1)<div style="width:100%;display:inline;">Cash equivalents have an original maturity of three months or less when purchased. </div></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Marketable Debt Securities</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table summarizes the available-for-sale debt securities classified within cash and cash equivalents and within marketable securities in the Company’s condensed consolidated balance sheet as of September 30, 2024 and December 31, 2023 (in thousands):</p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.022%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financial Assets:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. Treasury securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,274 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,281 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,274 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,281</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.022%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financial Assets:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. Treasury securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,855 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,856</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,855 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,856 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:justify;"> The Company has not recognized an allowance for credit losses on any securities in an unrealized loss position as of September 30, 2024 or December 31, 2023. The Company believes that any individual unrealized losses represent temporary declines resulting from changes in interest rates, and we intend to hold these marketable debt securities to their maturity. As of September 30, 2024, the amortized cost and estimated fair value of the Company's available-for-sale debt securities by contractual maturity are shown below (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Available-for-sale debt securities maturing: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> In one year or less </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,274</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,281 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total available-for-sale debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,274</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,281 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Marketable Equity Securities Marketable equity securities are reported at fair value with unrealized gains and losses related to mark-to-market adjustments included in income. Lineage's marketable equity securities have consisted of shares of common stock of OncoCyte Corporation ("OCX") and of Hadasit Bio-Holdings Ltd. ("HBL"). All share prices are determined based on the closing price of OCX and HBL common stock on the last trading day of the applicable quarter. Subsequent to June 30, 2024, Lineage no longer owned any shares of OCX. The following table represents the realized and unrealized (loss) gain on marketable equity securities for the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Loss on marketable equity securities, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="color:#000000;min-width:fit-

content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (60 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(21</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (170 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Loss recognized in earnings on marketable equity
  securities sold </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unrealized loss recognized on marketable equity
  securities held at end of period, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (37 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(17</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (147 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr>
</table> The following table summarizes the fair value of marketable securities held by the Company and their location in the Company's condensed consolidated balance sheet (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Marketable debt securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Included within cash and cash equivalents <span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-

size:6.7pt;position:relative;min-width:fit-content;">(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,332</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,856 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Included within marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,949</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Marketable equity securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Included within marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Cash equivalents have an original maturity of three months or less when purchased. 7332000885600049490001200050000 The following table summarizes the available-for-sale debt securities classified within cash and cash equivalents and within marketable securities in the Company’s condensed consolidated balance sheet as of September 30, 2024 and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.022%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Financial Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,274</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,281 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,274</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,281 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.022%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Financial Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,855</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,856 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,855 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,856</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table>12274000700001228100012274000700001228100088550001000885600088550001000885600<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">As of September 30, 2024, the amortized cost and estimated fair value of the Company’s available-for-sale debt securities by contractual maturity are shown below (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Available-for-sale debt securities maturing:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Estimated Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">In one year or less</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,274 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,281</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total available-for-sale debt securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,274 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,281 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>12274000122810001227400012281000 The following table represents the realized and unrealized (loss) gain on marketable equity securities for the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Loss on marketable equity securities, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (60 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(170</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Loss recognized in earnings on marketable equity
  securities sold</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unrealized loss recognized on marketable equity
  securities held at end of period, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(37</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (17 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (147 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr>
</table>-6000-60000-21000-1700000-23000-4000-23000-6000-37000-17000-147000 5. Property and Equipment, Net Property and equipment, including finance leases, are stated at cost, net of accumulated depreciation and amortization. The cost of property and equipment is depreciated or amortized using the straight-line method over the estimated useful life of the asset, ranging from 3 to 10 years. Finance lease right-of-use assets are amortized over the lease term. Leasehold improvements are amortized over the shorter of the useful life or the lease term. At September 30, 2024 and December 31, 2023, property and equipment, net was comprised of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="color:#000000;white-

space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Equipment, furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,742</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,614 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,262 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,313 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Right-of-use assets - finance lease </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,193 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> (3,880 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,013</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,245 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Depreciation and amortization expense was $141,000 and $143,000 for the three months ended September 30, 2024 and 2023, respectively, and $436,000 and $419,000 for the nine months ended September 30, 2024 and 2023, respectively. These amounts include amortization expense for right-of-use finance lease assets of $13,000 and $14,000 for the three months ended September 30, 2024 and 2023, respectively, and $41,000 and $37,000 for the nine months ended September 30, 2024 and 2023, respectivelyP3YP10Y At September 30, 2024 and December 31, 2023, property and equipment, net was comprised of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-

align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Equipment, furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,742</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,614 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,262 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,313 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Right-of-use assets - finance lease </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,193 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,880 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,013</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,245 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>3742000361400022620002313000202000198000419300038800002013000224500014100014300043600041900013000140004100037000 6. Goodwill and Intangible Assets, Net At September 30, 2024 and December 31, 2023, goodwill and intangible assets, net consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Goodwill (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,672</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,672 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Intangible assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Acquired IPR&D – OPC1 (from the Asterias Merger) (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">31,700</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,700 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Acquired IPR&D – VAC (from the Asterias Merger) (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,840 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,840 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Intangible assets subject to amortization: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Acquired patents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,953 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,953 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Acquired royalty contracts (3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 650 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 650 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total intangible assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 66,143 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 66,143 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Accumulated amortization (4) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (19,603 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-

bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (19,581 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Intangible assets, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,540</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 46,562 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitments and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment. (2) Asterias had two in-process research and development ("IPR&D") intangible assets that were valued at $46.5 million as part of the purchase price allocation that was performed in connection with the Asterias Merger. The fair value of these assets at the acquisition date consisted of $31.7 million pertaining to the OPC1 program and $14.8 million pertaining to the VAC platform. (3) Asterias had royalty cash flows under patent families it acquired from Geron Corporation. Such patent families are expected to continue to generate revenue, are not used in the OPC1 or the VAC platform, and are considered to be separate long-lived intangible assets under ASC Topic 805, Business Combinations. (4) The acquired patents and acquired royalty contracts were fully amortized as of the end of the first quarter of 2024. Lineage amortizes its intangible assets over an estimated period of 5 to 10 years on a straight-line basis. Lineage recognized $0 and $33,000 in amortization expense of intangible assets during the three months ended September 30, 2024 and 2023, respectively, and $22,000 and $98,000 during the nine months ended September 30, 2024 and 2023, respectively. </p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">At September 30, 2024 and December 31, 2023, goodwill and intangible assets, net consisted of the following (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Goodwill (1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,672 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,672 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">Intangible assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Acquired IPR&D – OPC1 (from the Asterias Merger) (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">31,700</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,700 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Acquired IPR&D – VAC (from the Asterias Merger) (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,840 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,840 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Intangible assets subject to amortization: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Acquired patents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,953 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,953 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Acquired royalty contracts (3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 650 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 650 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total intangible assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 66,143 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 66,143 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Accumulated amortization (4) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (19,603 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (19,581 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Intangible assets, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> <span style="color:#000000;min-

width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,540</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 46,562 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitments and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment. <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2) Asterias had two in-process research and development ("IPR&D") intangible assets that were valued at $46.5 million as part of the purchase price allocation that was performed in connection with the Asterias Merger. The fair value of these assets at the acquisition date consisted of $31.7 million pertaining to the OPC1 program and $14.8 million pertaining to the VAC platform. <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3) Asterias had royalty cash flows under patent families it acquired from Geron Corporation. Such patent families are expected to continue to generate revenue, are not used in the OPC1 or the VAC platform, and are considered to be separate long-lived intangible assets under ASC Topic 805. Business Combinations. <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4) The acquired patents and acquired royalty contracts were fully amortized as of the end of the first quarter of 2024. Lineage amortizes its intangible assets over an estimated period of 5 to 10 years on a straight-line basis. Lineage recognized $0 and $33,000 in amortization expense of intangible assets during the three months ended September 30, 2024 and 2023, respectively, and $22,000 and $98,000 during the nine months ended September 30, 2024 and 2023, respectively.
10672000106720003170000031700000148400001484000018953000189530006500006500006614300066143000196030001958100046540000465620004650000031700006 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">7. Accounts Payable and Accrued Liabilities At September 30, 2024 and December 31, 2023, accounts payable and accrued liabilities consisted of the following (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accounts payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,599</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,123 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accrued liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 384 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,097 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,477</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,270 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> At September 30, 2024 and December 31, 2023, accounts payable and accrued liabilities consisted of the following (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.4%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accounts payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,599</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,123 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Accrued liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 384 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,097 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,477</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,270 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>1599000205000249400031230003840001097000447700062700000 8. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value in accordance with ASC 820-10-50, Fair Value Measurements and Disclosures: • Level 1 – Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. • <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;">Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 – Inputs to the valuation methodology that are unobservable. Unobservable inputs are those in which little or no market data exists, reflect those that a market participant would use, and are therefore determined using estimates and assumptions developed by the Company. We have not transferred any instruments between the three levels of the fair value hierarchy. The carrying value of cash, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate their respective fair values due to their relative short maturities. We measure our cash equivalents and marketable securities at fair value on a recurring basis.The fair values of such assets were as follows as of September 30, 2024 and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.022%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.676%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.676%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.916%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.916%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements Using </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Balance at
September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Quoted Prices in Active Markets for Identical Assets
(Level 1) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant Other Observable Inputs
(Level 2) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant Unobservable Inputs
(Level 3) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:middle;"> Assets: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Money market fund (1) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,466</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Marketable debt securities (1) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,332 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;">

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Marketable debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,949 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Marketable equity securities (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total assets measured at fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,759</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.022%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements Using </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Balance at December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Quoted Prices in Active Markets for Identical Assets
(Level 1) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant Other Observable Inputs
(Level 2) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant Unobservable Inputs
(Level 3) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Money market fund (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,029</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,029 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Marketable debt securities (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,856 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> 8,856 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Marketable equity securities (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total assets measured at fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29,935</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 29,935 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
 <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Included in cash and cash equivalents in the accompanying condensed consolidated balance sheet. Marketable debt securities purchased with an original maturity of three months or less have been classified as cash equivalents. <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2) Lineage's marketable equity securities include the shares of stock of OCX and HBL. Both securities have readily determinable fair values quoted on the NASDAQ or TASE (Level 1). These securities are measured at fair value and reported as current assets on the accompanying condensed consolidated balance sheets based on the closing trading price of the security as of the date being presented. Subsequent to June 30, 2024, Lineage no longer owned any shares of OCX. The fair values of such assets were as follows as of September 30, 2024 and December 31, 2023 (in thousands):
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.022%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements Using </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Balance at
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Quoted Prices in Active Markets for Identical Assets
(Level 1) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant Other Observable Inputs
(Level 2) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant Unobservable Inputs
(Level 3) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;">

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Money market fund (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,466</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Marketable debt securities (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Marketable debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,949 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Marketable equity securities (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total assets measured at fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,759</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,759 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">   </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.022%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.676%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements Using </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> </tr> <tr style="height:8pt;background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Balance at December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="vertical-align:bottom;text-align:left;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Quoted Prices in Active Markets for Identical Assets
(Level 1) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="vertical-align:bottom;text-align:left;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant Other Observable Inputs
(Level 2) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="vertical-align:bottom;text-align:left;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant Unobservable Inputs
(Level 3) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Assets: </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom,">   </td> <td style="vertical-align:bottom,">   </td> <td style="vertical-align:bottom,">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Money market fund (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,029</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,029 </td> <td style="white-space:nowrap;vertical-align:bottom,">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Marketable debt securities (1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,856</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,856</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Marketable equity securities (2)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total assets measured at fair value</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 29,935 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29,935</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Included in cash and cash equivalents in the accompanying condensed consolidated balance sheet. Marketable debt securities purchased with an original maturity of three months or less have been classified as cash equivalents. <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2) Lineage's marketable equity securities include the shares of stock of OCX and HBL. Both securities have readily determinable fair values quoted on the NASDAQ or TASE (Level 1). These securities are measured at fair value and reported as current assets on the accompanying condensed consolidated balance sheets based on the closing trading price of the security as of the date being presented. Subsequent to June 30, 2024, Lineage no longer owned any shares of OCX.
1446600014466000733200073320004949000494900012000120002675900026759000210290002102900088560008856000500005000029935000299350000 9. Related Party Transactions In connection with the putative shareholder class action lawsuits filed in February 2019 and October 2019 challenging the

Asterias Merger (see Note 13 (Commitments and Contingencies)), Lineage agreed to pay the expenses for the legal defense of Neal Bradsher, a member of the Lineage board of directors, Broadwood Partners, L.P., a shareholder of Lineage and an affiliate of Mr. Bradsher, and Broadwood Capital, Inc., which serves as the general partner of Broadwood Partners, L.P., all of whom were named defendants in the lawsuits, prior to being dismissed. From inception of the matter through July 2023, Lineage incurred approximately $ 626,000 in legal expenses on behalf of the foregoing parties, and since then Lineage has not incurred any additional such expenses.

On February 6, 2024, Lineage entered into a stock purchase agreement with certain investors relating to the purchase and sale in a registered direct offering of an aggregate of 13,461,540 of Lineage's common shares. The offering price was $ 1.04 per common share. The offering closed on February 8, 2024. Broadwood Partners, L.P. purchased 6,730,770 common shares in the offering and Don Bailey, a member of Lineage's board of directors, purchased 96,155 shares in the offering.

10. Shareholders' Equity

Preferred Shares

Lineage is authorized to issue 2,000,000 preferred shares, no par value. The preferred shares may be issued in one or more series as the Lineage board of directors may determine by resolution. The Lineage board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The Lineage board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. As of September 30, 2024 and December 31, 2023, there were no preferred shares issued or outstanding.

Common Shares

At December 31, 2022, Lineage was authorized to issue 250,000,000 common shares, no par value. In September 2023, our shareholders approved an increase in the number of authorized common shares, no par value, from 250,000,000 to 450,000,000. As of September 30, 2024 and December 31, 2023, there were 188,837,375 and 174,986,671 common shares issued and outstanding, respectively.

At-The-Market Offering Program

In May 2020, Lineage entered into a Controlled Equity Offering℠ Sales Agreement (the "Prior Sales Agreement") with Cantor Fitzgerald & Co., as sales agent, pursuant to which Lineage could sell its common shares from time to time through an ATM program.

In December 2021, Lineage filed a prospectus supplement with the SEC in connection with the offer and sale of up to $ 64.1 million of common shares through the ATM program under the Prior Sales Agreement, which was updated, amended and supplemented by a prospectus supplement filed with the SEC on May 18, 2023 (the prospectus supplement filed in December 2021, as updated, amended and supplemented by the prospectus supplement filed in May 2023, the "Prior Prospectus Supplement").

In March 2024, Lineage terminated the Prior Sales Agreement and entered into a sales agreement (the "ATM Sales Agreement") with B. Riley Securities, Inc., as sales agent ("Sales Agent"), under which Lineage may offer and sell its common shares from time to time through an ATM program.

In March 2024, Lineage filed a prospectus supplement with the SEC in connection with the offer and sale of $ 40.00 million of common shares through the ATM program under the ATM Sales Agreement which was updated, amended and supplemented by a prospectus supplement filed with the SEC on May 14, 2024 in connection with the offer and sale of $ 39.97 million of common shares through the ATM program under the ATM Sales Agreement (the prospectus supplement filed in March 2024, as updated, amended and supplemented by the prospectus supplement filed in May 2024, the "2024 Prospectus Supplement").

Prior to its termination in March 2024, Lineage had sold 4,912,803 common shares under the Prior Prospectus Supplement at a weighted average price per share of $ 1.41 for gross proceeds of $ 6.9 million. During the three months ended March 31, 2024, Lineage sold 30,000 common shares under the Prior Prospectus Supplement at a weighted average price per share of $ 1.23 for gross proceeds of $ 37,000. During the three months ended June 30, 2024, Lineage sold 25,830 common shares under the 2024 Prospectus Supplement at a weighted average price per share of $ 1.30 for gross proceeds of $ 33,000. Lineage did not sell any common shares under the 2024 Prospectus Supplement during the three months ended September 30, 2024.

As of September 30, 2024, $ 39.97 million remained available for sale under the 2024 Prospectus Supplement.

The shares offered under the 2024 Prospectus Supplement are registered pursuant to Lineage's effective shelf registration statement on Form S-3 (File No. 333-277758), which was filed with the SEC on March 7, 2024 and declared effective on May 14, 2024.

Lineage agreed to pay Sales Agent a commission of up to 3.0% of the aggregate gross proceeds from the sale of shares under the ATM Sales Agreement, reimburse its legal fees and disbursements, and provide Sales Agent with customary indemnification and contribution rights. The Sales Agreement may be terminated by Sales Agent or Lineage at any time upon notice to the other party, or by Sales Agent at any time in certain circumstances, including the occurrence of a material and adverse change in Lineage's business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares.

2000000000000250000000000250000000450000000188837375188837375174986671174986671641000004000000039970000049128031.41690000030000 1.233700000025850000000000250000000045000000001888373751888373751749866711749866716410000040000000399700000491280 31.41690000030000 1.23370000002585 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">11. Stock-Based Awards Equity Incentive Plan Awards In September 2021, our shareholders approved the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan, and in September 2023, our shareholders approved an amendment to increase the number of common shares that may be issued thereunder by 19,500,000 (as amended to date, the "2021 Plan"). The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units ("RSUs"), and other stock awards. All of our employees (including those of our affiliates), non-employee directors and consultants are eligible to participate in the 2021 Plan. Subject to adjustment for certain changes in our capitalization, the aggregate number of our common shares that may be issued under the 2021 Plan will not exceed the sum of (i) 34,500,000 shares and (ii) the number of shares subject to awards granted under the Lineage Cell Therapeutics Inc. 2012 Equity Incentive Plan (the "2012 Plan") that were outstanding when the 2021 Plan became effective and are not issued because such awards expire or otherwise terminate. As a result of the approval of the 2021 Plan by our shareholders, no additional awards will be granted under the 2012 Plan. As of September 30, 2024, there were 21,727,737 shares available for grant under the 2021 Plan. A summary of activity under the 2021 Plan is as follows (in thousands, except per share amounts): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.11%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.662%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.942%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.662%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number
of Options
Outstanding
(in thousands) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Exercise Price
(per share) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Remaining
Contractual
Term (years) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Intrinsic Value
(in thousands) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:middle;"> Balance at December 31, 2023 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,824 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.42</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.63</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Options granted </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,567 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.11</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options exercised</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(20</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,40 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Options expired/forfeited/cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (563 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,808</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,30 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,45 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options exercisable at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,492</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,42 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,57 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options exercisable and expected to vest
  at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2,25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,808</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,30 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,45 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> <span style="white-space:pre-wrap;font-size:10pt;font-family:Times

*New Roman;min-width:fit-content;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number
of RSUs
Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average Grant
Date Fair Value
per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 668 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.11</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">RSUs forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.21 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> RSUs vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (67 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.50</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">501</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> A summary of activity of the 2012 Plan, and the 2018 inducement option (which was issued to a Lineage executive outside of all equity plans), is as follows (in thousands, except per share amounts): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number
of Options
Outstanding
(in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Exercise Price
(per share) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,839 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.83 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Options exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span*

style="min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (267 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.75</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options expired/forfeited/cancelled</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(504</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,068 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.84</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options exercisable at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,589</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.01 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> Stock-Based Compensation Expense Operating expenses within the condensed consolidated statements of operations include stock-based compensation expense as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td></tr><tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:middle;"> Research and development </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">172</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 260 </td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">476</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 729 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,158 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> 1,009 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,286 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,851 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,269 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,762</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,580 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of September 30, 2024, total unrecognized compensation costs related to unvested stock options and unvested RSUs under all equity plans, was $9.5 million, which is expected to be recognized as expense over a weighted average period of approximately 2.6years for stock options and 1.3 years for RSUs. Basic and Diluted Net Income (Loss) per Share Attributable to Common Shareholders Basic earnings per share is calculated by dividing net income or loss attributable to Lineage common shareholders by the weighted average number of common shares outstanding, net of stock options and RSUs, subject to repurchase by Lineage, if any, during the period. Diluted earnings per share is calculated by dividing the net income or loss attributable to Lineage common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under any outstanding stock options, RSUs, warrants (using the treasury-stock method), or convertible preferred stock (using the if-converted method). For the three and nine months ended September 30, 2024 and 2023, Lineage reported a net loss attributable to common shareholders, and therefore, all potentially dilutive common shares were considered antidilutive for those periods. The following common share equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three and Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,876 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,168 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 501 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 759 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 19500000345000002172773 7 A summary of activity under the 2021 Plan is as follows (in thousands, except per share amounts):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.942%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number
of Options
Outstanding
(in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Exercise Price
(per share) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Remaining
Contractual
Term (years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Intrinsic Value
(in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,824 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.42</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.63</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Options granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,567 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> <span style="color:#000000;white-space:pre-wrap;min-

*width:fit-content;">Options exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (20 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.40</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options expired/forfeited/cancelled</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(563</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.45</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Options exercisable at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,492 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.42</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.57</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Options exercisable and expected to vest
  at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.30 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.45 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number
of RSUs
Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average Grant
Date Fair Value
per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 668 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.11</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">RSUs forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.21 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> RSUs vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;border-bottom:0.5pt solid #ffffff03;"> (67 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.50</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">501</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table>108240001.42P8Y7M17D400065670001.11200001.45630001.37168080001.3P8Y5M12D100054920001.42P7Y6M25D01680080001.3P8Y5M12D10006680001.111000000
style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">A summary of activity of the 2012 Plan, and the 2018 inducement option (which was issued to a Lineage executive outside of all equity plans), is as follows (in thousands, except per share amounts):
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number
of Options
Outstanding
(in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Exercise Price
(per share) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,839 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.83</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options exercised</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(267</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.75 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"> Options expired/forfeited/cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (504 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.15</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,068</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.84 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Options exercisable at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,589 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.81 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table>108390001.832670000.755040002.15100680001.8495890001.81 Operating expenses within the condensed consolidated statements of operations include stock-based compensation expense as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
<tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr>
<tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr>
<tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr>
<tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:middle;"> Research and development </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">172 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">260</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 476 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">729</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,158</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,009</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,286</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,851</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation expense</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,269</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,762 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,580 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>1720002600004760007290001158000100900032860002851000133000012690003762000358000095000000P2Y7M6DP1Y3M18D The following common share equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three and Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,876 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,168 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 501 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 759 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>268760002687600023168000231680005010005010007590007590000 12. Income Taxes The provision for income taxes for interim periods is generally determined using an estimated annual effective tax rate as prescribed by ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances and changes in valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Lineage conducts business. ASC 740-270 also states that if an entity is unable to reliably estimate some or a part of its ordinary income or loss, the income tax provision or benefit applicable to the item that cannot be estimated shall be reported in the interim period in which the item is reported. For items that Lineage cannot reliably estimate on an annual basis, Lineage uses the actual year to date effective tax rate rather than an estimated annual effective tax rate to determine the tax effect of each item, including the use of all available net operating losses and other credits or deferred tax assets. Under ASC 740, a valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Lineage established a full valuation allowance as of December 31, 2018 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by its subsidiaries. For the tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 (“TCJA”) eliminated the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement for research activities performed in the United States, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it will decrease our tax deduction for research and development expenses in future years. The 2017 Tax Act subjects a U.S. stockholder to Global Intangible Low-Taxed Income (“GILTI”) earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. stockholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI; however, this deduction is limited to the company’s pre-GILTI U.S. income. For the three and nine months ended September 30, 2024, no GILTI was included in the Company’s tax provision; any GILTI incurred would be fully offset by net operating loss carryforwards. For the three and nine months ended September 30, 2023, Lineage incurred GILTI which was fully offset by net operating loss carryforwards. Lineage did not record a deferred tax benefit or provision expense for the three or nine months ended September 30, 2024 or for the three months ended September 30, 2023. For the first quarter of 2023, Lineage recorded a $1.8 million deferred tax benefit, due to the ability to offset certain deferred tax assets against the deferred tax liability associated with IPR&D, and the related release of the valuation allowance. It was determined that a portion of the deferred tax liability related to the indefinite lived assets may be realized prior to the expiration of certain pre 2018 net operating losses. 00000-1800000 13. Commitments and Contingencies Real Property Leases Carlsbad Lease In May 2019, Lineage entered into a lease for approximately 8,841 square feet of rentable space in an office park in Carlsbad, California. The lease was amended in December 2022, and the term was extended for a period of thirty-seven months (the “Extended Term”) commencing on March 1, 2023 (the “Extended Term Commencement Date”). Monthly base rent for the first twelve months of the Extended Term was $25,200, and is subject to 3% annual increases. Rent was abated for months two through four of the Extended Term. As security for the performance of its obligations under the lease, Lineage provided the landlord a security deposit of $17,850, which is included in deposits and other long-term assets on the condensed consolidated balance sheet as of September 30, 2024. In addition to base rent, Lineage pays a pro-rata portion of increases in certain expenses, including real property taxes, utilities (to the extent not separately metered to the leased space) and the landlord’s operating expenses, over the amounts of those expenses incurred by the landlord. These pro-rata charges are expensed as incurred and excluded from the calculation of the right-of-use (“ROU”) assets and lease liabilities. Carlsbad Sublease In September 2022, Lineage entered into a sublease for approximately 4,500 square feet of rentable industrial space in Carlsbad, California for a term that commenced on October 1, 2022 and was originally set to expire on March 31, 2024. In February 2024, Lineage extended the term of the sublease for 24 months through March 31, 2026 on similar terms. During the extension period, the base rent is $23,000 per month for the first twelve months and will increase to $23,500 for the remaining twelve months. As security for the performance of its obligations under the sublease, Lineage provided the landlord with a security deposit of $22,500, which is included in deposits and other long-term assets on the condensed consolidated balance sheet as of September 30, 2024. Cell Cure Lease As of September 30, 2024, Cell Cure leases approximately 2,096 square meters (approximately 22,600 square feet) of combined office and laboratory space in Jerusalem, Israel under a master lease, as amended, that expires <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;">December 31, 2027. Cumulative base rent and construction allowance payments are approximately 165,000 Israeli New Shekels ("ILS") per month (approximately $44,000 as of September 30, 2024), excluding any future rent escalations, and includes options to extend the lease term for five years. The U.S. dollar value of the ILS denominated base rent and construction allowance payments fluctuates based upon currency exchange rates. In addition to base rent, Cell Cure pays a pro-rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located, including parking usage fees. These pro-rata charges are expensed as incurred and excluded from the calculation of the ROU assets and lease liabilities. Cell Cure has security deposits denominated in ILS with the landlord for this master lease held as restricted cash during the term the lease. The U.S. dollars value of the ILS denominated security deposits fluctuates based upon currency exchange rates and was $456,000 as of September 30, 2024, which is included in deposits and other long-term assets on the condensed consolidated balance sheet.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Supplemental Information – Leases</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Supplemental cash flow information related to leases is as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:65.727%;box-sizing:content-box;"></td><td style="width:1.6%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.537%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.6%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.537%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash paid for amounts included in the measurement of </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating cash flows from operating leases</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 913 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">833</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating cash flows from finance leases</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financing cash flows from finance leases</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="text-indent:2pt;vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> Right-of-use assets obtained in exchange for lease obligations: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">597</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Finance leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 79 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.753%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.523%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.523%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Operating leases </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,362</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,522 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use lease liabilities, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,083</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 830 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use lease liabilities, noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,533 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">

</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,979 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total operating lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,616</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,809 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Finance leases </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">202</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Accumulated amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (74 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (67 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use assets, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">128</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 131 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use lease liabilities, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use lease liabilities, noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total finance lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">134</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 143 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Weighted average remaining lease term </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Operating leases </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2.7 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> 3.5 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Finance leases </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2.6 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 3.0 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:4pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Weighted average discount rate </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Finance leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> Future minimum lease commitments are as follows as of September 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.727%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Operating Leases </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Finance Leases </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Year Ending December 31, </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">293</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,165 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 730 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> Total lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,865 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;text-align:center;"> 147 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Less imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (249 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (13 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,616</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 134 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Operating lease expense was $0.3 million and $0.9 million for each of the three and nine months ended September 30, 2024 and 2023, respectively. Collaborations Roche Agreement In December 2021, Lineage entered into the Roche Agreement, wherein Lineage granted to Roche exclusive worldwide rights to develop and commercialize RPE cell therapies, including Lineage's proprietary cell therapy known as OpRegen, for the treatment of ocular disorders, including GA secondary to AMD. Under the terms of the Roche Agreement, Roche paid Lineage a $50.0 million upfront payment and Lineage is eligible to receive up to an additional $620.0 million in developmental, regulatory and commercialization milestone payments. Lineage also is eligible for tiered, double-digit-percentage royalties on net sales of OpRegen in the U.S. and other major markets. All regulatory and commercial milestone payments and royalty payments are subject to the existence of certain intellectual property rights that cover OpRegen at the time such payments would otherwise become due, and the royalty payments on net sales of OpRegen are subject to financial offsets based on the existence of competing products. Roche assumed responsibility for further clinical development and commercialization of OpRegen. Lineage is responsible for completing activities related to the ongoing clinical study, for which enrollment is complete, and performing certain manufacturing and process development activities. Unless earlier terminated by either party, the Roche Agreement will expire on a product-by-product and country-by-country basis upon the expiration of all of Roche's payment obligations under the agreement. Roche may terminate the agreement in its entirety, or on a product-by-product or country-by-country basis, at any time with advance written notice. Either party may terminate the agreement in its entirety with written notice for the other party's material breach if such party fails to cure the breach or upon certain insolvency events involving the other party. In January 2022, Lineage received the $50.0 million upfront payment from Roche. Subsequently, Lineage, via Cell Cure, paid $12.1 million to the IIA, and $8.9 million to Hadasit Medical Research Services and Development Ltd. ("Hadasit"). Such payments were made in accordance with obligations under the Innovation Law (as discussed below) and under the terms of Cell Cure's agreements with Hadasit (as discussed below). The payment obligation to Hadasit was reduced by $1.9 million in accordance with the provisions of such agreements discussed below that reduce the sublicensing fee payable to Hadasit for costs related to Lineage's performance obligations under the Roche Agreement. To the extent such costs are not incurred within five years after the execution of the Roche Agreement, Cell Cure will be required to pay Hadasit 21.5% of the amount of costs not incurred. ITI Collaboration Agreement In April 2021, Lineage entered into a collaborative agreement with Immunomic Therapeutics, Inc. ("ITI") whereby Lineage agreed to perform up to approximately $2.2 million worth of certain research, development, manufacturing, and oversight activities related to the development of an allogeneic VAC-CMV product candidate. ITI will reimburse Lineage for these costs and full-time employee costs for the manufacturing of the VAC-CMV product candidate. As of September 30, 2024, Lineage has a remaining performance obligation of approximately $1.6 million for the aforementioned activities. Upon execution of the agreement in April 2021, $0.5 million was paid by ITI to Lineage. Upon delivery of research-grade VAC-CMV product generated by Lineage, ITI paid an additional $0.5 million in August 2021. ITI is currently evaluating its next step under the agreement. Agreements with Hadasit and IIA The OpRegen program was supported in part with licenses to technology obtained from Hadasit, the technology transfer company of Hadassah Medical Center, and through a series of research grants from the IIA, an independent agency created to address the needs of global innovation ecosystems. A subset of the intellectual property underlying OpRegen was originally generated at Hadassah Medical Center and licensed to Cell Cure for further development. Under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744, and the regulations, guidelines, rules, procedures and benefit tracks thereunder (collectively, the "Innovation Law"), annual research and development programs that meet specified criteria and were approved by a committee of the IIA were eligible for grants. The grants awarded were typically up to 50% of the project's expenditures, as determined by the IIA committee and subject to the benefit track under which the grant was awarded. The terms of the grants under the Innovation Law generally require that the products developed as part of the programs under which the grants were given be manufactured in Israel. The know-how developed thereunder may not be transferred outside of Israel unless prior written approval is received from the IIA. Transfer of IIA-funded know-how outside of Israel is subject to approval and payment of a redemption fee to the IIA calculated according to formulas provided under the Innovation Law. In November 2021, the IIA research committee approved an application made by Cell Cure with respect to the grant of an exclusive license and transfer of the technological know-how for OpRegen to Roche. Under the provisions for the redemption fee, Lineage paid the IIA approximately 24.1% of the upfront payment it received under the Roche Agreement, or $12.1<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;"> million, and is obligated to pay the IIA approximately 24.1% of any milestone and royalty payments which may be received under the Roche Agreement, up to an aggregate cap on all payments, such cap growing over time via interest accrual until paid in full. As of September 30, 2024, the aggregate cap amount was approximately $94.8 million. Pursuant to the Second Amended and Restated License Agreement, dated June 15, 2017, between Cell Cure and Hadasit, and a certain letter agreement entered into on December 17, 2021, Cell Cure paid a sublicensing fee to Hadasit of $8.9 million or 21.5% of the $50.0 million upfront payment under the Roche Agreement (subject to certain reductions), and Cell Cure is obligated to pay Hadasit (i) a maximum of 21.5% of all milestone payments Lineage receives under the Roche Agreement (subject to certain reductions, including for costs related to Lineage's performance obligations under the Roche Agreement), and (ii) up to 50% of all royalty payments (subject to a maximum payment of 5% of net sales of products), Lineage receives under the Roche Agreement. The letter agreement generally terminates upon the termination of the Roche Agreement. Second Amendment to Clinical Trial and Option Agreement and License Agreement with Cancer Research UK In May 2020, Lineage and Asterias entered into a Second Amendment to the Clinical Trial and Option Agreement (the "Second CTOA Amendment") with CRUK and Cancer Research Technology ("CRT"). The Second CTOA Amendment amended the initial agreement and the first amendment to the Clinical Trial and Option Agreement, each of which is dated September 8, 2014, between Asterias, CRUK and CRT. Pursuant to the Second CTOA Amendment, Lineage assumed all obligations of Asterias and exercised early its option to acquire data generated in the Phase 1 clinical trial of VAC2 in non-small cell lung cancer being conducted by CRUK. Lineage and CRT effectuated the option by simultaneously entering into a license agreement (the "CRT License Agreement") pursuant to which Lineage paid a signature fee of £1,250,000 (approximately $1.6 million based upon exchange rates in effect when the fee was paid). For the primary licensed product for the first indication, the CRT License Agreement provides for milestone fees of up to £8,000,000 based upon initiation of a Phase 3 clinical trial and the filing for regulatory approval and up to £22,500,000 in sales-based milestones payments. Additional milestone fees and sales-based milestone payments would be payable for other products or indications, and mid-single-digit royalty payments are payable on sales of commercial products. Either party may terminate the CRT License Agreement for the uncured material breach of the other party. CRT may terminate the CRT License Agreement in the case of Lineage's insolvency or if Lineage ceases all development and commercialization of all products under the CRT License Agreement. Other Contingent Obligations We have obligations under license agreements and grants received from government entities to make future payments to third parties, which become due and payable on the achievement of certain development, regulatory and commercial milestones or on the sublicense of our rights to another party. These commitments include sublicense fees, milestone payments, redemption fees and royalties. Sublicense fees are payable to licensors or government entities when we sublicense underlying intellectual property to third parties; the fees are based on a percentage of the license-related revenue we receive from sublicensees. Milestone payments are due to licensors or government entities upon the future achievement of certain development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of any milestone or royalty payment received in respect of IIA-funded programs. Royalties are payable to licensors or government entities based on a percentage of net sales of licensed products. As of September 30, 2024, we have not included these commitments on our condensed consolidated balance sheet because the achievement and timing of these events are not fixed and determinable. Litigation – General From time to time, we are subject to legal proceedings and claims in the ordinary course of business. While management presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, cash flows, or overall trends in results of operations, legal proceedings are subject to inherent uncertainties, and unfavorable rulings or outcomes could occur that have individually or in aggregate, a material adverse effect on our business, financial condition or operating results. We are not currently subject to any pending material litigation, other than ordinary routine litigation incidental to our business. Asterias Merger In November 2018, Lineage, Asterias Biotherapeutics, Inc. ("Asterias"), and Patrick Merger Sub, Inc., a wholly owned subsidiary of Lineage, entered into an Agreement and Plan of Merger pursuant to which Lineage agreed to acquire all of the outstanding common stock of Asterias in a stock-for-stock transaction (the "Asterias Merger"). The Asterias Merger closed in March 2019. In October 2019, a putative class action lawsuit was filed against the company and certain other named defendants challenging the Asterias Merger. In February 2023, the court approved a Stipulation and Agreement of Compromise and Settlement pursuant to which, Lineage and certain insurers of the defendants paid $10.65 million (the "Settlement Amount") into a fund created for the benefit of the purported class and in consideration for the full and final release, settlement and discharge of all claims. Approximately $7.12 million of the Settlement Amount was funded by certain insurers and approximately $3.53 million was paid by Lineage during the first quarter of 2023. Lineage and all defendants have denied, and continue to deny, the claims alleged in the lawsuit and the settlement does not reflect or constitute any admission, concession, presumption, proof, evidence or finding of any liability, fault, wrongdoing or injury or damages, or of any wrongful conduct, acts or omissions on the part any defendant. Premvia Litigation Settlement In July 2019, the Company, along with other named defendants, was sued in the Superior Court of the State of California in a matter captioned Gonzalez v. Aronowitz, M.D., et al. The plaintiff asserted medical negligence and product liability causes of action relating to the 2017 and 2018 use in a clinical trial of a product candidate, Premvia, that the Company is no longer developing and has no plans to pursue, and that is not related to the cell therapy candidates the Company currently is developing. In February 2023, the Company and the other defendants each entered into settlement agreements with the plaintiff pursuant to which the defendants without admitting any liability, which the defendants expressly denied, each agreed to pay specified amounts to the plaintiff in exchange for a full settlement and release and discharge of claims. The Company's insurance covered the full amount paid by the Company excluding the $25,000 insurance deductible. HBL Books and Records Request On April 17, 2023, Cell Cure received a motion for disclosure of documents pursuant to Section 198A of the Israeli Companies Law 5759-1999. The motion was filed in the district court in Tel Aviv-Yafo (the "Court") by HBL Hadasit Bio-Holdings Ltd. ("HBL"), currently an approximately 5% shareholder of Cell Cure. According to the motion, the requested production of documents is intended to allow HBL to examine the possibility of pursuing a derivative action related to, among other things, the validity of an intercompany Collaboration and License Agreement (the "Intercompany Agreement") entered into between Lineage and Cell Cure pursuant to which Cell Cure conveyed certain rights and other assets to Lineage, and Lineage agreed to undertake certain liabilities and obligations of Cell Cure relating to the OpRegen program. In its motion, HBL alleges, among other things, that Lineage, in its capacity as Cell Cure's controlling shareholder, and members of Cell Cure's board of directors caused damage to Cell Cure because the Intercompany Agreement was an interested party transaction that was not fairly priced and exploits Cell Cure's resources for the benefit of Lineage. The motion seeks an order to compel Cell Cure to disclose and deliver to HBL the documents described in the motion, such additional, cumulative, or alternative relief as the court deems appropriate, and reimbursement of HBL's expenses, including attorneys' fees. The Court held a hearing on the motion on March 14, 2024 at which the Court proposed, and the parties agreed, to retain a third-party valuation firm to assess the fairness of the valuation that was performed in support of the Intercompany Agreement. It is impossible at this time to assess whether the outcome of this proceeding will have a material adverse effect on

Lineage's consolidated results of operations, cash flows or financial position. Therefore, in accordance with ASC 450, Contingencies, Lineage has not recorded any accrual for a contingent liability associated with this legal proceeding based on its belief that a liability, while possible, is not probable nor estimable, and any range of potential contingent liability amounts cannot be reasonably estimated at this time. Lineage records legal expenses as incurred. Employment Contracts Lineage has employment agreements with all of its executive officers. Under the provisions of the agreements, Lineage may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations. Indemnification In the normal course of business, Lineage may agree to indemnify and reimburse other parties, typically Lineage's clinical research organizations, investigators, clinical sites, and suppliers, for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of Lineage's products and services. Indemnification could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to Lineage products and services. The term of these indemnification agreements generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. In addition, Lineage has entered into indemnification agreements with officers and members of its board of directors that will require Lineage, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as officers or directors. The potential future payments Lineage could be required to make under the indemnification agreements described in this paragraph will generally not be subject to any specified maximum amount. Generally, Lineage has not been subject to any material claims or demands for indemnification. Lineage maintains liability insurance policies that limit its financial exposure under the indemnification agreements described in this paragraph. Accordingly, Lineage has not recorded any liabilities for these agreements as of September 30, 2024 or December 31, 2023. Royalty Obligations and License Fees We have licensing agreements with research institutions, universities and other parties providing us with certain rights to use intellectual property in conducting research and development activities in exchange for the payment of royalties on future product sales, if any. In addition, in order to maintain these licenses and other rights, we must comply with various conditions including the payment of patent related costs and annual minimum maintenance fees. As part of the Asterias Merger, Lineage acquired royalty revenues for cash flows generated under patent families that Asterias acquired from Geron Corporation. Lineage continues to make royalty payments to Geron from royalties generated from these patents. Royalty revenues and royalty payments are included within royalties, license and other revenues and cost of sales, respectively, in our condensed consolidated statements of operations. 0841202303-01252000.031785045002022-10-012024-03-31 In February 2024, Lineage extended the term of the sublease for 24 months through March 31, 2026 on similar terms.2026-03-312300023500225002096226002027-12-3116500044000options to extend the lease term for five years456000 Supplemental cash flow information related to leases is as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:65.727%;box-sizing:content-box;"></td><td style="width:1.6%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.537%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.6%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.537%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:middle;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:middle;"> </td><td style="vertical-align:middle;"> </td><td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:middle;"> </td><td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> Cash paid for amounts included in the measurement of </br> lease liabilities: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating cash flows from operating leases </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">913</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 833 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating cash flows from finance leases </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Financing cash flows from finance leases </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Right-of-use assets obtained in exchange for lease obligations: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">597</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Finance leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 79 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>91300083300060008000040000410005970000360007900 0 Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.753%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.523%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.523%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Operating leases </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,362</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,522 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use lease liabilities, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,083 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">830</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Right-of-use lease liabilities, noncurrent</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,533</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,979</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total operating lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,809</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Finance leases</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Right-of-use assets</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">198</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accumulated amortization</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(74</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(67</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Right-of-use assets, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 128 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 131 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use lease liabilities,

current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use lease liabilities, noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total finance lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">134</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 143 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:2pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Weighted average remaining lease term </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Operating leases </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2.7 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 3.5 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Finance leases </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2.6 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 3.0 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:4pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Weighted average discount rate </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;">6.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Finance leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr>
</table>2362000252200010830008300001533000197900026160002809000202000198000740006700012800013100054000520008000091000134000143000P2Y8M12DP3Y6M
style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Future minimum lease commitments are as follows as of September 30, 2024 (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.727%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Operating Leases </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Finance Leases </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> Year Ending December 31, </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">293</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,165 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 730 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> Total lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid

#000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,865 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;text-align:center;"> 147 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Less imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (249 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (13 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,616</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 134 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>2930001600011650006400073000039000677000280002865000147000249000130002616000134000300000300000900000900000500000006200000005000000012106

Includes shares owned by Lineage and ES Cell International Pte. Ltd. All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement. Included within royalties, license and other revenues recognized for the nine months ended September 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively. Excludes grants receivable which are outside the scope of ASU 2014-09. Cash equivalents have an original maturity of three months or less when purchased. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitments and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment. Asterias had two in-process research and development ("IPR&D") intangible assets that were valued at $46.5 million as part of the purchase price allocation that was performed in connection with the Asterias Merger. The fair value of these assets at the acquisition date consisted of $31.7 million pertaining to the OPC1 program and $14.8 million pertaining to the VAC platform. Asterias had royalty cash flows under patent families it acquired from Geron Corporation. Such patent families are expected to continue to generate revenue, are not used in the OPC1 or the VAC platform, and are considered to be separate long-lived intangible assets under ASC Topic 805, Business Combinations The acquired patents and acquired royalty contracts were fully amortized as of the end of the first quarter of 2024.